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Guanine-rich nucleic acids can fold into distinctive four-stranded G-quadruplex structures 
which are found in telomeric DNA repeats, as well as in sequences in promoter and other 
regulatory regions of genes, especially those involved in cellular proliferation. Small 
molecules that can selectively bind and stabilize the G-quadruplex structure have become of 
significant interest to researchers and are gaining momentum as a possible new class of 
anticancer agents [1]. Using a distamycin scaffold as a starting point, we introduced biaryl 
building blocks in place of pyrroles to switch preference from duplex to quadruplex DNA.  
This alteration in shape ensures that the molecules have low affinity for duplex DNA while 
increasing their interaction with a G-quadruplex structure, since the ligands have similar 
dimensions.  The structures of the biaryl polyamides previously reported by the Thurston 
group were tailored to enhance affinity for specific G-quadruplexes (e.g., c-kit1 vs c-kit2 vs 
HT4) while retaining the quadruplex vs duplex selectivity. A 66 member focused second 
generation biaryl polyamide library was synthesized based on structural information obtained 
from the previously reported polyamide types. Assessment of the G-quadruplex interaction of 
the library members was initially carried out using a FRET-based melting assay. Compound 
KN-242 with hybrid benzofused and biaryl building blocks showed significant selective 
stabilization of human Telomeric G-quadruplex. At 1 μm concentration it stabilized human 
Telomeric G-quadruplex by 32 ºC, while showing insignificant affinity for duplex DNA. 
FRET competition assays with C-kit quadruplexes and CT DNA further confirmed selective 
stabilization of telomeric quadruplexes. A short-term growth inhibitory experiment against 
six different cancer cell lines, MiaPaCa2, A549 MCF7, HeLa, U87MG, A431 and WI38 gave 
low micromolar IC50 values and between 5-8 fold selectivity for cancer cell lines compared 
with the non-cancerous WI 38 cell line. Therefore, given their low molecular weight, good 
water solubility and excellent cellular penetration properties, molecules of this type have the 
potential to be developed into either potential therapeutic agents or reagents that can probe 
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Chapter One: Introduction 
1.0  Introduction 
1.1 Cancer 
Cancer is a clinical condition which involves unregulated cell growth (abnormal cell 
division), intrusion (the invasion and resulting effects on neighbouring tissues), and 
occasionally metastasis (spreading of cancerous cells throughout the body by lymph or 
blood). Benign tumours are self-limited, and do not invade or undergo metastasis; therefore 
they are different from malignant cancers due to their self-contained nature.  
 
Cancers are started in transformed cells, caused by abnormalities in the genetic material [1]. 
Carcinogens (radiation, chemicals, or other infectious agents that promote the formation of 
cancer) might initiate these abnormalities. Malignant tumours develop through a multistep 
process involving alterations of tumour-suppressor genes and other genes in cancer cells - 
namely, oncogenes and microRNA [2]. In most cases, more than one mutation must occur in 
order for cancer to develop.  
 
Tumour cells can vary in sensitivity to different types of treatment such as chemotherapy and 
radiotherapy, as well as others, making it difficult to manage. This is why the initial stages of 
cancer development are important and are a pivotal point in developing rational treatments 
for cancer. As research is developing, it has become possible to target different types of 
cancer cells more specifically by targeted therapy where the drugs are acting directly on the 
identifiable molecular targets in tumours while minimizing healthy cell destruction. 
 
1.2 Hallmarks of Cancer 
Cancer research primarily targets mechanisms for governing the inter-conversion of healthy 
cells to malignant cells. To understand the complex and interrelated cancer development 
process, the mechanism was described as “six essential alterations in cell physiology that 
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collectively dictate malignant growth: self-sufficiency in growth signals, insensitivity to 
growth-inhibitory (antigrowth) signals, evasion of programmed cell death (apoptosis), 
limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis” (D. 
Hanahan & R. Weinberg) (Figure 1.1 a) [3]. Genome instability underlies these hallmarks 
that produce the genetic diversity, increasing acquisition and inflammation of these genes 
which in turn foster numerous hallmark functions. During the last decade, conceptual 
progress included two emerging hallmarks, in addition to the existing list (Figure 1.1 b). 
Tumours produce a different magnitude of complexities along with the cancer cells by 
creating a ‘‘tumour microenvironment’’, which contributes to gaining hallmark traits through 
recruiting a group of ostensibly normal cells. As such, an understanding of the concept and its 
applicability will guide us in developing new strategies for treating cancer [4]. 
 
Figure 1.1: a) The Hallmarks of Cancer; b) Emerging Hallmarks and Enabling 
Characteristics taken from Hanahan and Weinberg, 2011 [4]. 
 
1.3 Cancer Chemotherapy 
In 1940, nitrogen mustards and folic acid agonists were first used as chemotherapeutic agents 
for treating cancer. The new approach (termed “targeted therapy”) is now common, though 
many of the principles and limitations of chemotherapy are still applied in designing 




Chemotherapy involves treatment with anticancer drugs to destroy cancerous cells by 
interfering with cell division during different stages. Chemotherapy generally targets rapidly 
dividing cells and is non-specific to cancer cells, although some degree of specificity might 
be achieved in cancerous cells, as the DNA damage response in cancer cells has been found 
to be different from that of healthy cells [5]. However, chemotherapy could harm healthy 
tissue, especially those with higher turnover rates (e.g. intestinal lining). To get the maximum 
result, more than one drug is often given in the form of "combination chemotherapy", which 
is the most common method in practice. Recently, numerous potential anticancer targets were 
identified, which resulted in a great expansion of the drug development process. At present, 
the number of clinically useful anticancer drugs is growing significantly; the main challenges 
are optimising their clinical use as well as successfully and  rationally integrating them with 
existing anticancer therapies [5].  
 
The increasing knowledge of the biochemical steps engaged in cancer is encouraging the 
development of new anticancer drugs that exploit the differences between cancer cells and 
normal cells. Studying the patterns of gene and protein expression enable the successful 
identification of enzymes, receptors and other molecular targets that are exclusively-
expressed or over-expressed in cancer cells compared with normal cells.  
 
1.4 DNA as a Target for Anticancer Therapy 
Cancer brings changes to the DNA structure, causing an alteration of normal DNA 
regulation. Therefore, cancer cells do not respond to normal regulatory signals. DNA has 
been targeted for a long time for the invention of chemotherapeutic agents for inhibiting gene 
transcription, translation and other cellular processes - hence, anticancer drugs primarily 
work by binding to DNA. Cytotoxic agents target DNA non-specifically, and at present 
chemotherapeutics are designed to target DNA with high specificity. Currently, researchers 
are trying to develop new molecules that will target not only DNA but also their associated 
proteins and pathways more specifically.   
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1.5 DNA Structure 
DNA has been known to be polymorphic prior to our understanding of the three-dimensional 
form of DNA, and it has been shown that it can adopt more than one form (Figure 1.2) [7,8]. 
Over 60 years ago, fibre diffraction studies by Maurice Wilkins and Rosalind Franklin 
demonstrated that the A-form diffraction pattern was produced by dried, oriented DNA 
fibres, whereas the same fibre produced a different pattern, called the B form, in a moist 
form. The B-DNA form (Figure 1.2 a) is the common double helical form, where the helical 
axis runs through the Watson-Crick base pairs [6]. Nucleic acid structures are also found to 
be present in a number of triple- and quadruple-stranded structures, as well as in left-handed 
forms (Figure 1.2 c, f). Quadruplex structures (Figure 1.2 f) based on G-quartets are reported 
to form at the guanine-rich segments of the telomere and centromere, while their 
complementary cytosine-rich sequences fold to form an intercalated tetramer referred to as 
the i-motif [7]. The G-quadruple structures are of great interest for structural biologists, as 
they have been found to deregulate the telomerase enzyme that favours the division of some 
tumours [8], hence causing telomeres to be a significant target in designing anticancer drugs 
Moreover, the remainder of the DNA structures are reported to take numerous unusual 
conformations. Three strands with polypurine-polypyrimidine rich sequences in the 
eukaryotic genome have been found to form H-DNA (Figure 1.2 e), demonstrating an 
important part in DNA replication, metabolism and transcription. Oligonucleotides capable of 
forming triplexes were designed recently that act as "anti-gene" agents [8]. Therefore, 
uncommon DNA forms might have an important role in the basic cell regulation processes 
such as gene expression, chromosomal stability, cellular replication and programmed cell 
death, representing novel targets for structure, as well as sequence-specific drugs [7]. 
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Figure 1.2: Various forms of DNA. (a) B-DNA form, (b) Z-DNA form, (c) triplex DNA 
form, (d) cruciform DNA, (e) H-DNA form, (f) G-quadruplex DNA with different topology 
[9]. 
 
1.5.1 Double Helix DNA 
The double-helix model of the DNA structure (Figure 1.3 a) was first published in Nature by 
James D. Watson and Francis Crick in 1953 [10]. DNA is a long polymer of repeating 
nucleotide units of 22 to 26 Å wide, where each nucleotide is 3.3 Å (0.33 nm) long [11]. 
Alternating phosphate and sugar residues form the backbone of the DNA strand [12], where 
the sugar is 2-deoxyribose and joined with others via phosphodiester bonds formed by 
phosphate groups between the 3rd & 5th carbon of neighbouring sugar rings. In a double helix 
the ends of asymmetric antiparallel strands are termed as 5′ ends with a terminal phosphate 
group and 3′ ends with a terminal hydroxyl group. Four different bases {named cytosine (C), 
adenine (A), thymine (T) and guanine (G)} in DNA are linked to the sugar/phosphate 
backbone, completing the nucleotide structure (Figure 1.3 b). The DNA double helical 
structure is stabilized by two types of forces: the hydrogen bonds among the nucleotides and 
the base-stacking interactions between the aromatic nucleobases [13]. Conjugated π bonds of 
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nucleotide bases, in the aqueous environment of the cell, align themselves perpendicularly to 
the axis of the DNA structure, and thus minimize the interaction between the solvation shell 
and Gibbs free energy. All these hydrogen bonds acting internally and externally thus 
stabilize the DNA structure by bringing the two complementary strands together. 
Figure 1.3: (a) DNA and its building blocks, (b) Complementary base pairs in the DNA 
double helix [14]. 
 
1.5.2 Triplex DNA 
Nearly 56 years ago, intramolecular triple helical DNA and triplex DNA structures were first 
reported [15-18] and were found to form at polypurine-polypyrimidine (R.Y) tracts (Figure 
1.4 a). A third strand binds the minor groove with the major groove using either Hoogsteen or 
reversed Hoogsteen hydrogen bonds with a duplex resulting in a triplex formation (Figure 
1.4 b, c) under two conditions. Firstly, melting and refolding of the adjacent homopurine and 
homopyrimidine segments must occur in order to form intramolecular triplexes, and 
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secondly, the site-selective binding of the triplex-forming oligonucleotides (TFO's) like 
antigens with duplex DNA must also  occur to form triplexes [19]. There are two basic forms 
of triplexes, termed R.R.Y and Y.R.Y:  either one of these triplexes is formed depending on 
the overall proportion of base in the third strand, which can be either purine (R) rich or 
pyrimidine (Y) rich. Reaction conditions determine the formation of either of these triplexes: 
for example, an acidic pH favours the generation of Y.R.Y type triplexes, whereas for the 
formation of R.R.Y triplexes neutral pH and divalent metal cations are required, making it 
frequently available in normal physiological conditions [20]. R.R.Y type triplexes have been 
found to form rapidly as they can tolerate more versatile pairing schemes [21].  
 
Triplex formation is highly affected by the location of the formation and cannot be formed in 
every DNA location because of its structure, charge and rigid nature. Additionally, the DNA 
sequence is another important factor for triplex formation which needs to be either mirror 
repeats or palindromes of homopurine-homopyrimidine [22]. Triplex formation is again 
dependent on the pH of the medium as the protonation or non-protonation of certain bases 
dictates the generation of triplex structures [23].  
 
Triple helical DNA can be targeted selectively to control gene expression in vivo, which 
provides an opportunity to develop therapeutic agents such as anticancer and anti-viral drugs. 
The binding of oligonucleotides for triplex formation can be either in a parallel or an anti- 
parallel way. For the parallel binding motif, a low pH is required, allowing the protonation of 
cytosine, which is difficult under normal physiological conditions [24]. On the contrary, anti-
parallel motif formation is insensitive to pH [19]. 
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Figure 1.4: Diagram of triplex DNA (a) Triplex DNA structure, (b) Hoogsteen hydrogen 
bonding. (c) Reverse Hoogsteen hydrogen bonding [9]. 
 
1.5.3 Quadruplex DNA 
The four-stranded nucleic acid structures were discovered in 1958 while studying the 
polyinosinic acid fibre. The X-ray diffraction pattern indicated the presence of parallel three- 
or fourfold polynucleotide strands [25], which later on were proven to be quadruple-stranded 
[15, 26]. After a few years, Gellert and his team studied the X-ray diffraction patterns of 
guanosine monophosphate gels and proposed the formation of a cyclic structure by four 
guanine moieties through hydrogen bonds [6]. Presently, scientists are analysing the 
existence and functional importance of these quadruple DNAs, referred to as G-quadruplex 
structures (Figure 1.5), forming from specific guanine-rich sequences. These G-quartet 
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structures are considered important for basic cellular activities and can be very important 
targets for treating various diseases such as cancer.  
 
The G-quadruplex structures are generated by the folding of either a single polynucleotide 
molecule or by the association of two or four molecules. The guanine bases stack on each 
other in square planer geometry to form a tetrad structure (Figure 1.6), which is again 
stabilized through Hoogsteen hydrogen bond formation among the 4 guanine bases. These 
structures are reported to be found in telomeric regions, as well as in the promoters of certain 
genes like c-myc, c-kit, and bcl-2 with different structural patterns: for example, telomeric 
DNA forms parallel or antiparallel/parallel mixed-type structures in the presence of K+ ions, 
while in the presence of Na+ cations antiparallel structures are formed. In c-myc, promoters 
with four-looped parallel G-quadruplex structures are found, while in c-kit promoters four 
connecting loops are found in three stacked G-tetrads [27].  
 
Different biophysical experiments have identified around 375,000 potential G-tetrad-forming 
sequences in the human genome, although their existence has yet to be proven in vivo [29]. 
However, a multitude of indirect evidence indicates the presence of G-quadruplex structures 
at numerous places in the human genome and these are suggested to be involved in various 
cellular activities. For instance, a number of proteins isolated from yeast and ciliates showed 
selective binding ability to G-quadruplexes, as well as converting the duplex DNA to the 
quadruplex form in the presence of Na+ and K+ ions (~150 mM). These quadruple structures 
are found to control the expression of some genes that are involved in the process of 
carcinogenesis and in maintaining telomere organization [28]. Their capability to prevent 
telomeric elongation by inhibition of the enzyme telomerase, which is found to be over-







Figure 1.5: (A) Usual A-T and G-C coupling; (B) the G-quadruplex structure [28] 
 
1.5.3.1 General Features of Quadruplex Topology and Structure 
Guanine bases form the central part of G-quadruplexes where four guanine bases are 
organized in a rotationally symmetric way and form hydrogen bonds from N1–O6 and N2–
N7 of the resultant square [30]. Quadruplexes are formed by the participation of 1, 2 or 4 
different DNA/RNA strands, resulting in numerous different topologies that arise not only 
because of strand combinations that have different directions but also for different loop size 
as well as sequences (Figure 1.8 c). Possible unimolecular (i.e. intramolecular) (Figure 1.8 
e) sequences can be represented as GmXnGmXoXpGm (m= number of G residues, Xn, Xo & 
Xp= any arrangement of residues). The association of non-equal sequences can give rise to 
bimolecular (dimeric) (Figure 1.8 e) and tetramolecular (tetrameric) quadruplexes. Most of 
the bimolecular quadruplexes are produced through the binding of two identical sequences, 
Xn Gm Xo Gm Xp, (n & p may/may not be 0). Association of four Xn Gm Xo or GmXnGm 




Figure 1.6: Example of G-quadruplex structure [29]  
1.5.3.2 G-Quadruplex Stabilization 
Factors that stabilize the quadruplex include the base stacking interaction, hydrogen bonds, 
electrostatic interactions and the hydration shell [32]. In the formation of G-quadruplex 
structures, base stacking only needs to accommodate the guanine bases. However, quadruplex 
structures become unstable even in the presence of these stabilizing factors, due to the 
arrangement of the central guanine O6 carbonyl groups of the G-quartet. The O6 atoms 
forming a square planar structure for each tetrad give a twist of 30° and a rise of 3.3 A˚ 
between each tetrad step, generating a bipyramidal-antiprismatic arrangement for the eight 
O6 atoms (Figure 1.7). This arrangement of O6 carbonyl atoms forms negatively charged 
cavities between the G-tetrads that need to be neutralized by the coordination of cations. The 
overall stability of the finally folded quadruplex largely depends on the selection of a suitable 















Figure 1.7: Counter ion coordination between tetrad bases shown with a twist between bases. 
(a) Potassium metal ion is shown coordinated between the eight carbonyl O6 with an average 
coordination distance of 2.73 A˚. (b) A space filling model with potassium counter ions [33].  
 
1.5.3.3 Loop Structures of G-Quadruplexes 
G-tetrad structures are differentiated depending on the strand polarities and the guanine 
strands connecting loop location. The loops can be divided into three families: propeller, 
lateral and diagonal (Figure 1.8 d). The bases in the loops can also interact with the G-
tetrads. 
 
1.5.3.3.1 Propeller Loops 
Adjacent parallel strands are linked by a joining loop where the bottom G-quartet is joined 
with the top G-quartet forming propeller loops (Figure 1.8 D), sometimes also known as 
strand-reversal loops. Human telomeric DNA sequences form quadruplexes of this type in 
crystal structure and solution [34], and more recently this feature has been reported in a 
number of non-telomeric quadruplexes [35]. When any one of the four strands is in an anti-




1.5.3.3.2 Lateral Loops 
The first type of antiparallel loop, lateral or edge-wise loops (Figure 1.8 D), joins the 
neighbouring G-strands where two of these loops are present either on the same faces or on 
the opposite faces of a G-quadruplex structure, representing head-to-head or head-to-tail 
connections, respectively, in bimolecular G-quadruplex structures. As an example, this type 
of loop was found in asymmetric quadruplexes for the sequence d(TG4T2G4T) [36], as well 
as in the bimolecular quadruplex with a sequence of d(GGGCT4GGGC).  
 
1.5.3.3.3 Diagonal Loops 
The diagonal loop (Figure 1.8 D) is another form of anti-parallel loop that connects opposite 
G-strands, where the adjacent strands have to be of alternating directions between parallel 
and anti-parallel. This type of loop has been reported to be found in the telomeric region of 




Figure 1.8: (A) G-quadruplex structure. (B) G-quadruplex structure with cation coordination 
sites. (C) Classification of G-quadruplex structure based on strand polarity. (D) Three 
principal forms of loop. (E) Monomeric intramolecular and dimeric intermolecular G-
quadruplex structures [37]. 
 
1.5.3.4 Glycosidic Bond in Quadruplex 
The different strand directionality of the G-quartet structures is related to the conformational 
shape of the syn (1.1) or anti (1.2) (Figure 1.9) glycosidic bonds formed between the guanine 
base and the sugar. Bases are in anti-conformation when all of the four strands are in the 
parallel direction. If any one of the strands is in the anti-parallel direction (Figure 1.10) then 
the bases have to be in the syn (1.1) orientation to form the hydrogen bonds correctly, which 
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effects the direction of the backbone in relation to the G-tetrads, therefore resulting in 
grooves of various sizes. Depending on the topology and loop nature, grooves can be of 
various dimensions. The groove is of medium size when successive guanines are both anti 
(1.2) or both syn (1.1). When the first base is anti (1.2) and second base is syn (1.1), the 
groove is wider. The groove is narrower when the first is syn (1.1) and the second anti (1.2) 
[30]. The complexity of the groove depends on the type of connecting loop: in the case of 
lateral or diagonal loops the groove structure is simple, whereas in the case of propeller loops 





Figure 1.9: Glycosidic bonds within a G-quadruplex can rotate to form two preferred 




















Figure 1.10: Schematic diagram showing the potential strand polarity and related glycosidic 
bonds for intermolecular quadruplexes. a) Parallel with all anti glycosidic bonds. b) Parallel 
with all syn glycosidic bond. c-e) Alternating strand arrangements with the corresponding 
mixed syn anti relationships [33]. 
 
1.5.3.5 Evidence for the Presence of G-Quadruplex Structures in the Biological System 
Recently accumulated data reveal the existence of numerous putative G-quadruplexes 
forming guanine clusters in the evolutionarily distant genomes of prokaryotes [38] and 
humans [39] (Figure 1.11). A computational search of human genes for guanine-rich, 
potential G-quadruplex-forming sequences has identified 226,157 such sites [39], whereas 
analysis of >61,000 open reading frames of 18 prokaryotes’ genomes detected a statistically 
disproportionate incidence of tetraplex-forming sequences in the gene promoters [38]. 
Further analysis of nearly 17,000 human genes showed that gene function is correlated with 
the potential quadruplex-forming sequences. It was found that some classes of genes, such as 
tumour-suppressor genes, possess low tetraplex-forming potential, whereas others, like proto-
oncogenes, have a very high potential to fold into tetraplex structures due to the presence of 
unique genomic sequences. Since quadruplex-forming sequences are relatively short and 
quadruplexes are likely to be transiently formed, the detection of these regions in genomic 
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DNA is similar to a search for a needle in a haystack. However, quadruplex-recognizing 
specific antibodies, dye molecules and direct electron microscopy analysis provided rather 
convincing evidence for the relevance of these DNA structures in the genomes of several 
organisms [40]. 
 
For the first time, telomeric DNA was reported with the capability of forming G-quadruplex 
structures in biological systems. Several organisms containing single-stranded telomeric 
terminal sequences were found to form an association of G–G paired hairpin type structures 
[41], which, later on, was described in Tetrahymena telomeric DNA [42]. Williamson, for the 
first time, reported the important role of monovalent cations in forming and stabilizing the G-
quadruplex structures and suggested that the cations placed themselves in the cavity 
generated by the guanines of each tetrad [43]. Stylonychia lemnae telomeric DNA was used 
to establish the biological existence of the quadruplexes, where particular antibodies were 
used against the formed parallel- and antiparallel-quadruplex structures of the ciliate [44]. 
Recently, it has also been shown that the control of in vivo G-quadruplex formation depends 
on the telomere end-binding proteins TEBPα and TEBPβ through using the same antibody in 
ciliates, and during replication, phosphorylation of TEBPβ is required for resolving the 
quadruplex structures. In vivo G-quartet formation was further shown by the binding and 
detection of the radio-labelled ligand 360A (2,6-N,N´-methylquinolinio-3-yl-pyridine 
dicarboxamide) or the fluorescent ligand BMVC (3,6-bis(1-methyl-4-vinylpyridinium) 
carbazole diiodide. Along with the increasing evidence for the existence of human telomeric 
quadruplex structures, there is growing evidence for the biological existence of these 
quadruplexes in the non-coding regions of genes and particularly in the gene promoter sites. 
Recently, quadruplex-forming sequences were found to  be  near  the transcription start sites 
(TSS) of promoter regions, where there is a strong relation between nuclease-hypersensitive 
elements and quadruplex-forming sequences [45]. Researchers have suggested that the 
denaturation or unwinding of duplex DNA favours the formation of a quadruplex, which 




Figure 1.11: Probable locations of the G-quadruplex structures within cells. In nucleus (a) 
during replication (b) transient single stranded form of DNA. (c)Telomeric single stranded G-
rich overhangs. (d) G-quadruplexes in mRNA. Red crosses indicate possible blockage of the 
replication, transcription and translation process by G-quadruplexes [47]. 
 
1.5.3.6 The Proposed Biological role of Quadruplex DNA 
1.5.3.6.1 Regulation of Gene Transcription 
A significant amount of data supports the proposed role of quadruplex DNA structures in 
regulating gene transcription [38, 48]. Researchers have identified quadruplex-forming 
guanine-rich sequences in the regulatory regions of various genes by focusing on particular 
genes which can readily form different types of tetrahelices in vitro. In some cases, additional 
evidence was provided by the selective interaction of specific transcription proteins within 
the tetrahelix domains. In most cases, the quadruplex-generating sequences were found in 
gene promoter or enhancer regions, and the assumed negative or positive effects of such 
structures on transcription are mostly based on either indirect or in vitro accumulated results. 
However, all the evidence supports the idea that the quadruplex DNA structures serve as 
regulatory elements and control gene expression either by attracting or dispelling 
transcription factors [40].  
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One prominent example of the regulation of gene transcription by quadruplex structures is c-
myc (Figure 1.12). In one early report, it was shown that c-myc contains a guanine-rich 
sequence near the control region located at -142 to -115 bp of the promoter, which can fold to 
form an intramolecular quadruplex structure [49]. Previously, it was assumed that the 
quadruplex structure may act to promote transcription by attracting the nuclease 
hypersensitive binding proteins hnRNPs A1 and K and CNBP, but recent results indicate that 
it is likely to repress rather than stimulate transcription. Among the two intramolecular G-
tetrads formed by the c-myc control sequence [50, 51], only the chair-form one was found to 








Figure 1.12: Schematic diagram demonstrating the activation as well as the repression 
process of gene transcription including the part of NM23-H2 in converting guanine-rich 
single-stranded DNA into quadruplex DNA structures. The binding of TMPyP4 (1.32) 
stabilizes the G-quadruplex structure and inhibits the gene transcription [50]. 
 
A G→A point mutation in HeLa S3 cells increases the basal transcription of c-myc by 3-fold 
due to the lack of the formation of this tetraplex structure. On the contrary, the expression of 
c-myc was found to be diminished by stabilization of the tetrad structure with the cationic 
porphyrin TMPyP4 (1.32) (Figure 1.12) [50]. Therefore, after analysing these data, it can be 
proposed that the quadruplex domain in the c-myc control region acts to suppress 
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transcription. Moreover, some other ligands that bind and stabilize telomeric quadruplex 
DNA inhibiting telomerase activity were found to suppress the in vitro transcription of c-myc 
as well [52]. 
 
1.5.3.6.2 Telomere Metabolism 
Telomeres are DNA-protein complexes found at the end of linear eukaryotic chromosomes 
that protect the chromosome from degradation by fusion. The single-stranded guanine-rich 
telomeric DNA overhang folds back to form a specialized tertiary structure known as the G-
quadruplex structure. The length of the telomere is maintained by extending the protruding 3' 
guanine-rich strand by the ribonucleoprotein enzyme telomerase. Effects of the folding of 
telomeric DNA of Oxytricha nova to its role as primer for the elongation of the telomere by 
the telomerase enzyme was reported in an early study and was demonstrated that its extension 
by telomerase was blocked by the formation of a quadruplex structure (Figure 1.13 a) [53], 
suggesting that the interconversion of the telomeric DNA into the G-quartet structure may 
result in the delayed elongation of the guanine strand by telomerase.   
 
A huge number of significant investigations support the hypothesis that the formation of 
stable quadruplex structures at the telomeric ends act as negative controls and block their 
extension by telomerase [54]. More directly, several laboratories have reported the 
stabilization of the G-quadruplex structures of telomeric DNA through using various groups 
of drugs which inhibited telomeric elongation by telomerase (Figure 1.13 b). They 
demonstrated that the drugs that can bind and stabilize the G-quadruplex structures of 
telomeric sequences can also block the in vitro action of the telomerase, as well as serve to 
inhibit telomere elongation in vivo and the proliferation of cancer cells [55-57]. In addition to 
its inhibitory effect on telomeric elongation by telomerase, the unimolecular tetrad structure 
was found to diminish the efficiency of the assembly of telomeric complexes by hindering the 















Figure 1.13: Telomere length regulation a) Inhibition of the telomerase enzyme by G-
quadruplex formation at 3' end, which was further stabilized by ligand interaction inhibiting 
further telomere elongation. b) Schematic diagram showing the effects of inhibition of 
telomere elongation [59]. 
 
1.5.4 i-Motif DNA 
The i-motif (Figure 1.14) is a tertiary DNA structure generated by intercalating two parallel 
duplex structures in a head-to-tail fashion, where the strands are connected together through 
hemiprotonated C.C+ pairs. This structure can be generated by the association of a single, 
two or four strands containing four, two or one cytidine repeats, respectively. The 














Figure 1.14: Schematic diagram of the quadruplex and i-motif a) Intramolecular G-
quadruplex structure with a 1/2/1 loop pattern. b) An intramolecular i-motif with a 6/2/6 loop 
pattern [62]. 
 
Although the G-quadruplex structures have been studied extensively with respect to their 
loop structures and folding patterns, as well as their interactions with small ligands or DNA-
binding proteins, comparatively few investigations have been carried out on the i-motif 
structures. A slightly acidic pH favours and guides the interconversion of the C-rich single-
stranded DNA to the i-motif and forms an antiparallel structure [60]. The pH-dependent 
structure is found to be considerably affected by the cytosine base numbers, environmental 
condition and length of the loops [63]. There are diverse potential i-motif structures with 
changed intercalation and looping topologies [64]. It is well known that >40% of all genes 





A different type of B-DNA double helical structure was revealed in 1979 during an 
investigation into the DNA hexamer crystal structure of d(CGCGCG) where the two strands 
were found to be connected by Watson-Crick base pairing in an antiparallel direction, but the 
helix was left handed [66]. Due to the unusual zig-zag backbone, the structure was termed as 
Z-DNA (Figure 1.15 a). The base pairs were flipped upside down because of the rotating 
cytidine moieties and introduced a zig-zag shape in the backbone, leading to the conversion 
of B-DNA to Z-DNA. Additionally, the guanine residues rotated to the syn form from an 
anti-conformation (Figure 1.15 b). On the contrary, the mononucleotide repeat observed in 
the B-DNA had a dinucleotide repeat as the bases alternate in syn- and anti-conformations 
when moved along the Z-DNA sugar-phosphate chains. Alternate purine and pyrimidine 
moieties with d(CG) sequences readily form the Z-DNA because pyrimidine’s preferred anti- 
conformation [67] requires less energy to form Z-DNA.  
 
Although it is difficult to explain in vivo the presence of alternative forms of DNA, as well as 
reveal their biological role, considerable progress has been made for Z-DNA. A number of 
investigations support the existence of Z-DNA in prokaryotic cells, whereas it is complex for 
eukaryotic cells as the negatively supercoiled DNA is organised into nucleosomes [68].    
 
The C-myc gene, when studied using a computer program that scanned the nucleotide 
sequence and calculated the required energy for flipping the various sequences from B-DNA 
to Z-DNA, was demonstrated to contain three regions with high propensity to form Z-DNA 
[69]. In 1992 Schroth and co-workers carried out an extensive compilation and almost 137 
genes were scanned upstream and downstream to determine the most probable position for Z-
DNA-generating elements. The isolation and characterization of Z-DNA-selective proteins 














Figure 1.15: a) Various forms of double helix DNA b) The helix axis of A-, B-, and Z-DNA. 
 
1.6 DNA Replication and the End Replication Problem 
With the complementary structure of genomic DNA solved, the first mechanisms of its semi-
conservative replication (Figure 1.16) were proposed [71]. The semi-conservative replication 
is catalyzed by DNA polymerases in a 5´ to 3′ direction. This results in the continuous 
replication of one strand in the replication fork occurring unhindered, termed the ‘leading 
strand’, while the other ‘lagging strand’ requires significant RNA priming to allow the 
discontinuous synthesis of discrete Okazaki fragments, which are subsequently joined into 
continuous DNA. However, DNA is unable to replace the distal 5´-RNA primer on the 
lagging strand, which once digested results in an 8-12 nucleotide shortening of the 5´-DNA 
strand, affording the 3´-telomeric overhang [72, 73]. It has, however, subsequently been 
observed that the length of the 3´-overhang is greater than that predicted by the ‘end-
replication’ model, suggesting that a level of 5´-exonuclease processing is prevalent in the 
generation of the ~100-200 nucleotide overhang, which often terminates in 5´-CTAACC [74, 
75], and hence the 3´-overhang has a highly conserved part in the function of chromosomes. 
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Telomeric DNA is, therefore, shortened by ~50-200 nucleotides per replication cycle [76],  
suggesting that telomere attrition is linked to cellular ageing acting as a ‘counting’ 
mechanism to account for the limited replicative potential of normal human cells prior to the 











Figure 1.16: Telomere shortening during DNA replication.[78] 
 
1.7 Human Telomere 
Telomeres are protein-DNA complexes (Figure 1.17) present at the end of chromosomes and 
are responsible for genome stability. Human telomeric DNA consists of tandem repeats [79, 
80] of TTAGGG sequences with several kilobase pairs stretching outwards. During DNA 
replication, telomeres are gradually shortened, leading to a critical threshold when DNA 
replication is halted (replicative senescence). Human telomeric DNA forms t-loops (lasso-
type structures) and the 3´ single-strand end invades the double-stranded telomeric DNA 
repeat part [81]. The Shelterin complex (protein factors bound with telomeric DNA) regulates 
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telomere length and protects the chromosome end from DNA damage, recombination, 








Figure 1.17: Schematic diagram of the t-loop structure of the human telomere. Major 
telomere binding proteins are demonstrated here such as Pot1; TRF; TIN2; RAP1.[59] 
 
1.7.1 Telomeric Complex/ Shelterin complex 
Previously, mammalian telomeres were considered to be linear (Figure 1.18 a); however, 
recent research has demonstrated that telomeric ends contain 2 loops composing a duplex 
structure. According to this model, the T-loop is formed through the fold-back of the 
telomere into itself (Figure 1.18 b), whereas a D-loop is generated by the binding of the 3´ 
G-strand overhang with the double-stranded telomere repeat sequence of the 5´-end. The 
formation of these two structures hides the telomere overhang and protects the telomere from 
destruction.  
Researchers have demonstrated that for the integrity and function of the telomere, three 
factors are essential:  
• A minimum length of the TTAGGG repeating sequence  
• Overhang integrity and  
• Telomere-binding proteins regulation [83].  
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The Shelterin complex is a complex structure that brings together three telomeric DNA 
binding factors called TRF1, TRF2 and POT1, although most of the complex contains six 
basic elements: TRF1, TRF2, POT1, TIN2, TPP1 and RAP1 (Figure 1.18 c). The TIN2 
subunit binds simultaneously to TRF1, TRF2 and TPP1, whereas TPP1 joins POT1 with 
TIN2. Lastly, RAP1 is associated with TRF2. Along with this 6-member complex, Shelterin 
(Figure 1.18 d, e) has also been reported to be found as sub-complexes lacking either TRF1 
or TRF2/RAP1. Although the role of these subunits is yet to be identified, the function of 
TRF1, TRF2 and POT1 is well known [84]. 
 
Figure 1.18: Schematic diagram of the Shelterin complex a) Vertebrate telomere containing 
repetitive DNA sequence (5′-TTAGGG-3′)n. b) Formation of t-loop. c) Six-subunits of 
shelterin complex. d,e) Formation of Shelterin complex by binding of six sub-units.[85] 
 
1.8 Telomerase 
For chromosomal stability, a balance between DNA loss and gain is required at the end of the 
telomere and this balance is maintained by the repeat addition of nucleotides by a reverse 
transcriptase enzyme called telomerase [86]. The telomerase enzyme helps in maintaining 
sufficient telomeric length in various cells such as in human stem cells, reproductive cells and 
cancer cells through the addition of TTAGGG repeats, using its own RNA as the template for 
reverse transcription. Almost all human tumour cells have been found to exhibit telomerase 
activity, but not in neighbouring normal cells. Telomere length maintenance is essential for 
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infinite tumour cell proliferation, for avoiding the normal cellular senescence process and to 
become immortal. These cells gain immortality either through activation of telomerase 
enzyme, or through an alternative mechanism that maintains the telomere length. This makes 
telomerase a significant target for developing novel anti-cancer therapeutic agents [87].  
 
The telomere becomes short after avoiding the cell-cycle arrest checkpoint pathway. The 
extremely short telomere is considered as the double strand break and initiates the DNA 
damage response pathway by activating proteins such as Ku, Mrt-2/Rad17 and ATM. These 
proteins cause the homologous recombination/non-homologous end-joining of the 
chromosome. Cells which contain abnormal chromosomes enter into a crisis or the mortality 
M2 stage and start the apoptosis process. In the case of tumour cells, the bypass of these 
stages results in shorter telomeres, triggering the activation of the telomerase enzyme (Figure 
1.19), which maintains a definite telomere length. However, in the case of telomerase 
inactivity, human tumour cells are capable of maintaining their length through alternative 
mechanisms. The stability of the telomere length makes the cell immortal, as these cells can 
avoid the crisis, M1 and M2 phase of the usual cell death process and can divide indefinitely 













1.8.1 Components of human telomerase enzyme 
The telomerase enzyme includes two essential components (Figure 1.20):  
• hTR or hTERC:- Functional RNA component  
• hTERT:- Catalytic protein  
Two essential components constitute the telomerase enzyme. Either hTR or hTERC is the 
functional RNA component that acts as the template for synthesizing telomeric DNA. hTERT 
is the catalytic protein with reverse transcriptase activity [90]. In addition to the template 
region, telomerase RNA (TER) contains various functionally essential secondary structural 
elements, which are involved in protein binding, template restriction and catalytic functions. 
Along with the reverse transcriptase domain, telomerase reverse transcriptase (TERT) 
contains the telomerase-specific part required for TER and DNA substrate binding, as well as 
for telomerase function. The core parts of the enzyme are TER and TERT, which are capable 
enough to provide in vitro functional activity of the enzyme. For in vivo activity several 








Figure 1.20: Schematic diagram of the telomerase enzyme showing its two subunits [90] 
Among these two components, the hTR component is generously expressed in all tissues, 
even without telomerase enzymatic activity, whereas it is found to be five times more 
concentrated in malignant cells than normal cells. On the contrary, the hTERT moiety is 
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found to express at less than 1 to 5 copies per cell, which again is dependent on the cellular 
telomerase enzymatic activity. In normal cells hTERT expression is usually down-regulated, 
which up-regulates into immortal cells, making hTERT as the primary determinant for the 
activity of the enzyme [92]. Because of some baffling factors such as low cellular 
concentration and difficulties in the isolation process in soluble form in measurable 
quantities, structural information about TERT, TER, and other telomerase  proteins  only 
became available in recent years [91]. 
 
1.8.1.1 RNA Subunit (hTR) of Telomerase 
Human telomerase is a long 451 nucleotide RNA (hTR) containing an eleven nucleotide 
templating region (5′-CUAACCCUAAC-3′) found near the 5′ terminal and provides a 
template region for telomere synthesis. RNA polymerase II, in humans, helps the 
transcription of hTR at the 3' end for producing a mature transcript of 451 nts [93, 94]. At the 
5' end, it lays the template for reverse transcription for synthesizing d(GGTTAG) and the 
alignment domain (italicized) [92, 94]. It is suggested that at the 3′ terminal  of the DNA, the 
alignment domain hybridizes and places the telomere for synthesizing the telomeric repeats 
[94]. In this way, it can be said that telomerase RNA plays two roles: provides a binding site 
for RNP proteins, as well as providing a template region which can be copied by TERT in 
telomere DNA sequences [95]. 
 
These RNAs were discovered in a number of phylogenetically different species, including 2 
yeasts, 35 vertebrates and 24 ciliated protozoa (Figure 1.21). Even though these telomerase 
RNAs have different sizes and fundamental structures, all of them contain a pseudoknot 
domain that is similar to the template structure found in ciliate telomerase RNAs, consisting 
of a pseudoknot structure as well as a 3′-terminal hairpin structure containing 148–209 nt, as 
well as being relatively small [95]. In active telomerase, the structurally conserved domains 
demonstrate some particular functions. It has been found that for enzymatic activity  
CR4/CR5 and pseudoknot motifs are essential [94]. In vitro studies indicated that in the 
presence of the protein component, these two motifs can reconstitute telomerase activity [96]. 
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Other studies have shown that the hTERT-binding site containing nucleotide 33–147 and 











Figure 1.21: Schematic diagram representing the secondary structures of ciliate, vertebrate, 
and yeast (Saccharomyces) telomerase RNAs. Green: conserved regions; Dashed lines: these 
parts are not present in all species; Red: template region; Blue: template boundary;  Red 
brackets: putative stem-1of Saccharomyces RNA [98].  
 
1.8.2 Regulating Telomerase Access to Telomeres 
The human telomeric complex helps the cells to differentiate telomeres from degraded DNAs 
and protects the telomere from degradation and fusion. Additionally, the complex structure 
can sense as well as control telomere homeostasis through controlling telomerase enzyme 
accessibility. This DNA-protein complex of telomeres is assumed to convert stochastically 













Figure 1.22: Changes accompanying the cycle of capping (telomerase-inaccessible state) and 
temporary uncapping (telomerase accessible state) of telomeres in dividing cells with 
telomerase [100].  
 
Current studies show that the accessibility of telomerase can be regulated by positive or 
negative ways by telomere binding proteins [101]. The first detected telomeric proteins, 
TRF1 and TRF2, act as negative regulators by forming a t-loop with the duplex telomeric 
DNA. In telomerase-positive cells, telomere elongation is inhibited by the overexpression of 
either TRF1 or TRF2 [102]. Recent research has demonstrated that TRF1 and TRF2 controls 
the telomere length by interacting with the DNA damage repair complex. The TRF1-related 
protein TIN2 and tankyrase also showed negative regulation in maintaining telomere length. 
It has currently been found that the TRF1/Pin2-interacting protein PinX1 acts as a potent 




1.9 Telomere Length Regulation by Alternative Mechanisms  
Several different human cell lines and tumours can maintain the telomere length by 
alternative mechanisms in spite of lacking the telomerase enzyme. These processes are 
termed as alternative lengthening of telomeres (ALT) [104]. ALT can occur in common 
malignancies such as breast cancers. However, this mechanism is most frequently found in 
the tumours of mesenchymal origin, as these cells seem to have a propensity to activate the 
ALT mechanism [85]. It has been observed that ALT-positive cells contain telomeres of 
various length in the nucleus and in the ALT-associated PML bodies (APB) [105, 106]. 
Although there is little information about the exact mechanism, two have been proposed [85]: 
 
• Unequal T-SCE model (Figure 1.23 a): The telomere length is maintained by an 
exchange of an unequal telomere sister chromatid exchange (T-SCEs) process from 
one daughter cell to another, which allows that cell to divide indefinitely and leaves 
the other daughter cell with a short telomere length and reduced dividing capability.  
 
• Homologous recombination-dependent DNA replication model (Figure 1.23 b): 
According to this model, the telomere becomes elongated by synthesizing new 
telomeric DNA through the recombination-mediated process using the existing 




Figure 1.23: Schematic diagram of a) Unequal T-SCE model. b) Homologous 
recombination-dependent DNA replication model [85]. 
 
Increasing evidence indicates that, in mammalian cells, telomere length can be influenced by 
several factors without remarkable changes in telomerase activity. Proteins involved in 
homologous recombination (HR), like Rad54, can act as factors in ALT. Moreover, Rad51D, 
a Rad51 paralog essential for normal gene recombination, has also been found to be needed 
for maintaining telomere length as well as for telomere capping [107].  
 
1.10 Targeting Telomerase for Cancer Therapy 
Substantial research indicates that the telomeric length maintenance provides immortality to 
cancer cells. It has been observed that almost 90% of cancer cells have short telomeres and 
high telomerase activity. In contrast, the apoptotic process is induced with a shortening of the 
telomere due to the loss of telomeric sequences. Therefore, the telomerase enzyme and the 




1.10.1 Inhibiting the Catalytic Activity of Telomerase 
During early tumourigenesis, the reactivation of telomerase and creating a balance in 
maintaining telomeric length are principal steps. Based on the discussion above, it looks very 
reasonable that the telomerase enzyme or the proteins associated with telomere/telomerase 
complex can be targeted by small molecules which can inhibit malignant conversion and/or 
tumour development. The inhibition of the telomerase enzyme may produce site selective, 
novel anticancer drugs with wide spectrum (Figure 1.24). There are numerous possibilities of 
developing inhibitors that will act on the telomere/telomerase complex and a variety of ways 
are presently either under advanced preclinical investigations or in early clinical trials. 
 
Approaches include: 
• Inhibiting telomerase activity through telomerase inhibitor agents leading to 
accelerated senescence and cell death.  
• Eliminating telomerase-expressing cells by immune effectors.   
• Disrupting telomere function by expressing mutant telomerase RNA templates that 




Figure 1.24: Structures of several telomerase inhibitors. (a) GRN163L (1.3), (b) 
BIBR1532 (1.4), (c) BRACO19 (1.5), (d) RHPS4 (1.6) and (e) telomestatin (1.7) [54] 
 
1.11 Targeting the telomere 
Recently, experimental studies have indicated that telomere uncapping leads to rapid cell 
killing (Figure 1.25 b). The uncapping of chromosomal DNA can take place due to damage 
signals near the telomeric overhang and the analogous lagging strand, which can result in 
either rapid apoptosis or genomic instability. Additionally, static telomere conditions due to 
telomere-related senescence and premature senescence can also reduce the lag time to a 
greater extent, compared with telomere shortening by the telomerase enzyme inhibition 
alone. Thus, ligands that focus telomeres directly or uncap it can be more efficient 
monotherapeutic agents that might act more rapidly when compared with ‘pure’ enzyme 
inhibitors (Figure 1.25 a). Both the shortening and uncapping of the telomeres are effectively 
accomplished by telomere targeting agents (TTA), which also inhibit telomerase activity. 
Molecules, targeting particularly the telomeric repeat sequences, are defined as G-quadruplex 
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ligands. These include pentacyclic RHPS4 (1.6), trisubstituted BRACO19 (1.5), acridines, 
ethidium derivatives and cationic porphyrins TMPyP4 (1.32), as well as the natural product 
telomestatin (1.7) [54]. 
 
Figure 1.25: Comparative demonstration of the telomerase inhibition with direct telomere 
targeting. (A) Telomerase inhibition by G-quadruplex-ligands. (B) Inhibition of telomere 
capping by G-quadruplex-ligands [45]  
 
1.12 Telomeric G-Quadruplex Structure 
For targeting the formation of telomeric G-quadruplexes (Figure 1.26 a) clinically, it is 
necessary to understand further the structural features of human telomere in vivo. In recent 
years, much effort has been expanded to investigate further this sequence and this has been 
recently reviewed. 
 
The NMR analysis of a natural sequence with 22-mer (four TTAGGG repeats) demonstrated 
antiparallel topology in a Na+ ion solution  containing a diagonal and two lateral loops [108], 
while the crystal structure of this showed parallel topology containing three strand-reversal 
loops in K+ solution. NMR and X-ray crystallographic analysis of d(T2AG3)2T showed bi-
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molecular parallel topology in K+ solution [109]. The NMR study also revealed an anti-
parallel structure in equilibrium with the parallel structure (Figure 1.26 b). 
 
Figure 1.26: The structures of the intramolecular quadruplex in a Na+ solution, and the 
crystal and solution structure in K+ [56, 110]. 
 
Other variations in the telomeric sequence have shown different structures as determined by 
NMR. Some of these have resulted from the modification of the sequence in order to solve 
the structure. The wide varieties of topologies (Figure 1.27) published for sequences close to 
the human telomere sequence show the dynamic and heterogeneous nature of the human 
telomere quadruplex structure.  
 
More recently, many of the structures published have shown a (3+1) topology (Figure 1.27 
c). The (3+1) quadruplex topology covers those distinctive patterns of (3+1) syn (1.1) and 




Figure 1.27: Diagrams of different human telomeric intramolecular quadruplex structures. 
(a) Antiparallel topology in Na+ solution. (b) Parallel topology of crystal structure in K+. (c) 
(3 + 1) Hybrid topology (form 1) of human telomeric quadruplex in K+. (d) (3 + 1) Hybrid 
topology (form 2) [112]. 
 
A second form of the (3+1) structure (Figure 1.27 d) results from the two lateral loops and 
one side chain reversal loop. This form has mainly been seen in structures where the 3' end of 
the flanking sequence has been altered to include TT. One such structure is that of the NMR 
structure of the sequence d(TAG3(T2AG3)3TT) in a K
+ ion solution[113] in which these two 




Figure 1.28: Schematic diagram of hybrid form of  telomeric quadruplexes demonstrating 
equilibrium between the two forms in a K+ ion solution [45]. 
 
The importance of flanking sequences in all of these structures has been recently reported and 
it is suggested that these sequences have a large influence on the topological structure, as well 
as on the structural stability [112]. 
 
1.13 Non-Telomeric G-quadruplex DNA 
Recent studies have proposed that G-quadruplex structures might have various important 
roles in vivo. Much effort has been expanded in finding the location of other putative 
quadruplex forming sequences within the human gene that have been found, not only in 
human telomeres but also in various genomic loci, with potential roles in oncogene regulation 
by using bioinformatics for human and other genome sequences (Table 1.1) [39, 114]. In 
2005, two surveys of the genome by Huppert & co-workers and Todd et al. estimated that 
there could be, in principle, approximately 376,000 putative quadruplex-generating sequences 
present in the human gene. Higher than average numbers of putative quadruplex generating 
sequences were found in the promoter regions, suggesting that they might have a potential 
role in regulating expression of the gene (Figure 1.30) [39, 114]. Hence, various G-
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quadruplex-forming DNA sequences are located in the promoter regions of oncogenes like 
VEGF, c-myc, bcl-2, Rb, HIF-α, k-ras and c-kit genes, amongst others (Figure 1.29) [30, 31, 
112]. Of particular interest to this work are the two quadruplexes found in c-kit and to a lesser 
extent the c-myc G-quadruplex. 
Figure 1.29: Structures of genomic and related quadruplexes. Quadruplex formed within (a) 
the cmyc promoter sequence, (b) the bcl2 promoter sequence, (c) bimolecular quadruplex 
with extended hairpin loop, (d) c-kit 22-mer quadruplex [112]. 
 
Table 1.1: Nucleotide sequences present in cancer-related genes that can form quadruplex 
structures [31].  
Gene Sequence  
c-myc Pu27 TTATGGGGAGGGTGGGGAGGGTGGGGAAGG 
 Myc-2345 TGAGGGTGGGGAGGGTGGGGAA 
 Myc-1245 TGGGGAGGGTTTTTAGGGTGGGGA 
 Myc-22 TGAGGGTGGGTAGGGTGGGTAA 
 Pu241 TGAGGGTGGIGAGGGTGGGGAAGG 
c-kit c-kit1  CAGAGGGAGGGCGCTGGGAGGAGGGGCTG 
 c-kit2 CCCCGGGCGGGCGCGAGGGGAGGGGAGGC 
VEGF  CCCGGGGCGGGCCGGGGGCGGGGTCCCGGCGGGGCGGAG 
HIF-α  GCGAGGGCGGGGGAGAGGGGAGGGGCGCG 
bcl-2  GTCGGGGCGAGGGCGGGGGAAGGAGGGCGCGGGCGGGGA 
k-ras  GGGAGGGAGGGAAGGAGGGAGGGAGGGA 




















Figure 1.30: The association of the quadruplex generating sequences found in promoter of 
oncogenes and proto-oncogenes with the six hallmarks of cancer [62]. 
 
1.13.1 c-kit 
The c-kit proto-oncogene is expressed into melanocytes, mast cells and hematopoietic stem 
cells encoding 145–160 kDa tyrosine kinase receptors and has a function in cell survival, 
proliferation, and differentiation. Over-expression and/or mutation of the oncogene may be 
the cause of several types of cancer such as gastrointestinal stromal tumours (GIST), 
leukaemia, seminomas, pancreatic cancers and melanoma [115]. Therefore, the tyrosine 
kinase part of c-kit is a significant target for treating GIST.  
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The human c-kit promoter region has been found  to form two different quadruplex 
structures: c-kit1 d(AGGGAGGGCGCTGGGAGGAGGG)[116] and c-kit2 
d(CGGGCGGGCGCGAGGGGAGGGG)[117], which have been proved by biophysical and 
1-D NMR studies [118] and have currently been solved by NMR spectroscopy in a K+ 
solution [119]  (Figure 1.31). c-kit1 has a unique G-quadruplex-forming topology where 18 
of the 22 nucleotides have a tertiary structure. Four loops are present there; two single-
nucleotide double-chain-reversal loops, a two-residue loop and a five-residue d(AGGAG) 
stem-loop that collectively form the complex tertiary quadruplex structure usually not present 
in other simple quadruplexes like the parallel and antiparallel topology of the human 
telomere. However, it might be possible to target the c-kit1 quadruplex for designing 
selective small ligands because of the presence of two well-described clefts, stabilization of 
which will down-regulate the c-kit expression.  The simulation and modelling study 
summarized that c-kit may also be found in a few locations of the human gene; however, the 
probability of playing an important role with these in gene expression is quite low, and this 
again proves the exceptionality of this structure and its appropriateness for designing drugs 
[118, 120]. This unique structure and G-quadruplex-forming sequence may challenge the 






Figure 1.31: NMR structures of the c-kit quadruplex [112, 118]. 
The NMR investigations of the c-kit2 wild type (wt) sequence by Hsu et al. [120] revealed 
the presence of two dynamically different but structurally close populations, suggesting that 
the sequence is structurally heterogeneous. This was evident due to the presence of extra sets 
of resonances in the imino proton area of the NMR spectra. In the presence of K+, the 
modified sequence was shown to adopt parallel propeller topology, including one long loop. 
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The c-kit2 sequence has also been shown to have multiple conformations by FRET, CD and 
NMR, which show both parallel and antiparallel conformations which are dependent on the 
K+ concentration [120]. It has been hypothesized by Hsu and co-workers that the one long 
loop region present in the c-kit2 sequence allows greater conformational heterogeneity [120]. 
 
The c-kit quadruplex-forming sequences may be an attractive target for ligand design (Figure 
1.32). Gleevec (imatinib mesylate) (1.8), a small molecule inhibitor of c-kit, has been found 
to be effective for treating gastrointestinal stromal tumours (GIST)[121]. 3,8,10-
Trisubstituted isoalloxazines (1.10-1.15) are found to bind selectively to c-kit promoter 
quadruplexes and inhibit c-kit expression [122]. In one recent study indenoisoquinolines (1.9) 
have been found to inhibit cell growth in the GIST cell line (GIST882) by inhibiting both c-
kit transcription and KIT oncoprotein levels [123]. Recently, two novel ligands 
benzo[a]phenoxazines (1.16) have been identified to reduce c-kit expression in gastric cancer 
cells by reducing the transcription of the gene, as well as a demonstrated selectivity for c-kit 




Figure 1.32: Structures of some c-kit promoter quadruplex binding ligands [115, 121-123]. 
The various putative G-quadruplex-forming sequences that were recently identified represent 
further interesting targets for drug discovery. However, the huge number of potential G-
quadruplex-generating sequences also highlights an important issue; G-quadruplex ligands 
must be selective for a particular target, as there is a possibility for them to interact with a 
large variety of G-quadruplex targets in vivo. 
 
1.13.2 c-myc 
c-myc is an important oncoprotein and transcription factor that is essential for controlling cell 
growth and the determination of cell fate, including the induction of apoptosis. 
Overexpression and/or mutation of this oncoprotein cause a large number of human 
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malignancies like cervical, colon, breast, and prostate. P1 and P2 are important promoters of 
the c-myc gene (Figure 1.33 a); however, 80–90% of its transcriptional activities are 
regulated by the nuclease hypersensitivity element III1 (NHE III1) (27-base-pair) of the c-









Figure 1.33: (A) The human c-MYC gene promoter structure. (B) The functional role of NHE 
III1 structure  in transcriptional activation or silencing [45]. 
 
The nuclease hypersensitivity element (NHE) III is a 27-bp sequence located -142 to -115 bp 
upstream from the P1 promoter (5'-TGGGGAGGGTGGGGAGGGTGGGGAAGG-3')[50]. c-
myc, containing G-rich sequences, is capable of forming multiple quadruplexes because of 
the negative superhelicity produced during the transcription process and then stabilized by 
monovalent cations, such as K+ and Na+  [124]. Two NMR structures Myc-2345 and Myc-
1245 were identified for c-myc in a K+ ion solution, where each of them contained four G-
tracts and formed stable parallel intramolecular quadruplex structures in solution (Figure 
1.34). The G-tracts are joined through propeller loops and all the guanine bases are in an anti 
(1.2) conformation [51]. The first and third loops in both structures are single-nucleotide 
propeller loops, whereas the central loop in myc-2345 is a GA propeller loop, but that in 
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myc-1245 is a large six-base TTTTTA loop that destabilizes myc-1245 by 16°C compared 
with that of the myc-2345 sequence. The Pu241 consisting of five G-tracts shows unique 
features in the NMR structure. The 3′ terminal G in the last G-tract of P241 folds-back to 
form the G-tetrad and establish an adjacent G-A-G hydrogen-bonded triad, which is placed 






Figure 1.34: Propeller type parallel-strand NMR structures from sequences a) Myc-2345 and 
b) Myc-1245. c) A view of the c-myc complex with TMPyP4 (1.35), showing relevant ligand-
G-quartet distances [51, 112]. 
 
In vivo footprinting methods have shown that the silenced form and the transcriptionally 
active form of the c-myc promoter NHEIII1 are quite different [125]. Recently, it has been 
found that NHEIII1 acts as a silencer element for c-myc transcription and quadruplex 
generation in the promoter region, and is critically important for the transcriptional activity of 
c-myc [50]. Small molecules with binding and stabilizing abilities of this G-quadruplex are 
found to reduce the expression and transcription of c-myc and are anti-tumorigenic. Some of 
the reported ligands that stabilize c-myc G-quadruplex include quindoline derivatives, 
cationic porphyrins, and platinum complexes (Figure 1.35). The aromatic moieties of these 
molecules have shown to π-stack onto the terminal G-tetrad of the quadruplex, giving extra 
stabilization. Their side chains either contain a positive charge or can become protonated with 
biological pH help in forming electrostatic bonds with negatively charged phosphate residues 











Figure 1.35: Schematic diagram representing the regulation of the c-myc gene transcription 
through TMPyP4 (1.35) binding [50]. 
 
1.13.3 G-quadruplex found in other human promoters 
Promoter regions of some other human oncogenes like RET, HIF-1α, VEGF, PDGF-A, 
KRAS, c-MYB and bcl-2 are also reported to contain quadruplex forming sequence in their 
regulatory element and are also found to form intramolecular quadruplexes. The HIF-1α, 
VEGF, KRAS, and RET promoter region quadruplexes were suggested to form parallel 
quadruplexes [45] that were characterized by biophysical analyses like chemical footprinting 
and CD methods [118]. The G-quadruplexes of PDGF-A, with four G-tetrads, were found to 
form a mixed parallel-stranded structure. The bcl-2 oncogene product inhibits cell apoptosis, 
overexpression of which is related to a number of human tumours, such as B and T-cell 
lymphomas, cervical colorectal, breast, lung and prostate carcinomas. The principal promoter 
P1 of this gene, located within the nuclease hypersensitive site, is rich in guanine, and a 39-
bp GC-rich region near the 5'-end of the P1 promoter plays the principal role in regulating the 
transcription of the bcl-2 gene [127]. This 39-mer G-rich strand has six guanine repeats that 
are separated by one or more bases, which are capable of forming various intramolecular 
quadruplex structures [45]. NMR studies of the mixed parallel/anti-parallel bcl-2 
60 
 
unimolecular quadruplex showed that it contains two lateral loops and one propeller loop. 
Putative quadruplex-forming sequences have also been reported to be found in the k-ras and 
neuroblastoma oncogenes [128]. 
 
1.14 RNA G-quadruplex 
In 1990, G-quadruplexes were found in biologically relevant RNA from Escherichia coli 5S 
RNA, which contained a 19-nt oligonucleotide with the sequence UG4U, and was identified 
to form an extremely stable tetrameric aggregate in a K+ solution in vitro[129]. Later on, 
biophysical analysis of the UG4U motif led to the proposal that the quadruplex structure 
contains four G- and one U-quartet, all in parallel directions. Some other studies linked the 
G-quadruplex structures of RNA in viruses like HIV and the Herpes simplex virus with the 
processing and translational control in human transcripts. TERRA (telomeric repeat 
containing RNA) (Figure 1.36), a ~100 to 9000 nt sequence rich in guanine, derived from the 
transcription of a C-rich human telomere strand by RNA polymerase II, is another 
mentionable example which represents the importance of the RNA G-quadruplex. TERRA 
transcripts are found to be involved in chromatin remodelling, as well as in regulating 
telomerase activity [130]. In addition to TERRA, RNA G-quadruplex structures are found at 












Figure 1.36: Different topologies of TERRA RNA G-quadruplexes. (a) A planer quadruplex 
structure formed by hydrogen bonding. (b)  A bimolecular G-quadruplex with parallel 
topology in human telomeric RNA r(UAGGGUUAGGGU) in Na+ solution, (c) in a K+ 
solution and (d) in a K+-stabilized crystal. (e) Parallel topology of human telomeric RNA 
r(UAGGGU) G-quadruplex in K+ and Na+. (f) Two parallel G-quadruplex sub units 
assembling through 5'–5' stacking and (g) through 5'–3' stacking. (h) G-quadruplexes 
arranged in long human telomeric RNA sequences by alternate stacking [110]. 
 
Various biophysical studies have proved that the G-quadruplex structures formed from RNA 
sequences are more stable than their DNA counterparts, and structural explanations have 
been provided by X-ray crystallographic analysis of human telomeric RNA and DNA 
intramolecular quadruplexes [130]. In RNA G-quadruplexes, the hydroxyl groups of ribose 
C2' take part to form a hydrogen bond network through interactions with the backbone 
phosphate and oxygen atoms, sugar oxygen O4' and the H-bond acceptor N2 groups of 
quartet-forming guanines (Figure 1.37). Compared with their DNA counterparts, these 
structures are more stable because of these additional interactions, which not only reduce the 
entropy of the involved water molecules but also decrease the free energy required for the 
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formation of the RNA G-quadruplex. Furthermore, intramolecular DNA tetrads are very 
polymorphic [8, 31], whereas intramolecular RNA G-tetrads prefer to adopt a parallel 
conformation [132-136]. Moreover, in the transcriptome, the concentration of RNA 
quadruplexes might be much more compared with the DNA quadruplexes in genes, due to the 







Figure 1.37: Schematic representation of the intermolecular hydrogen bond formation in 
RNA G-quadruplexes [130].  
 
1.14.1 RNA G-quadruplexes in 5'-UTRs of mRNAs 
Transcribed RNA molecules are less constrained than the genomic DNA that can fold to form 
various intramolecular structures rapidly, which dictate the function and the fate of RNA. 
One specific example is the generation of secondary and tertiary structures within the 5' 
untranslated regions (UTRs) of mRNAs that function in regulating post-transcriptional gene 
expression [130]. Along with the general purine/pyrimidine base pairs, different non-covalent 
interactions, including G-quadruplex generation, are found to exist in 5'-UTRs. Recent 
computational analysis of all 5'-UTRs of the human transcriptome has found ~3000 5'-UTRs 
containing one or more RNA putative quadruplex-forming sequences (PQS), including 
several other proto-oncogenes, which allows us to assume that these quadruplexes have a 






Figure 1.38: G-quadruplexes in the coding strand are transferred to the mRNA and inhibit 
translation [139]. 
mRNA G-quartets were identified to regulate translation into the NRAS proto-oncogene, bcl-
2, the human Zic-1 zinc-finger protein, and the MT3 matrix metalloproteinase [139]. The 
human NRAS proto-oncogene contains an RNA G-quartet within 5'-UTR of the mRNA that 
inhibits translation (Figure 1.39), inferred from the fact that its deletion increased the 
translation efficiency by 3.7-fold [138]. A growing number of studies suggests the existence 
of the RNA G-quadruplex in many mRNAs that might be involved in regulating gene 
translation at various levels, including genes of clinical importance for human diseases. 
Stabilization of this RNA G-quadruplex with numerous small molecule ligands, such as 
RR82 (1.17), RR110 (1.18), 360A (1.19), PhenDC3 (1.20) and PhenDC6 (1.21) (Figure 











Figure 1.40: Chemical structures of some RNA G-quadruplex-binding molecules that inhibit 
the translation of RNA [130] 
 
1.15 G-quadruplexes as a Potential Anticancer Drug Target 
Growing knowledge about the biological importance of DNA and RNA G-quadruplex 
structures (Figure 1.41) has instigated interest into the research and development of G-
quadruplex-binding ligands. Drugs targeting the secondary and tertiary structure of either 
DNA or RNA represent a new approach to the design and development of anticancer drugs; 
the possibilities to target G-quadruplexes for therapeutic purposes were first reported by Sun 
et al. in 1997 [140]. This group proposed that quadruplex-stabilizing agents are capable of 
inhibiting the telomerase enzyme that is excessively expressed and activated in most of the 
malignant cells. Subsequently, PIPER (1.40), the perylene derivative, was discovered to 
facilitate G-quadruplex formation [141], which blocked the Sgs1-derived G-quadruplex 
unwinding [142] and paved the way for the development of G-quadruplex-binding agents. 
After that, numerous categories of small molecules containing diverse chemical features with 
enhanced selectivity and binding affinity were discovered and developed; the search for 
additional active molecules is ongoing. Various methods, including in silico, conventional 
65 
 
screening methods and rational structure-based drug design, are involved in the search for 
better molecules [59], and the structural data of the quadruplexes and quadruplex-ligand 
interactions are playing important roles in designing and developing G-quadruplex-binding 
molecules. G-quadruplex ligands can selectively bind and stabilize various forms of 
quadruplexes that showed related biological activity. For example, telomestatin (1.7) was 
reported as a potent telomerase inhibitor through the formation and stabilization of the 
basket-type telomeric quadruplex [143, 144]. Quarfloxacin® (1.103) has shown promising in 
vivo G-quadruplex binding activity against different types of tumours and is undergoing 
Phase II clinical trials. Again, some other G-quadruplex-interactive molecules with relatively 
low cytotoxicity have become prospective anticancer agents. In fact, G-quadruplex-targeting 












Figure 1.41: G-quadruplex formation during normal cellular events. (a) Protection of the 
telomere by quadruplex formation and the inhibition of the telomerase enzyme. (b) In non-
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telomeric regions, G-quadruplex structures are formed transiently from ds DNA for 
participating in cellular events [145]. 
1.15.1 Common Features of G-quadruplex-interactive Compounds  
Analysis of the ligands demonstrated several clear requirements for ligand-G-quadruplex 
DNA SAR. Hence, maximal DNA G-quadruplex binding agents require: 
 
• A large planar aromatic core for optimal π-π stacking interactions that is larger than 
that required for duplex DNA interactions to be able to afford G-quadruplex DNA 
selectivity. Optimal ligand dimensions will approach~11X11Å for the planar aromatic 
core, consistent with the dimensions of a G-quartet. The introduction of 
heteroaromatic electron-deficient rings may enhance the strength of π-π stacking 
interactions. 
 
• Cationic charge in order to afford water solubility of the large hydrophobic aromatic 
core and allow an electrostatic interaction with the DNA phosphate backbone. 
Cationic charge exists in three current forms: the in situ protonation of tertiary amine 
groups, N-methylation and metal ion coordination. Natural products and their 
analogues are uncharged, with no loss of potency. 
 
Hence, these two simple SAR criteria need to be considered and optimized when designing 
and developing novel G-quadruplex-targeting ligands. 
 
1.15.2 Modes of Interaction of Ligands with G-quadruplex Structures 
Various types of compounds, such as cationic porphyrin (TMPyP4, 1.32), acridine 
(BSU6039), polycyclic acridine (RHPS4, 1.6) and N,N’-bis-[2-(1-piperidino)ethyl]-3,4,9,10-
perylenetetracarboxylic diimide (PIPER, 1.40) were found to interact with G-quadruplexes 
with more specificity [146]. The specific geometry of the G-quadruplexes facilitates ligand 
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recognition through various types of binding modes, similar to that of double-stranded DNA 
intercalators. Three basic types of binding modes (Figure 1.42) are: 
• External Stacking: The stacking of ligands on the outer part of the G-tetrads are 
much more energetically favourable and the most probable binding mode (Figure 
1.42 a). Drugs, such as RHPS4 (1.6) [147] and BSU6039 [148], in their NMR studies, 







Figure 1.42: Schematic diagram representing various binding modes of ligands with G-
quadruplexes through a) external stacking, b) intercalating, and c)  the groove binding mode 
[146]. 
 
• Intercalating: G-quadruplex structures are very stable and rigid; therefore, any 
distortion of the integrity of these structures involves high energy. These features of 
quadruplex structures make it almost impossible for the ligands to show intercalator 
binding (Figure 1.42 b). 
 
• Loops and grooves binding: Several ligands have been found to bind with grooves 
and loops of quadruplex structures instead of π stacking interactions with the DNA 














Figure 1.43: a) 2:1 RHPS4–d (TTAGGGT)4 complex demonstrating the intercalation of the  
RHPS4 (1.6) with the AGGGT core. b) A stacking interaction of BSU6039 (cyan) onto the 
neighbouring G-quartet (blue) [147, 148].  
 
1.15.3 Structural types of G-quadruplex targeting ligands 
Zahler in 1991 demonstrated that K+ ion-stabilized quadruplexes are capable of inhibiting 
telomerase activity [53]. Since then, G-tetrad structures have been targeted for telomerase 
inhibition. There are numerous research groups who are working in this field and are 
searching for small organic molecules capable of binding and stabilizing G-quadruplexes. 
Therefore, these ligands can inhibit either telomerase enzyme activity or G-quadruplex-
related gene expression. Even though some potential and promising molecules have been 
discovered as lead compounds through structure-based design and organic synthesis, a potent 
quadruplex-binding drug is yet to be discovered. Common structural types of G-quadruplex 




• Anthraquinones and related inhibitors 
The symmetric molecule 2,6-disubstituted aminoalkylamido anthraquinone BSU-1051 (1.22) 
(Figure 1.44 a) is the first such quadruplex-interactive ligand with telomerase inhibitory 
activity [140]. The cytotoxic effect of the AQ series has been reduced by designing a series of 
2,7-fluorenone (2,7-FO) (1.23) (Figure 1.44 a) derivatives to prevent redox cycling by 
removing one of the quinone carbonyl moieties [150].  
 
• Acridine analogues 
Rational drug design and molecular modelling led to the development of 3,6-substituted 
acridines (1.24) (Figure 1.44 b). The nitrogen atom of the central ring of the chromophore is 
protonated at a physiological pH, which increases electron deficiency within the 
chromophore, resulting in quadruplex binding. It was also assumed that the pseudo-cationic 
nitrogen atom would increase water solubility compared with the anthraquinone ligands 
[151].  
 
A series of 3,6,9-trisubstituted acridines (1.25) (Figure 1.44 c) were rationally designed and 
synthesized [152] and showed better binding affinity for the quadruplexes due to their 
structural features. A pentacyclic acridine, 3,11-difluoro-6,8,13-trimethyl(8H)-quino [4,3,2-
kl]acridinium methylsulfate (RHPS4, 1.6, Figure 1.44 d), was also found to be a potent 





Figure 1.44: The general structure of G-quadruplex ligands; a) Anthraquinone regioisomers 
(1.22) and 2,7-fluorenones (1.23), b) 3,6-bisamidoacridines (1.24), c) 3,6,9-
trisamidoacridines (1.25), d) RHPS4 (1.6) [146].   
 
• Quindoline analogues 
Four aromatic rings containing tetracyclic chromophore ligands, consisting of a fused five-
membered ring in the middle, have been developed, which give the molecules a crescent 
shape. De-substituted derivatives of the natural product quindoline (1.27, 1.28) (Figure 1.45 
a II, a III) showed more modest activity than the mono substituted benzo[b]naphtho [2,3-
d]furan (1.26) (Figure 1.45 a I) [153-155]. Interestingly, 11 substituted quindolines (1.29) 
(Figure 1.45 a IV) showed better telomerase inhibitory activity than the de-substituted ones, 






• Quinacridine analogues 
FRET assay has shown that the pentacyclic dibenzophenanthroline and quinacridine (1.30, 
1.31) (Figure 1.45 b I, b II) derivatives are capable of stabilizing G-quadruplex structures. 
The aromatic rings in the chromophore are fused in a linear fashion, giving it a crescent 
shape.   
 
Figure 1.45: The structure of G-quadruplex ligands; a) Quindoline analogues, b) 






• Cationic porphyrins and related analogues 
➢ Cationic porphyrins 
The Porphyrin analogues were found to interact with the quadruplex structures, probably 
because of the planer geometry of the aromatic rings (TMPyP4, 1.32, TMPyP2, 1.33) (Figure 
1.46 a, b).  
➢ Pentacationic manganese (III) porphyrin 
A porphyrin analogue, pentacationic manganese (III) porphyrin (1.34) (Figure 1.46 c) with 
one central aromatic core and four cationic arms, showed much more selectivity towards the 
quadruplex structure than the duplex DNA, with a selectivity factor of nearly 10000-fold 
[158].  
➢ Expanded porphyrin 
 A core-modified expanded porphyrin analogue, 5,10,15,20-[tetra(N-methyl-3-pyridyl)]-
26,28-diselenasapphyrin chloride (Se2SAP, 1.35, Figure 1.46 d), has been developed, 
synthesized [159] and identified to bind to c-myc quadruplexes more selectively than duplex 
DNA, as well as other G-quadruplexes.  
➢ Porphyrazines 
By substituting the four benzene moieties in the macrocycle periphery of the porphyrin, new 
non-symmetrical phthalocyanine azo analogues (tetrapyridinoporphyrazines) have been 
devised and synthesized. These molecules are different from the porphyrin cores by having 
individual pyrrole units linked by nitrogen atoms in the meso positions. The pyridyl groups of 
the 3,4-tetrapyridinoporphyrazine (3,4-TPyPz, 1.36, Figure 1.46 e) compounds can be 
methylated to give 3,4-tetramethylpyridinium porphyrazines (3,4-TMPyPz, 1.37, Figure 1.46 
f). Both 3,4-TMPyPz (1.37) and 3,4-TMPyPz zinc(II) (1.38) (Figure 1.46 g) showed strong 
and selective binding affinity towards human telomeric G-quadruplex DNA [160]. 
Octacationic quaternary ammonium zinc phthalocyanine (ZnPc, 1.39, Figure 1.46 h) is 






Figure 1.46: The structure of cationic porphyrins; a) TMPyP4 (1.32), b) TMPyP2 (1.33), c) 
Pentacationic manganese (III) porphyrin (1.34), d) Se2SAP (1.35), e) 3,4-TPyPz (1.36), f) 3,4-
TMPyPz (1.37), g) 3,4-TMPyPz zinc(II) (1.38), h) ZnPc (1.39). 
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• Perylene derivatives 
The polycyclic compound N,N’-bis[-(1-piperidino)-ethyl]-3,4,9,10-perylenetetracarboxylic 
diimide (PIPER, 1.40, Figure 1.47 a) was identified to be suitable for quadruplex binding by 
use of the DOCK programme and found to bind to quadruplexes more specifically than 
duplex DNA.  
 
Figure 1.47: The structure of some perylene derivatives; a) Two side chains, b) Four side 
chains. 
 
• Natural Products 
Another group of molecules that has been investigated as G-quadruplex binders are natural 
compounds and their synthetic analogues, including distamycin [162], berberine and 
berberine derivatives [163-165], and the capping of binding platforms with neomycin. 
 
➢ Telomestatin and its derivatives 
Telomestatin (SOT-095, 1.7), one of the most potent in vitro telomerase inhibitors, was 
extracted from a marine actinomycete Streptomyces anulatus 3533-SV4. The compound 
contains seven oxazole rings and one thiazoline ring [146]. Telomestatin derivatives such as 
macrocyclic hexaoxazole HXDV and bistrioxazole acetate have been reported to be 
synthesized [166, 167]. HXDV (1.43) (Figure 1.48 a I) binds to quadruplex DNA (through a 
non-intercalative “terminal capping” mode) preferentially than to duplex or triplex DNA. 
Bistrioxazole acetates (1.44) (Figure 1.48 a II) were designed based on the telomestatin 
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structure, and contain a macrocyclic bisamide structure, one of which demonstrated 
telomerase inhibitory activity with a telIC50 value of 2 µm. 
 
➢ Berberine derivatives 
Although the antimicrobial activity of the alkaloid berberine (1.45) (Figure 1.48 b I), isolated 
from Chinese herbs, was known for a long time, its telomerase inhibitory activity was first 
reported in 1999 [165]. Later on, 13 substituted berberine analogues (1.46) (Figure 1.48 b II) 
were reported with telomerase inhibiting activity through telomeric G-quadruplex binding 
[164]. Recently, 9 substituted derivatives of berberine (1.47) (Figure 1.48 b III) have been 
found to induce antiparallel quadruplex formation, with stabilization either in the presence or 
absence of metal cations and with a stronger binding affinity than berberine. Their higher 
inhibitory activity against telomerase might be because of the inclusion of methylene units 
and an amino group at the 9 position [168]. 
 
➢ Quinoanthroxazine derivatives 
Although fluoroquinolones like norfloxacin are widely used for their antimicrobial activity, 
some tetracyclic quinolone derivatives showed strong anticancer activity through interactions 
with topoisomerase II. Fluoroquinoanthroxazines (FQA, 1.48, Figure 1.48 c) are 
fluoroquinolone derivatives with extended aromatic rings and have shown binding affinities 
for G-quadruplex DNA by stacking interactions, which might be because of their extended 
phenoxazine ring [146].  
 
• Bisquinolinium compounds 
Bisquinoline-substituted triazines (Figure 1.49a), such as 115405 (1.51) and 12459 (1.49), 
can inhibit the human telomerase enzyme at nanomolar concentrations [169]. Another class 
of bisquinoline analogues (Figure 1.49 a), such as 307A (1.50) and 360A (1.52), were 
synthesized by joining two quinolinium moieties with a 2,6-pyridodicarboxamide unit. The 
central pyridodicarboxamide unit can give the ligand a crescent shape through the generation 
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of syn–syn conformations, by forming internal H-bonds, which favour G-quartet overlaps. 
Based on this, compounds have been reported in which pyridine cores have been replaced by 
bipyridine and phenanthroline (1.53, 1.54) units (Figure 1.49 b), which increased the 
aromaticity of the central core without disrupting the hydrogen bonding capability [170].  
 
Figure 1.48: Structure of some natural quadruplex binding ligands; a) telomestatins (1.43, 




• Biaryl polyamides 
Based on the distamycin scaffold, in 2009 Rahman and co-workers reported a series of new 
biaryl polyamides (Figure 1.49 c) with significant selectivity for quadruplexes over duplex 
DNA and modest selectivity for different quadruplex types [171]. The pyrroles of distamycin 
were replaced with biaryl building blocks in order to switch binding preferences for 
quadruplex over duplex DNA.  The design of the new polyamide constructs positioned the 
biaryl units at either end of the polyamide core, in order to gain ligand diversity. The 
introduction of a biaryl unit significantly altered the classical crescent-shaped structure of the 
molecules, forcing them to adopt a U-shaped scaffold instead.  This alteration in shape 
ensured that the molecules had a lower binding affinity for duplex DNA, while increasing 
their interaction with a G-quadruplex structure, since the ligands have similar dimensions.  In 
contrast to previous attempts to produce quadruplex-selective distamycin analogs [172], these 
biaryl polyamides offer synthetic versatility and significant quadruplex selectivity.  They 
consist of two different structural motifs: Motif-1 (1.55), containing one biaryl unit; and 
Motif-2 (1.56), which has dimers of biaryl units (Figure 1.49 c).   
 
Therefore, given their low molecular weight, good water solubility and excellent cellular 
penetration properties, molecules of this type have the potential to be developed into reagents 
that can probe DNA structure, and/or down-regulate individual signalling pathways in cells 
without the need for microinjection, transfection or electroporation (as is the case with 











1.15.4 Examples of some G-quadruplex Binding Ligands  
Many chemotherapeutic agents (like cisplatin, mitomycin C, chloroethyl nitrosoureas, and 
daunomycin) show non-specific interactions with DNA. Therefore, it has become important 
to develop small drug-like molecules with selective binding affinity for specific secondary 
and tertiary structures in DNA, as well as having site-specific effects, while minimizing side 
effects. Because of recent developments in G-quadruplex research, detailed information about 
their structures, thermodynamic stabilities and potential biological activities are available, 
which makes these structures an interesting target for developing cancer-specific drugs. An 
increasing number of research groups are now working on targeting these G-quadruplex 
structures by developing G4 binding ligands for inhibiting cancer development, depending on 
two mechanisms (Figure 1.50). Firstly, over-expression of oncogenes (c-Myc, c-kit, KRAS, 
etc.) may be repressed by deactivating their promoters. The second approach involves the 
inhibition of the telomerase enzyme that catalyses the synthesis of the 3´-overhang of 











Figure 1.50: Ligand-mediated G-quadruplex stabilization may regulate gene expression 




For the first time, the duplex DNA intercalating agent ethidium was reported to stabilize the 
G-quartet structure generated by d(TTTTGGGG) in a Na+ ion solution [174].  This 
apparently showed a strong binding between the G-tetrad stacks, through intercalation. It was 
suggested that this inhibits the telomerase enzyme, although no further attempts were made to 
prove this. However, recent studies of ethidium binding for different quadruplexes 
demonstrated a weak quadruplex affinity, while also observing a 12-fold greater affinity for 
duplex and triplex DNA [175].  
 
Anthraquinones (1.57) and 3,6-disubstituted acridines (1.61) were the first reported 
telomerase inhibitors. After that, trisubstituted acridines, porphyrins, and triazines were 
synthesised for increased potency [176]. A significantly important molecule of this series is 
BRACO-19 (1.5), a 3,6,9-trisubstituted acridine that was developed and analysed by Neidle 
et al. [177]. Furthermore, 9-[4-(dimethylamino)phenylamino]-3,6-bis(3-
pyrrolidinopropionamido)-acridine inhibited tumour growth both in in vitro and in in vivo 
analysis at less than 1 μM concentrations [173]. The inhibitors interact with quadruplexes by 
π–π stacking and stabilize the quadruplex structures by the electrostatic interaction between 
the positively charged side chains of inhibitors and negatively charged phosphate DNA 
backbone, resulting in telomere complex disruption. BRACO-19 (1.5) has produced some 
potentially interesting results, demonstrating telomerase inhibition as well as telomere 
dysfunction, leading to apoptosis [178]. Another molecule, BRACO-20 (1.60), has 30-fold 
higher affinities for quadruplexes than duplex DNA. Additionally, BRACO-20 (1.60) showed 
telomerase inhibition potential, with an EC50 value of 0.06 µM [179]. Although BRACO-19 
(1.5) stabilized the quadruplex structure effectively, its affinity for duplex DNA (ΔTm=14.5 
°C at 1µM)[180] is comparatively higher than many other ligands, which was a major 
drawback for the progression of the compound towards clinical trials. 
 
Another important family of G-quadruplex-binding ligands is based on the porphyrin 
scaffold, with the original agent TMPyP4 (1.32). TMPyP4 (1.32) inhibits both telomerase 
(IC50 ≈ 0.7–10 μM) and Taq DNA polymerase (IC50 ≈ 2 μM). The process of inhibition of 
telomerase by TMPyP4 (1.32) depends on the chemical groups present at the meso positions. 
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Substitution by pyridinium only at the meso positions was successful in enhancing activity, 
while the other substituents showed no enhancement of activity. However, the structure–
activity relationship analysis demonstrated that, for better porphyrin-DNA binding, two 
forces - base stacking and electrostatic interactions - are important. Although TMPyP4 (1.32) 
demonstrated some good antitumor activity in vivo, it has poor DNA specificity and high 
toxicity. Thus, TMPyP4 (1.32), which binds to every type of DNA with nearly similar 
affinities (Kd ≈ 200 nM), might not be considered as a structure-specific ligand [173]. 
 
Natural compounds such as berberine (1.45, 1.58) and telomestatin (1.7) were reported to 
inhibit telomerase. Telomestatin, (1.7) obtained from Streptomyces anulatus 3533-SV4, 
demonstrated telomerase inhibitory activity at a 5 nM concentration. Structural analysis of 
telomestatin (1.7) revealed the presence of macrocyclic linkages of two methyloxazoles, five 
oxazoles and one thiazoline ring, which helped in the total synthesis of the ligand. 
Telomestatin (1.7) reduced cell growth in vitro as well as in vivo in a number of human 
tumours, such as multiple myeloma, neuroblastomas and leukaemia. Berberine (1.45, 1.58) is 
an antibiotic alkaloid which showed anticancer activity by down-regulating telomerase 
activity through G-quadruplex binding [181]. 
 
Perylenedicarboximides [182] have been found to initiate G-quadruplex structure formation 
and inhibit telomerase according to the side chain basicity and length. The first reported 
molecule of this series was PIPER (1.40), and recently a new series of highly water soluble 
perylenes has been reported, such as DAPER4C (1, 6) (1.41) and coronene (CORON) (1.63) 
analogues with 3/4 side chains containing different basic moieties. Compared with previous 
perylene analogues, all of them showed evidence of improved interactions with quadruplexes, 




Figure 1.51: Examples of some known G-quadruplex ligands [176, 179]. 
 
The success of telomestatin (1.7) as a quadruplex-binding agent encouraged the synthesis of 
several macrocycles containing quinacridine (1.30, 1.31), oxazole (1.59) and quinoline (1.62) 
moieties that were studied as G-quadruplex-binding ligands. Recently, macrocyclic hexa-
oxazoles, which have structural similarities to telomestatin, have been synthesized using a 
similar strategy that combined a planar macrocyclic hexa-oxazole pharmacophore with basic 
side chains. These molecules demonstrated excellent G-quadruplex specificities and act as 
potent telomerase inhibitors in both cell-free and cell-based assay systems [183]. 
 
G-quadruplexes contain planer, square-like, electron-rich π-surfaces that can act as molecular 
recognition targets. Fujita and co-workers have utilized this feature of the quadruplex 
structure for designing supramolecular structures (Figure 1.52) known as the platinum 
“square” complexes. A platinum molecular square [Pt(en)(4,4'-dipyridyl)] (1.64) has been 
reported to be an excellent G4 binding and telomerase inhibiting agent. According to 
molecular modelling studies, the binding affinity of these ligands arises from the square 
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arrangement of the four bipyridyl ligands and the highly electropositive nature of the overall 
complex, as well as hydrogen bonding interactions between the ethylenediamine ligands and 
the phosphates of the DNA backbone [184].   
         
 
 
Figure 1.52: Left: Structure of the platinum molecular square. Right: G-quadruplex and the 
platinum molecule complex [184]. 
 
The metallo-supramolecular cylinders [M2L3](PF6)4 and [M2L3]Cl4 (M=Ni or Fe) (1.65) were 
found to discriminate between DNA duplex and G-quadruplex DNA. The chiral compound 
has a bi-metallo triple helicate structure, and two pairs of enantiomers M and P (Figure 1.53), 
each of which has a hydrophobic surface and a size (length ~18 Aº, diameter ~8 Aº) 
compatible with G-quartets (length ~14 Aº, width ~11 Aº). The P-enantiomer demonstrated a 






















Figure 1.53: (A) Structures of the M (left) and P-enantiomer (right) of [Ni2L3]
4+ cation. (B) 
Structures of the M (left) and P-enantiomer (right) of [Fe2L3]
4+ cation [185]. 
 
A family of urea-based non-polycyclic aromatic ligands with alkylaminoanilino side chains 
has been developed and synthesized as G4 binding ligands. These molecules showed binding 
potential for particular quadruplexes and significant selectivity over duplex DNA. Initial 
biological studies showed cancer cell selectivity for some of the ligands as well [186]. 
 
 
Several 4,5-bis(dialkylaminoalkyl)-substituted acridines (1.66) were synthesized from 
acridine, and their G4-stabilizing potentials were evaluated using various biophysical 
methods. Among the 4,5-disubstituted molecules, the dimethylaminopropyl substituted 
acridine derivative showed significant sub-micromolar TRAP inhibitory activity 
(IC50 = 0.15 μM) [187]. 
 
The naphthalene diimide derivative 1.67 showed high potency against primary tumour GIST 
cell lines. Human gastrointestinal stromal tumours (GIST) usually occur because of mutations 
in the tyrosine kinase receptor of the proto-oncogene kit. Reoccurrence of tumour regrowth 
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happens with imatinib treatment because of the development of resistant mutants in its target 
kinase domain of kit. A naphthalene diimide analogue (1.67) was used to target kit genes 
directly in GIST therapy through kit quadruplex stabilization, and hence kinase resistance 
may be circumvented [188]. 
 
Based on the distamycin scaffold, a new class of biaryl polyamides (1.55 and 1.56) has been 
reported recently by Rahman et al., which has shown high selectivity for the G-quartet, as 
well as having showed potent cytotoxic effects in various cancer cell lines. Their U-shaped 
planer form facilitates more in binding the surface area of the quadruplexes than the grooves 
of double-stranded DNA. These ligands showed potent growth inhibitory activity against 
human colorectal carcinoma (HT29) and human lung carcinoma (A549) lines [189]. 
 
Derivatives of 1,3-substituted symmetrical phenylene bisbenzimidazole systems 
demonstrated prominent effects on quadruplex stability, depending on the types of 
substitution on aromatic skeletons. Two isomeric bisbenzimidazole-based compounds, p-
Phenbbim (1.69) and m-Phenbbim (1.68), were designed and synthesized, both of which 
stabilized the quadruplex structures. The G4 binding ability of these compounds depended on 
the shape of the molecules. As an example, the linear isomer was found to stabilize the Na+-
induced intramolecular quadruplex, while the V-shaped isomer showed structural transition 




Bis-phenanthroline (bis-Phen) ligands (1.70) containing two Phen moieties covalently linked 
through an amine or thioether bond have been found to recognize different G-4 structures. 
The transition metal ions Mn2+, Ni2+, Cu2+, and the biologically relevant Mg2+ and Zn2+, 
efficiently form 1:1 bis-Phen complexes with a large planar structure capable of recognizing 
the G4 structures. These complexes induce quadruplex formation from linear G-rich 
sequences, and are also effective telomerase inhibitors, with the Ni(II) complexes being 
effective in the sub-micromolar range [191]. 
86 
 
It has also been found that some phthalocyanines bind to G4 structures with a high affinity 
and selectivity due to the presence of a large π planar structure and bulky cationic groups. 
Water-soluble octacationic zinc phthalocyanine (ZnPc) (1.41) has been found to be an 
excellent G4 stabilizer and telomerase inhibitor [161]. Although cationic ligands have a great 
advantage in terms of cell permeability, it may not be possible to fully eliminate the 
electrostatic interaction between the cationic groups and dsDNA of cell nuclei; this can be 
solved by making the ligand non-ionic or anionic. Telomestatin, a non-ionic ligand, can bind 
to telomeric G-quadruplex structures with high selectivity, but has less solubility. On the 
other hand, only a few anionic molecules were analysed for their binding ability to G-
quadruplexes and subsequent telomerase inhibitory effects. However, one anionic copper 
phthalocyanine (Cu–APC) (1.71), containing four sulfonic groups, has been shown to bind to 
telomere G-quadruplexes with high selectivity [192]. 
 
More recently, a pair of furan-based cyclic homo-oligopeptides (1.72) has been reported to 
specifically target G-quadruplexes. These ligands induced G4 formation effectively in a 22-
mer c-MYC DNA sequence and also stabilized that structure. It has a high affinity for 
quadruplex structures without showing any affinity for duplex DNA, demonstrating 
selectivity for G-quadruplex structures. Moreover, these ligands caused apoptosis in HeLa 
cells by down-regulating up to 90% of the c-MYC transcripts. Therefore, these molecules 






































Figure 1.54: The structure of a) some 4,5-bis(dialkylaminoalkyl)-substituted acridines (1.66), 
b) naphthalene diimide derivatives (1.67), c) m-Phenbbim (1.68), d) p-Phenbbim (1.69), e) 
bis-phenanthroline ligands (1.70), f) anionic copper phthalocyanine (Cu–APC) (1.71), g) 
furan-based cyclic homooligopeptides, ligand 1 and ligand 2 (1.72), h) TSIZ01 (1.73), i) 




Recently, an acridine based triaryl-substituted imidazole derivative TSIZ01 (1.73) has been 
reported as a new potential quadruplex binding and stabilizing ligand. TSIZ01 (1.73) 
exhibited a high level of selectivity for telomeric quadruplexes (F21T) rather than duplex 
DNA (F10T). According to the FRET melting assay, TSIZ01 (1.73) stabilized the human 
telomeric G-quadruplex (F21T) effectively with a ΔTm value of 23.5 °C at 1 µM 
concentration compared with the duplex hairpin DNA (ΔTm = 2.7 °C at 1 µM). When the 
concentration of the compound was raised to 3 µM, it stabilized the quadruplex more, with an 
increase in the melting temperature (ΔTm) to 32 °C. Moreover, the quadruplex selectivity of 
the compound was further established through FRET-based competition assays, which 
showed that the thermal stabilization of F21T by the compound was still retained even with 
the addition of a 15-fold excess of duplex DNA competitors. Again, TSIZ01 (1.73) has a 
higher binding affinity towards the quadruplex DNA with an equilibrium binding constant 
(KA) value of 2.19 X 106 M-1, which is 8.7-fold higher than that of duplex DNA (KA = 2.51 
X 105 M-1). All these studies established that TSIZ01 (1.73), with good stability, has good 
selectivity for telomeric G-quadruplex DNA, along with potent binding and stabilizing 
activity [194]. 
 
A series of 2-phenyl-benzopyranopyrimidine (PBPP) derivatives with alkylamino side chains 
was reported for the first time as a new class of highly selective G-quadruplex ligand. In 
addition to the rotatable C-C single bond between the benzopyranopyrimidine moiety (1.74) 
and the phenyl group, which allows various conformation, the PBPP structure forms an 
intramolecular  hydrogen bond, improving the planarity of the molecule due to enhancing the 
π-delocalization. The cationic amino side chains enhanced the G-quadruplex binding potency 
through an interaction with the grooves and loops of G4 structures, as well as its aqueous 
solubility. All the results obtained from the biophysical analyses demonstrated that de-
substituted PBPP derivatives have a stronger G-4 binding affinity and stabilizing potential, as 
well as more selectivity over duplex DNA than the mono-substituted derivatives. 
Furthermore, compound 11b (1.75) (ΔTm= 16.5 °C and KD= 4.5 for telomeric G-quadruplex, 
and ΔTm= 0.4 °C for duplex DNA) was identified as the most promising telomerase inhibitor 




Depending on bis(phenylenethynyl) amides (1 and 2) (1.76, 1.77), two novel G-quadruplex 
ligands 1,2,3-triazole-linked diethynylpyridine amides (3a-c) (1.78, 1.79, 1.80) and 
trisubstituted diethynyl-pyridine amides (4a,b) (1.81, 1.82) have been reported by Dash and 
co-workers to exhibit enhanced binding potential to  both G4s and specificity promoter G-
quadruplexes, compared with the first generation of diaryl-ethynyl amides. The parent 
molecules contain N,N-dimethyl-propylamine side chains and are conformationally flexible 
due to free rotation around the triple bond. The best first generation molecule, 2 (1.77), was 
modified to generate 1,4-triazole-linked amides (1.78, 1.79, 1.80) and trisubstituted amides 
(1.81, 1.82) in order to get an improved binding ability as well as differential recognition of 
these molecules towards various classes of G-quadruplex sequences. Compared with other 
molecules, 3a (1.78) and 4a (1.81) were found to have greater selectivity for the G-
quadruplex than the duplex DNA. Among the bis-triazole ligand series, 3a (1.78), having 
primary amino groups, showed the highest degree of stabilization, with ΔTm values of 17.1, 
11.8, 20.0, 16.5 and 0.7 °C for k-ras, c-myc, c-kit1, c-kit2 quadruplexes and duplex DNA, 
respectively, at  a 1 µM ligand concentration, whereas the trisubstituted ligand with N,N-
dimethylamino side chains, 4a (1.81), showed the best G-quadruplex stabilization potential in 
this series, showing nearly the highest measurable ΔTm values for c-myc and c-kit2 
quadruplexes by Förster Resonance Energy Transfer (ΔTm = 17.0 and 21.8 °C at 1 µM, 
respectively). Ligand 4a (1.81) also exhibited stronger stabilization for k-ras (ΔTm = 33.0 




Figure 1.55: Structure of bis(phenylenethynyl) amides (1 and 2) (1.76, 1.77), 
diethynylpyridine amides (3a-c) (1.78, 1.79, 1.80) and trisubstituted diethynyl-pyridine 
amides (4a,b) (1.81, 1.82) [196].  
 
Cell based assay and biophysical analysis have shown that two benzo [a] phenoxazine (BPO) 
derivatives (BPO-1, BPO-2) (1.83, 1.84) bind to the G-quartet sequences of the gastric 
carcinoma cell (HGC-27) c-KIT promoter with a high affinity, and reduce the transcription of 
the luciferase reporter, as well as down-regulate endogenous c-KIT expression. Both of them 
contain an N-(3-dimethylaminopropyl) amino carbonyl side chain at the 11 position of the 
BPO moiety. These ligands have a stronger affinity for c-kit2, having Kd values of 1.0 ± 0.3 
and 1.1 ± 0.3 µM for BPO-1 (1.83) and BPO-2 (1. 84), respectively, than c-kit1 (Kd = 9.6 ± 4 
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µM for 1 and 8.3 ± 0.1  µM for 2), resulting in a 9.6- and 7.5-fold preference for binding c-
kit2 over c-kit1, for 1 and 2, respectively. BPO-1 (1. 83) showed a 10-fold higher Kd value for 
double–stranded DNA binding compared with c-kit2 (Kd = 9.8 ± 1.7 µM), whereas no 
binding of BPO-2 (1. 84) with dsDNA was detected. These data are easily comparable with 
the previously reported c-kit binding ligands such as trisubstituted isoalloxazines (Kd ranging 
from 2.8-9.7 µM), triarylpyridines (Kd ranging from 0.2-25 µM) and oxazole-based peptide 
macrocycles (Kd ranging from 4-31 µM). Again, BPO-2 (1. 84) was found to reduce the c-
KIT mRNA expression in the range of 2.6-3.5-fold, whereas BPO-1 (1. 83) showed a time-
dependent response with a maximum reduction of 2.9 fold at 24 h, compared with the control. 
Moreover, these compounds have a good aqueous solubility, less cytotoxic effects and easy 
synthetic routes [197]. 
 
 
Figure 1.56: Structure of BPO-1 (1. 83) and BPO-2 (1. 84) [197]. 
 
A series of novel quinoline-benzo-[5,6]- dihydroisoquindolium (QBDI) compounds (3a, 3f, 
3g, and 3j) (1.85, 1.86, 1.87, 1.88), derivatives of the natural alkaloid berberine, showed an 
enhanced binding affinity and selectivity for the tetrad structures of c-myc and illustrated 
good inhibition of the c-myc transcription into tumour cells but not into normal cells. These 
compounds contained a hexacyclic ring system, having one additional pyridine ring and 
amino acid on the barberine scaffold, expanding the aromatic planer surface of barberine 
(1.45), resulting in enhanced quadruplex-stabilization ability and binding selectivity. The 
compounds demonstrated an effective stabilization of c-myc quadruplexes, with ΔTm values 
ranging from 20 to 29 °C, whereas the compound 3j (1.88) had the highest ΔTm value of 29 
°C and derivative 3a had a value of 20 °C, both of  which were higher compared with the 
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reference compound barberine (1.45) (ΔTm = 1 °C). Furthermore, FRET-based competition 
assays of these derivatives proved their selectivity towards G-quadruplexes over duplex 
DNA. Subsequent bioassays indicated that 3j (1.88) down-regulated c-myc transcription and 
inhibited lymphoma cell growth, but did slightly affect the healthy cell [198].   
  
 
Compound n R 
3a (1.85) 2 N(CH3)2 
3f (1.86) 3 N(CH3)2 
3g (1.87) 3 morpholyl 
3j (1.88) 6 NH2 
 
Figure 1.57: The structure of QBDI compounds [198]. 
 
 From Clausena harmandiana and C. excavata, several carbazole alkaloids have been 
isolated and reported to have significant cytotoxic activity against cancer cell lines. Recently, 
3,6-bis(1-methyl-4-vinylpyridinium) carbazole diiodide (BMVC) (1.89), a carbazole 
derivative, has shown good G-quadruplex stabilization with a ΔTm of 13 °C, as well as 
showing telomerase inhibitory activity. Based on this carbazole chromophore, a series of 1,8-
dipyrazolcarbazole (DPC) derivatives (6a–6d, 7a–7d) (1.90, 1.91) have been designed, which 
contained two pyrazole groups to have better π-π stacking interactions with the G-
quadruplex. These molecules form intramolecular hydrogen bonds, improving molecular 
planarity through increased π-delocalization and the cationic side chains, which could interact 
with the grooves and loops of the G-quadruplex; this may be effective for selective binding 
with the G-quadruplex, as well as its aqueous solubility. These molecules have been reported 
to interact more selectively with c-myc G-quadruplexes than telomeric G-quadruplex 
structures, and RT-PCR analysis has proven that,  from this series, 7b can down-regulate c-
myc expression in the Ramos cell line, but not in the CA46 cell line with the NHE III1 






Figure 1.58: The structures of BMVC (1.89) and DPC derivatives (1.90, 1.91) [126]. 
 
Recently two naphthalene derivatives, N,N′-bis[3-[3-(2,2′-dipicolyl)methylaminopropyl]-
methylaminopropyl]naphthalene-1,4,5,8-tetracarboxylic acid diimide (1) (1.92) and its zinc 
complex (2) (1.93) have been analysed against two telomere sequences, 
[TAGGG(TTAGGG)3] and [AGGG(TTAGGG)3]. Various biophysical analyses have proven 
that these ligands have higher binding affinities for hybrid-type quadruplex structures formed 
in a K+ ion solution. Moreover, analogue 2 (1.93) showed a higher binding affinity towards 
the investigated oligonucleotides over compound 1 (1.92), suggesting that the Zn2
+complex 
of the naphthalenediimide derivative facilitated additional electrostatic or coordination 
interactions between positively charged zinc ions and the negatively charged G4 DNA [199]. 
 
High-throughput virtual screening has been used recently to identify the natural product 
carbamide (1.94), which stabilized the c-myc G-quadruplex. This compound contains the 
sesquiterpene lactone skeleton, where a diphenyl ether unit and a tetracyclic moiety are 
linked through urea moieties. These classes of molecules were known for their anti-
inflammatory activity, but biological analysis of the carbamide against the c-myc G-
quadruplex showed transcriptional inhibition of the c-myc gene by inhibiting the Taq 
polymerase-mediated DNA extension and stabilizing the c-myc promoter G-quadruplex 
activity. Some other analogues (analogues 1- 5) (1.95-1.99) were designed and synthesized to 
establish the SAR of the molecule. Analogues 1 (1.95) and 3 (1.97) showed moderate 
activity, whereas analogue 2 (1.96) showed lower activity compared with carbamide. 
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Furthermore, analogues 4 (1.98) and 5 (1.99) showed no activity against the c-myc G-
quadruplex [200].  
 
Figure 1.59: The structure of a) Naphthalenediimide derivative, b) Carbamide (1.94) and its 
analogues [199, 200]. 
 
The new Ru(II) complex [Ru(bpy)2L](ClO4)2 (bpy = 2,2′-bipyridine, L = 1,10-
phenanthrolineselenazole) (1.100) was reported to bind selectively and change the steric 
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configuration of the G-quadruplex DNA of the 5′-AG3(T2AG3)3-3′ sequence. Furthermore, 
this complex was found to inhibit telomerase by stabilizing the quadruplex by 11 °C [201]. 
Rahman and co-workers have reported, for the first time, the quadruplex binding and 
stabilizing ability of a prenylated dioxopiperazine alkaloid, Cristatin A (1a/b) (1.101, 1.102). 
This molecule, previously known as an immunosuppressive agent, represents a novel series 
of G-quadruplex binding ligands and stabilized human telomeric G-quartet with ~10 times 
more selectivity than the duplex DNA. Moreover, it has the capability to differentiate 
between various G-4 structures. More importantly, this molecule contains more drug-like 
features compared with previously reported compounds, and represents a new scaffold for 
further exploration [202].   
 
Figure 1.60: Structure of a) Ru(II) complex (1.100), b) Cristatin A (1.101, 1.102) [201, 202]. 
The G-quadruplex binding capability and selectivity for the quadruplexes over duplex DNA 
is insufficient for the ligands to be therapeutically effective. The ligand needs to have the 
ability to discriminate between different quadruplex structures and should bind to one 
topology in the presence of others, which might be very challenging, as there are very few 
recognition points for discriminating between different G-quadruplex structures. Although 
various target sites like loops and grooves along with the quartet structure were considered 





Laurence Hurley and his group designed quarfloxin (1.103) (Figure 1.61) from the G-
quadruplex-interactive fluoroquinolones and it is the first drug currently in Phase II clinical 
trials for treating neuroendorine tumours as a single agent therapy. Quarfloxin (1.103), 
because of its wide therapeutic window and in vivo efficacy against a wide variety of 
tumours, is going to be in additional Phase II trials [204]. Quarfloxin (1.103) has been found 
to be highly selective towards ribosomal DNA (rDNA) over duplex DNA (400-fold 
selectivity) and selectively enters the nucleolus in cancer cells, resulting in a low level of 
toxicity [205]. Moreover, quarfloxin (1.103) has shown higher selectivity for the 
quadruplexes in c-myc promoters than other quadruplex structures, as well as duplex or 
single-stranded DNA. Quarfloxin (1.103) lacks topoisomerase-II and -I poisoning activities 
and has shown potent and tumour-selective activity both in vitro and in vivo.  
 











1.16 The Aim of this Study 
The overall goal of the project is to exploit the recent structural information on human 
telomeric DNA (in particular c-myc and c-kit quadruplexes) to guide the rational design of 
quadruplex-specific small molecule ligands. Based on the promising quadruplex-selectivity 
observed for the reported biaryl polyamides [189], the main objective is to synthesize 
libraries of novel ligands based on this template that have enhanced the selectivity and 
binding affinity for quadruplex versus duplex DNA, and selectivity for quadruplexes of 
different types within specific oncogene sequences, in order to gain an understanding of 
structure-activity relationships for molecules of this type.   
 
The specific objectives are as follows: 
• To synthesise novel G-quadruplex targeting ligands using a variety of chemical 
approaches. 
• To evaluate the new molecules using FRET-based DNA thermal denaturation assays 
(including duplex competition), CD and surface plasmon resonance (Quantity binding 
affinities and kinetics) for determining their affinity and selectivity for a particular 
quadruplex, such as the parallel G-quadruplexes found within the c-kit and c-myc 
oncogene promoters.   
• To evaluate the novel ligands for cytotoxicity in short and long term assays in tumour 
cell lines. 
• The subsequent use of the results to compare the newly synthesized ligands with those 
previously synthesized to obtain structure activity relationships (SARs). SARs should 




Chapter Two: Experimental techniques for the investigation of G-
quadruplex/ligand interactions 
2.0 Biophysical and Biological Techniques for the Investigation of G-quadruplex 
Ligands 
2.1 Biophysical techniques 
A large number of methods are available to study the interaction between natural and 
synthetic ligands and the G-quadruplex structures. Some of the methods are very simple, 
employed for analysing properties like ligand affinity and selectivity, while some others are 
sophisticated and complex, analysing kinetics, thermodynamics, stoichiometry and 
conformational data for establishing structure activity relationships. The main focus of 
designing quadruplex ligands is the selectivity of the ligand towards quadruplexes over 
duplex DNA; hence the analysing methods used should be able to detect and investigate the 
selectivity of the ligands for various types of quadruplex structures and other secondary 
structures, as well as their binding modes. Each method has its own advantages and 
disadvantages; therefore, to get complete information about G-quadruplex/ligand interactions, 
more than one method is usually used. Here, some of the common methods are discussed.     
 
2.1.1 Optical spectroscopic methods 
Optical spectroscopic methods were used for recognizing double-stranded DNA previously, 
but, at present, these methods have been adapted for analysing quadruplex nucleic acids. 
Among other methods, C (UV-Vis), circular dichroism (CD) and fluorescence spectroscopy 
are preferred, as these methods are rapid, need small sample amounts and are non-destructive, 
as well as these instruments being routinely available in laboratories. Generally, melting 
temperatures are measured, which provides information about the stabilization or 
destabilization of the quadruplex structure by the ligand under investigation. Besides, these 




2.1.1.1 UV-visible (UV-Vis) Spectroscopy 
The UV-visible (UV-Vis) spectroscopic method is probably the simplest and the most 
commonly used method to obtain information about the stability of the G-quadruplex 
structure and its interaction with the ligands. 
 
Generally, ligands show an absorption band that can be clearly observed in the visible range. 
Therefore, by analysing the shift of position of the maxima for this band for the unbound and 
bound ligand in solution, it is possible to investigate the interaction of the ligand with the 
DNA, and the magnitude of this shifting gives an idea about the strength of the interaction. 
Similar analysis can be performed with quadruplex/ligand interactions. Additionally, with the 
qualitative information, quantitative information such as stoichiometries and binding 
constants can be determined by performing titration of the DNA with the ligands and vice 
versa. There are various examples (Figure 2.1) which utilize this method to study 
quadruplex/ligand interactions [206].  
Figure 2.1: An example of the titration of a ligand with a G-quadruplex structure monitored 
by UV-visible molecular absorption. a) Experimental data obtained upon the titration of 
TMPyP4 (1.32) porphyrin with k-ras, inset: fit of the experimental data to the proposed 
model at 445 nm, b) distribution diagram and c) spectra of the recovered species using 
multivariate analysis [206]. 
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Thermodynamic parameters of the G-quadruplex/ligand interactions can be calculated from 
UV-monitored melting experiments where the melting temperature and the thermodynamic 
parameters are determined from the change in absorbance as a function of temperature. Due 
to π-stacking of the bases in duplex DNA, the UV absorption of nucleic acid is usually 
greatly reduced from 260 nm, which is again recovered upon thermal denaturation. This 
simple denaturation experiment by heating is commonly performed to investigate the 
stabilization and destabilization of double-stranded DNA by the ligands. This same method 
can be used for quadruplex DNA, but the absorbance is measured at 295 nm instead of 265 
nm, where it shows maximum absorbance. At this wavelength, the transition is inverted 
compared with the classical duplex melting profile. This is a simple method, since sample 
preparation is easy and requires small sample amounts. The association of ligands with the G-
quadruplex structure increases the melting temperature, and G-quartet dissociation leads to a 
decrease in absorbance [28]. UV spectroscopy has been used for the kinetic investigation of 
various G-quadruplex structures and the binding of ligands to G-quadruplex structures. 
 
2.1.2 Circular Dichroism (CD) Spectroscopy        
The CD spectroscopy method has become one of the most essential techniques for studying 
the G-quadruplex structure and G-quadruplex/ligand interactions. It measures the 
conformational changes in the DNA structure that are induced by modification of the 
environment, such as temperature, the nature and/or concentration of counterions, pH or the 
addition of crowding agents, in addition to chemical modifications. Titrations of 
quadruplexes with the quadruplex-binding ligands induce changes in the conformation of the 
quadruplex structure, which can be correlated with the characteristics of the ligands under 
investigation. 
 
CD measures the differences in the way that a sample interacts with the left handed and right 
handed polarised light. Chiral molecules act differently with the left handed and right handed 
polarised light, leading to a change in the absorbance spectrum. The conformation of the 
quadruplex structures can be roughly determined from the position and magnitude of CD 
bands by comparison with those of known structures in solution. A positive band in the CD 
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spectrum at 260 nm is assigned to a parallel quadruplex structure, such as the four stranded 
intermolecular quadruplexes formed by the sequence d(TTGGGGT), while a positive band at 
290 nm and a negative band at 260 nm is considered for antiparallel conformation, which was 
formed by dimers of the thrombin binding aptamer sequence d(GGTTGGTGTGGTTGG) or 
d(GGGGTTTTGGGG) [207]. These reference sequences were assessed by CD by Bolton and 













Figure 2.2: The CD spectra of the four reference quadruplex DNAs [207]. 
CD spectroscopy can be used for monitoring the thermal unfolding of the quadruplex 
structures by plotting the measured ellipticity at the wavelength corresponding to the 
maximum of a positive band (around 260 nm for parallel structures or 288 nm for antiparallel 
structures) versus temperature [206]. Furthermore, CD can be used to study the G-




2.1.3 Molecular Fluorescence 
Other than molecular absorption and CD spectroscopy, molecular fluorescence is probably 
one of the most commonly used techniques for studying G-quadruplex/ligand interactions. 
This technique is highly sensitive, has a wide concentration range and is more selective than 
the other methods. For studying G-quadruplex/ligand interactions, several approaches of 
molecular fluorescence are used.   
 
2.1.3.1 Fluorescence Spectroscopy 
The fluorescence spectroscopic method is used to study the folding pattern of the quadruplex 
structures. In this dye–quencher pairings method (Figure 2.3), synthetic oligonucleotides 
containing a fluorophore dye, such as fluorescein at one end and a fluorescence quencher like 
dabcyl or methyl red at the other end, are used. Folding of the oligonucleotide in a preferred 
configuration brings the dye and quencher group close to each other, resulting in quenching 
of the fluorescence. Separation of the groups, due to the melting of the oligonucleotide at 
increased temperatures, increases the fluorescence signal. This technique is routinely used to 






Figure 2.3: A typical fluorescence melting profile. Schematic representation of the melting 
of a quadruplex-forming oligonucleotide that has been labelled with a fluorophore (green) 




2.1.3.2 Fluorescence Resonance Energy Transfer (FRET) assay 
Fluorescence Resonance Energy Transfer (or FRET) is a physical phenomenon first 
described over 50 years ago and is widely used today in biomedical research and drug 
discovery. FRET is dependent on the transfer of energy from a donor molecule to an acceptor 
molecule in a non-radioactive way, which is based on the distance between the donor and 
acceptor. As it is sensitive to distance, FRET has been used to investigate molecular 
interactions. The donor molecule is the dye or chromophore that initially absorbs the energy; 
the acceptor is the chromophore to which the energy is subsequently transferred. This 
resonance interaction occurs over greater than interatomic distances, without conversion to 
thermal energy, and without any molecular collision. The transfer of energy leads to a 
reduction in the donor’s fluorescence intensity and excited state lifetime, and an increase in 
the acceptor’s emission intensity. A pair of molecules that interact in such a manner that 
FRET occurs is often referred to as a donor/acceptor pair. 
 
For efficient FRET to occur, the donor and acceptor molecules must be in close proximity to 
one another and typically in a 10-100Å range, as well as the condition that the absorption or 
excitation spectrum of the acceptor must overlap with the fluorescence emission spectrum of 
the donor (Figure 2.4 b). The degree to which they overlap is referred to as the spectral 
overlap integral (J). The donor and acceptor transition dipole orientations must be 
approximately parallel. If the donor-acceptor pairs are compatible, the most critical element 
necessary for FRET to occur is the close proximity of the pairs. Förster demonstrated that the 
efficiency of the process (E) depends on the inverse sixth-distance between the donor and 
acceptor (Equation 2.1) [210]. 
 
E = Ro6/(Ro6 + r6)      Ro= Förster distance 
                                                                       r= Actual distance between donor and acceptor 
 
 






Figure 2.4: a) Jablonski diagram illustrating the FRET process, b) Absorption and 
fluorescence spectra of an ideal donor-acceptor pair. The brown coloured region is the 
spectral overlap between the fluorescence spectrum of donor and the absorption spectrum of 
the acceptor. 
 
Usually, the donor and acceptor molecules are different, and either by the appearance of 
acceptor fluorescence or by quenching of fluorescence of the donor can FRET be detected. A 
fluorescent molecule is always chosen as the donor moiety. With appropriate excitation, 
electrons from the donor moiety jump from the ground state (So) to a higher vibrational level 
and within picoseconds these electrons come back to the lowest vibrational levels (S1), which 
eventually decay back to the ground state (So) by emitting a photon of light. When conditions 
for FRET to occur are met, decay as donor fluorescence and energy transfer to the acceptor 
will compete for the decay of excitation energy. With resonance energy transfer, the energy 
(rather than the photon) is transferred to the acceptor molecule, whose electrons in turn 
become excited, as described for the donor molecule. The subsequent return to the ground 
state emits a photon (Figure 2.4 a). 
 
The ‘FRET melting assay’ utilizes this basic principle where the increase in temperature 
leads to the denaturing or melting of the macromolecule, causing the distance between the 
105 
 
probes to increase, leading to an increase in fluorescent energy. The technique has been found 
to be very useful to investigate various types of nucleic acid structures [211];  however, 
availability of suitable labelled substrates limits its use in biological systems. However, this is 
not a problem for studying quadruplex DNA stability, as synthetic DNA is usually used for 
all analysis relating to G-quadruplex formation and labelled oligonucleotides can be obtained 
easily [209].   
 
Mergny and co-workers first used this FRET technique in 2001 for investigating the G-
quartet structures [212]. A synthetic oligonucleotide containing a FRET pair on both the 5' 
and 3' end of a suitable Förster diameter was used, which, upon folding, brought the donor 
and acceptor moieties close to each other for efficient FRET to occur (Figure 2.5 a). 
Sometimes, energy can be transferred to the acceptor from the donor by collision due to the 
close proximity of the moieties, resulting from the generation of a G-quadruplex structure 
[209]. The unfolding of the oligonucleotide results in a loss of FRET, as the donor-acceptor 
pair is too far apart to transfer any energy (Figure 2.5 b). The melting of G-quadruplex-
ligand structure can be monitored by carefully choosing the pair so that they provide different 
fluorescence absorbance/emission spectra for folded and unfolded structures.    
 
To conduct the FRET melting assay in our research, we selected the fluorescent dye 
‘fluorescein’ (FAM, 2.1) at the 5' end as donor and ‘tetramethylrhodamine’ (TAMRA, 2.2) 
(Figure 2.6) at the 3' end as an acceptor dye and a single stranded guanine rich nucleotide 
chain containing 21-bases as our quadruplex-forming oligonucleotide (QFO). Using the 
FRET system distance between the donor (FAM, 2.1) and the acceptor (TAMRA, 2.2), 
moieties can be measured in terms of the fluorescence of the donor (FAM, 2.1). At low 
temperatures, the oligonucleotide is folded to form a quadruplex structure, which brings the 
probes within the Förster radius (R0), resulting in the quenching of the emission radiation of 
FAM (2.1) by TAMRA (2.2). An increase in temperature toward the melting point of the 
oligonucleotide leads to the unfolding of the oligonucleotide, causing the fluorphores to be 
separated sufficiently for the FRET efficiency to be significantly diminished (Figure 2.5 b). 
Stabilization of the quadruplex structure upon addition of the ligand results in an increase in 
the melting temperature of the ligand-bound oligonucleotide. The magnitude of the change in 
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melting temperature gives an idea about the binding efficiency of the ligand to the quadruplex 
structure.   
Figure 2.5: a) The structure of the dual probe labelled QFO, b) Schematic representation of 
FRET-based melting temperature experiments [28]. 
 
 Figure 2.6: The structure of FAM (2.1) and TAMARA (2.2).  
 
The FRET technique allows analysis to be conducted in a variety of ionic conditions; it is a 
simple, rapid, convenient and cost-effective method and can easily be adapted for 96-well 
plate high-throughput screening. For this reason, it has been adopted by various groups, and a 
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large number of molecules with diverse structural features have been screened by using this 
technique. However, this method has some disadvantages. Sometimes, it can give false 
positives due to the quenching of the donor emission by the planer chromophore present in 
the ligands, and sometimes it can produce false negatives because of the folding of the QFO 
with the ligands in such a way that the distance between the donor and acceptor prevent 
efficient FRET to occur. To avoid the problem of false positives, the absorbance for the 
ligands should be checked beforehand, to make sure that they do not absorb at the same 
wavelength as the acceptor. The DNA bases, especially guanine, can also cause the 
quenching of the donor emission; hence, it should be separated from the donor moiety. 
 
Competitive FRET-melting Assay 
The selectivity of the ligands towards a G-quadruplex structure is considered as an important 
point during designing G-quadruplex-interactive agents, and can be determined by using 
FRET melting experiments where duplex, triplex and other quadruplex-forming sequences 
can be used as a competitor (Figure 2.7). Every compound should be tested against one or 
more suitable competitors, as the duplex and other competitor sequences are present in 
extremely high concentrations compared with G-quadruplex-forming sequences in the 
biological media. Hence, G-quadruplex-interactive ligands have to be highly selective in 
order to interact with particular quadruplex structures in an environment rich in duplexes and 
other competitors.  The competitive FRET melting assay is thus an effective and efficient 
method for assessing the selectivity of ligands with a wide variety of duplex sequences. 
 
Competitors that can trap a drug lower the stabilization potential of the quadruplex. The drug 
should be challenged by a number of competitors that should follow the criteria stated below: 
• The competitor should have no effect on the melting temperature of the labelled 
oligonucleotide in the absence of the quadruplex-interactive ligands. The competitor 





• The competitor’s stability should be significantly higher than that of the fluorescent 
quadruplex under the experimental conditions. If it melts before the quadruplex 
structure, the unfolded, single-stranded competitor will no longer be able to bear its 
binding capability [213]. 
 
Calf thymus DNA (CTDNA) is DNA that contains a wide variety of oligonucleotides of 
various lengths. Because of this, it is a good competitor DNA, allowing competition from a 
variety of sequences, creating a more accurate simulation of the in vivo conditions. The 
melting temperature measured by UV was found to be 81 °C and preliminary FRET control 































Figure 2.7: Competitive FRET assay. The addition of competitor to a selective ligand/G-
quadruplex will result in no change in ΔTm. The addition of competitor to a non-selective 
ligand/G-quadruplex will result in the transfer of the ligand to the competitor sequence and 
thus lowering the stabilization of the G-quadruplex and decreasing the ΔTm. 
 
2.1.3.3 Fluorescent Intercalator Displacement (FID) Assay 
Rapid and automated methods were needed to be developed for screening and comparing the 
properties of the huge number of emerging G-quadruplex-interactive ligands over the last few 
years. In 2006 Monchaud and his group developed the fluorescent intercalator displacement 
assay (G4-FID) for investigating the binding affinity and selectivity of G-quadruplex binding 
ligands, which is based on the displacement of thiazole orange (TO, 2.4) from the 







Addition of competitor DNA 





routinely used to investigate the binding affinity, sequence selectivity and binding 
stoichiometry for duplex DNA binding agents [215]. This method is dependent on the change 
in fluorescence of the intercalating agents, such as ethidium bromide (2.3) or thiazole orange 
(2.4) (Figure 2.9), when bound to DNA. On binding to DNA, the fluorescence property of 
the intercalator agent is enhanced, which is then decreased when it is displaced by a DNA 
binding ligand. The same principle is used for the assay of G-quadruplex/ligand interactions, 
where the change in fluorescence of the thiazole orange (2.4) is measured upon the addition 
of G-quadruplex-binding ligands. The technique is non-destructive, simple, fast and can be 
carried out with a small sample amount. Adaptation to a 96-well format is possible, allowing 






Figure 2.8: Schematic representation of the two main steps of the G4-FID assay, i.e., (a) 
labelling of the DNA matrices (quadruplex or duplex DNA) by Thiazole Orange (TO) (2.4) 
and (b) displacing the fluorescent probe from the DNA matrices by a small molecule 
candidate [216]. 
 




Several assumptions must be appropriately considered during the use of the FID technique. 
One important assumption involves the binding sites; it is assumed that the ligand and TO 
(2.4) will bind at the same site, and thus the ligand displaces TO (2.4). However, it is possible 
that the binding site may be different for the ligand and TO (2.4) and the ligand will not 
displace TO (2.4). The stoichiometry of the ligand quadruplex is also unknown, and may be 
different to that of TO (2.4). 
 
Secondly, the equilibrium and kinetics of binding of the ligand and TO (2.4) will be affected 
by the concentration of ligand and TO (2.4) in solution. If the concentration of TO (2.4) is 
kept constant every time, then it will not affect the comparison between ligands; however, it 
is important to check the conditions before comparing results with ligands assessed with a 
different TO (2.4) concentration. 
 
2.1.4 Equilibrium Dialysis 
The equilibrium dialysis method, first introduced in 1975 to investigate the interaction of 
small organic molecules with double stranded DNA [217], has been adapted to study ligand 
recognition by triplex and quadruplex nucleic acids [218]. This is a simple method used to 
investigate ligand binding and determine preferential nucleic acid confirmations for nucleic 
acid recognition. Dialysis is a physical process involving the diffusion of one or more solutes 
through a semi-permeable membrane - the flow of molecules will depend on the relationship 
between their size and the membrane pore size. In this process, nucleic acids of different 
confirmations are placed in dialysis tubes that permit the diffusion of small organic molecules 
while still retaining the nucleic acids. These tubes are emerged in a solution containing the 
drug solution and the ligands are allowed to pass through the semi-permeable membrane of 
the dialysis tube (Figure 2.10). Thus, some ligands will interact with the oligonucleotides, 
while the others will remain free in the solution. At equilibrium conditions, the concentration 
of free ligands will be the same in both compartments, although the ligand concentration will 
be higher in the oligonucleotide-containing chamber as it contains ligand both in bound and 
unbound form and will be dependent on the affinity of the ligand toward various types of 
oligonucleotides present in the dialysis tubes. Measurement of the concentration of the 
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unbound ligand and the bound ligand in both chambers allows the investigation of 
equilibrium-binding constants and ligand sequence selectivity. As, in this test, the ligand is in 
close contact with either various sequences of nucleic acids or various forms of quadruplex 
structures, the concentration of the ligand may vary in the dialysis chamber depending on the 








Figure 2.10: Experimental device used for equilibrium dialysis [28]. 
 
2.1.5 Mass Spectrometry 
Mass spectroscopy has been adopted to study the interactions between nucleic acids and 
ligands. Although there are several mass spectroscopic techniques available, the electrospray 
ionization (ESI) technique is used widely because of its soft ionization [206, 219]. In ESI 
techniques, the mass of both the G-quadruplex and the G-quadruplex/ligand complex can be 
determined easily, since the non-covalent bond between the ligand and the quadruplex 
remains unchanged, due to minimum fragmentation when the biomolecules are sprayed to the 
mass spectrometer [219]. In the ESI-MS technique, the sample is transferred in the gaseous 
phase, but the qualitative result is similar to that in solution. Here, the MS gives individual 
signals for each different species with different masses detected and is a very straightforward 
method for determining the stoichiometry of the complexes. The ESI-MS technique can be 
used to obtain the number of DNA strands involved,  the number of bound cations (if present) 
and the number of bound ligands. 
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2.1.6 Quantitative Analysis of Binding Events 
Thermodynamic and kinetic parameters are very important for understanding the driving 
force for ligand/quadruplex complex formation. Isothermal titration calorimetry (ITC) and 
surface plasmon resonance (SPR) have been found to be useful in recent years to investigate 
these parameters of quadruplex/ligand interactions. 
 
2.1.6.1 Isothermal Titration Calorimetry (ITC) 
Isothermal titration calorimetry (ITC) is a biophysical method used to measure 
thermodynamic parameters directly, including the binding affinity constant (KA), changes in 
enthalpy (ΔH), and entropy (ΔS), as well as the binding stoichiometry between the ligands 
and the G-quadruplex structure in solution [220]. Previously, the ITC technique was used for 
studying duplex DNA/ligand interactions [221], but recently it has been used for 
quadruplex/ligand interactions [222]. From measurements of small changes in temperature, 
Gibbs energy changes (ΔG) and entropy changes (ΔS) can be calculated according to the 
equation 2.2: 
 
ΔG = -RT ln K = ΔH - T ΔS 
 
Equation 2.2: Equation for calculating Gibbs energy changes.  
In order to determine these thermodynamic parameters, the ligands are usually titrated into 
the oligonucleotide solution and the heat response is recorded. These heat values are usually 
corrected for the heat of ligand dilution. The representation of the heat values as a function of 
the molar ratio between the ligand and the G-quadruplex is known as the binding isotherm. 
Finally, fitting the binding isotherms to the proposed model allows the thermodynamic 
parameters to be obtained [206]. 
 
ΔG = Gibbs energy change 
R = Gas constant 
T = Absolute temperature    
ΔH = Enthalpy change 
ΔS = Entropy change    
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This method is fast and highly informative, without the need of any chemical tag or having to 
immobilize the DNA or ligands, and can be controlled entirely by computer. However, a 
large amount of DNA and ligands are required, and it is not possible to adapt this into a high 
throughput setup. 
 
2.1.6.2 Surface Plasmon Resonance (SPR) 
The surface plasmon resonance (SPR) technique provides quantitative information about the 
affinity between the ligand and the DNA, and can be used to determine the stoichiometry, 
strength and kinetics of the interactions [223, 224]. SPR is an optical technique utilising the 
reduction in intensity of circular polarized light that is reflected from the surface of a thin 
metal film-coated glass prism. Surface plasmons of the metal are excited by the minima in a 
reflected light density occurring at a specific angle. The created evanescent electromagnetic 
field spreads from the surface into the surrounding medium for a short distance (~200 nm). 
The angle at which the resonance occurs becomes a function of the refractive index of the 
medium in the vicinity of the surface. By recording the variation in value of this angle, the 
SPR can detect interactions involving free species in solution and one that is covalently 
bound to the surface [28]. 
 
In order to study the binding interactions of small organic molecules with proteins, different 
types of quadruplex-forming oligonucleotides have been immobilized on the surface of the 
sensor chips where the sequence of the oligonucleotides depends on the purpose of the study. 
Usually, intramolecular quadruplexes are used for the study, since the intermolecular 
quadruplexes dissociate during the regeneration step. Various ways such as forming amide, 
disulfide or thioether bonds are used to attach oligonucleotides covalently onto the surface. In 
most of the studies, biotin-functionalized oligonucleotides are applied for attachment onto 
streptavidin-coated surfaces. This prevents the non-specific binding of ligands with 
streptavidin, resulting in a more rapid and effective method for SPR studies. The SPR 




• SPR sensors predominantly require aqueous solvents, which becomes problematic for 
the solubility of the aromatic G-quadruplex-binding compounds used in the study.  
• The non-specific binding of the compounds to sensor chips is another problem.  
• Ligands can bind on the surface of the plastic parts of the instrument, resulting in 
fewer ligands reaching the surface [225]. 
 
2.1.7 Dimethylsulphate (DMS) Footprinting 
Dimethylsulphate (DMS) footprinting is one of the earliest methods used to determine 
particular features of the quadruplex, which was part of the Maxam and Gilbert protocol for 
DNA sequencing. The methylation of the N7 position of guanine by DMS (2.5) leads to facile 
depurination (Scheme 2.1). The addition of piperidine (2.10) to the solution leads to cleavage 
at the now abasic site, and gel electrophoresis allows the visualization of the length of the 
cleaved fragments, resulting in a ladder with peaks corresponding to every guanine in a 
sequence. When the N7 is hydrogen bonded, as in a G-quadruplex, it is protected from 





Scheme 2.1: A schematic diagram of the DMS footprinting method. 
2.1.8 X-Ray Diffraction and NMR Spectroscopy 
All the techniques described above provide information about the recognition of a G-
quadruplex structure by small organic molecules. It is possible to obtain the stabilization 
potential, selectivity, affinity constants, and the stoichiometry of the formed complex, but not 
the structural information. Structural information can be very important to investigate the 
process involved in recognition of G-quadruplex structures by small organic molecules at the 
molecular level, and these data can be utilized for the further improvement of the existing 
ligands. The X-Ray diffraction and NMR spectroscopy techniques provide structural 
information about the interactions of ligands with the G-quadruplex, and various reports have 
been published providing the structural information of a number of G-quadruplex/ligand 





Table 2.1: An example of some solved structures of complexes formed between 
quadruplexes and small organic molecules [28]. 
Ligand Method G-quadruplex sequence PDB 
BRACO19 X Ray d[TAGGGTTAGGGT]2 3CE5 
Distamycin A NMR d[TGGGGT]4 2JT7 
TMPyP4 X-Ray d[TAGGGTTAGGG]2 2HR 
TMPyP4 NMR d(TGAGGGTGGIGAGGGTGGGGAAGG) 2A5R 
RHPS4 NMR d[TTAGGGT]4 1NZM 
  
2.1.8.1 X-Ray Diffraction Spectroscopy 
X-Ray crystallography provides information at the atomic level during structure 
determination and is able to identify various topologies of the quadruplex structure. A solid 
crystal structure is formed from the complex formed between the ligand and the quadruplex 
structure, and thus reflects the state of matter in a condensed state. Analysis of the crystal 
structures of quadruplex and quadruplex/ligand complex provide information about the 
binding site and the mode of interaction of the ligand with the quadruplex [148]. Moreover, 
visualization of hydrogen bonds involved in the stabilization of the complexes is possible 
with X-ray crystallography. X-Ray crystallography has been widely used to design rationally 
more quadruplex-selective drugs by modifying the chain used for the substitution of aromatic 
rings [226]. Furthermore, it has been used to distinguish differences between the DNA and 
RNA quadruplex structures and suggested that it is possible to design ligands that can 
discriminate between DNA and RNA quadruplexes [227]. 
 
Although X-ray crystallography is the most precise method for obtaining structural 
information, the process is extremely time-consuming and needs expertise. It is very difficult 
to grow perfect crystals, and many different conditions have to be considered before growing 
crystal structures. Additionally, once a crystal is obtained it is very difficult and time-
consuming to mount the crystal. Furthermore,  it may not be perfect. If more than one phase 
is present, there may be more than one set of refraction patterns, which makes analysis very 
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difficult. Complex and expensive machinery is also required to generate the X-rays and 
measure the diffraction pattern.    
     
2.1.8.2 Nuclear Magnetic Resonance (NMR) Spectroscopy 
Nuclear magnetic resonance (NMR) has become an essential tool for investigating nucleic 
acids that provides structural information of a complex at an atomic level. NMR provides the 
most complete structural data on interactions involved in the recognition process in solution 
and it has been successfully used to study ligand/G4 interactions. NMR is mainly used to 
determine the correlations between signals due to ligands and those attributable to nucleic 
acid, in order to determine the contact area. The use of NOESY is essential in this context 
[28].  
 
For G-quadruplex structures, characteristic NMR signals have been found in regions of 
amino and imino protons between 8 and 13 ppm, approximately, considering a typical proton 
spectrum [228]. Intermolecular G-quadruplexes have shown better resolved signals in the 
NMR spectrum than that of an intramolecular structure.  Higher-dimensional NMR 
techniques allow more than one species in equilibrium to be detected and determine their 
relative populations. 
The NMR technique can be coupled with other methods to obtain more precise information 
about the G-quadruplex/ligand interaction. For example, by using an NMR titration 
experiment, the stoichiometry and binding mode of the complex can be determined [229]. 
Again, Trotta and collaborators coupled NMR with molecular modelling techniques to 
investigate the interaction of six potential quadruplex-binding ligands with a quadruplex-
forming oligonucleotide [230]. Sometimes, researchers combined the use of two different 
NMR methods; first, the NMR titration method for identifying and confirming the G-
quadruplex/ligand interaction, and secondly to calculate the structure of the complex. Several 




Structure determination by NMR depends on sequence-forming stable species in solution. 
The presence of various topologies of quadruplex structures in solution limits the use of this 
process [228]. The use of modified or mutated sequences of the original quadruplex that will 
form only a single species in solution can help to overcome this problem.  
 
2.1.9 Molecular Modelling 
2.1.9.1 Molecular Modelling to Aid NMR 
NMR spectroscopy and molecular modelling are closely related. The distance restraints 
obtained from NOE connectivities are utilized for structure calculation and refinement, and 
molecular modelling is used to propose the 3D solution structure. 
 
2.1.9.2 Stability and Thermodynamics of G-quadruplex/ligand Complexes 
In order to investigate structure, dynamics, surface properties and the thermodynamics of 
quadruplex and quadruplex/ligand interactions, molecular modelling and molecular dynamics 
methods are now used routinely. These methods have been used to understand and improve 
the recognition of quadruplexes by small organic molecules. In order to design more selective 
and potent G-quadruplex binders, models have been used as a starting point. Molecular 
dynamic simulation studies can also be used to investigate complexes between the 
quadruplex and ligand in order to complement experimental data lacking atomic resolution.  
 
In the computational studies, the first step involves the manual docking of the ligand under 
investigation onto a quadruplex, and it is imperative that one must carefully consider whether 
the chosen binding site is in agreement with known data about this ligand. 
 
2.1.10 Polyacrylamide Gel Electrophoresis 
Based on size and charge, DNA molecules can be separated by gel electrophoresis 
experiments by using an electric field. In an electrophoresis chamber, usually agarose or 
120 
 
polyacrylamide gel is placed and connected to a power source. Smaller molecules move 
faster than the larger molecules through the gel when an electric current is applied. In the 
case of the study of drug-DNA interactions, the distance moved by the free G-quadruplex 
structure and the bound structure may be different. By using the spectroscopic methods, such 
as molecular fluorescence or UV-visible absorption, the molecules, with a required previous 
staining step, can be detected [206]. 
 
Under strict conditions, folded motifs can be identified quickly against unfolded single-
stranded DNA. With careful consideration about the speed (voltage) of the run and the 
stability of the quadruplex, additional analysis of possible structures can be made. 
Quadruplex stability can be sensitive to temperature and buffering conditions used during the 
experiment. The DNA can be visualized by using radioactive labels, EtBr staining or other 
dyes [33]. 
 
2.1.11 Sedimentation Velocity Analysis and Sedimentation Equilibrium  
Buoyant density, sedimentation coefficients and the molecular weights of DNA and 
quadruplexes can be determined by using density gradient ultra-centrifugation. 
Hydrodynamic properties, such as translational diffusion, sedimentation coefficients (S) and 
correlation times of the DNA structures, can be calculated through bead modelling on atomic-
level model structures. Hydrodynamic properties have been used in conjunction with the 
program HYDROPRO [231] to help differentiate between known or inferred structural 
conformations measured by analytical ultra-centrifugation.  
 
2.1.12 Cross-Linking DNA and Topology  
Adjacent guanine nucleotides have been identified successfully through the cross-linking of 
DNA bases by using di-functional platinum complexes, and so provide distance constraints 
for the construction of G-quadruplex-folded motifs [232]. Compounds suitable for cross-
linking, such as cis- and trans-Pt(NH3)2 or cis- and trans-diamminediaquaplatinum(II), are 
able to link covalently the N7 of purine bases together. If the N7 of guanines are involved in 
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G-tetrad formation, they will not be able to cross-link. Adenine-containing sequences can 
participate in forming additional cross-linking, but efficiency will be reduced by 10 times, 
since they are less nucleophilic. Once the products are formed, the folded structures can be 
investigated by either mass spectrometry or by 3'-exonuclease digestion and subsequent 
analysis by gel electrophoresis. 
 
2.1.13 Other Methods 
In addition to the principal methods, there are numerous biophysical techniques available that 
have been used to investigate the quadruplex structures and G-quadruplex/ligand interactions. 
These include viscometry titrations, DNA footprinting, Raman spectrometry, nuclease 
sensitivity, photocrosslinking, infrared spectroscopy and high performance liquid 
chromatography-photodiode array (HPLC-PDA).    
 
2.2 Biological Methods 
G-quadruplex/ligand interactions have also been studied by using a number of biochemical 
methods. Some of these are briefly described here.  
 
2.2.1 Polymerase Chain Reaction (PCR) 
Most of the methods used for investigating G-quadruplex/ligand interactions are based on the 
polymerase chain reaction or PCR, and one of the most widely used methods is the PCR stop 
assay method, which studies the interference of ligands with polymerase activity to obtain 
more information about the ligand stabilization of the G-quadruplex [233]. If the quadruplex 
structure is stabilized by the investigated ligand, bands of paused polymerase activity near the 
guanine rich portion are observed on the electrophoresis assays on the PCR products, and the 
inhibition of polymerase activity is proportional to the intensity of the paused bands. A large 
number of molecules have been investigated by using this method to analyse their interaction 




2.2.2 Telomerase Repeat Amplification Protocol (TRAP) 
The telomerase repeat amplification protocol (TRAP) assay has been widely used to 
investigate telomerase activity in cell extracts, as well as the telomerase inhibitory property of 
small molecules [235, 236]. The telomerase enzyme is found to over-express in 85% of 
cancer cells and is rarely found in other somatic cells. Hence, the TRAP assay has been used 
in the detection of telomerase activity in numerous human malignancies as a diagnostic tool 
in the early diagnosis of malignancy, as a potential prognostic indicator and as a means to 
identify telomerase inhibitors [237]. The recent development of G-quadruplex ligands as 
potential telomerase inhibitors prompted the utilization of the TRAP assay for evaluating the 
efficacy of the G-quadruplex/ligand complex against telomerase activity.  
Figure 2.11: The steps of the Telomeric Repeat Amplification Protocol (TRAP) assay [238]   
The in vitro TRAP assay uses a telomeric substrate (TS) primer that is elongated by 
telomerase. The elongated TS primers are then specifically amplified via PCR and the use of 
a reverse primer, ACX. Through comparing the extent of primer elongation of treated, 
positive (untreated) and negative (no telomerase) protein extracts, the in vitro telomerase-
inhibiting properties of G-quadruplex ligands can be determined. TRAP products are 
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visualized as ladders, with bands corresponding to elongated TRAP products. Ladder length 
is indicative of telomerase activity. The traditional TRAP assay is conducted in two stages 
(Figure 2.11): 
 
• The telomerase enzyme extends the primer when it is incubated with the TS primer in 
buffer conditions suitable for primer elongation. After the addition of four repeats, the 
DNA sequence becomes capable of folding into a G-quadruplex structure, resulting in 
the inhibition of telomerase activity by preventing its access to the TS (Figure 2.12). 
Upon ligand-induced quadruplex stabilization, the substrate single-stranded DNA is 
sequestered, inhibiting telomerase’s ability to add further hexanucleotide repeats, 
resulting in short products. In the absence of quadruplex-stabilizing ligands, the 
quadruplex structure becomes unstable, and the telomerase enzyme is free to further 












Figure 2.12: The TRAP assay in the presence of G-quadruplex-binding ligands. 
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• The second stage uses PCR to amplify the elongated TRAP products to enable 
visualization and semi-quantification. PCR is a well-known technique used to amplify 
a small section of a particular DNA sequence. The reaction involves the template 
sequence to be amplified, using DNA polymerase and primers. The telomerase 
products from step 1 serve as templates for the PCR amplification. The primer utilizes 
a CX reverse primer (5'-GCG CGG [CTTACC]3 CTA ACC-3') and TS as a forward 
primer (5'-AAT CCG TCG AGC AGA GTT-3'), and Taq-polymerase is used. 
Traditional TRAP additionally utilizes a standard internal control (S-IC). This S-IC is 
not elongated, and is used to guard against false-positive results, arising through 
quadruplex ligands inhibiting the PCR-stage of TRAP, resulting in differential 
amplification of TRAP products from positive control (untreated) and treated ligand-
containing samples.  
• The length of the telomere extension fragments can then be measured by gel 
electrophoresis. 
 
Although this two-stage TRAP assay was widely used in the assessment of G-quadruplex 
ligands as telomerase inhibitors [235], its validity was questioned upon the discovery that 
ligand-induced G-quadruplexes inhibit Taq polymerase [239]. This differential amplification 
of TRAP products demonstrated false-positive results, and a suitably-modified TRAP assay 
was consequently developed [240]. 
 
2.2.2.1 TRAP-LIG Modified TRAP Assay 
De Cian and co-workers demonstrated that the TRAP assay is not appropriate for determining 
telomerase inhibitory activity by quadruplex ligands. They suggested that these molecules 
might interfere with the PCR of a sequence that is capable of forming G-quadruplexes but 
nonetheless leaves the internal control unaffected. Moreover, the presence of some ligands in 
the PCR steps inhibits Taq-polymerase [239]. To avoid this problem, in some laboratories the 
compounds were first screened for Taq-polymerase inhibition, and then preceded for the 




Reed et al. reported a modification of the TRAP assay protocol known as the TRAP–LIG 
modified TRAP assay that overcame the problem of inhibiting Taq-polymerase. In this 
process, bound ligands are removed before the PCR amplification step, which eliminates the 
possibilities of both PCR inhibition and the inhibition of Taq polymerase activity because of 
the presence of ligand-ligand complexes in the extended products and ligand–quadruplex 
complexes and unbound ligands, respectively. This new procedure, TRAP–LIG, has been 
tested and the results have been found to be reliable and reproducible for investigating 
telomerase inhibition, and can be made without a separate Taq polymerase assay [240]. 
The TRAP–LIG assay is a three-step process (Figure 2.13), following a similar protocol for 
the direct assay, except for the introduction of an intermediate aqueous washing and freeze-
drying step prior to PCR amplification step. Hence the steps are:  
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Figure 2.13: A schematic diagram of the steps involved in the TRAP–LIG assay [240] 
1. Initial elongation of a primer sequence by telomerase in the presence of a ligand. 
2. Removal of all bound ligands by aqueous washing. 
3. PCR amplification of the pure extended products of telomerase elongation [240]. 
 
 
2.2.3 Sulfhorhodamine B Assay (SRB) 
Short-term potent cell growth inhibition is a usual pre-requisite for anti-cancer drugs. As 
such, there are several assays to determine the toxic/growth-inhibitory effects of ligands in 
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the high-throughput fashion required by drug discovery groups. The two most common 
assays are the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 2.15) 
assay and the sulfhorhodamine-B (SRB, 2.14) assay (Figure 2.14 a, b).   
 
In vitro cytotoxicity screening is mostly performed using the sulforhodamine B (SRB, 2.14) 
assay, developed in 1990 [242]. This assay depends on the ability of SRB (2.14) to bind to 
protein components of cells that have been fixed to tissue-culture plates by trichloroacetic 
acid (TCA). The bright-pink aminoxanthene dye SRB (2.14), containing two sulfonic groups, 
can under mild acidic conditions bind to the basic amino-acid residues which again dissociate 
under basic conditions. The amount of extracted dye from stained cells is directly 











Figure 2.14: a) The structure of sulfhorhodamine-B (SRB, 2.14); b) A schematic diagram for 
the formation of formazan (2.16). 
The effectiveness of the SRB (2.14) assay is often compared with another method using the 
tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide or MTT 
(2.15). MTT (2.15) can be reduced by formed NADH from metabolic active cells, resulting in 
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a purple-coloured formazan (2.16) (Figure 2.14 b), which can be detected by a photometer. 
As most of the NADH is formed in the mitochondria, 1-methoxy-phenazine methosulphate is 
needed as an electron-carrier to transfer the reduction equivalents from the mitochondrial 
matrix into the medium. Because of the nature of its mechanism of action, the MTT (2.15) 
assay can only detect viable cells, whereas the SRB (2.14) method cannot differentiate 
between viable and dead cells. Several studies have proven that the result obtained by the 
SRB (2.14) assay correlated well with those of the MTT (2.15) assay, although the IC50 
values obtained by the SRB (2.14) assay were slightly higher. The SRB (2.14) assay, 
however, has several advantages over the MTT (2.15) assay. For example, some compounds 
can directly interfere with MTT’s (2.15) reduction without effecting cell viability, while SRB 
(2.14) staining is rarely affected by this type of interference. Again, SRB (2.14) staining is 
not dependent on the cell’s metabolic activity; therefore, optimization of the assay conditions 
for specific cell lines is easier than for the MTT (2.15) assay [243]. 
 
The SRB (2.14) assay has been optimized and adopted as the routine method by the NCI for 
drug discovery programs. Therefore, it has led the SRB (2.14) assay to become the chosen 
assay over tetrazolium-based assays.  
 
2.2.4 Long-term Population Doubling Studies  
Short-term cell growth inhibition investigations such as the SRB (2.14) assay provide insight 
on whether compounds are biologically active. However, they provide no information in 
determining the mechanism of action of the compound, such as molecular targeting, 
cytostatic or cytotoxic (necrotic or apoptotic) mechanisms. The mechanism of action of a 
compound is a useful preliminary tool in assessing whether a compound presents a viable 
therapeutic window and is important for pre-clinical evaluation.  
 
There are two methods to elucidate the mechanism of action of G-quadruplex ligands; i) 
long-term sub-cytotoxic concentrations or ii) short-term post-cytotoxic concentrations. Two 
different methods are needed due to the fact that some cellular responses are rapid (DNA-
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damage response/apoptotic factors), whereas some are significantly slower (telomere-
dysfunction induced Ubiquitin-mediated telomerase degradation). Cells are counted weekly 
and are re-seeded at a given concentration. Population doublings (Pd) can be calculated from 
the following formula (Equation 2.3), and the drug is added twice weekly. 
 
Pd = log (Nf/N0)/log2 
 
Equation 2.3: The formula for calculating population doublings (Pd) from cell count. 
The cumulative number of population doublings is plotted against time. The data represent 
the extent of the proliferative/replicative capacity of viable cells in the presence of drugs 









Figure 2.15: The effect of RHPS4 (1.6) on the long-term proliferation of MCF-7 cells where 
a cessation of growth on day 14 at 0.5 and 1 μM and reduction in proliferative 
capacity/population doubling at 0.2 μM RHPS4 (1.6) was found [244].  
 
Chapter Three: Results and Discussion 
N0 = No of cells seeded 
Nf = No of cells counted on day 7 
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3.0   Results and Discussion 
3.1 Results and Discussion: Chemical 
3.1.1 Aryl Polyamides as G-quadruplex Ligands  
N-Methyl pyrrole/imidazole-based polyamides have long been recognized for their ability to 
bind to the minor groove of duplex DNA and studies have proved that pyrrole-imidazole 
polyamides can be cell-permeable and can inhibit the transcription of specific genes[245]. 
With the realisation that small quadruplex-binding ligands could function as transcriptional 
repressors of c-myc via stabilization of upstream proximal G-quadruplex structures [50], G-
quadruplex anti-cancer drug discovery has progressed into developing DNA-binding agents 
with selectivity and high-affinity towards telomeric and non-telomeric G-quadruplexes.  
Dervan and co-workers originally showed how distamycin-like polyamides containing N-
methylpyrroles and N-methylimidazole amino acids bind to the minor groove of duplex DNA 
at AT-rich regions and demonstrated this to be an important probe for protein interactions 
with double-stranded DNA [246, 247]. Dervan and co-workers further showed that 
covalently linked polyamides with multiple pyrrole or imidazole moieties along a γ-
aminobutyric acid chain form specific and high affinity DNA-binding agents. Subsequently, 
further studies have demonstrated that distamycin and distamycin-derivatives can also inhibit 
protein interactions with G-quadruplex DNA by stacking on the planar end-terminal G-tetrad 
of G-quadruplexes in 2:1 (ligand:G-tetrad) stoichiometry and contacting the flanking bases. 
These findings proved distamycin’s importance as a probe of G-quadruplex DNA-protein 
interactions [247].  
Polyamides containing more than five heterocyclic rings usually display reduced duplex 
affinity, which is a desirable characteristic for a G-quadruplex ligand owing to the relatively 
unknown degree and direction of bending in DNA (helical phasing) [248]. Polyamide 
quadruplex ligands are therefore usually elongated and contain several heterocyclic-rings in 
linear and/or branched form, providing a basis for ligand-tetrad stacking interactions. This 
correlation was demonstrated by Neidle and co-workers as an increase in heterocyclic groups 
resulted in an increased affinity and selectivity for G-quadruplex DNA over duplex DNA 
which is suggested to be consistent with a mixed groove/G-quartet stacking binding mode 
[172]. Unexpectedly, however, Neidle and co-workers observed longer-length polyamides 
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having greater quadruplex stabilization suggesting potential interactions with quadruplex 
grooves, as opposed to the commonly observed end-stacking paradigm.  
Two distinct binding modes of distamycin with protein-G-quadruplex have been proposed 
which can be distinguished by sensitivity to distamycin and include  
(i) distamycin molecules bind as dimers in two of the four grooves of a quadruplex, and  
(ii)  two molecules of distamycin A extend over each of the two G-tetrad planes in a 4 : 1 
binding mode [172]. 
Isothermal titration colorimetry (ITC) can be utilized to assess such 
stereochemical/stoichiometric interactions to characterize the energetics of ligand-quadruplex 
interactions [249]. ITC showed the polyamide based Dist-A compound (Figure 3.1) bound 
with a 4:1 complex suggesting Dist-A formed dimers bound simultaneously to two opposite 
grooves of the quadruplex [222]. Although clearly not all polyamide-based compounds will 
bind in this manner, it provides evidence to suggest polyamide compounds can intercalate 
with the grooves of quadruplexes.  
It is feasible therefore to assume that aryl polyamide based ligands may either stack onto the 
end-planar G-tetrad surfaces (commonly seen for most G-quadruplex ligands) or intercalate 
with quadruplex grooves (seen with Dist-A), although the former is still most likely due to 
the complex steric-hindrance observed in quadruplex grooves.  
 
Figure 3.1: Structure of distamycin A.  
 
3.1.2 Overview of Design and Evaluation of Ligands  
There is a growing interest in small molecules that can bind selectively and stabilize G-
quadruplex DNAs due to their potential as transcription/translation regulators and selective 
telomere targeting agents, which represent a new class of therapeutic agent.  Most 
quadruplex-binding ligands studied to date contain functionalized polycyclic aromatic 
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systems such as acridines, anthraquinones, indoloquinolines and porphyrins.[189]  A few of 
these have been shown to produce quadruplex-related biological effects, even though their 
physicochemical features are conventionally non-drug-like.  Due to their distinctive structural 
features, it is possible to target particular G-quadruplex nucleic acid structures selectively 
without binding to the more-abundant duplex DNA.  A common approach to G-quadruplex 
ligand design is the use of relatively large aromatic groups to interact with terminal G-
quartets through π−π interactions (end-stacking), explaining why the majority of quadruplex-
binding molecules studied to date are based on functionalized polycyclic aromatic systems.  
The first small molecule reported to bind to G-quadruplex DNA was an anthraquinone 
derivative [179].  Following this, molecules containing similar structural motifs such as 
fluorenones and acridines were developed. 
Recently, Rahman and co-workers reported a series of novel biaryl polyamides with 
significant selectively towards G-quadruplex compared with duplex DNA, and modest 
selectivity between different quadruplex types [[189]. Using a distamycin scaffold as a 
starting point, biaryl building blocks were introduced in place of pyrroles to switch 
preference from duplex to quadruplex DNA.  Introduction of the biaryl unit significantly 
altered the classical crescent-shaped structure of the molecules, forcing them to adopt a U-
shaped scaffold instead.  This alteration in shape ensures that the molecules have low affinity 
for duplex DNA while increasing their interaction with a G-quadruplex structure, since the 
ligands have similar dimensions (Figure 3.3).  In contrast to previous attempts to produce 
quadruplex-selective distamycin analogues [172], these biaryl polyamides offer synthetic 
versatility and significant quadruplex selectivity.  They consist of two different structural 
motifs: Motif-1 containing one biaryl unit, and Motif-2 which are dimers of biaryl units 
(Figure 3.2). 
 
Figure 3.2: Structural motifs of the biaryl polyamides (X = O, S or N; Y = C or N). 
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Preliminary data suggested that it is possible to tailor the structure of these molecules to 
enhance affinity for specific G-quadruplexes (e.g., c-kit1 vs c-kit2 vs HT4).  The ligands 
proposed in this project were designed based on the concept of systematically lengthening 
and modifying the first-generation molecules while maintaining quadruplex contour in order 
to enhance (i) stacking interactions and (ii) non-bonded interactions with loops and grooves 
in the various quadruplex structures.  This was done by introducing additional rings, 
heteroatoms in existing rings and additional functional groups to enhance hydrogen bonding 
opportunities and thus selectivity between different quadruplex structures.   
 
Figure 3.3: Model of the biaryl-polyamide 
compound overlapping the planar terminal G-
tetrad of the human intramolecular telomeric 
quadruplex [189].  
 
 
To achieve the goal of this project, libraries of 
compounds were synthesized and were screened 
by using various biophysical and biological techniques. After synthesis of the first library of 
molecules, the compounds were screened through a FRET based melting assay to identify a 
lead molecule with the highest degree of G-quadruplex stabilization and greater affinity 
towards the G-quadruplex over duplex DNA. These molecules were further analysed against 
several cancer cell lines and a normal cell line to determine their cytotoxicity. Other 
biophysical techniques such as CD-spectroscopy were applied to ensure the efficacy of the 
selected lead molecules. The lead molecules were then modified at various points to improve 
the G-quadruplex stabilization potential, binding affinity and selectivity of the molecules, 
which were then subjected to further analysis by biophysical and biological techniques. 
3.1.3 Design of Library Types 
Three different types of solution phase libraries, Type-1, Type-2 and Type-3, were planned 
on the basis of the structure of the building blocks in the target molecules. All the molecules 
in these libraries contain varying numbers of aromatic rings and various points of 





Figure 3.4: Structural motifs of the Type-1 and Type-2 library. 
3.1.3.1 Type-1 Library 
The Type-1 library molecules (Figure 3.5) are based on a non-variable core (black, pink 
circle) and two variable cores R1 (red) and R2 (blue). These molecules contain two building 
blocks which are connected together by an amide linkage where the non-variable core 
contains a tertiary amine group which facilitates purification by use of an SCX-2 cartridge. 
SCX cartridges are loaded with modified silica containing a sulfonic acid group which acts as 
a cation exchange resin and exchanges its acid group with the basic functional groups of the 
product. Therefore, the products with basic groups are kept bound inside the cartridge while 
impurities come out of the cartridge. Washing the column with ammonia methanol then 
releases the bound product from the silica. Of the two building blocks, one is a biaryl unit, 
which contains one five membered (R1) and one six membered ring (R2). The biaryl part of 
these molecules contains either a furan or a thiophene ring (Figure 3.6) joined to π-electron 
rich aryl groups (Figure 3.7) in either the 2/5 or 2/4 positions with the expectation of 
increasing affinity for G-quartets through additional π−π interactions (end-stacking). A 2/5 or 
2/4 substituent ensures different shape characteristics which can potentially affect the way the 
molecules can interact with the terminal quartet of the G-quadruplex. The molecular weight 
of members of the proposed library varies from 473 to 555. Twenty-one molecules containing 
the Type-1 structural motif were synthesized. Depending on the arrangement of the building 




Figure 3.5: Structural types of library-1. 
 
3.1.3.1.1 Synthesis of Type-1 Library 
A linear synthetic approach was adopted for synthesis of the Type-1 library (Scheme 3.2). 
Starting from the ethyl 1-(3-aminobenzyl)piperidine-4-carboxylate building block, which was 
purchased from a commercial source, the compounds were synthesized in two steps. Every 
molecule in this library contains a tertiary nitrogen in the ring which offered the advantage of 
SCX cartridge purification after each step. 
The first step involved amide coupling between the amine and three different bromo 
heterocyclic acids in a parallel fashion. 2.0-2.5 equivalents of HOBt were used to activate the 
carboxylic acids, and 1.75-2.0 equivalents of DIC were used as a coupling reagent depending 
on the substrate.  
 
Figure 3.6: Bromo heterocyclic acids used to synthesize the Type-1 and Type-2 libraries. 
HOBt reacts with activated acyl groups (e.g. carboxylic acid + DCC/DIC) to form 
intermediates referred to as activated esters. DIC (N,N'-diisopropylcarbodiimide) activates 
the carboxylic acids towards amide formation. In the amide coupling reactions most often 
carbodiimides are used as the dehydrating agents which activate the acid group and help the 
amide bond formation in the presence of additives like N-hydroxybenzotriazole or N-
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hydroxysuccinimide.  Dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide 
(DIC), and EDCI are some commonly used carbodiimides. Among these we chose DIC as it 
has several advantages over the others like that it is a liquid and easy to use. Additionally, the 
by-product, N,N'-diisopropylurea, is soluble in organic solvents and easily removed by 
extraction. Moreover, this is less likely to cause allergic reaction compared with DCC. The 
lone pair electron on the nitrogen of the carbodiimide makes it a nucleophile, which takes the 
acidic proton and becomes an electrophile leaving a neucleophilic carboxylate group. The 
positively charged nitrogen atom then attracts the N=C bonding electron to complete its lone 
pair and the carbon atom forms a bond with the carboxylate. This complex is further activated 
by HOBt as the hydroxyl oxygen of HOBt forms a bond with the carbonyl carbon of the 
carboxylate through its lone pair electron, while releasing the corresponding urea based on 
the carbodiimide used. The activated acid then reacts with the amine forming the amide bond 
releasing the HOBt (Scheme 3.1).  
 
 
Scheme 3.1: General overview of amide coupling using DIC and HOBt. 
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The reaction mixture here was allowed to stir overnight. After 16 hours, the reaction mixture 
was passed through a SCX-2 cartridge (with a sorbent mass 10 times that of the product 
mass). SCX-2 cartridges are packed with silica-based sulfonic acid cationic exchange resins. 
Due to the presence of tertiary nitrogen in the starting material, all of these compounds were 
retained in the cartridge. The cartridges were then washed with DCM (3x) and DMF (3x) 
twice and finally MeOH (2x) to remove impurities and excess reagents. The trapped 
compounds were released from the cartridge using 5-10 ml of 2M NH3 in MeOH and the 
solvent evaporated in vacuo. This trap and release method was highly effective in this case. 
The O-acylisourea can react with an additional carboxylic acid to give an acid anhydride,  
which can react further to give the desired amide. An unwanted reaction pathway involves 
the rearrangement of the O-acylisourea to the stable N-acylurea. The use of solvents with low 
dielectric constants, such as dichloromethane and chloroform, can minimize this side 
reaction. In the case of the synthesis of Type-1 library members, dichloromethane was used 
as the solvent.  
 
Scheme 3.2: General scheme for the synthesis of Type-1 library molecules. 
The next step in the synthetic route was the cross coupling reaction to attach an aryl moiety 
directly to the terminal five-membered heterocyclic ring of intermediate 3 using a C-C bond 
formation reaction. A Suzuki cross-coupling reaction under microwave conditions was 
selected for its convenience and high yield in similar reactions. The Suzuki cross-coupling 
reaction is an extremely versatile reaction for generating carbon-carbon bonds. It involves 
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reaction of an aryl- or vinyl-boronic acid with an aryl- , vinyl- or an alkyl-halide catalyzed by 
palladium. It is widely used to synthesize poly-olefins, styrenes and substituted biphenyls. 
The reaction also works with pseudohalides, such as triflates (OTf), to replace halides, and 
also with boron-esters instead of boronic acids with a relative reactivity of R2-I > R2-OTf > 
R2-Br >> R2-Cl. 
 
First published in 1979 by Akira Suzuki, the Suzuki reaction relies on a palladium catalyst 
such as tetrakis(triphenylphosphine)palladium(0) to effect part of the transformation. The 
palladium catalyst (more strictly a pre-catalyst) is 4-coordinate, and usually involves 
phosphine supporting groups, as shown below (Scheme 3.3) 
 
The mechanism of the Suzuki reaction (Scheme 3.3) is best viewed from the perspective of 
the palladium catalyst. The first step is oxidative addition of palladium to the halide 2 to form 
the organopalladium species 3. Reaction with base gives intermediate 4, which via 
transmetalation with the boronate complex 6 forms the organopalladium species 8. Reductive 
elimination of the desired product 9 restores the original palladium catalyst 1. 
 
Scheme 3.3: The Suzuki cross-coupling catalytic cycle 
The reaction conditions, solvents and microwave heating time were optimized through small 
scale trial reactions. Finally a combination of EtOH, toluene and water (9:3:1) was used as 
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the reaction solvent with 1.2 equivalents of boronic acid and 3.0 equivalents of K2CO3 as 
base. A 0.1 equivalent of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4  was used as the 
catalyst. Microwave heating time was varied from 8-10 minutes.  
 
For this Type-1 library three commercially available bromo heterocyclic acids (Figure 3.6) 
and seven different boronic acids (Figure 3.7) were used to obtain the final 21 compounds.  
 





3.1.3.1.2 Structures of 21 Member Type-1 Library 
The structures of the synthesized library compounds (Table 3.1) are listed below: 
Table 3.1: Structures of 21 member Type-1 library. 
 































Table 3.1: Structure of 21 member Type-1 Library (continued). 
 













































3.1.3.1.3 Purification of Type-1 Library Members 
All compounds were purified by passing through sulphonic acid based IsoluteTM SCX-2 
cartridges, which were washed with DCM (3x) and DMF (3x) twice, and finally MeOH (2x) 
to remove impurities and excess reagents. The products were released from the cartridges 
using 2M NH3 in MeOH, and concentrated in vacuo to obtain the final products. Product 
purity was in the range of 90-95% through this catch and release method, which required no 
further purification. 
 
3.1.3.1.4 Characterization of Type-1 Library Molecules 
The synthesized molecules were analysed using LCMS to ascertain their purity (Table 3.2). 
High resolution mass spectrometry (HRMS), and IR and NMR spectroscopic techniques (See 



















Table 3.2: LCMS and HRMS data of the Type-1 Library molecules. 
 
Code No. Mass obtained by LCMS Mass obtained by HRMS 
KN-39 (4.9) 491.11 490.2342 
KN-40 (4.10) 507.08 506.2114 
KN-41 (4.11) 507.15 506.2114 
KN-45 (4.13) 543.00 543.2316 
KN-46 (4.14) 527.10 527.2554 
KN-47 (4.15) 543.05 543.2318 
KN-48 (4.17) 529.96 529.2158 
KN-49 (4.18) 528.94 529.2151 
KN-50 (4.19) 512.99 513.2415 
KN-51 (4.21) 489.17 489.1844 
KN-52 (4.22) 490.14 489.1826 
KN-53 (4.23) 473.13 473.2070 
KN-54 (4.25) 499.85 500.2032 
KN-55 (4.26) 499.92 500.2029 
KN-56 (4.27) 483.88 484.2251 
KN-57 (4.29) 539.09 539.2015 
KN-58 (4.30) 539.09 539.2015 
KN-59 (4.31) 523.12 523.2250 
KN-60 (4.33) 554.99 555.1767 
KN-61 (4.34) 554.99 555.1775 
KN-62 (4.35) 539.05 539.2028 
144 
 
3.1.3.2 Type-2 Library 
Type-2 library molecules contain four variable cores R1 (tail part, pink circle), R2 
(heterocyclic part, green), R3 (biaryl moiety, red) and R4 (capping acid, blue), which are 
connected by amide linkages (Figure 3.8). Initially the tail portion of the molecules was kept 
fixed and the R2, R3 and R4 portions of the molecule were changed randomly depending on 
the commercially available building blocks, and 12 molecules were synthesized. These were 
subjected to initial screening by FRET based melting assay to identify their G-quadruplex 
binding potential. Two of the molecules (KN-88 and KN-119) were found to be highly 
effective in stabilizing G-quadruplex and showed high selectivity towards G-quadruplex over 
duplex DNA (Table 3.11 and AP1). These molecules were further analysed for their 
cytotoxic activity against various cancer and healthy cell lines and found to be cytotoxic 
against the cancer cell lines at nanomolar concentrations (Table 3.15, 3.16). These two 
molecules were considered as the lead molecules and were modified further at various 
positions and are grouped as Type-3 molecules. 
 
Figure 3.8: Example of Type-2 library molecules. 
 
3.1.3.2.1 Type-2 Library 
The 12 membered Type-2 library compounds (Figure 3.9) contain three building blocks 
where two of the building blocks contain biaryl units and the third is either a benzofused ring 
or a five membered heterocyclic ring. All three building blocks are connected by an amide 
linkage. These molecules contain three variable cores R2 (pink), R3 (red) and R4 (blue). R2 
contains either a five membered heterocyclic ring or a benzofused ring, R3 is a biaryl unit 
that was synthesized in house and contains a variable five membered heterocyclic ring and 
145 
 
finally, R4, the capping acid, containing various aromatic rings. In some of the compounds 
there is a –CH2– group between the terminal biaryl building block located in the capping 
acid, which increases the length of the molecule, with the expectation that this will cover an 
extended length of the quadruplex. In each case the molecules contain an N,N'-
dimethylaminopropyl amine tail, which facilitates purification. The molecules in this library 
are again divided into three sub types depending on the synthetic route. The molecular weight 
of the compounds varies from 503 to 715. Depending on the synthetic procedure these 
molecules are sub-divided into three classes. 
 
Figure 3.9: Structural types of library-2. 
 
3.1.3.2.1.1 Design of Sub Type-1 Molecules 
All three molecules of this type contain the non-variable N,N'-dimethylaminopropyl tail that 
is connected to a pyrrole at position 2 of the five membered ring. This pyrrole forms an amide 
bond with 5-bromoheterocyclic acid through its amine present at position 5. The 
bromoheterocyclic acid used here contains a five membered ring, which is furan in this case. 
The 5th position of furan is again linked with a benzene ring through a C-C bond where the 





3.1.3.2.1.2 Synthesis of Sub Type-1 Molecules 
A linear synthetic approach was adopted to obtain the amine building blocks for the synthesis 
of three compounds of this library. The first involved nitration of 2,2,2-trichloro-1-(1-methyl-
1H-pyrrol-2-yl)ethanone 5 (Scheme 3.4) using concentrated HNO3 acid and acetic anhydride. 
The reaction was conducted at -5 ºC and the nitric acid was added very slowly over a period 
of 1 hour. The reaction was very vigorous but efficient. Then the tail was added through the 
coupling of N,N'-dimethylaminopropyl amine in THF at room temperature to obtain 
intermediate 7. This reaction proceeded smoothly without any coupling reagent because of 
the presence of the terminal chlorides. The nitro group of intermediate 7 was reduced using 
hydrogen in the presence of a 0.1 equivalent of Pd/C catalysts using a hydrogenator. Ethanol 
was used as a solvent in this reaction step. The next step was addition of 5-bromo furan-2-
carboxylic to intermediate 8. DIC and HOBt were used as the coupling reagents, which 
followed the same mechanism previously mentioned (Scheme 3.1). The reaction proceeded 





Scheme 3.4: General scheme for the synthesis of Sub Type-1 library compounds of library-2. 
 
The Suzuki coupling reaction was carried out to obtain the intermediate 10 from the bromo 
heterocyclic intermediate. The reaction was completed within 10-12 minutes. Two boronic 
acids, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline and (3-aminophenyl)boronic 
acid (Figure 3.10) were used to obtain two different intermediate amines. The final step 
involved coupling the heterocyclic carboxylic acid. The reactions were carried out in 
dichloromethane except for cases where the heterocyclic acid was not soluble in DCM. In 




Figure 3.10: Boronic acids used for the synthesis of Sub Type-1 and Sub Type-3 library 
members. 
 
3.1.3.2.1.3 Design of Sub Type-2 Molecules 
Sub Type-2 molecules contain a benzofused heterocyclic moiety in R2, which is similarly 
connected to the tail N,N'-dimethylaminopropyl through an amide linkage at position 2 of  
R2. The heterocyclic ring of R2 here is furan in most cases, but also contains thiophene in 
some cases. The R2 moiety is then linked with the R3 by an amide bond. R3 is variable and 
contains either furan or a thiophene ring. The five membered ring of R3 forms a direct C-C 
bond either at position 4 or at 5 with boronic acids depending on the bromoheterocyclic acid 
used for synthesizing the R3 part of the molecules. The boronic acid part of R3 contains a six 
membered ring that forms an amide linkage with R4. 
 
3.1.3.2.1.4 Synthesis of Sub Type-2 Molecules 
In the first step of the synthesis of Sub Type -2 (Scheme 3.6), bromo heterocyclic acid was 
added to the commercially available starting material, methyl 5-aminobenzo[b]thiophene-2-
carboxylate 12, in the presence of DIC and HOBt. Reaction was complete after 16 hours, 
which was followed by purification by silica gel column chromatography. 100% DCM was 
used as the solvent to elute the compounds. This was an efficient method as 95% pure 
product was obtained in high yield (75-84%). The intermediate (13) was then hydrolysed in 
the presence of a 0.5 M solution of NaOH in dioxane at room temperature. Esters can 
undergo hydrolysis under acid or basic conditions. Under basic conditions, hydroxide acts as 
a nucleophile, while an alkoxide is the leaving group (Scheme 3.5). Progress of the reaction 
was monitored by TLC. The reaction was complete within 30 minutes, and aqueous work up 





Scheme 3.5: General scheme for ester hydrolysis. 
 
The tail (N, N'-dimethylaminopropyl amine) was then added by DIC/HOBt-mediated 
coupling which was followed by Suzuki coupling reaction in the presence of palladium 
catalyst. Three boronic acids (Figure 3.11) were used in the Suzuki coupling step to obtain 
three intermediate amines. The last step involved formation of an amide bond between 
intermediate 16 and two different acids (Figure 3.12) in DMF with DIC/HOBt used as the 
coupling reagent.  Initially these reactions were incomplete, even after 16-24 hours. However, 
trial and error on some small scale reactions showed that addition of 2.0 equivalents of acid 
allowed the reactions to proceed smoothly to completion within 3 hours.  
 
Figure 3.11: Boronic acids used for the synthesis of Sub Type-2 and Sub Type 3 library 
members. 
 




 Scheme 3.6: General scheme for the synthesis of Sub Type-2 library compounds of library-
2. 
 
3.1.3.2.1.5 Design of Sub Type-3 Molecules 
This group of molecules contains benzofuran as R2 in every case, which is connected to the 
tail at position 2 and the bromo furan moiety at position 5 through the amide bond. Either the 
furan or R3 forms a direct C-C bond with two different boronic acids where the amino group 
on the boronic acid moiety is at positions 3 and 4. This positioning of the amino groups on 
the R3 moiety helps in attaining slightly different shape characteristics of the synthesized 
molecules. Finally, the capping part was added to complete the synthesis of the molecules. In 




3.1.3.2.1.6 Synthesis of Sub Type 3 Molecules 
This library contains two compounds and these were synthesised from a commercially 
available molecule, 5-aminobenzofuran-2-carboxylic acid, containing both amine and acid 
groups. The tail N,N'-dimethylaminopropyl amine, was first added by amide coupling. This 
reaction was fast and complete within 2 hours to afford intermediate 20 (Scheme 3.7). 5-
Bromofuroic acid was then coupled in the presence of DIC/HOBt. Suzuki coupling was 
carried out with two boronic acids (Figure 3.11) to give intermediates 22 and 23. Both of 
these reacted with a heterocyclic acid (Figure 3.13) in DIC/HOBt to afford two final 
compounds.  
 





Figure 3.13: Heterocyclic acid used for the synthesis of Sub Type-3 molecules. 
 
3.1.3.2.1.7 Purification of Type-2 Library Members 
After completion of the reaction, the mixtures were initially passed through SCX-2 (silica 
based sulphonic acid) cartridges to catch the basic compounds. The cartridge was washed 
with DCM (2X), DMF (2X) and methanol (2X) and then eluted with 2M NH3 in methanol. 
This ensured removal of impurities and excess reagents. TLC and LCMS analysis showed 
that 4 of the 14 compounds were more than 95% pure and did not require further purification. 
Other molecules showed minor to moderate impurities by TLC. These were purified using 
flash chromatography on silica gel employing a 18:1:1 ratio of DCM:2 molar 














3.1.3.2.1.8 Structure of Type-2 Library Members 
Structures of the synthesized molecules of this group are listed below (Table 3.3). 
Table 3.3: Structures of 12 member Type-2 library. 






























Table 3.3: Structures of 12 member Type-2 library (continued). 















3.1.3.2.1.9 Characterization of 12 Member Type 2-A Library 
Synthesised library compounds were analysed using LCMS (Table 3.4), IR and NMR to 
ascertain their purity and elucidate their structures (detail in experimental chapter). High 


























nt: Not tested 
 
3.1.3.2.2 Optimization of KN-88 and KN-119 
Type-1 and Type-2 library molecules were analysed using various biophysical and biological 
tests, such as FRET melting assay, TRAP analysis, SRB assay, and modified TRAP, to 
identify the best molecules among the groups. In FRET analysis two molecules, KN-88 and 
KN-119, showed the highest degree of quadruplex stabilization with 21.20 and 19.00 °ΔTm 
stabilization (Table 3.11), respectively, while showing no binding affinity for the control 
duplex DNA at 1µm concentration. These two molecules also showed some stabilization of 
other quadruplex sequences like Ckit-1(Table 3.12) and Ckit-2 (Table 3.13). In SRB assay 
these two molecules demonstrated significant efficacy with IC50 values of 1.4µm and 0.2µm 
Code No. 
Mass obtained by 
LCMS 
Mass obtained by 
HRMS 
KN-24 (4.52) 504.02 504.2261 
KN-78 (4.72) 692.55 692.1985 
KN-79 (4.74) 697.41 nt 
KN-83 (4.75) 713.39 nt 
KN-88 (4.76) 692.72 692.2009 
KN-89 (4.77) 697.57 697.2620 
KN-90 (4.78) 693.30 693.1954 
KN-91 (4.79) 698.53 698.2559 
KN-110 (4.54) 639.21 639.2424 
KN-112 (4.55) 639.52 639.2390 
KN-119 (4.80) 679.22 679.2230 
KN-120 (4.81) 679.75 679.2230 
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for the pancreatic cancer cell line (Table 3.16), while the IC50 for the normal cell line was 
over 25.0µm. Considering and comparing the results obtained from the biophysical and 
biological assays these two molecules, KN-88 and KN-119, were considered as the lead 
compounds for further optimization. Again, of these two, KN-119 demonstrated a better 
combination of biophysical and biological results which made it the main lead molecule. The 
following library type compounds were then synthesized optimizing the various modification 
points of KN-119. 
 
3.1.3.2.3 Type-3 Library 
Following from the initial screening data of the synthesized molecules, two lead compounds, 
KN-88 and KN-119, were selected for further modifications. A type-2B library of 34 
compounds was synthesized by modifying the structures of KN-88 and KN-119, which 
contain one non-variable biaryl core R3 (black) and three variable cores R1 (tail, pink), R2 
(heterocyclic moiety, red) and R4 (capping acid, blue) (Figure 3.14). Depending on the type 
of modification, type-2B molecules were again classified into three groups termed as type-
3A, type-3B and type-3C.  
 
Figure 3.14: Structure of Type-2B molecules. 
  
 
3.1.3.2.3.1 Type-3A Library Molecules 
157 
 
3.1.3.2.3.1.1 Design of Type-3A Library Molecules 
Type-3A library molecules were synthesized by modification of the lead compound KN-119 
containing only one variable core R2 (red) (Figure 3.15). The rest of the structures were kept 
the same for all the compounds of this library. The R2 core contains a benzofused 
heterocyclic ring where the heterocyclic five membered ring bears various heteroatoms such 
as oxygen, nitrogen and sulphur at various positions (Figure 3.16). The tail N,N'-
dimethylaminopropyl facilitated purification of these compounds using a SCX-2 cartridge. 
The molecular weight of the molecules from this group varies from 674.77 to 755.86.   
 




KN-130 KN-143 KN-145 
 KN-144  
Figure 3.16: The structural variations of R2 with their linking positions. The numbers below 
these structures/names are the ligands in which these groups are present. 
 
3.1.3.2.3.1.2 Synthesis of Type-3A Library Molecules 
Synthesis of molecules of this group started with the commercially available starting material 
containing an acid and a nitro group 26 (Scheme-3.8). In the first step an amide coupling 
reaction was made between the acid 26 and the tail N,N'-dimethylpropylamine in the presence 
of DIC/HOBt to obtain intermediate product 27. Either DCM or DMF was used as solvent 
depending on the solubility of the acid. The reaction was carried out at room temperature and 
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after 1-2 hours was found to be complete, as monitored by LCMS and TLC. Hydrogenation 
was then conducted to obtain product 28 from 27 in the presence of palladium on activated 
carbon and hydrogen gas, which reduced the nitro group to the amine. The product 29 was 
obtained by a DIC/HOBt mediated amide coupling reaction between 28 and bromo 
heterocyclic acid, which was subsequently subjected to Suzuki coupling in the presence of 
boronic acid, catalyst Pd(PPh3)4 and K2CO3 to obtain product 30. Finally a further amide 
coupling reaction was carried out between 30 and the heterocyclic capping acid to obtain the 
final product 31 in the presence of DIC/HOBt.    
 
 
Scheme 3.8: General scheme for the synthesis of Type-3A library compounds. 
 
3.1.3.2.3.1.3 Purification of Type-3A Library Compounds 
After completion of the reaction, the mixtures were initially passed through SCX-2 (silica 
based sulphonic acid) cartridges to catch basic compounds. Before pouring the reaction 
mixture in the SCX-2 cartridge, the cartridge was activated with DCM (2X) and methanol 
(2X). The reaction mixture was allowed to pass through the cartridge under gravity and then 
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washed with DCM (2X), DMF (2X) and methanol (2X) and the product was eluted with 2M 
NH3 in methanol. This ensured removal of impurities and excess reagents. TLC and LCMS 
analysis showed that 5 of the 6 compounds were more than 95% pure and did not require 
further purification. KN-136 showed minor impurities by TLC. This compound was purified 
using flash chromatography on silica gel employing a 18:1:1 ratio of DCM:2M 
NH3/methanol:methanol as the mobile phase. This provided the pure compounds in 45-85% 
yield after purification. 
 
3.1.3.2.3.1.4 Structure of Type-3A Library Molecules 
Structures of the synthesized molecules are listed below (Table3.5).  
Table 3.5: Structure of 4 member Type-3A library molecules. 
 



















3.1.3.2.3.1.5 Characterization of Type-3A Library Molecules 
The synthesised library compounds were analysed using LCMS (Table 3.6), IR and NMR to 
ascertain their purity and elucidate their structures (detail in experimental chapter). High 
resolution mass spectrometry (HRMS) was used to confirm their accurate mass (Table 3.6). 
 
Table 3.6: HRMS and LCMS values of Type-3A library molecules. 
 
Code No. 
Mass obtained by 
LCMS 
Mass obtained by HRMS 
KN-130 (4.99) 692.55 693.1954 
KN-143 (4.100) 675.30 675.2422 
KN-144 (4.101) 679.74 680.2996 
KN-145 (4.102) 751.25 751.2708 
 
 
3.1.3.2.3.2 Type-3B Library 
3.1.3.2.3.2.1 Design of Type-3B library 
A 13 membered library of Type-3B compounds (Figure 3.17) was synthesized by modifying 
the final capping acid (R4) of the lead molecule KN-119. These compounds contain three 
non-variable cores R1 (tail), R2 (benzofused heterocyclic ring) and R3 (biaryl unit) and one 
variable core R4 (capping acid, red and blue, black circle). The variable core R4 has another 
biaryl linkage between the five membered heterocyclic ring (red) (Figure 3.18) and the six 
membered ring (blue), which is either benzofused or a six membered heterocyclic ring 
(Figure 3.19). Four molecules (KN-149, KN-150, KN-158, and KN-164) contain a methyl 
side chain on the five membered heterocyclic ring. All of these compounds contain the tail 
N,N'-dimethylaminopropyl which facilitates purification using an SCX-2 cartridge. The 
molecular weight of the molecules from this group varies from 649.72 to 703.19. Depending 
on the synthetic procedure these compounds can be subdivided into two groups as shown 




Figure 3.17: Structure of Type-3B molecules. 
    
KN-148 KN-156 KN-176 KN-149 
KN-154 KN-157  KN-150 
KN-155 KN-160  KN-158 
KN-159 KN-161  KN-164 
 
Figure 3.18: The structural variations of the five membered heterocyclic ring of R4 with 
linking positions. The numbers below these structures/names are the ligands in which these 












KN-148 KN-149 KN-154 
KN-156 KN-176 KN-157 




KN-150 KN-155 KN-159 
 KN-160 KN-161 
 
Figure 3.19: The structural variations of the six membered moieties of R4 with linking 
positions. The numbers below these structures/names are the ligands in which these groups 
are present. 
3.1.3.2.3.2.2 Synthesis of Subtype-1 Molecules of Type-3B Library 
Synthesis of subtype-1 molecules of the Type-3B library (Scheme 3.10) started with the 
commercially available starting material 5-nitrobenzofuran-2-carboxylic acid (35) and the tail 
N,N'-dimethylaminopropyl. The amide coupling reaction between these starting materials in 
the presence of DIC/HOBt generated product 36 which, upon hydrogenation in the presence 
of Pd on activated carbon, produced 37. Again, a typical amide coupling reaction was 
conducted between 37 and bromofuroic acid to obtain product 38. Upon Suzuki coupling, 
product 39 was obtained from 38 which was subjected to amide coupling with the final 
capping acids. The final capping acids were either collected from an available commercial 
source or were synthesized in house by conducting a Suzuki coupling reaction between a 






Scheme 3.9: General scheme for the synthesis of biaryl capping acids in house. 
 
 






3.1.3.2.3.2.3 Synthesis of Subtype-2 Molecules of Type-3B Library 
Subtype-2 molecules of this library were synthesized following a procedure analogous to that 
employed for subtype-1 molecules, except for the final two steps (Scheme 3.11). Here, an 
amide coupling reaction was carried out between product 39 and various five membered 
bromo-heterocyclic acids in the presence of DIC and HOBt producing 41. Then, a Suzuki 
coupling reaction was conducted to obtain the final product 42 and different commercially 
available boronic acids in the presence of the catalyst tetrakis triphenyl phosphine palladium 
and a base K2CO3.    
 
Scheme 3.11: General scheme for the synthesis of Sub Type-2 molecules of Type-3B library. 
 
3.1.3.2.3.2.4 Purification of Type-3B Library Compounds 
As all the molecules in this Type-3B library contained the N,N'-dimethylaminopropyl tail, 
they could be purified easily using SCX-2 cartridge methodology. A similar catch and release 
method as that described previously was used for purifying the compounds in this series. 
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TLC and LCMS analysis showed that all compounds were more than 95% pure and did not 
require further purification. This provided pure compounds in 45-75% yield. 
 
3.1.3.2.3.2.5 Structure of 12 Member Type-3B Library 
The structures of the synthesized molecules are listed below (Table 3.7). 
 
Table 3.7: Structure of 12 Member Type-3B Library molecules. 



























Table 3.7: Structure of 12 Member Type-3B Library molecules (continued). 



















3.1.3.2.3.2.6 Characterization of Type-3B Library Molecules 
The synthesised library compounds were analysed using LCMS (Table 3.8), IR and NMR to 
ascertain their purity and elucidate their structures (detail in experimental chapter). High 











Table 3.8: Type-3B Library molecules with HRMS and LCMS values. 
 
Code No. 
Mass obtained by LCMS Mass obtained by HRMS 
KN-148 (4.112) 656.87 657.2337 
KN-149 (4.114) 690.93 690.2399 
KN-150 (4.116) 649.61 650.2171 
KN-154 (4.123) 672.61 673.2125 
KN-155 (4.125) 688.22 688.2739 
KN-156 (4.129) 673.20 673.2122 
KN-157 (4.130) 689.14 689.1873 
KN-158 (4.133) 687.59 688.2205 
KN-159 (4.127) 675.04 675.2450 
KN-160 (4.131) 704.13 704.2563 
KN-161 (4.132) 690.98 691.2228 
KN-176 (4.117) 691.58 692.2034 
 
3.1.3.2.3.3 Type-3C Library 
3.1.3.2.3.3.1 Design of Type-3C library 
 
A 15 membered library of Type-3C was synthesized by modifying the R1 (tail, red) moiety of 
the lead molecule KN-119 (Figure 3.20). These compounds carry one variable part R1 and 
three non variable cores R2 (benzofused heterocyclic moiety), R3 (biaryl), and R4 (capping 
acid). The tail moiety contains various types of aromatic and heterocyclic rings (Figure 
3.21), which are connected by an amide linkage with the R2 core and are separated by one or 
more carbon linkers. For one molecule of this group, the synthesis was started from an ester 
rather than an acid which was hydrolysed in the next step to obtain the free acid group.  As 
these molecules do not have the typical tail of the others, the purification process varied, but 
most of the compounds were purified by use of an SCX-2 cartridge by the catch and release 




Figure 3.20: Structure of Type-3C molecules. 
 
Figure 3.21: Amines used in the synthesis of Type-3C molecules. 
 
3.1.3.2.3.3.2 Synthesis of Type-3C Library Molecules 
Product 43 was synthesized from the commercially available starting material 5-
nitrobenzofuran-2-carboxylic acid, 35 and various amines by the DIC/HOBt mediated amide 
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coupling reaction. As solvent, either DCM or DMF was used depending on the solubility of 
the corresponding starting materials. After purification, 43 was subjected to hydrogenation to 
convert the nitro group into an amine by following the method described earlier. The 
hydrogenated product 44 was then used for the next amide coupling reaction with 
bromofuroic acid to obtain product 45. Suzuki coupling between 45 and 3-aminophenyl 
boronic acid created the biaryl linkage and the product 46 was subjected to final amide 
coupling with the heterocyclic acid to obtain the desired compound 47. One of the molecules 
was synthesized by starting from the ester 48, which formed an amide bond with bromofuroic 
acid first to form 49. After purification, product 49 was subjected to hydrolysis, which freed 
the acid group for a further amide coupling reaction with the amine to form product 45. 
(Scheme 3.12)      
 




3.1.3.2.3.3.3 Purification of Type-3C Library Compounds 
Although some of the molecules from this group do not contain the N,N'-
dimethylaminopropyl tail, which facilitates the purification step, most of these compounds 
were  purified using the SCX-2 cartridge methodology. A similar catch and release method as 
that described above was followed for purifying these molecules. TLC and LCMS analysis 
showed that all compounds were 85-95% pure with some purified further using conventional 
silica column chromatography. Other compounds were purified using flash chromatography 
and solvent of various composition and gradients was used depending on the nature of the 
compounds. Solvent mixtures for flash chromatography were selected from TLC results with 


















3.1.3.2.3.3.4 Structure of 14 Member Type-3C Library 
Structures of the synthesized molecules are listed below (Table 3.9). 
Table 3.9: Structures of Type-3C library molecules. 
 































Table 3.9: Structures of Type-3C library molecules (continued). 






















3.1.3.2.3.3.5 Characterization of 14 Member Type-3C Library 
 
The synthesised library compounds were analysed using LCMS (Table 3.10), IR and NMR 
to ascertain their purity and elucidate their structures (detail in experimental chapter). High 




Table 3.10: Type-3C library with HRMS and LCMS values. 
 
Code No. 
Mass obtained by 
LCMS 
Mass obtained by 
HRMS 
KN-200 (4.210) 764.64 764.2539 
KN-202 (4.211) 763.95 764.2536 
KN-207 (4.212) 778.03 778.2693 
KN-212 (4.213) 702.14 702.2375 
KN-217 (4.214) 688.19 688.2223 
KN-222 (4.215) 704.33 704.2179 
KN-232 (4.217) 690.83 690.2371 
KN-237 (4.218) 702.27 702.2373 
KN-242 (4.219) 716.86 716.2528 
KN-247 (4.220) 716.90 716.2526 
KN-252 (4.221) 717.64 717.2483 
KN-257 (4.222) 766.42 766.2313 
KN-267 (4.223) 716.36 716.1622 
KN-272 (4.224) 662.28 662.2063 
 
3.2 Results and Discussion: Biological 
FRET analyses of all synthesized molecules were carried out by me. FRET analysis and other 
biological analysis of some of the synthesized molecules was carried out by Sunil Lagh of the 
UCL School of Pharmacy 
3.2.1 Biophysical Evaluation of the Biaryl Polyamide Series  
3.2.2 Fluorescence Resonance Energy Transfer (FRET) Melting Assay 
The binding and stabilizing potential of all the synthesized biaryl polyamide ligands were 
investigated against a series of oligonucleotide sequences like the F21T, Duplex, ckit1, ckit2, 
cmyc, DRH, and CDRH.   
 
The FRET data (Table 3.11) demonstrated that some molecules, such as KN-88, KN-119, 
and KN-242, have a significant level of G-quadruplex stabilizing ability against the F21T 
sequence with ΔTm values ranging from 22 °C to 34 °C, while a few molecules have 
moderate stabilizing potential (9-19 ΔTm °C). Several other compounds showed mild G-
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quadruplex stabilizing ability (2-7 ΔTm °C) against the F21T sequence.  The rest of the series 
have low to zero stabilizing ability. On the contrary, the biaryl polyamide molecules 
demonstrated negligible binding potential towards the duplex DNA (Appendix, Table AP1). 
Again, these molecules showed no stabilization of the DRH sequence (Appendix, Table 
AP4) while a few of the compounds showed low binding affinity towards the CDRH 
sequence (Appendix, Table AP5) having a ΔTm value near 3 °C.  Only, KN-148 had mild 
activity (7 ΔTm °C) against cmyc (Table 3.14), whereas a few of the other molecules showed 
low to zero stabilization potential. KN-242 demonstrated good stabilization of both ckit1 
(Table 3.11) and ckit2 (Table 3.12) with ΔTm values of 16 °C and 13 °C, respectively.  
Along with KN-242, KN-148, KN-247 and KN-252 showed significant stabilization of the 









Among the analysed molecules, FRET data demonstrates that KN-232, KN-237, KN-242, 
and KN-247 [c=1 μm] showed significantly high G-quadruplex stabilizing potential for F21T 
with a ΔTm of 22-34 °C (Table 3.11). KN-242 and KN-247 showed the highest level of G- 
quadruplex stabilization with ΔTm values of 34.43 °C (standard deviation ± 0.21) and 28.53 
°C (standard deviation ± 1.32), respectively at 1 μm. This level of stabilization is 
significantly higher than the conventional G-quadruplex binding ligands such as BRACO=19, 
telomestatin and the recently developed acridone and naphthalene diimide (ND) G-
quadruplex targeting agents showing ΔTms of 20-30 °C [250, 251]. One recently developed 
G-quadruplex binding ligand from an acridine based triaryl-substituted imidazole derivative, 
TSIZ01 (1.82), showed G-quadruplex stabilization of 32 ºC at 3 μm and 23.5 ºC at 1 μm 
concentration for F21T [311].  Again, KN-88, KN-119, KN-148, KN-158, KN-212 and KN-
217 showed a moderate level of G-quadruplex stabilization potential with ΔTm values ranging 
from 14 ºC to 21 ºC at 1 μm concentration against F21T, while KN-252 (ΔTm 12.40 ºC), KN-
227 (ΔTm 9.38 ºC), KN-161 (ΔTm 7.03 ºC) and KN-207 (ΔTm 6.95 ºC) showed mild activity. 
Moreover, the biaryl-polyamides have better selectivity towards the G-quadruplex DNA over 
duplex DNA as these molecules showed negligible stabilization of duplex DNA compared 
with their acridone and ND derivatives. The [ΔTm]Quadruplex: [ΔTm]Duplex ratio for the aryl-
polyamides is extremely high (<300), whereas this ratio for the acridone/ND is relatively low 
(~3-10). Therefore, in contrast with current G-quadruplex ligands in the literature, the greater 
degree of stabilization, as well as the extremely high level of selectivity of the synthesized 
biaryl polyamide ligands towards the F21T over the duplex DNA makes the aryl polyamide 






























ΔTm values for F21T 
Code MW 5 μm 2 μm 1 μm 
KN-24 (4.52) 504.02 6.90 ± 0.20 2.43 ± 0.69 0.53 ± 0.10 
KN-39 (4.9) 491.11 4.93 ± 0.00 2.20 ± 0.06 0.43 ± 0.12 
KN-40 (4.10) 507.38 0.00 ± 0.06 0.00 ± 0.12 0.00 ± 0.00 
KN-41(4.11) 507.15 0.07 ± 0.10 0.00 ± 0.05 0.00 ± 0.12 
KN-45 (4.13) 543.00 0.27 ± 0.05 0.00 ± 0.12 0.00 ± 0.05 
KN-46 (4.14) 527.10 4.77 ± 0.11 3.00 ± 0.12 0.23 ± 0.17 
KN-47 (4.15) 543.05 1.77 ± 0.17 1.00 ± 0.05 0.17 ± 0.12 
KN-48 (4.17) 529.96 0.33 ± 0.05 0.13 ± 0.10 0.10 ± 0.11 
KN-49 (4.18) 528.94 1.07 ± 0.12 0.63 ± 0.17 0.33 ± 0.05 
KN-50 (4.19) 512.99 0.63 ± 0.05 1.60 ± 0.05 1.10 ± 0.12 
KN-51 (4.21) 489.17 1.90 ± 0.05 1.20 ± 0.12 0.73 ± 0.11 
KN-52 (4.22) 490.14 1.97 ± 0.17 1.70 ± 0.05 0.97 ± 0.05 
KN-53 (4.23) 473.13 0.70 ± 0.11 0.43 ± 0.12 0.57 ± 0.11 
KN-54 (4.25) 499.85 0.83 ± 0.12 0.67 ± 0.06 0.63 ± 0.06 
KN-55 (4.26) 499.92 1.43 ± 0.06 1.33 ± 0.10 0.70 ± 0.13 
KN-56 (4.27) 483.88 0.77 ± 0.10 0.47 ± 0.06 0.00 ± 0.12 
KN-57 (4.29) 539.09 1.17 ± 0.12 0.33 ± 0.00 0.00 ± 0.11 
KN-58 (4.30) 539.09 1.00 ± 0.12 0.20 ± 0.00 0.00 ± 0.10 
KN-59 (4.31) 523.12 0.00 ± 0.06 0.00 ± 0.10 0.00 ± 0.17 
KN-60 (4.33) 554.99 0.03 ± 0.00 0.00 ± 0.06 0.00 ± 0.00 
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ΔTm values for F21T 
Code MW 5 μm 2 μm 1 μm 
KN-61 (4.34) 554.99 0.60 ± 0.10 0.37 ± 0.17 0.07 ± 0.12 
KN-62 (4.35) 539.05 2.93 ± 0.06 1.40 ± 0.2 1.00 ± 0.00 
KN-78 (4.72) 692.55 1.27 ± 0.12 0.60 ± 0.11 0.47 ± 0.05 
KN-79 (4.74) 697.81 3.40 ± 0.10 1.83 ± 0.17 0.50 ± 0.10 
KN-83 (4.75) 713.39 6.50 ± 0.28 3.73 ± 0.37 1.73 ± 0.11 
KN-88 (4.76) 692.72 36.37 ± 0.51 32.77 ± 1.09 21.20 ± 0.74 
KN-89 (4.77) 697.57 18.50 ± 0.39 7.67 ± 0.20 3.13 ± 0.14 
KN-90 (4.78) 693.30 0.87 ± 0.12 0.53 ± 0.00 0.23 ± 0.11 
KN-91 (4.79) 698.53 0.93 ± 0.17 0.60 ± 0.22 0.03 ± 0.17 
KN-110 (4.54) 639.33 4.00 ± 0.17 7.83 ± 0.12 2.07 ± 0.12 
KN-112 (4.55) 639.32 1.463 ± 0.00 0.835 ± 0.05 0.632 ± 0.10 
KN-119 (4.80) 676.13 22.18 ± 0.05 20.18 ± 0.10 19.00 ± 0.00 
KN-120 (4.81) 676.21 6.15 ± 0.17 4.85 ± 0.34 2.95 ± 0. 36 
KN-130 (4.99) 692.81 22.48 ± 0.35 8.55 ± 1.00 3.85 ± 0.30 
KN-143 (4.100) 674.77 21.51 ± 0.20 9.51 ± 1.16 5.01 ± 0. 81 
KN-144 (4.101) 679.77 20.38 ± 0.30 9.31 ± 0.05 5.78 ± 0.45 
KN-145 (4.102) 750.86 25.51 ± 1.41 16.11 ± 0.64 10.15 ± 0.17 
KN-148 (4.112) 656.68 17.38 ± 0.11 17.55 ± 0.25 15.45 ± 0.21 
KN-149 (4.114) 689.78 7.45 ± 0.36 3.01 ± 0.55 1.85 ± 0.20 
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Table 3.11: ΔTm values for F21T at 5 μm, 2 μm, and 1 μm concentrations with standard 
deviations (continued). 
 
ΔTm values for F21T 
Code MW 5 μm 2 μm 1 μm 
KN-150 (4.116) 649.72 2.50 ± 0.32 1.13 ± 0.45 0.96 ± 0.17 
KN-154 (4.123) 672.75 5.50 ± 1.18 2.70 ± 0.32 2.26 ± 0.17 
KN-155 (4.125) 687.74 11.53 ± 2.31 2.00 ± 0.58 0.76 ± 0.20 
KN-156 (4.129) 672.75 1.93 ± 0.40 1.46 ± 0.34 0.56 ± 0.20 
KN-157 (4.130) 688.81 1.86 ± 0.50 1.00 ± 0.05 0.80 ± 0. 11 
KN-158 (4.133) 687.76 21.53 ± 0.41 20.60 ± 0.29 18.00 ± 0.31 
KN-159 (4.127) 674.71 28.80 ± 2.10 6.56 ± 0.28 2.23 ± 0.23 
KN-160 (4.131) 703.81 11.96 ± 0.36 6.23 ± 1.00 2.63 ± 0.75 
KN-161 (4.132) 690.76 19.26 ± 0.10 11.2 ± 0.15 7.03 ± 0. 63 
KN-176 (4.117) 691.82 8.11 ± 0.07 5.36 ± 0.20 3.77 ± 0.46 
KN-200 (4.210) 763.86 1.18 ± 0.10 0.88 ± 0.10 0.22 ± 0.55 
KN-202 (4.211) 763.86 2.45 ± 0.21 1.35 ± 0.15 1.05 ± 0.06 
KN-207 (4.212) 777.89 -2.32 ± 0.10 10.48 ± 0.36 6.95 ± 0.06 
KN-212 (4.213) 701.79 23.02 ± 0.38 18.28 ± 0.50 14.98 ± 0.20 
KN-217 (4.214) 687.76 27.12 ± 0.25 21.02 ± 0.06 16.15 ± 0.55 
KN-222 (4.215) 703.76 12.85 ± 0.12 8.95 ± 0.23 7.25 ± 0.25 
KN-232 (4.217) 689.78 42.38 ± 0.35 34.46 ± 3.98 22.38 ± 2.61 
KN-237 (4.218) 701.79 40.96 ± 1.20 29.73 ± 2.12 22.03 ± 1.83 
KN-242 (4.219) 715.82 41.78 ± 0.92 40.53 ± 1.11 34.43 ± 0.21 
KN-247 (4.220) 715.25 40.03 ± 0.40 35.03 ± 3.53 28.53 ± 1.32 
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Table 3.11: ΔTm values for F21T at 5 μm, 2 μm, and 1 μm concentrations with standard 
deviations (continued). 
 
ΔTm values for F21T 
Code MW 5 µm 2 μm 1 μm 
KN-252 (4.221) 716.80 40.46 ± 1.10 31.66 ± 4.66 12.40 ± 0.15 
KN-257 (4.222) 765.83 -0.53 ± 2.36 0.10 ± 0.05 0.86 ± 0.47 
KN-267 (4.223) 715.80 -0.70 ± 1.61 1.23 ± 0.86 1.90 ± 3.11 
KN-272 (4.224) 661.73 37.80 ± 3.23 9.967 ± 0.93 4.58 ± 0.21 
 
cKit-1 (Table 3.12 and AP2) and c-Kit-2 (Table 3.13 and AP3) sequences are non-telomeric 
sequences with G-quadruplex forming potential. Among the analysed molecules, only KN-
242 showed good stabilization ability against both sequences with ΔTm values of 16.550 ºC 
and 12.733 ºC, respectively at a 1 μm concentration. However, KN-148, KN-242, KN-247 
and KN-252 showed a significant level of cKit-2 stabilization having a ΔTm value of 10-13 
ºC. KN-88 and KN-119 [c=1  μm], with good F21T stabilization potential, however, 
demonstrated low stabilization, with ΔTms of ~5-6 οC and ~3-4 οC for cKit-1 and cKit-2, 
respectively. On the contrary, the ND derivative compound 1, Braco-19 and TMPyP4 (1.32) 
[c=0.5  μm] showed signification stabilization, with ΔTms of ~18-29 οC and ~6-12 οC for 













Table 3.12: ΔTm values for C-Kit1 at 5 μm, 2 μm, and 1 μm concentrations with standard 
deviations. 
 
ΔTm values for C-kit1 
Code MW 5 µm 2 μm 1 μm 
KN-39 (4.9) 491.11 2.75 ± 0.12 2.36 ± 0.20 2.23 ± 0.17 
KN-78 (4.72) 692.55 1.78 ± 0.05 2.38 ± 0.12 1.19 ± 0.62 
KN-88 (4.76) 692.72 3.80 ± 0.00 20.37 ± 0.12 6.24 ± 0.20 
KN-89 (4.77) 697.57 3.86 ± 0.12 0.73 ± 0.05 2.11 ± 0.70 
KN-119 (4.80) 676.13 10.028 ± 0.52 8.02 ± 0.14 5.50 ± 0.09 
KN-120 (4.81) 676.21 4.48 ± 0.50 2.28 ± 0.32 2.51 ± 0.52 
KN-130 (4.99) 692.81 4.91 ± 0.28 1.38 ± 0.21 1.25 ± 0.21 
KN-143 (4.100) 674.77 14.46 ± 0.63 5.22 ± 0.42 1.88 ± 0.45 
KN-144 (4.101) 679.77 2.72 ± 0.00 4.48 ± 0.96 2.98 ± 0.61 
KN-145 (4.102) 750.86 24.91 ± 0.36 10.11 ± 2.40 6.48 ±0. 47 
KN-148 (4.112) 656.68 4.03 ± 0.12 2.95 ± 0.10 2.01 ± 0.00 
KN-149 (4.114) 689.78 3.05 ± 0.46 2.01 ± 0.28 1.05 ± 0.38 
KN-150 (4.116) 649.72 4.88 ± 0.46 2.82 ± 0.17 2.31 ± 0.69 
KN-154 (4.123) 672.75 13.91 ± 0.10 1.95 ± 0.20 2.08 ± 0.55 
KN-155 (4.125) 687.74 10.81 ± 0.49 3.55 ± 0.40 1.48 ± 0.40 
KN-156 (4.129) 672.75 2.08 ± 0.85 0.71 ± 0.11 1.51 ± 0.92 
KN-159 (4.127) 674.70 29.31 ± 0.45 12.4 ± 2.75 7.38 ± 0.42 






Table 3.12: ΔTm values for C-Kit1 at 5 μm, 2 μm, and 1 μm concentrations with standard 
deviations (continued). 
 
ΔTm values for C-kit1 
Code MW 5 µm 2 μm 1 μm 
KN-161 (4.132) 690.76 43.93 ± 0.63 7.85 ± 1.30 4.85 ± 0.90 
KN-176 (4.117) 691.82 12.43 ± 0.77 5.01 ± 0.30 4.38 ± 0.00 
KN-212 (4.213) 701.79 4.81 ± 0.23 3.29 ± 0.52 2.01 ± 0.11 
KN-217 (4.214) 687.76 3.12 ± 0.51 2.10 ± 0.29 1.140 ± 0.10 
KN-232 (4.217) 689.78 36.81 ± 1.55 11.81± 3.89 4.35 ±0.61 
KN-237 (4.218) 701.79 35.68 ± 2.34 12.18 ± 0.20 5.25 ± 1.11 
KN-242 (4.219) 715.82 41.58 ± 0.90 27.51 ± 1.27 16.55 ± 3.42 
KN-247 (4.220) 715.25 39.85 ± 0.30 16.5 ± 3.44 3.05 ± 3.40 
KN-252 (4.221) 716.80 35.75 ± 3.57 16.81 ± 1.80 4.78 ± 0.35 
KN-267 (4.223) 715.80 2.31 ± 0.20 0.48 ± 0.30 1.18 ± 0.81 













Table 3.13: ΔTm values for C-kit2 at 5 μm, 2 μm, and 1 μm concentrations with standard 
deviations. 
 
ΔTm values for C-kit2 
Code MW 5 µm 2 μm 1 μm 
KN-88 (4.76) 692.72 22.66 ± 0.40 7.67 ± 0.53 3.00 ± 0.21 
KN-89 (4.77) 697.57 7.78 ± 0.02 8.31 ± 0.83 6.40 ± 0.00 
KN-90 (4.78) 693.30 2.53 ± 0.16 2.58 ± 0.20 2.37 ± 0.30 
KN-119 (4.80) 676.13 8.33 ± 0.07 6.03 ± 0.23 4.30 ± 0.10 
KN-120 (4.81) 676.21 9.03 ± 1.22 5.12 ± 0.23 2.69 ± 0.08 
KN-130 (4.99) 692.81 13.38 ± 0.71 6.29 ± 0.11 2.93 ± 0.82 
KN-150 (4.116) 649.72 3.18 ± 0.71 1.15 ± 0.10 1.03 ± 0.10 
KN-154 (4.123) 672.75 11.75 ± 0.58 9.02 ± 0.66 7.02 ± 0.05 
KN-155 (4.125) 687.74 15.01± 0.20 10.29 ± 0.23 4.61 ± 0.12 
KN-159 (4.127) 674.70 26.21 ± 0.66 13.76 ± 0.28 5.42 ± 0.53 
KN-160 (4.131) 703.81 11.85 ± 0.88 6.03 ± 0.09 3.62 ± 0.12 
KN-161 (4.132) 690.76 18.53 ± 0.90 10.42 ± 0.19 6.92 ± 0.28 
KN-176 (4.117) 691.82 -7.86 ± 1.01 3.02 ± 0.24 1.05 ± 0.29 
KN-207 (4.212) 777.89 9.33 ± 0.40 6.13 ± 0.61 3.67 ± 0.25 
KN-212 (4.213) 701.79 17.50 ± 1.15 7.87 ± 0.12 3.87 ± 0.25 
KN-217 (4.214) 687.76 18.43 ± 0.64 8.53 ± 0.95 5.30 ± 0.36 
KN-222 (4.215) 703.76 11.53 ± 0.50 6.90 ± 0.53 4.63 ± 0.47 
KN-232 (4.217) 689.78 23.46 ± 1.38 11.46 ± 1.57 4.63 ± 0.90 
KN-237 (4.218) 701.79 23.83 ± 1.30 11.63 ± 2.09 5.46 ± 1.79 
KN-242 (4.219) 715.82 17.83 ± 2.91 17.67 ± 0.77 12.73 ± 0.75 
183 
 
Table 3.13: ΔTm values for C-kit2 at 5 μm, 2 μm, and 1 μm concentrations with standard 
deviations (continued). 
 
ΔTm values for C-kit2 
Code MW 5 µm 2 μm 1 μm 
KN-247 (4.220) 715.25 20.46 ± 0.85 16.33 ± 0.36 11.80 ± 1.38 
KN-252 (4.221) 716.80 24.60 ± 0.11 15.10 ± 0.56 10.67 ± 1.41 
KN-257 (4.222) 765.83 2.73 ± 0.96 1.30 ± 0.53 1.20 ± 0.03 
KN-267 (4.223) 715.80 1.67 ± 0.97 2.30 ± 0.66 1.97 ± 0.15 
KN-272 (4.224) 661.73 19.87 ± 1.68 10.27 ± 1.15 6.13 ± 0.26 
 
The compounds were investigated against c-Myc (Table 3.14), DNA/RNA hybrid duplex 
(DRH) (Appendix, Table AP4) sequence, and cDRH sequence (Appendix, Table AP5) 
(control DNA hairpin sequence, where U of DRH sequence was replaced with T). No 
significant stabilization was observed against any of the sequences. Only, KN-148 
demonstrated a very mild level of stabilization against the C-myc sequence with a ΔTm of 













Table 3.14: ΔTm values for C-myc at 5 μm, 2 μm, and 1 μm concentrations with standard 
deviations. 
ΔTm values for C-myc 
Code MW 5 µm 2 μm 1 μm 
KN-45 (4.13) 543.00 0.36 ± 0.40 1.57 ± 0.02 1.40 ± 0.57 
KN-46 (4.14) 527.10 0.30 ± 1.79 1.70 ± 0.39 2.133 ± 0.64 
KN-47 (4.15) 543.05 0.60 ± 0.31 1.23 ± 0.59 1.37 ± 0.08 
KN-48 (4.17) 529.96 1.23 ± 0.48 -0.60 ± 2.66 1.27 ± 0.44 
KN-56 (4.27) 483.88 -0.13 ± 0.08 0.60 ± 0.25 1.00 ± 0.13 
KN-88 (4.76) 692.72 5.50 ± 0.20 2.87 ± 0.13 2.43 ± 0.15 
KN-91 (4.79) 698.53 1.33 ± 0.13 1.07 ± 0.15 1.37 ± 0.28 
KN-119 (4.80) 676.13 9.33 ± 0.70 4.66 ± 0.15 3.03 ± 0.58 
KN-120 (4.81) 676.21 3.13 ± 0.15 2.67 ± 0.11 2.200 ± 0.10 
KN-130 (4.99) 692.81 5.70 ± 0.10 3.17 ± 0.08 2.43 ± 0.15 
KN-143 (4.100) 674.77 6.73 ± 0.28 2.67 ± 0.08 2.27 ± 0.05 
KN-144 (4.101) 679.77 8.67 ± 1.60 1.67 ± 0.36 2.23 ± 0.15 
KN-145 (4.102) 750.86 10.40 ± 0.00 4.63 ± 0.15 3.50 ± 0.00 
KN-148 (4.112) 656.68 10.30 ± 0.00 10.30 ± 0.00 6.93 ± 0.22 
KN-149 (4.114) 689.78 2.30 ± 0.00 2.07 ± 0.71 2.20 ± 0.10 
KN-150 (4.116) 649.72 4.60 ± 0.25 2.60 ± 0.17 2.03 ± 0.89 
KN-200 (4.210) 763.86 2.03 ± 0.13 2.00 ± 0.10 2.00 ± 0.10 
KN-202 (4.211) 763.86 1.87 ± 0.08 1.50 ± 1.05 2.33 ± 0.21 
KN-207 (4.212) 777.89 3.10 ± 0.10 2.43 ± 0.15 2.67 ± 0.28 





Table 3.14: ΔTm values for C-myc at 5 μm, 2 μm, and 1 μm concentrations with standard 
deviations (continued). 
 
ΔTm values for C-myc 
Code MW 5 µm 2 μm 1 μm 
KN-217 (4.214) 687.76 10.30 ± 0.00 4.50 ± 0.17 2.73 ± 0.08 
KN-222 (4.215) 703.76 4.87 ± 0.08 2.83 ± 0.13 2.87 ± 0.08 
KN-232 (4.217) 689.78 15.77 ± 1.41 3.70 ± 3.35 1.80 ± 0.05 
KN-242 (4.219) 715.82 8.53 ± 0.11 9.63 ± 1.78 2.80 ± 1.10 
KN-247 (4.220) 715.25 13.70 ± 0.35 9.57 ± 0.51 3.33 ± 1.13 
KN-252 (4.221) 716.80 17.26 ± 0.15 7.67 ± 0.94 2.67 ± 1.19 
 
 
3.2.3 Biological Evaluation of the Synthesized Compounds 
Based on the FRET results of the synthesized molecules, Type-1 and Type-2 compounds 
were analysed for their biological activity in collaboration with Professor Neidle’s group at 
the School of Pharmacy, UCL using several biological assays such as: 
• Telomere repeat amplification protocol assay (TRAP) 
• Sulforhodamine B assay (SRB) 
• Population doubling assay 
• Modified TRAP assay 
• Β-galactosidase senescence studies 
• hTERT expression, and 
• k-Ras expression. 
 
Type-3 molecules could not be analyzed using these assays because of lack of facilities as the 
group moved from the School of Pharmacy, UCL, to King’s College London. 
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3.2.3.1 Telomere Repeat Amplification Protocol Assay (TRAP)  
Some biaryl polyamides were selected for further biophysical analysis to establish their G-
quadruplex binding ability depending on the initial result obtained from FRET melting assay. 
KN-88 and KN-119 showed good quadruplex stabilization and selectivity for quadruplex 
over duplex DNA, as well as demonstrating significant result in cell culture assays. 
Therefore, these compounds were selected as lead molecules for the further design of new 
compounds. Telomerase inhibiting activity of these ligands was assessed along with a few 
other biaryl polyamides in order to compare their activities.  
 
Telomerase inhibition can be identified by stabilization of the TS oligonucleotide. The aryl 
polyamide series, at 25 μm concentrations, was subjected to in vitro biophysical assessment 
to investigate their telomerase inhibition and their activity was compared with that of the 
known telomerase inhibitors Braco19 and Telomestatin with TRAP EC50 values of 6.3 μm 







Figure 3.23: Biophysical TRAP-LIG assay denaturing gel. The effect of the aryl polyamide 
series [c=25 μm] on telomerase activity. Lane description: -ve; no telomerase, 2-10 indicative 
















Figure 3.24: Biophysical TRAP-LIG assay denaturing gel. The effect of the aryl polyamide 
series [c=25 μm] on telomerase activity. Lane description: +ve; telomerase positive extract, 














Figure 3.25: Quantified biophysical TRAP-LIG-assay. Number of bands and integrated lane 




Generally, no significant telomerase inhibition was observed (as measured by the number and 
integrated intensity of TRAP artefacts) throughout the series at relatively high ligand 
concentration (25 μm), when compared with the known G-quadruplex ligands, Braco19, 
TMPyP4 and Telomestatin, with TRAP EC50 values of 6.3 μm, 8.9  μm, and 0.6  μm 
respectively [240]. However, compound KN-158 showed relatively significant telomerase 
inhibition (~30%), whereas compounds KN-88, KN-119, KN-130 and KN-143 showed 
moderate telomerase inhibition (~20%). Hence, no further dose-response investigations were 
required because of this low inhibition. To establish structure activity relationships, higher 
concentrations (commonly up to 100 μm) could be used, but biophysical data may not be 
translated biologically as these high concentrations effect solubility.  
 
Additionally, these ligands are poorly soluble in diethylpyrocarbonate (DEPC) H2O at 1mM 
concentration and some of these ligands are not entirely in solution at these concentrations. In 
particular, KN-156 and KN-157 were poorly soluble in 1mM DEPC H2O. For studying 
structure-activity relationships it could be mentioned that KN-88, KN-119, KN-130, KN-143 
and KN-158 show some anti-telomerase activity. 
 
Although a TRAP EC50 [c=25 μm] could not be evaluated for any ligands from the aryl-
polyamide series, some structure-activity relationships could be determined. The ligands 
(KN-88, KN-119, KN-130 and KN-143) containing the terminal R1 [2-(2,3-
dihydrobenzofuran-5-yl)-4-methylthiazole] group (Figure) demonstrate some (~20%) 
biophysical telomerase inhibition, whereas the terminal R1 [2-(benzofuran-5-yl)-4,5-
dimethylthiazole] motif containing ligand KN-158 demonstrated the most significant (30%) 




Figure 3.26: 2-(2,3-Dihydrobenzofuran-5-yl)thiazole R1 motif seen on ligands KN-88, KN-







Figure 3.27: 2-(2,3-Dihydrobenzofuran-5-yl)-4-methylthiazole R1 motif seen on ligand KN-
158. 
 
The subtle structural difference between the two moieties seems to be due to the addition of a 
methyl group on the thiazole, i.e. the 4-methylthiazole to a 4,5-dimethylthiazole. Another 
ligand, KN-164, which is a derivative of KN-158 showed no significant telomerase 
inhibition. The end-terminal of compounds KN-158 and KN-164 alternate between the aryl 
rings 2,3- dihydrofuran (KN-158) and 2,3-dihydrothiophene (KN-164) that are contiguous 
with a benzene ring.  
 
3.2.3.2 Surforhodamine B Assay (SRB)  
The biaryl polyamide ligands were screened against various cancer cell lines, as well as a 
normal cell line, to evaluate their short-term (96 h) growth-inhibitory effect using the SRB 
assay (Table 3.15). After analysing the results, two ligands, KN-88 and KN-119, were 
identified as the lead-compounds and were screened against a wide range of cancer cell lines 














Table 3.15: IC50 values determined by the SRB assay evaluating the biaryl polyamide series. 
25 μm was the highest concentration used, since several compounds presented solubility 




MCF7 A549 MIA-Paca-2 WI38 
IC50 ( μm) SE IC50 ( μm) SE IC50 ( μm) SE IC50 ( μm) SE 
KN-143 
(4.100) 
1.8 0.4 2.4 0.2 1.4 0.1 22.1 1.1 
KN-144 
(4.101) 
6.6 0.7 7.0 0.3 1.1 0.4 >25 n/a 
KN-145 
(4.102) 
1.7 0.3 3.1 0.6 2.1 0.2 19.2 2.1 
KN-146 
(4.103) 
4.3 1.1 5.4 0.7 1.8 0.1 >25 n/a 
KN-148 
(4.112) 
2.5 0.4 3.2 0.6 2.3 0.1 21.1 1.9 
KN-149 
(4.114) 
5.3 1.5 8.2 0.9 2.0 0.1 >25 n/a 
KN-150 
(4.116) 
1.2 0.2 3.2 0.6 1.1 0.2 16.5 1.5 
KN-154 
(4.123) 
2.6 0.6 5.0 0.3 2.4 0.1 15.3 2.1 
KN-155 
(4.125) 
2.3 0.4 3.2 0.4 1.6 0.2 19.1 1.5 
KN-156 
(4.129) 
2.1 0.5 2.4 0.4 1.9 0.1 17.5 1.1 
KN-157 
(4.130) 
2.5 0.4 3.7 0.6 1.0 0.2 12.1 0.9 
KN-158 
(4.133) 
3.7 0.3 5.7 0.5 3.9 0.3 >25 n/a 
KN-159 
(4.127) 
3.2 0.6 7.1 0.7 1.9 0.1 10.9 0.9 
KN-160 
(4.131) 




Table 3.15: IC50 values determined by the SRB assay evaluating the biaryl polyamide series. 
25 μm was the highest concentration used, since several compounds presented solubility 
issues at higher concentrations (continued). 
KN 
Ligands 
MCF7 A549 MIA-Paca-2 WI38 
IC50 ( μm) SE IC50 ( μm) SE IC50 ( μm) SE IC50 ( μm) SE 
KN-161 
(4.132) 
5.4 1.9 5.9 0.3 3.2 0.1 >25 n/a 
KN-88 
(4.76) 
2.3 0.2 3.1 0.2 0.7 0.1 15.5 1.1 
KN-119 
(4.80) 
2.7 0.2 3.0 0.2 0.3 0.1 >25 n/a 
KN-130 
(4.99) 
1.3 0.1 4.7 0.3 3.1 0.1 >25 n/a 
 
 
Table 3.16: IC50 values determined by the SRB assay evaluating KN-88, KN-119 and KN-
130. 25 μm was the highest concentration used, since several compounds presented solubility 




RCC4 HPAC PC3 
IC50            
(μm) 
SE IC50            
(μm) 
SE IC50            
(μm) 
SE 
KN-88 (4.76) n/a n/a 1.4 0.1 2.5 0.2 
KN-119 (4.80) n/a n/a 0.2 0.1 1.7 0.2 
KN-130 (4.99) 8.3 0.2 n/a n/a n/a n/a 
 
The biaryl polyamide ligands were found to be active (IC50<5 μm) against the tumourigenic 
cell lines A549, MCF7 and MIA-PaCa-2. Among these molecules, two of the ligands, KN-88 
and KN-119, were identified as the lead-compounds and were subject to further investigation 
in HPAC and PC3 cell-lines. Consequently, KN-119 was considered to be the lead 
compound. The IC50 values for KN-119 in A549 and MCF7 (2.7 and 3 μm respectively) have 
been found to be comparable with the lead compound from the acridine series, BRACO-19 




Moreover, KN-119 demonstrated no cell growth inhibition at 25 μm with WI38 fibroblast 
cells. Hence, the therapeutic index, defined by the ratio IC50
[WI38]:IC50
[MIA-PaCa-2], exceeds 83 
for KN-119. Up to 100 μm drug concentrations should be used to determine the definite 
therapeutic index. However, the biological relevance of using such high drug concentrations 
in monolayer cell culture studies is controversial as growth inhibition at high concentrations 
could be attributed to a large number of factors including unknown solubility compared with 
effective inhibition of the molecular target. 
 
These polyamide ligands demonstrated an ordered and consistent activity throughout the 
tumourigenic cell-lines such as MCF7 (breast), A549 (lung) and MIA-PaCa-2 (pancreatic) 
cell lines, with the highest activity against (measured by IC50) MIA-PaCa-2 (~1-2 μm), 
MCF7 (~2-4 μm) and A549 (~3-5 μm), which might be due to the subtle changes in structure. 
However, the selective toxicity seen towards MIA-PaCa-2 cells is significant. KN-88 and 
KN-119, which were considered as the lead-compounds with IC50 values of 0.7 and 0.3 μm, 
respectively, were subsequently screened against an additional pancreatic cell-line, HPAC, in 
order to confirm their selective toxicity towards pancreatic cell-lines (as opposed to a MIA-
PaCa-2 specific trait). KN-88 and KN-119 produced IC50 values of 1.4 and 0.2 μm 
respectively. As KN-88 did not demonstrate the same degree of selective toxicity for HPAC, 
KN-119 was chosen as the lead compound to study against MIA-PaCa-2 cells as it showed 
consistent toxicity against the screened pancreatic cell lines. The degree of toxicity in KN-
119 in A549, MCF7, MIA-PaCa-2 and WI38 (2.7, 3.0, 0.3 and >25 μm, respectively) 
produced a therapeutic index (defined by IC50[healthy cells]:IC50[cancer cell]) of >9, >8, >83 for 
A549, MCF7 and MIA-PaCa-2, respectively.  
 
In 2009, our group reported the first generation of biaryl polyamides [189]. Among the 
reported molecules, ligand-2 demonstrated IC50 values in A549, MCF7 and WI38 of 2.1, 2.0 
and 9.2 μm respectively, which clearly implies that the second generation molecules are 
significantly more consistent and potent than the first-generation biaryl polyamides.  
Additionally, the therapeutic indexes of ligand-2 are 4.3 and 4.6 in A549 and MCF7 
respectively. Hence, the potency and the significantly larger therapeutic index of KN-119 
suggested that KN-119 has increased selectivity for cancerous cells. Generally, this can be 
extrapolated to all ligands reported in this thesis, which are selective for tumourigenic cells 
over healthy cells, a trait which the first-generation ligands do not entirely demonstrate.  
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Tetrasubstituted naphthalene diimide ligand, ND-2, is currently the most potent G-quadruplex 
ligand against MIA-PaCa-2 cells with IC50 values of 0.07 μm and 5.5 μm in MIA-PaCa-2 and 
WI38, respectively [250], and a therapeutic index of ~780. The ND ligands are the result of 
successive generations of drug-development and are not selective towards pancreatic cancers 
over other cancer cells. Hence, these polyamide ligands might be an alternative choice as a 
potent G-quadruplex-ligand.  
 
Pancreatic tumours are k-Ras dependent and the selective toxicity of KN-119 towards MIA-
PaCa-2 (8-10 folds more potent for MIA-PaCa-2 than MCF7 and A549) suggested that KN-
119 could function as a transcriptional repressor of k-Ras. So, studies investigating the effect 
of KN-119 on k-Ras expression were conducted and are discussed later. 
 
3.2.3.3 Population Doubling Studies  
KN-119 showed a dose-dependent effect on MIA-PaCa-2 cells when subjected to long-term 
population doubling studies and were analyzed following treatment profile iii IC50, 0.5 x IC50 




Figure 3.28: The 16-day effect of KN-119 on population doublings in MIA-PaCa-2 cells. 
The cumulative number of population doublings was determined every 4 days. Each data-




There was no significant growth inhibition at 4-days in MIA-PaCa-2 cultures in 0.5 x IC50 or 
0.2 x IC50 cultures. The cell-count for the 1 x IC50 culture represented 50% of the control, in 
line with the SRB data. At 8-days, increasing numbers of non-adherent cells made the 
cultures look unhealthy in 0.2 x IC50 and 0.2 x IC50 cultures and was subsequently 
discontinued as the required number of cells for re-seeding could not be obtained from the 
IC50 culture. At 12-days, 0.2 x IC50 and 0.2 x IC50 cultures looked increasingly non-adherent, 
while moderate growth inhibition was observed at 16-days, although the required number of 
cells for re-seeding could not be obtained from the 0.2 x IC50 culture. 
 
KN-119 inhibited cell proliferation (with reference to the number of cells) in long-term 
population doubling studies at 0.2 and 0.5 x IC50 doses for up to 12-days, where a decreased 
rate of cell proliferation suggested that, KN-119 may influence senescence factors at sub-
cytotoxic concentrations. Up to 40-days treatments at 0.1 x IC50 should be conducted to 
investigate this completely. Senescence would be indicated by a decreased rate of 
proliferation, but crucially not a decrease in the number of cells seeded to the number of 
viable cells at the end of treatment.  
 
The number of adherent cells decreased at 0.5 x IC50 between days 12 and 16 (10,000 viable 
cells seeded, but only ~8,700 viable cells remained – data not shown) resulting in 
discontinuation of the investigation for this condition, due to lack of cells, and required re-
seeding. A cytotoxic mechanism however, refers to the decrease in the number of cells, while 
a cytostatic mechanism would theoretically maintain a minimum of ~10,000 cells in culture. 
Again, a reduction in cell number was also seen at 1 x IC50, between 4-8 days, although this 
was expected at cytotoxic concentrations. To confirm completely the mechanism of action of 
ligand KN-119 being entirely cytotoxic, the β-galactosidase assay should be conducted to 
identify the presence of senescence biomarkers in KN-119-treated MIA-PaCa-2 cells. 
3.2.3.4 Modified Biological TRAP  
The basic mechanism of action of the G-quadruplex ligands can be investigated by in 
vivo/biological-TRAP, which assumes that the ligands permeate cell-walls, enter the nuclei, 





Although, KN-158 was marginally more potent than KN-119 and KN-88 in the in 
vitro/biophysical telomerase inhibition assay, and KN-88 showed better stabilizing effect  
against the F21T sequence in the biophysical FRET studies, only KN-119 was assessed in 
vivo using treatment profiles i and ii, as described in 4.3.2.3, because of its better activity 
against pancreatic cancer cell lines. Moreover, KN-119 stabilized the F21T sequence in 
FRET, which suggested that KN-119 could function as a telomerase inhibitor and KN-119 












Figure 3.29: Biological modified TRAP assay (The effect of 0.2 μm KN-119 (0.6 x IC50) on 
telomerase activity in Mia-PaCa-2 cells after 7-days [treatment profile i]).  
 
The results from the treatment profiles i and ii of the modified-TRAP assay for KN-119 
failed to establish a biologically-relevant concentration with an effective EC50 for telomerase 
inhibition (Figures 3.31 and 3.32, respectively). In vivo modified TRAP suggested some 
inhibition (~30%) at 0.3 μm for 5-days, but MIA-PaCa-2 cells in culture were increasingly 
non-adherent and no IC50 could be established. The effect of unhealthy cells/degree of 
confluency on telomerase activity is unknown and could be responsible for this observed 
telomerase inhibition. Therefore, for compound KN-119, no clear correlation could be 




















Figure 3.30: Biological TRAP-LIG assay denaturing gel. The effect of 0.3 μm KN-119 on 













Figure 3.31: Quantified biological TRAP-LIG-assay. Number of bands and integrated lane 
intensity were measured, quantified and normalized with respect to the controls. +ve control 
indicative of telomerase positive MIA-PaCa-2 extract. 
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3.2.3.5 β-Galactosidase Senescence Studies  
β-Galactosidase is a known biomarker for the senescent cell phenotype (flattened/enlarged 
cells expressing β-galactosidase) [251]. A senescent cell phenotype has been observed upon 
treatment with the G-quadruplex ligands quinolone and quindolone derivatives causing 
telomere dysfunction [156, 169]. A senescence detection kit (Cell Signaling Technology, 
USA) is readily available commercially which can detect β-galactosidase expression. This kit 
employs a chemically modified galactoside, X-Gal. Upon exposure to β-galactosidase-
positive senescent cells, X-Gal is cleaved by β-galactosidase to form a blue/green precipitate 
within cells, which can be monitored and quantified by microscopy. 
 
Senescence, as indicated by β-galactosidase activity, was measured at two stages in the long-
term treatment experiment, as described in 4.3.2.3 treatment profile iii. The degree of 
senescence in MIA-PaCa-2 cells using the lead-compound KN-119 was quantified (Table 
3.13). The number of senescent cells was determined at two time-points, 8 and 16-days.  
 
Table 3.17: The long-term senescent effect of KN-119 on MIA-PaCa-2 cells. The values 




% senescent cells after treatment 
8 days 16 days 
Control 1.8 ± 0.1 2.1 ± 0.1 
0.2 x IC50 6.4 ± 2.1 9.1 ± 2.1 
0.5 x IC50 14 ± 2.5 17 ± 2.5 
 
KN-119 has moderate β-galactosidase activity in MIA-PaCa-2 cultures compared with 
BRACO-19. BRACO-19, on 7-28 day long-term studies with 2 μm in DU145 cultures (96 h 
IC50 of 22.3 μm) demonstrated significant β-galactosidase activity after 7 and 14 days (~40-
50% β-gal positive cells) [253]. Each ligand demonstrates a significant difference in its 
degree of toxicity, which is attributed to different mechanisms of action. However, it is noted 
that KN-119 does not up-regulate β-galactosidase expression significantly (14-17%) at 
discontinued time-points. Nonetheless, when combined with the population doubling study, 
which demonstrated reduced cell-number, it can be suggested that KN-119 operates via a 
predominantly cytotoxic rather than cytostatic-dependent mechanism. To confirm this 
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definitively, a protein expression investigation of senescent factors p16 and p21 should be 
conducted. 
3.2.3.6 hTERT Expression  
A decrease in telomerase activity and hTERT protein expression levels were measured by the 
modified-TRAP assay in the in vivo hTERT inhibition assay. Dislocation of hTERT from 
telomere causes displacement of the enzyme from the substrate resulting in telomerase 
inhibition. The presence of two non-telomeric PQS within the promoter of hTERT [254] 
suggests that G-quadruplex ligands may act as transcriptional repressors of hTERT. 
However, neither TRAP nor protein expression studies can elucidate whether G-quadruplex 
ligands transcriptionally repress hTERT or promote hTERT displacement and degradation at 
the telomere. 
 
In the modified-TRAP and protein-expression assays, telomerase inhibition is evaluated by 
the decrease in hTERT, and hTERT displacement is observed by confocal microscopy, which 
shows reduced co-localization of hTERT to the telomere. β-Actin was used as a control to 
investigate the effect of the biaryl polyamide ligands on hTERT levels. To ensure 
reproducibility, protein was extracted on three-independent occasions, as outlined in 4.3.2.3 








Figure 3.32: The effect of 0.3 μm KN-119 on hTERT after 1, 3 and 5-days in MIA-PaCa-2 






Figure 3.33 Quantified gel showing the effect of 0.3 μm KN-119 on hTERT after 1, 3 and 5-
days in MIA-PaCa-2 cells. Quantitative figure indicative of two full-repeats, i.e. lysates 
obtained from two different MIA-PaCa-2 treatment cultures. Control indicative of untreated 
MIA-PaCa-2 extract.  
 
In accordance with the TRAP data, the hTERT expression results suggest that at cytotoxic 
conditions KN-119 reduces both hTERT levels and activity. However, as the IC50 value 
cannot be established under these cytotoxic conditions (treatment profile ii as described in 
4.3.2.3), it can be assumed that the cytotoxic mechanism of KN-119 is not entirely dependent 
on hTERT-inhibition. 
 
On day-5, for KN-119, TRAP exhibited ~30% inhibition and hTERT expression was down-
regulated by ~40% while ND2 at 0.5 x IC50 reported ~50% telomerase inhibition (EC50) in 
MCF7 cells after 7-days of treatment [250]. Similar findings from two distinct assay reports 
suggest a valid result; however, the cells used for protein extracts (extracted from three-
independent investigations) appeared unhealthy after 5-days treatment. Hence, in order to 
have a valid result, long-term (40-day) sub-cytotoxic concentrations of KN-119 treatments 
should be conducted, along with the short-term (1-day) post-cytotoxic concentrations.  
 
Since, KN-119 demonstrated no telomerase inhibition in MIA-PaCa-2 cells at 0.6 x IC50 for 
5-days and 1 x IC50 was unable to produce an EC50 after 5-days of treatment, it is unlikely 
that 0.5 x IC50 for 7-days will result in an EC50. Although no EC50 was established and further 
treatment profiles are required to consolidate the result, coupling the data-sets from hTERT 
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protein expression analysis, in vivo and in vitro modified-TRAP, it is likely that KN-119 is 
not a significant hTERT inhibitor. 
 
3.2.3.7 k-Ras Expression  
The biaryl-polyamide ligands demonstrated different degrees of selective toxicity towards the 
k-Ras-dependent pancreatic cell lines MIA-PaCa-2 and HPAC. However, the overall activity 
of KN-119 against the pancreatic cell line made it a suitable candidate for assessing its effect 
on k-Ras expression. Treatment profiles i and ii, as described in 4.3.2.3, were conducted in 






Figure 3.34: The effect of 0.2 μm KN-119 on k-Ras after 7-days in MIA-PaCa-2 cells. 








Figure 3.35: The effect of 0.3 μm KN-119 on k-Ras after 1, 3 and 5-days in MIA-PaCa-2 
cells. (Treatment profile ii as described in 4.3.2.3).  
 
The results from both treatment profiles the sub-cytotoxic long-term (7-day) culture (Figure 
3.34) and the cytotoxic dose over 3-time points (Figure 3.35) that demonstrated no inhibition 
of k-Ras expression suggesting that KN-119 does not function as a transcriptional repressor 
of k-Ras and does not act via a k-Ras dependent pathway. Cytotoxic short-term treatment 
profiles (3x, 5x and 10x reported IC50 values for varied time points (12 h to 3-day) should be 
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tried instead of the sub-cytotoxic long-term treatment profiles in order to explore the result, 
which might not be feasible due to toxicity of the compound.  
 
Considering the lag time required for cell membrane permeation, nuclei-entry and 
transcription-translation events, acute (12 h) high-dose treatments, however, are still unlikely 
to demonstrate a change in k-Ras expression and it can be concluded that KN-119 does not 
inhibit k-Ras expression. 
 
3.3 Structure Activity Relationship 
The structure activity relationship analysis was made by assessing three series-wide 
investigations as follows,  
i) ΔTm oC from FRET 
ii) TRAP and Biophysical modified-TRAP  
iii) IC50 values from SRB assays 
 
The following methods were adopted for structure-function analysis:  
i) From each investigation the strongest/weakest ligands were identified.  
ii) Consistency in activity of the ligands was identified by comparing the strongest/weakest 
ligands from FRET and modified-TRAP assays.  
iii) Consistency in activity of the ligands was identified by comparing the strongest/weakest 
ligands for SRB assay. 
iv) Comparison of ligands from part ii) and part iii) led to identification of consistently 
strong/weak ligands from all four investigations.  
 
The structure activity relationship analysis was made in two segments. Firstly, the molecules 
were analysed based on their FRET data and it was tried to establish a relationship between 
the changes in activity of the molecules with subtle modifications within the structure of the 
molecules. The other way of investigation was based on the hypothesis that ligands with 
significant FRET ΔTmoC values for F21T are more likely to function as telomerase inhibitors 
in the biophysical modified-TRAP, as well as could be co-related with the results from SRB 
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assays. All of the synthesized biaryl polyamide ligands could not be investigated using all the 
biophysical and biological assays such as TRAP, SRB, PD, and other assays mentioned 
earlier because of lack of facilities; however, a partial SAR could be established. Although 
this method is simplistic and bound to have several caveats, it is based on a grouping of 
biophysical and biologically-relevant investigations.  
 
Initial modification of the biaryl polyamides developed by Rahman and co-workers showed 
some degree of G-quadruplex stabilization with better G-quadruplex selectivity over duplex 
DNA [172]. To develop molecules with better binding affinity and selectivity, some 
modification in motifs 1 and 2 of the first generation ligands was conducted. Library-1 
second generation molecules contain only one non-variable core (blue circle), such as motif 
1, whereas in library-2 ligands, a benzofused (purple circle) moiety was introduced after the 
tail moiety, which also contains a variable capping moiety (orange circle). 
 
 
Figure 3.36: Comparison of first and second generation ligand structures.   
 
The FRET data for the library-1 ligands against all investigated sequences showed complete 
loss in binding affinity. For molecules containing similar central cores, loss in activity may be 
attributed to the changes in the tail and capping moieties. However, the π-electron rich central 
core helps the molecules in π-π stacking with the G-quartet. The molecular modelling of the 
first generation biaryl ligands showed that the central core facilitates the U-shape formation 
of the molecules resulting in better selectivity towards the G-quadruplex over duplex DNA. 
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As with the previous results for the library-2 ligands, KN-88 and KN-119 demonstrated better 
G-quadruplex stabilization potential and selectivity than the first generation ligands. These 
molecules contain similar structural features analogous to the first generation motif 2 ligands, 
with the exception of the benzofused moiety. The presence of the tail moiety for other 
library-2 molecules did not show any significant effects. Hence, the enhancement in activity 
in the FRET assay might be due to the presence of the benzofused moiety. Although, KN-88 
and KN-119 have a similar tail, central core and final capping moieties, KN-88 containing the 
benzothiophene ring showed better stabilization of the F21T sequence than KN-119 with the 
benzofuran ring. The subtle change from furan to thiophene in the benzofused ring resulted in 
an increased binding affinity of 2.20 °C. 
 
KN-119 demonstrated consistently good results in other biophysical and biological analyses. 
Therefore, depending on the initial screening results some of the other second generation 
biaryl polyamides were designed based on KN-119 as the lead compound. Three points of 
modification of ligand KN-119 were selected and the resulting molecules were analysed by 
FRET melting assay. In these series, no significant stabilization of F21T was observed due to 
the change in the benzofused moiety (R2) where the highest level of F21T stabilization was 
observed with the modification of the tail motif (R1). KN-148 and KN-158, formed by 
modification of the final capping acid (R4), demonstrated significant binding affinity towards 
the human telomeric G-quadruplex DNA. Again, with these two molecules, the minor change 
in the structure of R4 from furan to 4-methylthiazole resulted in enhancement in the 
stabilization potential. Interestingly, the G-quadruplex stabilization ability of the ligands 
increased with increasing carbon number in the tail R1, as is evident from the FRET data for 
KN-212, KN-217, KN-232, KN-237, KN-242 and KN-247 (Table 3.18) (Figure 3.37). 
Although, KN-119 and KN-232 have similar structure, elongation of the tail molecule R1 by 
only one carbon in KN-232 caused an increase in FRET ΔTm value by 3 °C over KN-119. 
Although, both molecules have similar structure, the binding ability of KN-247 was almost 
double that of its analogue KN-212, which is because of the extra carbon present in the tail of 
KN-247. A similar pattern was observed in the case of molecules KN-217, KN-237 and KN-
242. However, the highest degree of stabilization was found with KN-242 with a pyrrolidine 
unit and a 4 carbon tail instead of the N,N-dimethyl propylamine tail of KN-119. Again, the 
stabilization ability of the ligand fell slightly when the tail contained the methylpiperazine 
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ring used in KN-252. Therefore, it can be suggested that for good G-quadruplex stabilization 
four carbons should be present in the tail. 
 
Figure 3.37: Structure of the active molecules.   
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Table 3.18: Structure-function analysis of the aryl polyamide series. The table shows the 




























 Table 3.18: Structure-function analysis of the aryl polyamide series. The table shows the 
























Analysis of the FRET data presented some promising G-quadruplex binding ligands which 
further correlated with the available biophysical and biological data. Although all the 
compounds were not screened through TRAP and SRB assays, we tried to establish a 
combined SAR between the molecules and their activity from the available data.  
 
It is evident that KN-88, KN-119 and KN-148 are consistently good ligands in the SRB, 
TRAP and FRET assays. However, despite this, KN-158 showed good biophysical properties 
in TRAP and FRET, but displaying poor biological properties in the SRB assay. In contrast, 
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KN-150, with moderate biophysical properties in TRAP and FRET, demonstrated good 
biological properties via SRB analyses of the data. Although KN-159 and KN-144 showed 
some (~5%) telomerase inhibition in TRAP, they seemed to be the poorest ligands 
collectively in terms of analysis of the SRB and FRET data. Ligand KN-149, similar to KN-
144, produced the poorest data in terms of SRB analysis.  
 
3.3.1 R1.1 - The First Ring Moiety  
 
The thiazole ring in this position has been found to be important for activity of the 
compounds. The ligands KN-88 and KN-119 showed better results in the SRB assay although 
their TRAP data are not significant. Again, the thiazole ring containing ligand KN-143 and 
KN-145 at this position show good SRB data (although both show an IC50 in WI38 cells of 
~20 μm and no significant toxic selectivity towards MIA-PaCa-2). The consistently good 
SRB-data from ligands containing the thiazole moiety suggest next-generation ligands should 
maintain the thiazole group at R1.1 (Figure 3.38).  
 
The 2-methylthiazole moiety containing derivatives KN-130, KN-149, KN-150 and KN-158 
demonstrated varied results. Although, KN-158 showed good ΔTm values in FRET and 
modified-TRAP, it presents relatively-poor SRB data. KN-130 and KN-149 showed poor 
results in FRET and SRB while KN-130 demonstrated mild telomerase inhibition (~20%). 
Again, moderate FRET activity was found for the ligand KN-150, which showed relatively 
better results in the SRB assays (although giving an IC50 in WI38 cells of ~17 μm and no 
significant toxic selectivity towards MIA-PaCa-2). Due to such variation in results it can be 
suggested that the 2-methylthiazole moiety may not be a crucial moiety. Among the furan 
ring containing derivatives only KN-148 showed a good level of activity in FRET, while the 
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other ligands, KN-154, KN-155 and KN-159 are poor in FRET. On the contrary, KN-154, 
KN-155 and KN-159 showed moderate activity in SRB and TRAP assays, but KN-148 had 
poor activity. This suggests that the efficacy of KN-148 is not dependent on the furan moiety 
but on either its R1.2 terminal contiguous ring system or R2-moiety (Table 3.19).  
 
As only two ligands KN-144 and KN-146 contain a benzene ring, hence it is difficult to 
assess the relative effect of it. Although, KN-144 shows some toxic selectivity towards MIA-
Pa-Ca-2 cells, both ligands gave relatively poor results in the SRB, FRET and modified-
TRAP assays. Little structure-function analysis can be performed because of the lack of 
ligands with the benzene ring in this position.  
 
Thiophene ring containing ligands KN-156, KN-157, KN-160 and KN-161 showed varied 
results for different assays. All have identical R2-ring systems, along with the similar R1.1 
moiety. SRB-assay demonstrates that KN-156 and KN-157 are good, while KN-160 and KN-
161 are poor. FRET data show KN-156, KN-157 and KN-160 are poor while KN-161 is 
moderate. TRAP data show KN-156 to be moderate, KN-157 to have little effect while KN-
160 and KN-161 have no effect. Such variation in results leads to the assumption that the 














Table 3.19: Structure-function analysis of the aryl polyamide series. The table shows the 
stronger (top) and poorer (bottom) ligands and their variable motifs. FRET (ΔTm F21T), %- 



















   
19.00 18 0.3 
88 
   
21.20 17 0.7 
148 
   
15.45 3 2.3 
158 
   
18.00 27 3.9 
130 
   
3.85 20 3.1 
150 
   
10.00 5 1.1 
144 
   




Table 3.19: Structure-function analysis of the aryl polyamide series. The table shows the 
stronger (top) and poorer (bottom) ligands and their variable motifs. FRET (ΔTm F21T), %- 

















   
1.85 n/a 2 
159 
   
2.33 8 1.9 
161 
   
7.03 0 3.2 
 
3.3.2 R1.2 - The Terminal Contiguous Ring Moiety  
 
Different classes of ring-systems in the derivatives make it difficult to conduct a structure-
function relationship analysis. However, interestingly, ligands with the 2,3-di-hydro-
benzofuran ring system (KN-88, KN-119, KN-130, KN-143) are the most potent in SRB-
assays. Amongst these molecules, the most potent ligand contains thiazole as opposed to 
furan as the R1.1 first-ring group (Figure 3.38).  
3.3.3 R2 - The Benzofused Ring Moiety  
1H-indole (KN-143) and 3-phenyl-1H-indole (KN-145) R2-based ring systems containing 
ligands are potent in SRB-assays, though KN-145 showed better FRET data towards F21T. 
This could not be fully attributed to the change of the R2 ring to 3-phenyl-1H-indole from 
1H-indole as TRAP data for KN-145 are negligible, whereas KN-143 showed moderate 
activity. 
The R2-ring systems of KN-88, KN-119 and KN-130 contain benzothiopene, benzofuran and 
benzothiazole, respectively. SRB data for KN-130 show poorer degree of potency (apart from 
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in MCF7 cells) than KN-88 and KN-119. This suggests that the benzothiopene and 
benzothiazole terminal contiguous-ring moieties (single-substituted azoles as opposed to 
disubstituted azoles) have better degree of potency and selectivity for MIA-Pa-Ca-2 cells 
(Table 3.19).  
 
It was understandable that lack of TRAP and SRB data for all synthesized biaryl polyamide 
ligands made it impossible to establish a complete structure activity relationship. However, 
analysis of FRET data for F21T gives some idea about the standard structural features that 
are necessary for optimum G-quadruplex stabilization and better selectivity. 
 
3.3.4 Biological Evaluation of Type-3 Library Molecules. 
 
New generation biaryl polyamides were designed and synthesized depending on the reported 
first generation biaryl polyamides by Rahman and co-workers. Initial synthesis and screening 
of Type-1 and Type-2 molecules by FRET provided two lead molecules KN-88 and KN-119. 
Among these two lead molecules, KN-119 showed better activity against two different types 
of pancreatic cancer cell line, which made it the first choice for further modification. 
Modification of the lead molecule, KN-119, resulted in Type-3 library molecules which were 
initially analysed by FRET melting assay. FRET data of those molecules demonstrated 
significant increase in G-quadruplex binding ability by 17 C for KN-242 compared with 
KN-119. From assessment of the first type molecules it was evident that there is a correlation 
between the biophysical and biological activities as KN-119 showed good activities in both 
types of assay (please see Table 3.11 and section 3.2). The biological analyses were not 
conducted because of lack of facilities as the group moved from the School of Pharmacy, 
UCL to King’s College London. However, it can be assumed that their biological activity and 









Chapter Four: Experimental 
4.0 Experimental-Chemical 
4.1.1 General Experimental (Chemistry)  
All reagents and solvents used were supplied from the commercial suppliers Sigma-Aldrich 
and Fluka. Reactions requiring anhydrous conditions were conducted in glassware, which had 
been oven-dried overnight and used the following day. All reactions were monitored by 
analytical thin-layer chromatography (TLC) performed using the indicated solvent on E. 
Merck silica gel 60 F254 plates (0.25 mm). TLC plates were visualized using UV light (254 or 
360 nm) and /or by staining the plates with either a cerium sulphate-ammonium molybdate 
solution or basic KMnO4 followed by heating. A LCMS machine (liquid chromatography 
coupled with mass spectrometry) was also used to monitor the progress of the compounds. 
Solvents were removed using a rotary evaporator at or below 40 °C and the compounds 
further dried using low pressure vacuum pumps. Purification of the compounds was achieved 
by column chromatography using Merck Flash Silica Gel 60 (230-400 mesh). 1H and 13C 
NMR spectra were recorded on either Bruker Avance 400 MHz or Bruker Avance 500 MHz 
spectrometers. Chemical shifts (δ H) are quoted in ppm (parts per million) and referenced to 
either the CDCl3 residual chloroform signal (
1H δ = 7.26, 13C δ = 77.2) or the d6-DMSO 
residual dimethyl-sulfoxide signal (1H δ = 2.54, 13C δ = 40.45) or MeOD residual methanol 
signal (1H δ = 3.31, 13C δ = 49.00).  Multiplicities in the 1H NMR spectra are quoted as: s = 
singlet, d = doublet, t = triplet q = quartet, m = multiplet, dd = double doublet, ddd = double 
double doublet, dt = double triplet, td = triple doublet. The code (0) in the 13C NMR spectra 
denotes the presence of a quaternary carbon. High resolution mass spectra (HRMS) were 
obtained on a Thermo Navigator mass spectrometer coupled with a LC using electrospray 
ionisation (ES) and time-of-flight (TOF) mass spectrometry. Infrared spectra were recorded 
on a Perkin Elmer spectrum 1000 instrument. 
 
4.1.2 General procedure for purification by ‘Catch and Release’ method 
The sulphonic acid based SCX-2 resin cartridges were purchased from Biotage Synthesis 
(Virginia, USA) with different sorbent capacities (500 mg, 1 gm, 2 gm, 5 gm and 10 gm). 
The cartridges contained propylsulfonic acid functionalized silica. The strong cation 
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exchange sorbent is a very good choice for basic drug extraction. The cartridges were first 
activated by an initial wash with 2 column volumes of DCM and 2 column volumes of 
methanol. The reaction mixtures were then poured onto the cartridge (sorbent mass should be 
10 times that of the calculated mass of the product) and the solvent was allowed to pass 
through the cartridges under gravity. The cartridges were washed with DCM (3X), DMF (3X) 
and methanol (1X) and the cycle was repeated three times to remove the impurities under 
vacuum to accelerate the elution. Products were released from the cartridge using 2M NH3 in 




















4.1.3 General Procedures 
4.1.3.1 Method A: Amide coupling between heterocyclic amine and heterocyclic base 
using HOBT and DIC 
The acid (from 1.0 to 2.5 eq.) was dissolved in DCM/DMF (5-50 ml, depending on the 
amount of acid and solubility) in a round bottom flask/ Green House Parallel Synthesizer vial 
fitted with a magnetic stirrer. DIC (1.75 eq.) and HOBT (2.0 eq.) were added to the stirred 
solution at room temperature and the mixture was allowed to stir for between 45 minutes to 6 
hours depending on the reactivity of the acid. The amine (1.0 eq.) was added after the initial 
activation step and the reaction mixture was allowed to stir until the reaction was deemed 
complete by TLC or LCMS. The reaction mixture was purified either by applying to a 
conditioned cartridge and the coupled product released by the ‘Catch and Release’ method 
described above or by using conventional column chromatography. 
 
4.1.3.2 Method B: Standard hydrogenation procedure 
The starting material was dissolved in either ethyl acetate or ethanol (maximum 150 ml) and 
a slurry of 10% Pd/C (10% w/w compared to the starting material) in the same solvent was 
added. The mixture was hydrogenated in a Parr hydrogenator at 45 psi until the H2 uptake 
ceased. The progress of the reaction was monitored by either TLC or LCMS and the reaction 
mixture was filtered through a layer of celite and the residue washed with either ethyl acetate 
or ethanol. The solvent was removed under vacuum using a rotary evaporator to give the 
reduced product. 
 
4.1.3.3 Method C: Microwave assisted Suzuki coupling between heterocyclic bromide 
and different boronic acids   
The heterocyclic bromide (1.0 eq.), the boronic acid (1.2-1.5 eq.), K2CO3 (3.0 eq.) and 
tetrakis Pd(PPh3)4 (0.1 eq.) were added to an Emrys
TM Process microwave vial containing a 
magnetic stirrer under nitrogen. An appropriate amount (5 ml for every 125 mg of substrate) 
of solvent mixture (Ethanol/Toluene/Water – 9:3:1) was added to the microwave vial under 
nitrogen and the vial was sealed with a ResealTM septum. The suspension was then irradiated 
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at microwave wavelengths and kept at 100 °C for 5-30 minutes depending on the substrate. 
The progress of the reaction was monitored by LCMS. For heterocyclic products containing 
the N,N-dimethylaminopropyl tail, the reaction mixtures were applied to a SCX-2 cartridge 
and purified by the ‘Catch and Release’ method described earlier. For products without a tail 
the reaction mixture was filtered through a celite layer and the residue washed with ethyl 
acetate. The solvent was removed under vacuum and the crude products were further purified 
using flash chromatography to give the pure product. 
 
4.1.3.4 Method D: Hydrolysis of aromatic methyl ester 
A 0.5 M aqueous solution of NaOH was added to a solution of the methyl ester in dioxane (1 
ml for every 25 mg of ester). The reaction mixture was allowed to stir for 1.0-6.0 hours at 
which point TLC showed completion of the reaction. Excess dioxane was evaporated under 
vacuum and the residue was dissolved in water. The aqueous layer was acidified with 1M 
citric acid solution. The product was extracted with ethyl acetate and the organic layer was 
sequentially washed with water and brine, and finally dried over MgSO4. The excess solvent 
was removed under vacuum and the product dried in a vacuum oven.  
 
4.1.3.5 Method E: Nitration 
Fuming nitric acid (37.5 ml) was added drop wise over a period of 1 hour to a mechanically 
stirred solution of the substrate (1.0 eq.) in acetic anhydride (475 ml), which was kept at -5 
°C using an acetone/dry ice bath. After complete addition the temperature of the reaction 
mixture was gradually raised to 10 °C over a period of 3 hours, with continuous stirring. The 
reaction mixture was again cooled to -30 °C using an acetone/dry ice bath and diluted with 
500 ml of isopropanol; the resulting precipitate was dried in a vacuum. 
 
4.1.3.6 Method F: Procedure for disposing Pd/C waste 
A Pd/C catalyst was used for the hydrogenation reaction. The catalyst was adsorbed on the 
celite bed over a filter paper after finishing the reaction. A slurry of celite was prepared using 
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ethanol, which was passed under vacuum over several layers of filter paper to prepare the 
celite bed. The reaction mixture was poured over the bed after completion of the reaction, 
which trapped the Pd/C catalyst. The celite bed was then disposed of according to the 
standard procedure of the university in a separate container specified for Pd/C waste. 
 
4.1.4 Type-1 Library synthesis 
Procedure for the synthesis of ethyl 1-(3-(5-bromothiophene-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.3). (Amide coupling). 
2.0 eq of HOBT (32 mg) and 1.75 eq. of DIC (145 µl) were added to a solution of 4.2 (270 
mg) in DCM (10 ml). After 30 minutes, 1.30 eq. of 4.1 (277 mg) was added and the reaction 
mixture was allowed to stir overnight. After 16 hours the reaction mixture was passed 
through a SCX-2 cartridge (5.0 gm) and the cartridge was washed with DCM (3x), DMF (3x) 
twice and finally MeOH (2x). The product 4.3 was released from the cartridge using 5.0 ml 
2M NH3 in MeOH and concentrated in vacuo to obtain 460.0 mg light brown, oily mass. 
Ethyl 1-(3-(5-bromothiophene-2-carboxamido)benzyl)piperidine-4-carboxylate (4.3):  
 
Light brown, oily mass. IR (FTIR, νmax/cm-1) 635.14, 692.83, 775.02, 860.27, 1024.69, 
1046.66, 1094.97, 1129.45, 1167.22, 1249.40, 1323.56, 1362.67, 1439.07, 1487.34, 1553.13, 
1613.41, 1724.62, 2967.27, 3339.66; 1H NMR (400 MHz, CDCl3, TMS); δ 1.12 (d, J=6.4 Hz, 
3H), 1.22 – 1.24 (m, 2H),1.80 – 1.85 (m, 2H), 2.02 (t, J=10.0 Hz, 2H),2.26 – 2.29 (m, 1H), 
2.86 – 2.88 (m, 2H), 3.54 (s, 2H), 4.14 (q, J=6.8 Hz, 2H), 6.85 (d, J=3.79 Hz, 1H),7.06 (d, 
J=4.0 Hz, 1H), 7.28 (d, J=7.6 Hz, 1H), 7.42 (d, J=4.0 Hz, 1H), 7.47 (s, 1H), 7.61 (dd, J=8.4, 
7.2 Hz, 1H), 7.98 – 7.99 (m, 1H); 13C NMR (100 MHz, CDCl3); δ 14.3, 29.05, 29.5, 41.1,  
53.00, 61.5, 63.34, 64.7, 120.1, 121.06, 124.2, 124.5, 128.50, 132.15, 134.32, 135.6, 138.2, 
139.62, 140.1, 161.1, 175.8;  m/z (+EI) calc. For C20H23BrN2O3S (M+) 451.38, found 452.83 
(M+H)+; Yield: 95%. 
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Procedure for the synthesis of ethyl 1-(3-(5-bromofuran-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.5) 
2.0 eq of HOBT (31 mg) and 1.75 eq. of DIC (141 µl) were added to a solution of 4.2 (262 
mg) in DCM (10 ml). After 30 minutes, 1.30 eq. of 4.4 (253 mg) was added and the reaction 
mixture was allowed to stir for 3 hours. After 3 hours the reaction mixture was passed 
through a SCX-2 cartridge (5.0 gm), which was washed with DCM (3x), DMF (3x) twice and 
finally MeOH (2x). The product 4.5 was released from the cartridge using 5.0 ml 2M NH3 in 
MeOH and concentrated in vacuo to obtain 234.0 mg light brown solid. 
Ethyl 1-(3-(5-bromofuran-2-carboxamido)benzyl)piperidine-4-carboxylate (4.5):  
 
Light brown solid.  IR (FTIR, νmax/cm-1) 635.14, 692.83, 775.02, 860.27, 1024.69, 1046.66, 
1094.97, 1129.45, 1167.22, 1249.40, 1323.56, 1362.67, 1439.07, 1487.34, 1553.13, 1613.41, 
1724.62, 2967.27, 3339.66; 1H NMR (400 MHz, CDCl3, TMS); δ 1.22 (t, J=4.0 Hz, 3H), 1.8 
– 1.82 (m, 2H), 1.93 – 1.94 (m, 2H), 2.14 – 2.18 (m, 2H), 2.30 – 2.33 (m, 1H), 2.95 – 2.97 
(m, 2H), 3.48 (s, 1H), 3.56 (s, 2H), 4.11 (q, J=7.2 Hz, 2H), 6.80 (d, J=3.79 Hz, 1H), 7.10 (d, 
J=7.2 Hz, 1H), 7.19 (d, J=3.6 Hz, 1H),  7.3 (t, J=7.61 Hz, 1H),  7.51 (s, 1H), 7.67 (dd, J=1.2, 
6.8 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 14.24, 28.25, 29.5, 41.1, 53.00, 60.31, 63.11, 
64.7, 113.69, 117.47, 120.58, 122.50, 124.50, 128.04, 134.32, 135.7, 137.24, 147.29,161.24, 
175.88;   m/z (+EI) calc. For C20H23BrN2O4 (M+) 435.31, found 436.94 (M+H)
+; Yield: 90%. 
Procedure for the synthesis of ethyl 1-(3-(4-bromothiophene-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.7):  
2.0 eq of HOBT (31 mg) and 1.75 eq. of DIC (141 µl) were added to a solution of 4.2 (250 
mg) in DCM (10 ml). After 30 minutes, 1.30 eq. of 4.6 (256 mg) was added and the reaction 
mixture was allowed to stir for 3 hours. After 3 hours the reaction mixture was passed 
through an SCX-2 cartridge (5.0 gm) and the cartridge washed with DCM (3x), DMF (3x) 
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twice and finally MeOH (2x). The product 4.7 was released from the cartridge using 5.0 ml 
2M NH3 in MeOH and concentrated in vacuo. 245.0 mg light brown, oily mass was obtained. 
Ethyl 1-(3-(4-bromothiophene-2-carboxamido)benzyl)piperidine-4-carboxylate (4.7): 
 
Light brown, oily mass. IR (FTIR, νmax/cm-1) 635.14, 692.83, 775.02, 860.27, 1024.69, 
1046.66, 1094.97, 1129.45, 1167.22, 1249.40, 1323.56, 1362.67, 1439.07, 1487.34, 1553.13, 
1613.41, 1724.62, 2967.27, 3339.66; 1H NMR (400 MHz, CDCl3, TMS); δ 1.22 – 1.24 (m, 
3H), 1.78 – 1.82 (m, 2H), 1.86 – 1.89 (m, 2H), 2.27 – 2.31 (m, 1H), 2.88 – 2.89 (m, 2H), 
2.956 (s, 1H), 3.50 (d, J=8.4 Hz, 2H), 4.14 (q, J=7.2 Hz, 2H), 7.09 (d, J=7.6 Hz, 1H), 7.21 – 
7.25 (m, 1 H), 7.30 (t, J=8.0 Hz, 1H), 7.43 (d, J=1.2 Hz, 1H), 7.50 (s, 1H), 7.62 – 7.63 (m, 
1H), 8.14 (s, 1H); 13C NMR (100 MHz, CDCl3); δ 14.24, 28.21, 29.5, 41.1, 52.94, 60.35, 
62.99, 64.2, 110.78, 120.1, 121.1, 125.36, 129.07, 132.5, 133.6, 135.5, 136.07, 139.23, 161.8, 
175.24;   m/z (+EI) calc. For C20H23BrN2O3S (M+) 451.38, found 452.53 (M+H)
+; Yield: 
98%. 
Procedure for the synthesis of ethyl 1-(3-(5-(4-acetamidophenyl)furan-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.9) using ethyl 1-(3-(5-bromofuran-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.5) N-(4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)acetamide (4.8). (Suzuki coupling).  
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq., 9 mg) was 
added to a solution of 4.5 (1.0 eq., 34 mg) and 4.8 (1.2 eq., 25 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq., 32 mg) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 8 minutes. After LCMS analysis revealed complete reaction, the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (2.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.9 was released from the 
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cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo to obtain 31 mg of a 
light cream, oily mass. 
Ethyl 1-(3-(5-(4-acetamidophenyl)furan-2-carboxamido)benzyl)piperidine-4-
carboxylate (4.9):  
 
 
Light cream, oily mass. IR (FTIR, νmax/cm-1) 695.36, 723.20, 777.41, 968.33, 1254.62, 
1301.51, 1395.69, 1463.43, 1519.13, 1660.07, 1725.58, 2361.96, 2947.66, 3262.19; 1H NMR 
(400 MHz, CDCl3, TMS); δ 1.25 (t, J=7.07 Hz, 3H), 1.81 – 1.83 (m, 2H), 1.89 – 1.92 (m, 
2H), 2.06 – 2.08 (m, 2H), 2.26 (s, 3H), 2.89 (s, 2H), 2.96 (s, 1H), 3.51 (s, 2H), 4.13 (q, 
J=7.24 Hz, 2H), 6.80 (d, J=3.79 Hz, 1H), 7.12 (d, J=7.58 Hz, 1H), 7.31 – 7.33 (m, 2H), 7.48 
– 7.51 (m, 1H), 7.55 – 7.57 (m, 1H), 7.66 – 7.67 (m, 1H), 7.72 – 7.75 (m, 1H), 8.03 (d, 
J=2.27 Hz, 1H), 8.06 (d, J=2.53Hz, 1H), 8.11 (s, 1H), 8.18 (s, 1H); 13C NMR (100 MHz, 
CDCl3); δ 14.24, 24.82, 28.25, 53.00, 60.31, 63.11, 76.72, 77.04, 77.36, 108.06, 113.69, 
117.47,119.01, 120.58, 125.50, 128.50, 129.04, 132.03, 132.05, 132.15, 134.32, 137.24, 
139.62, 144.22, 147.29,151.24, 155.88, 175.4; m/z (+EI) calc. For C28H31N3O5 (M+) 489.56, 
found 491.11 (M+H)+; Yield: 90%. 
Procedure for the synthesis of ethyl 1-(3-(5-(4-acetamidophenyl)thiophene-2-
carboxamido)benzyl)piperidine-4-carboxylate  (4.10) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq., 33 mg) was 
added to a solution of 4.3 (1.0 eq., 129 mg) and 4.8 (1.2 eq., 90 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq., 118 mg) in a 10 ml microwave 
vial containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
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100 °C for 10 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (2.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.10 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 120 mg light cream oil 
was obtained as product. 
Ethyl 1-(3-(5-(4-acetamidophenyl)thiophene-2-carboxamido)benzyl)piperidine-4-
carboxylate  (4.10):  
 
Cream oil. IR (FTIR, νmax/cm-1) 630.87, 734.65, 797.03, 1047.27, 1259.00, 1301.51, 1388.22, 
1443.02, 1541.85, 1595.69, 1637.12, 2335.36, 2361.75, 2919.25; 1H NMR (400 MHz, 
CDCl3, TMS); δ 1.24 (t, J=7.07 Hz, 3H), 1.62 (br. s., 4H), 1.83 – 1.85 (m, 2H), 1.92 – 1.95 
(m, 2H), 2.19 (s, 1H), 2.25 (s, 3H), 3.54 (s, 2H), 4.14 (q, J=7.07 Hz, 2H), 7.13 (d, J=7.58 Hz, 
1H), 7.31 (d, J=4.04 Hz, 1H),  7.35 – 7.38 (m, 1H), 7.54 (d, J=5.05 Hz, 1H), 7.61 (d, J=3.79 
Hz, 1H), 7.647 (d, J=7.33 Hz, 1H), 7.94 (dd, J=8.59, 2.5 Hz, 1H), 7.97 (s, 1H), 8.28 (d, 
J=8.84 Hz, 1H), 8.57 (d, J=2.27 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 14.3, 24.50, 29.05, 
29.8, 41.1, 53.00, 53.3, 61.5, 63.34, 119.7, 120.1, 121.06, 124.4, 127.7, 127.9, 128.50, 
129.04, 132.15, 134.32, 137.24, 138.2, 139.62, 145.7, 148.5, 151.24, 155.88, 168.9, 175.3;  
m/z (+EI) calc. For C28H31N3O4S (M+) 505.63, found 507.38 (M+H)
+; Yield: 93%. 
Procedure for the synthesis of ethyl 1-(3-(4-(4-acetamidophenyl)thiophene-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.11) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq., 22 mg) was 
added to a solution of 4.7 (1.0 eq., 85 mg) and 4.8 (1.2 eq., 59 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq., 78 mg) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
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100 °C for 10 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (2.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.11 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 77 mg light creamy, oily 
mass was obtained as product. 
Ethyl 1-(3-(4-(4-acetamidophenyl)thiophene-2-carboxamido)benzyl)piperidine-4-
carboxylate (4.11):  
 
Light cream, oily mass IR (FTIR, νmax/cm-1)  630.99, 785.77, 1186.34, 1258.67, 1307.74, 
1520.78, 1648.70, 1718.45, 2359.48, 2630.49, 3090.43; 1H NMR (400 MHz, CDCl3, TMS); δ 
1.25 – 1.27 (m, 3H), 1.79 – 1.82 (m, 2H), 1.88 – 1.92 (m, 2H), 2.07 – 2.11 (m, 1H), 2.24 (s, 
3H), 2.88 – 2.90 (m, 2H), 3.51 (s, 2H), 4.13 (q, J=7.07 Hz, 2H), 7.12 (d, J=7.83 Hz, 1H), 
7.33 (t, J=7.96Hz, 1H), 7.54 (s, 1H), 7.65 (d, J=1.52 Hz, 1H), 7.67 (d, J=1.52 Hz, 1H), 7.86 
(s, 1H), 7.89 – 7.90 (m, 2H), 7.92 (d, J=2.27 Hz, 1H), 8.04 (s, 1H), 8.27 (d, J=8.59 Hz, 1H), 
8.53 (d, J=1.77 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 14.24, 24.82, 28.21, 29.4, 29.7, 
41.7, 52.94, 60.35, 62.99, 113.78, 119.13, 120.1, 121.5, 1221.1, 125.36, 126.82, 127.08, 
128.9, 129.07, 132.5, 136.07, 139.23, 145.37, 151.3, 159.56, 161.8, 168.4, 175.24; m/z (+EI) 
calc. For C28H31N3O4S (M+) 505.63, found 507.15 (M+H)
+; Yield: 80%. 
Procedure for the synthesis of ethyl 1-(3-(5-(6-ethoxynaphthalen-2-yl)thiophene-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.13) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq., 22 mg) was 
added to a solution of 4.3 (1.0 eq., 60 mg) and 4.12 (1.2 eq., 34 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq., 55 mg) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
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microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 8 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (2.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.13 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 51 mg light yellow, oily 
mass was obtained as product. 
Ethyl 1-(3-(5-(6-ethoxynaphthalen-2-yl)thiophene-2-carboxamido)benzyl)piperidine-4-
carboxylate (4.13):  
 
Light yellow, oily mass. IR (FTIR, νmax/cm-1) 629.55, 780.81, 1046.05, 1191.72, 1248.92, 
1318.08, 1391.81, 1445.78, 1487.48, 1545.45, 1603.77, 1727.25, 2341.08, 2806.20, 2927.54, 
3271.31; 1H NMR (400 MHz, CDCl3, TMS); δ 1.25 – 1.27 (m, 3H), 1.50 (t, J=7.07 Hz, 3H), 
1.80 – 1.82 (m, 2H), 1.88 – 1.90 (m, 2H), 2.08 – 2.11 (m, 1H), 2.89 – 2.90 (m, 2H), 2.96 (s, 
2H), 3.51 (s, 2H), 4.13 (q, J=7.07 Hz, 2H) 4.18 (q, J=7.07 Hz, 2H), 7.11 (d, J=7.58 Hz, 1H), 
7.14 (d, J=4.0 Hz, 1H), 7.20 (dd, J=2.0, 7.56 Hz, 1H), 7.33 (t, J=7.83 Hz, 1H),  7.40 (d, 
J=3.97 Hz, 1H),  7.53 (s, 1H), 7.64 – 7.68 (m, 2H), 7.73 (dd, J=2.02, 7.58 Hz, 1H),   7.75 (s, 
1H), 7.78 (d, J=8.59 Hz, 2H),  8.04 (s, 1H); 13C NMR (100 MHz, CDCl3); δ 14.3, 14.77, 
28.27, 29.5, 41.1, 52.95, 60.26, 63.56, 64.2, 64.7,  106.51, 118.88, 119.98, 120.45, 123.27, 
124.47, 124.88, 127.57, 128.55, 128.96, 129.51, 129.72, 132.12, 135.6, 137.19, 137.70, 
141.2, 150.20, 157.64, 159.82, 176.9, 207.00; m/z (+EI) calc. For C32H34N2O4S (M+) 542.69, 
found 543.00 (M+H)+; Yield: 85%. 
Procedure for the synthesis of ethyl 1-(3-(5-(6-ethoxynaphthalen-2-yl)furan-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.14) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq., 22 mg) was 
added to a solution of 4.5 (1.0 eq., 60 mg) and 4.12 (1.2 eq., 36 mg) in a 9:3:1 combination of 
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EtOH, toluene and water in the presence of K2CO3 (3.0 eq., 57 mg) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 8 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (2.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.14 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 48 mg light cream, oily 
mass was obtained as product. 
Ethyl 1-(3-(5-(6-ethoxynaphthalen-2-yl)furan-2-carboxamido)benzyl)piperidine-4-
carboxylate (4.14):  
 
Light cream oily mass. IR (FTIR, νmax/cm-1) 630.53, 664.57, 785.97, 1204.42, 1444.64, 
1545.38, 1648.70, 1726.19, 1736.53, 2087.85, 2186.04, 2516.79, 3085.27, 3348.83; 1H NMR 
(400 MHz, CDCl3, TMS); δ 1.25 – 1.27 (m, 3H), 1.52 (t, J=6.95 Hz, 3H), 1.82 – 1.85 (m, 
2H), 1.91 – 1.93 (m, 2H), 2.30 – 2.33 (m, 1H), 2.89 – 2.91 (m, 2H), 3.53 (s, 2H), 4.16 – 4.18 
(m, 4 H), 6.86 (d, J=3.54 Hz, 1H), 7.13 (d, J=7.83 Hz, 1H),  7.16 (d, J=2.53Hz, 1H), 7.23 (dd, 
J=9.09, 2.5 Hz, 1H), 7.36 (d, J=4.0 Hz, 1H), 7.37 (d, J=2.50Hz, 1H), 7.48 (dd, J=7.58, 
3.03Hz, 1H), 7.58 (d, J=1.52Hz, 1H), 7.68 – 7.70 (m, 2H), 7.77 (dd, J=7.96, 1.3 Hz, 1H), 
7.86 (d, J=9.09 Hz, 1H), 7.79 (s, 1H), 8.15 (s, 1H), 8.18 (s, 1H);  13C NMR (100 MHz, 
CDCl3); δ 14.1, 14.8, 28.27, 29.5, 41.1, 52.95, 60.26, 63.56, 64.2, 64.7,  106.51, 108.88, 
108.98, 120.45, 121.7, 121.9, 123.27, 124.47,125.88, 127.57, 128.55,130.7, 129.72, 132.12, 
135.6, 137.19, 141.2, 146.70, 150.20, 157.64, 162.82, 175.00; m/z (+EI) calc. For 
C32H34N2O5 (M+) 526.62, found 527.10 (M+H)




Procedure for the synthesis of ethyl 1-(3-(4-(6-ethoxynaphthalen-2-yl)thiophene-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.15) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq., 22 mg) was 
added to a solution of 4.7 (1.0 eq., 60 mg) and 4.12 (1.2 eq., 34 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq., 55 mg) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 8 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (2.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.15 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 53 mg light cream, oily 
mass was obtained as product. 
Ethyl 1-(3-(4-(6-ethoxynaphthalen-2-yl)thiophene-2-carboxamido)benzyl)piperidine-4-
carboxylate (4.15):  
 
 
Light cream, oily mass. IR (FTIR, νmax/cm-1) 628.65, 666.05, 735.62, 902.94, 1218.19, 
1363.71, 1434.28, 1713.28, 1736.53, 2335.91, 2969.45, 3452.19; 1H NMR (400 MHz, 
CDCl3, TMS); δ 1.24 (m, 3H), 1.51 (t, J=7.07 Hz, 3H),1.81 (m, 2H), 1.91 (m, 2H), 2.07 (m, 
2H), 2.30 (m, 1H), 2.89 (m, 2H),3.52 (s, 1H), 4.14 (q, J=8.0 Hz, 2H), 4.19 (q, J=8.0 Hz, 2H), 
7.12 (d, J=7.33 Hz, 1H), 7.15 (d, J=2.27 Hz, 1H),  7.20 (dd, J=2.5, 8.84 Hz, 1H), 7.34 (t, 
J=7.83 Hz, 1H),  7.55 (s, 1H), 7.68 (m, 1H), 7.71 (d, J=1.78 Hz, 1H), 7.72 (d, J=1.52Hz, 1H), 
7.78 (s, 1H), 7.80 (s, 1H), 8.00 (d, J=1.77 Hz, 1H), 8.02 (d, J=1.52 Hz, 1H); 13C NMR (100 
MHz, CDCl3); δ 14.3, 14.6, 29.27, 29.5, 41.1, 53.5, 53.95, 61.26, 64.2, 64.7,  107.51, 118.88, 
120.45, 121.0, 123.27, 124.88, 125.6, 127.57, 128.55, 128.96, 129.51, 129.72, 130.12, 134.6, 
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135.19, 135.6, 137.70, 144.3, 154.20, 157.64, 161.82, 173.00;  m/z (+EI) calc. For 
C32H34N2O4S (M+) 542.69, found 543.05 (M+H)
+; Yield: 89%. 
Procedure for the synthesis of ethyl 1-(3-(5-(6-methoxynaphthalen-2-yl)thiophene-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.17) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq., 22 mg) was 
added to a solution of 4.3 (1.0 eq., 60 mg) and 4.16 (1.2 eq., 28 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq., 55 mg) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 8 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (2.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.17 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 55 mg colourless oily 
mass was obtained as product. 
Ethyl 1-(3-(5-(6-methoxynaphthalen-2-yl)thiophene-2-carboxamido)benzyl)piperidine-
4-carboxylate (4.17):  
 
Colourless oily mass. IR (FTIR, νmax/cm-1) 629.97,785.97, 1028.78, 1121.77, 1369.74, 
1444.64, 1604.79, 1728.78, 1969.00, 2041.34, 2337.0, 2361.75, 2630.49, 3271.31; 1H NMR 
(400 MHz, CDCl3, TMS); δ 1.25 – 1.27 (m, 3H), 1.78 – 1.81 (m, 2H), 1.86 (br s, 2H), 2.01 – 
2.05 (m, 2H), 2.27 – 2.30 (m, 1H), 2.86 – 2.88 (m, 2H), 3.50 (s, 2H), 3.94 (s, 3H), 4.13 – 4.15 
(m, 2H), 7.10 (d, J=8.08 Hz, 1H), 7.14 (d, J=3.79 Hz, 1H), 7.19 (dd, J=7.58, 3.03Hz, 1H), 
7.31 (t, J=7.83 Hz, 1H), 7.39 (d, J=7.7 Hz, 1H), 7.54 (s, 1H), 7.66 – 7.88 (m, 2H), 7.70 – 7.72 
(m, 1H), 7.76 (s, 1H), 7.79 (s, 1H), 7.90 (s, 1H), 8.04 (s, 1H); 13C NMR (100 MHz, CDCl3); δ 
13.86, 29.9, 30.58, 40.83, 52.61, 52.63, 55.02, 59.92, 62.94, 105.43, 119.10, 119.36, 120.5, 
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121.2, 122.96, 124.19, 124.52, 128.11, 128.27, 129.17, 129.41,131.77, 134.19, 135.6, 135.9, 
139.25,139.29,149.77,157.94,161.7, 174.93;  m/z (+EI) calc. For C31H32N2O4S (M+) 528.66, 
found 529.96 (M+H)+; Yield: 91%. 
Procedure for the synthesis of ethyl 1-(3-(4-(6-methoxynaphthalen-2-yl)thiophene-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.18) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq., 22 mg) was 
added to a solution of 4.7 (1.0 eq., 60 mg) and 4.16 (1.2 eq., 28 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq., 55 mg) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 8 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (2.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.18 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 60 mg yellow, oily mass 
was obtained as product. 
Ethyl 1-(3-(4-(6-methoxynaphthalen-2-yl)thiophene-2-carboxamido)benzyl)piperidine-
4-carboxylate (4.18):  
 
Yellow, oily mass. IR (FTIR, νmax/cm-1) 630.39, 775.64, 853.12, 1027.97, 1231.81, 1266.42, 
1318.08, 1442.13, 1487.18, 1549.29,1607.18,1727.33, 2067.18, 2358.87, 2852.71, 2927.43, 
3271.31; 1H NMR (400 MHz, CDCl3, TMS); δ 1.23 – 1.25 (m, 3H), 1.76 – 1.78 (m, 2H), 
1.86 – 1.89 (m, 2H), 2.02 (t, J=10.99 Hz, 2H) 2.27 – 2.31 (m, 1H), 2.86 (d, J=11.12Hz, 2H), 
3.47 (s, 2H), 3.92 (s, 3H), 4.13 (q, J=10.99 Hz, 2H), 7.09 (d, J=7.33 Hz, 1H), 7.13 (s, 1H), 
7.16 (dd, J=1.8, 8.97 Hz, 1H), 7.31 – 7.33 (m, 1H), 7.44- 7.45 (m, 1H), 7.57 (s, 1H), 7.68 – 
7.70 (m, 2H), 7.74 – 7.77 (m, 2H), 7.95 (s, 1H), 8.07 (s, 1H); 13C NMR (100 MHz, CDCl3); δ 
14.47,  29.5, 31.20, 41.43, 53.19, 53.5, 55.59, 60.55, 63.29, 105.94, 119.34, 120.98, 122.3, 
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124.4, 125.04, 127.73, 128.06, 128.6, 129.17, 129.26, 129.84, 130.37, 134.19, 134.8, 135.6, 
135.7, 140.29, 141.0, 143.31, 158.17, 175.59; m/z (+EI) calc. For C31H32N2O4S (M+) 528.66, 
found 528.94 (M+H)+; Yield: 98%. 
Procedure for the synthesis of ethyl 1-(3-(5-(6-methoxynaphthalen-2-yl)furan-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.19) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.5 (1.0 eq., 50 mg) and 4.16 (1.2 eq., 29 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 8 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (1.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.19 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 43 mg cream, oily mass 
was obtained as product. 
Ethyl 1-(3-(5-(6-methoxynaphthalen-2-yl)furan-2-carboxamido)benzyl)piperidine-4-
carboxylate (4.19):  
 
Cream oily mass. IR (FTIR, νmax/cm-1) 629.60, 690.40, 783.39, 1026.19, 1205.50, 1367.15, 
1547.97, 1659.04, 1737.23, 1938.00, 2360.90, 2925.06, 3266.14, 3400.15; 1H NMR (400 
MHz, CDCl3, TMS); δ 1.24 (t, J=7.20 Hz, 3H), 1.79 – 1.80 (m, 2H), 1.89 – 1.91 (m, 2H), 
2.05 (t, J=11.12Hz, 2H), 2.29 – 2.32 (m, 1H), 2.91 – 2.93 (m, 2H), 3.51 (s, 2H), 3.94 (s, 3H), 
4.12 (q, J=7.16 Hz, 2H), 6.84 (d, J=3.54 Hz, 1H), 7.10 (d, J=7.58 Hz, 1H), 7.15 (d, J=2.27 
Hz, 1H), 7.20 (dd, J=2.5, 8.84 Hz, 1H),  7.34 – 7.35 (m, 2H), 7.58 (s, 1H), 7.75 (d, J=7.58 
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Hz, 1H), 7.78 – 7.80 (m, 2H), 7.82 (d, J=8.84 Hz, 1H), 8.16 (s, 1H), 8.23 (s, 1H); 13C NMR 
(100 MHz, CDCl3); δ 14.15, 28.19, 30.86, 41.12, 52.93, 53.3, 55.30, 60.20, 63.10, 105.85, 
107.46, 117.57, 118.92, 119.66, 120.48, 122.85, 123.40, 124.67, 125.23, 127.45, 128.63, 
128.89, 129.78, 134.56, 137.44, 139.45, 146.61, 156.15, 158.34, 175.17, 206.98;  m/z (+EI) 
calc. For C31H32N2O5 (M+) 512.60, found 512.99 (M+H)
+; Yield: 87%. 
Procedure for the synthesis of ethyl 1-(3-(5-(benzofuran-2-yl)thiophene-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.21) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.3 (1.0 eq., 50 mg) and 4.20 (1.2 eq., 22 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 8 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (1.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.21 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 45 mg colourless oil 
was obtained as product. 
Ethyl 1-(3-(5-(benzofuran-2-yl)thiophene-2-carboxamido)benzyl)piperidine-4-
carboxylate (4.21):  
 
Colourless oil. IR (FTIR, νmax/cm-1) 629.25, 734.68, 1047.89, 1090.77, 1221.36, 1267.75, 
1360.93, 1440.10, 1547.68, 1609.96, 1658.17, 1710.70, 2180.87, 2360.43, 2928.69;  1H 
NMR (400 MHz, CDCl3, TMS); δ 1.24 (t, J=7.07 Hz, 3H), 1.76 – 1.78 (m, 2H), 1.87 – 1.89 
(m, 2H), 2.00 – 2.02 (m, 2H), 2.26 – 2.29 (m, 1H), 2.85 (d, J=11.6 Hz, 2H), 2.95 (s, 1H), 3.47 
(s, 2H), 4.13 – 4.15 (m, 2H), 6.99 (s, 1H), 7.08 – 7.11 (m, 1H), 7.24 (t, J=7.45 Hz, 1H), 7.31 
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(d, J=3.79 Hz, 1H), 7.50 (d, J=8.34 Hz, 1H), 7.56 – 7.55 (m, 2H), 7.64 (d, J=8.34 Hz, 1H), 
7.67 – 7.69 (m, 1H), 8.02 (s, 1H); 13C NMR (100 MHz, CDCl3); δ 14.16, 28.23, 29.3, 41.11, 
52.92, 53.7, 60.21, 62.97, 103.12, 111.18, 120.66, 120.9, 121.12, 123.36, 124.56, 128.45, 
129.01, 129.4, 135.95, 135.98, 137.05, 138.05, 138.87, 139.50, 150.01, 154.74, 175.27, 
175.28;  m/z (+EI) calc. For C28H28N2O4S (M+) 488.60, found 489.17 (M+H)
+; Yield: 90%. 
Procedure for the synthesis of ethyl 1-(3-(4-(benzofuran-2-yl)thiophene-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.22) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.7 (1.0 eq., 50 mg) and 4.20 (1.2 eq., 22 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 8 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (1.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.22 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 50 mg colourless oil 
was obtained as product. 
Ethyl 1-(3-(4-(benzofuran-2-yl)thiophene-2-carboxamido)benzyl)piperidine-4-
carboxylate (4.22):  
 
 
Colourless, oily mass. IR (FTIR, νmax/cm-1) 629.20, 698.15, 734.74, 1090.77, 1221.72, 
1362.08, 1439.71, 1550.55, 1656.45, 1708.11, 1969.00, 2041.34, 2335.91, 2919.89, 3394.18;  
1H NMR (400 MHz, CDCl3, TMS); δ 1.24 (t, J=7.07 Hz, 3H), 1.78 – 1.80 (m, 2H), 1.87 – 
1.89 (m, 2H), 2.03 (td, J=2.15, 4.0, 11.31 Hz, 2H), 2.28 – 2.31 (m, 1H), 2.88 – 2.90 (m, 2H), 
3.48 (s, 2H), 4.13 (q, J=7.07 Hz, 2H), 6.87 (s, 1H), 7.10 (d, J=7.58 Hz, 1H), 7.25 (dd, J=0.9, 
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7.5 Hz,  1H), 7.29 – 7.30 (m, 1H), 7.31 – 7.33 (m, 1H), 7.49 (d, J=8.08 Hz, 1H), 7.56 – 7.57 
(m, 2H), 7.66 (d, J=8.08 Hz, 1H), 7.86 (d, J=1.01 Hz, 1H), 8.03 – 8.05 (m, 1H), 8.24 (s, 1H); 
13C NMR (100 MHz, CDCl3); δ 14.16, 29.5, 29.7, 41.11, 52.92, 53.5, 60.21, 62.97, 103.12, 
111.5, 120.1, 120.9, 121.12, 123.36, 124.7, 128.5, 129.3, 129.6, 135.4, 135.7, 135.98, 140.05, 
141.2, 144.9, 154.74, 156.5, 164.27, 175.28;   m/z (+EI) calc. For C28H28N2O4S (M+) 488.60, 
found 490.14 (M+H)+; Yield: 92%. 
Procedure for the synthesis of ethyl 1-(3-(5-(benzofuran-2-yl)furan-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.23) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.5 (1.0 eq., 50 mg) and 4.20 (1.2 eq., 22 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 8 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (1.0 gm) and washed with DCM 
(3x) and DMF (3x) twice and finally MeOH (2x). The product 4.23 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 38 mg light cream, oily 




Light cream, oily mass. IR (FTIR, νmax/cm-1) 629.68, 701.06, 736.90, 1093.35, 1170.84, 
1221.26, 1266.40, 1362.54, 1443.09, 1487.98, 1573.19, 1667.61, 1710.43, 1974.16, 2358.14, 
2916.46, 3436.69; 1H NMR (400 MHz, CDCl3, TMS); δ 1.25 (t, J=7.07 Hz, 3H), 1.81 – 1.83 
(m, 2H), 1.89 – 1.91 (m, 2H), 2.06 – 2.08 (m, 2H), 2.29 – 2.33 (m, 1H), 2.88 – 2.91 (m, 2H), 
3.51 (s, 2H), 4.13 (q, J=7.16 Hz, 2H), 6.92 (d, J=3.54 Hz, 1H), 7.11 (d, J=7.83 Hz, 1H), 7.14 
– 7.16 (m, 1H), 7.30 – 7.32 (m, 1H), 7.33 – 7.34 (m, 1H), 7.35 (d, J=3.8 Hz, 1H), 7.48 – 7.51 
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(m, 1H), 7.53 (d, J=1.01 Hz, 1H), 7.57 (s, 1H), 7.63 – 7.64 (m, 1H), 7.67 – 7.69 (m, 1H), 7.74 
(dd, J=1.2, 8.08 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 14.1, 29.5, 29.7, 41.11, 52.92, 53.3, 
60.21, 62.97, 103.12, 108.5, 108.7, 111.5, 120.1, 120.9, 121.12, 123.36, 124.7, 128.5, 129.6, 
135.4, 135.7, 135.98, 140.9, 146.9, 154.74, 156.5, 164.27, 175.28; m/z (+EI) calc. For 
C28H28N2O5 (M+) 472.53, found 473.13 (M+H)
+; Yield: 75%. 
Procedure for the synthesis of ethyl 1-(3-(5-(isoquinolin-7-yl)thiophene-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.25) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.3 (1.0 eq., 50 mg) and 4.24 (1.2 eq., 36 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 8 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (1.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.25 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 40 mg light cream, oily 
mass was obtained as product. 
Ethyl 1-(3-(5-(isoquinolin-7-yl)thiophene-2-carboxamido)benzyl)piperidine-4-
carboxylate (4.25):  
 
Light cream, oily mass. IR (FTIR, νmax/cm-1) 629.54, 783.39, 1046.86, 1121.77, 1214.76, 
1281.91, 1319.12, 1367.15, 1442.31, 1485.97, 1547.22, 1648.70, 1727.07, 2180.87, 2360.00, 
2852.71, 2921.88, 3328.16; 1H NMR (500 MHz, CDCl3, TMS); δ 1.25 (t, J=7.09 Hz, 3H), 
1.79 – 1.81 (m, 2H), 1.88 – 1.90 (m, 2H), 2.05 – 2.08 (m, 2H), 2.29 – 2.31 (m, 1H), 2.87 – 
2.89 (m, 2H), 3.49 (s, 2H), 4.13 (q, J=7.15 Hz, 2H), 7.10 (d, J=7.57 Hz, 1H), 7.31 (t, J=7.88 
Hz, 1H), 7.44 – 7.45 (m, 1H), 7.55 (s, 1H), 7.67 (d, J=4.10 Hz, 2H), 7.99 – 8.01 (m, 2H), 
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8.06 (d, J=2.21 Hz, 1H), 8.14 (d, J=8.83 Hz, 1H), 8.18 (dd, J=0.9, 8.83 Hz, 1H), 8.92 (dd, 
J=1.7, 4.26 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 13.94, 28.02, 29.5, 40.91, 52.69, 53.5, 
59.96, 62.72, 118.81, 120.36, 121.69, 124.23, 124.40, 125.05, 128.22, 128.71, 129.16, 
130.18, 135.0, 135.8, 135.91, 136.4, 137.43, 138.57, 143.4, 148.39, 150.61, 159.44, 174.93;  
m/z (+EI) calc. For C29H29N3O3S (M+) 499.62, found 499.85 (M+H)
+; Yield: 79%. 
Procedure for the synthesis of ethyl 1-(3-(4-(isoquinolin-5-yl)thiophene-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.26) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.7 (1.0 eq., 50 mg) and 4.24 (1.2 eq., 36 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 8 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (1.0 gm) and washed with DCM 
(3x) and DMF (3x) twice and finally MeOH (2x). The product 4.26 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 48 mg light cream, oily 
mass was obtained as product. 
Ethyl 1-(3-(4-(isoquinolin-5-yl)thiophene-2-carboxamido)benzyl)piperidine-4-
carboxylate (4.26):  
 
Light cream, oily mass. IR (FTIR, νmax/cm-1) 628.41, 782.19, 835.05, 1046.86, 1222.55, 
1318.08, 1364.57, 1440.50, 1485.97, 1550.87, 1651.29, 1711.71, 2041.34, 2361.75, 2916.48, 
3395.34; 1H NMR (500 MHz, CDCl3, TMS); δ 1.22 (t, J=7.09 Hz, 3H), 1.73 – 1.75 (m, 2H), 
1.84 (dd, J=3.15, 13.24 Hz,  2H), 2.00 – 2.03 (m, 2H), 2.25 – 2.27 (m, 1H), 2.85 – 2.91 (m, 
2H), 3.45 (s, 2H), 4.11 (q, J=7.15 Hz, 2H), 7.08 (d, J=7.57 Hz, 1H), 7.29 – 7.31 (m, 1H), 
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7.38 (dd, J=4.1, 8.20 Hz, 1H), 7.60 – 7.63 (m, 1H), 7.69 (dd, J=1.58, 7.88 Hz, 1H), 7. 73 (d, 
J=1.58 Hz, 1H), 7.83 (dd, J=2.22, 8.83 Hz, 1H), 7.89 (d, J=2.21 Hz, 1H), 8.07 – 8.09 (m, 
2H), 8.09 (d, J=3.15 Hz, 1H), 8.59 (s, 1H), 8.87 (dd, J=1.7, 4.26 Hz, 1H); 13C NMR (100 
MHz, CDCl3); δ 14.42,  28.52, 29.3,  41.39, 53.15, 53.8, 60.48, 63.19, 119.41, 121.00, 
121.94, 124.81, 125.54, 126.24, 127.71, 128.41, 128.73, 129.16, 130.32, 133.25, 136.35, 
138.02, 139.94, 140.83, 142.26, 147.91, 150.71, 160.19, 175.47;  m/z (+EI) calc. For 
C29H29N3O3S (M+) 499.62, found 499.92 (M+H)
+; Yield: 88%. 
Procedure for the synthesis of ethyl 1-(3-(5-(isoquinolin-7-yl)furan-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.27) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.5 (1.0 eq., 50 mg) and 4.24 (1.2 eq., 38 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 8 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (1.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.27 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 40 mg cream oil was 




Cream oil. IR (FTIR, νmax/cm-1) 629.72, 785.97, 1023.61, 1214.76, 1364.57, 1547.97, 
1728.78, 1736.53, 1857.93, 1971.58, 2051.67, 2335.91, 2360.03, 2780.36, 3266.14; 1H NMR 
(500 MHz, CDCl3, TMS); δ 1.25 – 1.27 (m, 3H), 1.79 – 1.81 (m, 2H), 1.90 – 1.93 (m, 2H), 
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2.06 – 2.09 (m, 2H), 2.30 – 2.31 (m, 1H), 2.88 – 2.92 (m, 2H), 3.52 (s, 2H), 4.13 (q, J=7.07 
Hz, 2H), 6.95 (d, J=3.78 Hz, 1H),  7.12 (d, J=7.88 Hz, 1H), 7.34 (t, J=7.88 Hz, 1H), 7.38 (d, 
J=3.47 Hz, 1H), 7.47 – 7.49 (m, 1H), 7.58 – 7.61 (m, 1H), 7.67 (d, J=4.10 Hz, 1H), 7.77 (dd, 
J=1.10, 8.04 Hz, 1H), 8.06 (dd, J=1.89, 8.83 Hz, 1H), 8.17 (d, J=8.83 Hz, 1H), 8.22 (d, 
J=1.89 Hz, 1H),  8.25 (s, 1H), 8.94 (dd, J=1.7, 4.26 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 
14.20,  28.29, 29.1, 41.40, 53.01, 53.3, 60.22, 63.11, 108.96, 117.48, 119.06, 120.55, 121.66, 
122.01, 128.38, 129.17, 130.23, 130.42, 132.06, 135.6, 135.9,  140.1, 145.6, 147.59, 148.26, 
150.66, 155.09, 155.97, 175.15;  m/z (+EI) calc. For C29H29N3O4 (M+) 483.56, found 483.88 
(M+H)+; Yield: 79%. 
Procedure for the synthesis of ethyl 1-(3-(5-(dibenzo[b,d]furan-3-yl)thiophene-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.29) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.3 (1.0 eq., 65 mg) and 4.28 (1.2 eq., 36 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 10 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (1.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.29 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 57 mg light cream oil 
was obtained as product. 
Ethyl 1-(3-(5-(dibenzo[b,d]furan-3-yl)thiophene-2-carboxamido)benzyl)piperidine-4-




Light cream, oily mass. IR (FTIR, νmax/cm-1) 628.20, 697.91, 734.33, 1047.87, 1119.28, 
1188.78, 1220.47, 1263.69, 1316.68, 1360.45, 1418.81, 1443.78, 1487.80, 1546.74, 1657.75, 
1710.70, 2925.50; 1H NMR (500 MHz, CDCl3, TMS); δ 1.25 – 1.27 (m, 3H), 1.78 – 1.80 (m, 
2H), 1.88 – 1.90 (m, 2H), 2.04 – 2.06 (m, 2H), 2.27 – 2.29 (m, 1H), 2.88 – 2.90 (m, 2H), 3.49 
(s, 2H), 4.13 (q, J=7.15 Hz, 2H), 7.10 (d, J=7.57 Hz, 1H), 7.31 (t, J=7.88 Hz, 1H), 7. 38 – 
7.41 (m, 1H), 7.46 – 7.48 (m, 2H), 7.51 – 4.53 (m, 1H), 7.55 – 7.58 (m, 1H), 7.60 (s, 1H),  
7.67 – 7.68 (m, 1H), 7.78 (d, J=4.10 Hz, 1H), 7.87 (d, J=4.10 Hz, 1H), 7.91 (dd, J=1.2, 7.57 
Hz, 1H),  7.98 – 8.00 (m, 1H), 8.02 (s, 1H); 13C NMR (100 MHz, CDCl3); δ 14.18, 28.30, 
29.3, 41.20, 52.94, 53.0, 60.20, 63.04, 111.5, 111.92, 113.0,  120.56, 120.77, 121.0, 123.15, 
123.23, 125.14, 126.65, 128.43, 129.27, 132.03, 132.11, 135.7,  136.5, 137.2, 139.63, 140.1, 
148.4, 150.0, 156.19, 161.9, 175.20;  m/z (+EI) calc. For C32H30N2O4S (M+) 538.66, found 
539.09 (M+H)+; Yield: 73%. 
Procedure for the synthesis of ethyl 1-(3-(4-(dibenzo[b,d]furan-4-yl)thiophene-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.30) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.7 (1.0 eq., 65 mg) and 4.28 (1.2 eq., 37 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 10 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (2.0 gm) and washed with DCM 
(3x) and DMF (3x) twice and finally MeOH (2x). The product 4.30 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 61 mg light yellow oil 








carboxylate (4.30):  
 
Light yellow oily mass. IR (FTIR, νmax/cm-1) 629.82, 695.57, 751.96, 778.22, 1047.42, 
1116.60, 1186.34, 1319.08, 1364.57, 1437.95, 1487.32, 1551.12, 1609.96, 1639,03, 1726.03, 
2335.91, 2917.38, 3312.66; 1H NMR (500 MHz, CDCl3, TMS); δ 1.23 – 1.25 (m, 3H), 1.77 – 
1.79 (m, 2H), 1.86 – 1.89 (m, 2H), 2.01 – 2.03 (m, 2H), 2.26 – 2.27 (m, 1H), 2. 86 – 2.90 (m, 
2H), 3.45 (s, 2H), 4.11 (q, J=7.25 Hz, 2H), 7.08 (d, J=7.57 Hz, 1H), 7.30 – 7.32 (m, 1H), 
7.34 (d, J=7.57 Hz, 1H), 7. 37 – 7.38 (m, 1H), 7.41 – 7.43 (m, 1H), 7.49 – 7.52 (m, 1H), 7.62 
– 7.63 (m, 1H), 7.65 – 7.67 (m, 1H), 7.68 – 7.70 (m, 1H), 7.86 (dd, J=1.1, 7.72 Hz, 1H), 7.95 
– 7.97 (m, 1H), 8.22 (d, J=1.26 Hz, 1H), 8.32 (d, J=1.26 Hz, 1H), 8.46 (br.s, 1H); 13C NMR 
(100 MHz, CDCl3); δ 14.15, 28.23, 28.26, 41.17, 52.89, 53.4, 60.17, 62.98, 111.78, 113.5, 
119.76, 120.68, 120.85, 121.1, 122.98, 123.14, 123.95, 125.10, 125.18, 127.37, 128.21, 
128.81, 134.5, 135,6, 135.9, 137.32, 139.52, 139.58, 142.58, 152.82, 156.05, 175.19;  m/z 
(+EI) calc. For C32H30N2O4S (M+) 538.66, found 539.09 (M+H)
+; Yield: 79%. 
Procedure for the synthesis of ethyl 1-(3-(5-(dibenzo[b,d]furan-3-yl)furan-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.31) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.5 (1.0 eq., 40 mg) and 4.28 (1.2 eq., 23 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 10 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (1.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.31 was released from the 
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cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 39 mg colourless oil 
was obtained as product. 
Ethyl 1-(3-(5-(dibenzo[b,d]furan-3-yl)furan-2-carboxamido)benzyl)piperidine-4-
carboxylate (4.31):  
 
Colourless oily mass. IR (FTIR, νmax/cm-1) 630.79, 696.25, 723.98, 754.16, 796.15, 844.04, 
1025.47, 1119.81, 1183.76, 1219.81, 1262.45, 1319.31, 1363.24, 1447.97, 1487.79, 1546.45, 
1610.05, 1665.82, 1711.68, 2341.08, 2926.67;  1H NMR (500 MHz, CDCl3, TMS); δ 1.08 (t, 
J=7.09 Hz, 3H), 1.64 – 1.65 (m, 2H), 1.73 – 1.76 (m, 2H), 1.90 – 1.92 (m, 2H), 2.13 – 2.16 
(m, 1H), 2. 71 – 2.73 (m, 2H), 3.36 (s, 2H), 3.96 (q, J=6.94 Hz, 2H), 6.95 (d, J=7.57 Hz, 1H), 
7.18 (t, J=7.72 Hz, 1H), 7. 23 (td, J=.05, 7.41, 7.41 Hz, 1H), 7.28 – 7.30 (m, 1H), 7.30 – 7.31 
(m,  1H), 7.34 – 7.36 (m,  1H), 7.37 – 3.40 (m, 1H), 7.43 – 7.45 (m, 1H), 7.48 – 7.49 (m, 1H), 
7.50 – 7.52 (m, 1H), 7.58 (dt, J=1.06, 7.96 Hz, 1H), 7.79 (dd, J=1.2, 4.41 Hz, 1H), 7.81 (d, 
J=0.95 Hz, 1H), 8.11 (s, 1H); 13C NMR (100 MHz, CDCl3); δ 14.19, 28.28, 29.0, 41.19, 
52.97, 53.1, 60.20, 63.08, 108.9, 111.83, 112.25, 114.72, 120.51, 120.77, 120.78, 122.79, 
123.05, 125.24, 128.42, 128.51, 128.96, 132.03, 132.11, 134.3, 137.49, 141.0, 146,73, 
151,16, 156.11, 157.0, 162.0, 175.14; m/z (+EI) calc. For C32H30N2O5 (M+) 522.59, found 
523.12 (M+H)+; Yield: 81%. 
Procedure for the synthesis of ethyl 1-(3-(5-(dibenzo[b,d]thiophen-3-yl)thiophene-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.33) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.3 (1.0 eq., 42 mg) and 4.32 (1.2 eq., 25 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
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100 °C for 8 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (1.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.33 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 38 mg yellowish, oily 
mass was obtained as product. 
Ethyl 1-(3-(5-(dibenzo[b,d]thiophen-3-yl)thiophene-2-carboxamido)benzyl)piperidine-4-
carboxylate (4.33):  
 
Yellowish, oily mass. IR (FTIR, νmax/cm-1) 629.52, 695.89, 734.83, 755.36, 1047.64, 
1092.50, 1221.45, 1320.93, 1362.01, 1438.37, 1487.72, 1547.68, 1651.16, 1710.70, 2341.08, 
2935.40, 3418.26;  1H NMR (500 MHz, CDCl3, TMS); δ 1.24 (t, J=7.09 Hz, 3H), 1.79 – 1.81 
(m, 2H), 1.86 (d, J=12.30 Hz, 2H), 2.03 (t, J=10.88 Hz, 2H), 2.27 – 2.30 (m, 1H), 2. 88 – 
2.91 (m, 2H), 3.48 (s, 2H), 4.13 (q, J=6.73 Hz, 2H), 7.10 (d, J=7.57 Hz, 1H), 7.30 (t, J=7.88 
Hz, 1H), 7. 49 – 7.51 (m, 2H), 7.52 (d, J=7.57 Hz, 1H), 7.59 (d, J=4.73 Hz,  2H), 7.67 (t, 
J=6.62 Hz, 2H), 7.77 (d, J=3.78 Hz, 1H), 7.87 (dd, J=3.3, 5.20 Hz, 1H), 8.15 (d, J=8.20 Hz, 
1H), 8.18 – 8.19 (m, 1H); 13C NMR (100 MHz, CDCl3); δ 14.21, 28.33,  29.5, 41.23, 52.97, 
53.0, 60.23, 63.05, 120.75, 121.64, 121.79, 122.66, 123.05, 123.2, 124.74, 125.08, 126.08, 
127.19, 128.47, 129.19, 132.06, 135.04, 135.7, 135.9, 137.69, 138.74, 139.72, 141.0, 147.64, 
148.2, 161.8, 175.24;   m/z (+EI) calc. For C32H30N2O3S2 (M+) 554.72, found 554.99 
(M+H)+; Yield: 91%. 
Procedure for the synthesis of ethyl 1-(3-(4-(dibenzo[b,d]thiophen-4-yl)thiophene-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.34) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.7 (1.0 eq., 54 mg) and 4.32 (1.2 eq., 33 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
239 
 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 8 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (1.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.34 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 46 mg cream oily mass 
was obtained as product. 
Ethyl 1-(3-(4-(dibenzo[b,d]thiophen-4-yl)thiophene-2-carboxamido)benzyl)piperidine-4-
carboxylate (4.34):  
 
Cream oily mass. IR (FTIR, νmax/cm-1) 624.90, 694.64, 722.06, 752.39, 869.93, 1047.62, 
1118.85, 1178.28, 1256.08, 1317.77, 1364.88, 1437.69, 1485.98, 1549.53, 1609.82, 1654.66, 
1725.49, 2341.08, 2801.03, 2931.90, 3059.43, 3260.98; 1H NMR (500 MHz, CDCl3, TMS); δ 
1.23 (t, J=7.09 Hz, 3H), 1.75 – 1.79 (m, 2H), 1.85 – 1.88 (m, 2H), 2.00 – 2.02 (m, 2H), 2.25 – 
2.26 (m, 1H), 2. 86 – 2.89 (m, 2H), 3.45 (s, 2H), 4.11 (q, J=6.94 Hz, 2H), 7.08 (d, J=7.57 Hz, 
1H), 7.28 – 7.30 (m, 1H), 7.39 – 7.41 (m, 1H), 7.47 – 7.48 (m, 1H), 7.48 – 7.49 (m, 1H), 7.49 
– 7.51 (m, 1H), 7. 52 – 7.53 (m, 1H), 7.60 – 7.63 (m, 2H), 7.66 (dd, J=1.2, 7.88 Hz, 1H), 7.83 
– 7.85 (m, 1H), 7.89 (d, J=1.58 Hz, 1H), 8.11 (d, J=1.26 Hz, 1H), 8.16 – 8.18 (m, 1H); 13C 
NMR (100 MHz, CDCl3); δ 14.15, 28.27,  28.29, 41.18, 52.89, 53.0, 60.18, 62.99, 119.09, 
120.76, 121.64, 121.72, 122.63, 122.8, 123.05, 123.2, 124.4, 124.59, 125.01, 125.18, 126.30, 
128.36, 129.19, 135.58, 135.6, 135.8,  137.91, 139.15, 140.26, 144.1, 162.48, 175.20; m/z 
(+EI) calc. For C32H30N2O3S2 (M+) 554.72, found 554.99 (M+H)
+; Yield: 70%. 
Procedure for the synthesis of ethyl 1-(3-(5-(dibenzo[b,d]thiophen-3-yl)furan-2-
carboxamido)benzyl)piperidine-4-carboxylate (4.35) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.5 (1.0 eq., 37 mg) and 4.32 (1.2 eq., 23 mg) in a 9:3:1 combination of 
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EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 8 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (1.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product 4.35 was released from the 
cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo. 46 mg colourless oil 
was obtained as product. 
Ethyl 1-(3-(5-(dibenzo[b,d]thiophen-3-yl)furan-2-carboxamido)benzyl)piperidine-4-
carboxylate (4.35):  
 
Colourless oil. IR (FTIR, νmax/cm-1) 631.34, 695.57, 721.40, 754.98, 791.40, 1025.78, 
1048.11, 1119.96, 1182.94, 1322.61, 1439.86, 1487.65, 1542.18, 1591.88, 1609.94, 1666.13, 
1726.87, 2363.64, 2852.71, 2916.88, 3307.49; 1H NMR (500 MHz, CDCl3, TMS); δ 1.24 (t, 
J=m, 3H), 1.81 – 1.83 (m, 2H), 1.91 – 1.95 (m, 2H), 2.08 (d, J=10.40 Hz,  2H), 2.30 – 2.31 
(m, 1H), 2. 90 – 2.93 (m, 2H), 3.53 (s, 2H), 4.13 (q, J=7.25 Hz, 2H), 7.04 (d, J=3.78 Hz, 1H), 
7.14 (d, J=7.57 Hz, 1H), 7.36 (t, J=7.72 Hz, 1H), 7. 40 – 7.43 (m, 1H), 7.51 (d, J=1.89 Hz, 
1H), 7.52 – 7.54 (m, 1H), 7.54 – 7.58 (m, 1H), 7.67 – 7.68 (m, 1H), 7.70 – 7.72 (m, 1H), 7.90 
– 7.93 (m, 2H), 8.16 – 8.18 (m, 2H), 8.38 (s, 1H); 13C NMR (100 MHz, CDCl3); δ 14.18, 
28.5, 29.5, 41.20, 52.97, 53.6, 60.17, 63.07, 108.9, 109.76, 120.52, 121.67, 121.77, 122.50, 
122.70, 123.7, 124.51, 124.79, 124.81, 127.31, 128.41, 128.50, 131.86, 132.10, 134.88, 
135.09, 135.5, 139.77, 146.96, 155.95, 162.5, 175.12; m/z (+EI) calc. For C32H30N2O4S (M+) 




4.1.5 Type-2 Library synthesis 
4.1.5.1 Sub type 1 Library synthesis 
 
General procedure for the synthesis of 2,2,2-trichloro-1-(1-methyl-4-nitro-1H-pyrrol-2-
yl) ethanone (4.37). 
Fuming nitric acid (37.5 ml) was added drop wise over a period of 1 hour to a mechanically 
stirred solution of 2,2,2-trichloro-1-(1-methyl-1H-pyrrol-2-yl) ethanone (1.0 eq., 100 gm) 
(4.36) in acetic anhydride (475 ml), which was kept at -5 °C using an acetone/dry ice bath. 
After the addition was complete, the temperature of the reaction mixture was gradually raised 
to 10 °C over a period of 3 hours with continuous stirring. The reaction mixture was again 
cooled to -30 °C using an acetone/dry ice bath and diluted with 500 ml of isopropanol. The 
resulting precipitate was collected using a Buchner flask and dried in a vacuum. 710 mg 
yellow crystalline powder was obtained. 
2,2,2-Trichloro-1-(1-methyl-4-nitro-1H-pyrrol-2-yl) ethanone (4.37):  
 
Yellow crystalline powder. IR (FTIR, νmax/cm-1) 630.76, 688.78, 714.79, 749.37, 814.51, 
853.33, 1111.00, 1183.53, 1225.52, 1406.45, 1426.38, 1494.51, 1514.83, 1691.56, 3139.95; 
1H NMR (400 MHz, CDCl3, TMS); δ 4.04 (s, 3H), 7.74 (s, 1H), 7.94 (s, 1H); 13C NMR (100 
MHz, CDCl3); δ 39.80, 94.83, 117.46, 121.47, 130.25, 135.3, 173.7; m/z (+EI) calc. For 
C7H5Cl3N2O3 (M+) 271.49, found 271.23 (M+H)
+; Yield: 71%. 
General procedure for the synthesis of N-(3-(dimethylamino)propyl)-1-methyl-4-nitro-
1H-pyrrole-2-carboxamide (4.39). 
N,N-dimethylpropane-1,3-diamine (1 eq., 1.4 µl) (4.38) was added to a mechanically stirred 
solution of 2,2,2-trichloro-1-(1-methyl-4-nitro-1H-pyrrol-2-yl)ethanone (1 eq., 3.0 gm) (4.37) 
in  THF (50.0 ml). The reaction mixture was allowed to stir for 2 hours. After completion of 




N-(3-(dimethylamino)propyl)-1-methyl-4-nitro-1H-pyrrole-2-carboxamide (4.39):  
 
Cream crystalline solid. IR (FTIR, νmax/cm-1) 789.72, 1138.06, 1211.26, 1301.51, 1414.54, 
1469.90, 1498.81, 1590.13, 1658.18, 2163.56, 2823.99, 3126.84, 3385.19; 1H NMR (400 
MHz, CDCl3, TMS); δ 1.74 – 1.77 (m, 2H), 2.31 (s, 6H), 2.5 (t, J=8.0, Hz, 2H), 3.5 (q, J=8.0, 
5.0, Hz, 2H), 4.0 (s, Hz, 3H), 6.20 (d, J=2.0, Hz, 1H), 7.51 (d, J=2.0, Hz, 1H), 8.66 (s, 1H); 
13C NMR (100 MHz, CDCl3); δ 26.0, 35.5, 39.8, 47.0, 47.1, 58.6, 115.9, 127.99, 131.02, 
134.7, 162.7;  m/z (+EI) calc. For C11H18N4O3 (M+) 254.29, found 254.95 (M+H)
+; Yield: 
81%. 
General procedure for the synthesis of 4-amino-N-(3-(dimethylamino)propyl)-1-methyl-
1H-pyrrole-2-carboxamide (4.40). 
N-(3-(Dimethylamino)propyl)-1-methyl-4-nitro-1H-pyrrole-2-carboxamide (1.0 eq., 500 mg) 
(4.39) was dissolved in the minimum amount of ethyl acetate (30 ml) and a catalytic amount 
of 10% Pd/C (40 mg) was added as a slurry in ethyl acetate. The reaction mixture was shaken 
overnight at 45 psi in a Parr hydrogenator. After completion of the reduction, the suspension 
was filtered with caution over celite using a Buchner flask (Procedure for Pd/C waste 
disposal in section 4.1.3.6) and the filtrate was concentrated to obtain 441 mg colourless oil. 
4-Amino-N-(3-(dimethylamino)propyl)-1-methyl-1H-pyrrole-2-carboxamide (4.40):  
 
Colourless oil. IR (FTIR, νmax/cm-1) 630.39, 1035.66, 1216.48, 1229.16, 1283.22, 1365.62, 
1436.08, 1529.13, 1580.48, 1633.12, 1737.52, 2356.88, 2946.50, 3307.70; 1H NMR (400 
MHz, CDCl3, TMS); δ 1.74 – 1.77 (m, 2H), 2.31 (s, 6H), 2.5 (t, J=8.0, Hz, 2H), 3.5 (q, J=8.0, 
5.0, Hz, 2H), 4.0 (s, Hz, 3H), 6.20 (d, J=2.0, Hz, 1H), 7.51 (d, J=2.0, Hz, 1H), 8.66 (s, 1H); 
13C NMR (100 MHz, CDCl3); δ 25.7, 36.9, 39.6, 45.7, 59.3, 109.8, 129.1, 147.6, 158.6; m/z 
(+EI) calc. For C11H20N4O (M+) 224.30, found 225.40 (M+H)
+; Yield: 100%. 
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General procedure for the synthesis of 4-(5-bromofuran-2-carboxamido)-N-(3-
(dimethylamino)propyl)-1-methyl-1H-pyrrole-2-carboxamide (4.42). (Amide coupling). 
2.0 eq of HOBT (535 mg) and 1.75 eq. of DIC (536.0 µl) were added to a solution of 4.40 (1 
eq., 444 mg) in DCM. After 30 minutes, 1.30 eq. (492 mg) of 4.41 was added and the 
reaction mixture was allowed to stir for 3 hours. After completion of the reaction, the mixture 
was passed through a SCX-2 cartridge (5.0 gm); the cartridge was washed with DCM (3x), 
DMF (3x) twice and finally MeOH (2x). The product 4.42 was released from the cartridge 
using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo to obtain a brown oily mass (337 
mg). 
4-(5-Bromofuran-2-carboxamido)-N-(3-(dimethylamino)propyl)-1-methyl-1H-pyrrole-
2-carboxamide (4.42):  
 
Brown oil. IR (FTIR, νmax/cm-1) 636.44, 744.67, 924.48, 958.03, 1028.54, 1112.71, 1144.42, 
1204.86, 1284.31, 1401.60, 1437.75, 1465.50, 1525.01, 1633.48, 2357.96, 2938.39, 3334.27; 
1H NMR (400 MHz, CDCl3, TMS); δ 1.89 – 1.91 (m, 2H), 2.52 (s, 6H), 2.76 (t, J=6.4 Hz, 
2H), 3.23 (s, 2H), 3.92 (s, Hz, 3H), 6.48 (d, J=3.6 Hz, 1H), 6.65 (d, J=2.0 Hz, 1H), 7.6 (dd, 
J=1.6, 2.0 Hz, 1H), 7.8 (dd, J=1.6, 2.0  Hz, 1H), 8.01 (s, 1H), 8.22 (s, 1H); 13C NMR (100 
MHz, CDCl3); δ 23.5, 34.7, 37.5, 40.1, 43.4, 57.1, 101.8, 112.4, 114.8, 116.6, 118.2, 122.1, 
122.3, 147.4, 152.1, 159.5; m/z (+EI) calc. For C16H21BrN4O3 (M+) 397.27, found 399.29 
(M+H)+; Yield: 76%. 
Procedure for the synthesis of methyl 5-(5-bromofuran-2-
carboxamido)benzo[b]thiophene-2-carboxylate (4.44) 
2.0 eq of HOBT and 1.75 eq. of DIC (340.0 µl) were added to a solution of 4.43 (1 eq., 500 
mg) in DCM. After 30 minutes 1.20 eq. (553 mg) of 4.41 was added and the reaction mixture 
was allowed to stir for 3 hours. After completion of the reaction, the mixture was dried. It 
was then dissolved in a small amount of DCM and coated over silica. The final compound 
was purified using a silica column. Either 100% DCM or 100% CHCl3 was used to purify and 
obtain compound 4.44, which was dried in vacuo; 700 mg light yellow powder was obtained 
as the product.  
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Methyl 5-(5-bromofuran-2-carboxamido)benzo[b]thiophene-2-carboxylate (4.44): 
 
Light yellow powder. IR (FTIR, νmax/cm-1) 629.77, 788.56, 1160.51, 1258.67, 1473.06, 
1529.88, 1710.17, 1992.25, 2361.75, 2914.72; 1H NMR (400 MHz, CDCl3, TMS); δ 3.97 (s, 
3H), 6.55 (dd, J=0.76, 3.54 Hz, 1H), 7.14 (d, J=2.27 Hz, 1H), 7.24 (dd, J=0.76, 3.54 Hz, 1H), 
7.86 – 7.89 (m, 1H), 8.05 (s, 1H), 8.09 (s, 1H), 8.38 (d, J=2.02 Hz, 1H); 13C NMR (100 MHz, 
CDCl3); δ 50.5, 112.0, 114.5, 115.3, 115.9, 117.0, 122.3, 123.03, 134.7, 138.5, 140.1, 141.2, 
150.1, 162.2, 162.7; δ m/z (+EI) calc. For C15H10BrNO4S (M+) 380.21, found 382.18 
(M+H)+; Yield: 76%. 
Procedure for the synthesis of methyl 5-(4-bromothiophene-2-
carboxamido)benzo[b]thiophene-2-carboxylate (4.46) 
2.0 eq of HOBT and 1.75 eq. of DIC (340.0 µl) were added to a solution of 4.43 (1 eq., 500 
mg) in DCM. After 30 minutes, 1.20 eq. (599 mg) of 4.45 was added and the reaction mixture 
was allowed to stir for 3 hours. After completion of the reaction, the mixture was dried, the 
residue dissolved in a small amount of DCM and coated over silica. The final compound was 
purified using a silica column. Either 100% DCM or 100% CHCl3 was used to purify 
compound 4.46, which was dried in vacuo; 800 mg yellow powder was obtained as the 
product.  
Methyl 5-(4-bromothiophene-2-carboxamido)benzo[b]thiophene-2-carboxylate (4.46): 
 
Yellow powder. IR (FTIR, νmax/cm-1) 711.15, 821.39, 1076.07, 1151.87, 1254.73, 1429.80, 
1519.51, 1580.92, 1667.63, 2364.00, 3101.02; 1H NMR (400 MHz, CDCl3, TMS); δ 3.97 (s, 
3H), 7.50 (d, J=1.52 Hz, 1H), 7.56 – 7.58 (m, 2H), 7.73 (br.s, 1H), 7.85 (d, J=8.84 Hz, 1H), 
8.05 (s, 1H), 8.32 (d, J=4.0 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 51.2, 109.1, 115.2, 
116.8, 117.0, 122.8, 130.7, 133.0, 135,1, 138.9, 139.2, 140.1, 141.6, 161.2, 162.03; m/z (+EI) 
calc. For C15H10BrNO3S2 (M+) 396.28, found 397.88 (M+H)
+; Yield: 84%. 
245 
 
General procedure for the synthesis of 4-(5-(4-aminophenyl)furan-2-carboxamido)-N-
(3-(dimethylamino)propyl)-1-methyl-1H-pyrrole-2-carboxamide (4.48). (Suzuki 
coupling).  
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq., 54 mg) was 
added to a solution of 4.42 (1.0 eq., 187.0 mg) and 4.47 (1.2 eq., 124 mg) in a 9:3:1 
combination of EtOH, toluene and water in the presence of K2CO3 (3.0 eq., 195 mg) in a 10 
ml microwave vial containing a magnetic stirrer. The reaction vessel was flushed with 
nitrogen during each addition. The reaction mixture was sealed in an inert nitrogen 
environment and heated with microwave radiation in an EMRYSTM Optimizer Microwave 
Station (Personal Chemistry) at 100 °C for 15 minutes. After LCMS analysis revealed 
complete reaction the cooled reaction mixture was passed through an IsoluteTM SCX-2 
cartridge (2 gm) and washed with DCM (3x), DMF (3x) twice and finally MeOH (2x). The 
product 4.48 was released from the cartridge using 10.0 ml 2M NH3 in MeOH and 
concentrated in vacuo to obtain a light cream oily mass (131 mg). 
4-(5-(4-Aminophenyl)furan-2-carboxamido)-N-(3-(dimethylamino)propyl)-1-methyl-
1H-pyrrole-2-carboxamide (4.48):  
 
Cream oil. IR (FTIR, νmax/cm-1) 634.44, 743.67, 804.16, 958.03, 1019.54, 1112.71, 1161.42, 
1204.86, 1284.31, 1413.60, 1437.75, 1465.50, 1522.01, 1633.48, 1736.91, 2357.96, 2938.39, 
3234.27; 1H NMR (400 MHz, CDCl3, TMS); δ 1.90 – 1.92 (m, 2H), 2.53 (s, 6H), 2.86 (t, 
J=6.4, Hz, 2H), 3.57 – 3.60 (m, 2H), 3.90 (s, Hz, 3H), 6.48 (d, J=3.6, Hz, 1H), 6.70 (d, J=2.0, 
Hz, 1H), 6.80 – 6.82 (m, 2H), 7.30 (d, J=2.0, Hz, 1H), 7.50 (d, J=3.6, Hz, 1H), 7.65 – 6.67 
(m, 2H), 8.05 (s, 1H), 8.27 (s, 1H); 13C NMR (100 MHz, CDCl3); δ 25.4, 35.9, 40.1, 45.7, 
57.9, 108.9, 108.11, 115.1, 119.9, 120.5, 122.3, 123.7, 125.2, 126.0, 129.36, 135.2, 140.5, 
144.6, 147.02, 150.1, 156.7, 160.0; m/z (+EI) calc. For C22H27N5O3 (M+) 409.48, found 




Procedure for the synthesis of 4-(5-(3-aminophenyl)furan-2-carboxamido)-N-(3-
(dimethylamino)propyl)-1-methyl-1H-pyrrole-2-carboxamide (4.50) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq., 54 mg) was 
added to a solution of 4.42 (1.0 eq., 150.0 mg) and 4.49 (1.2 eq., 100 mg) in a 9:3:1 
combination of EtOH, toluene and water in the presence of K2CO3 (3.0 eq., 195 mg) in a 10 
ml microwave vial containing a magnetic stirrer. The reaction vessel was flushed with 
nitrogen during each addition. The reaction mixture was sealed in an inert nitrogen 
environment and heated with microwave radiation in an EMRYSTM Optimizer Microwave 
Station (Personal Chemistry) at 100 °C for 15 minutes. After LCMS analysis revealed 
complete reaction the cooled reaction mixture was passed through an IsoluteTM SCX-2 
cartridge (2 gm) and washed with DCM (3x), DMF (3x) twice and finally MeOH (2x). The 
product 4.48 was released from the cartridge using 10.0 ml 2M NH3 in MeOH and 
concentrated in vacuo to obtain a brown oil (105 mg). 
4-(5-(3-Aminophenyl)furan-2-carboxamido)-N-(3-(dimethylamino)propyl)-1-methyl-
1H-pyrrole-2-carboxamide (4.50):  
 
Brown oil. IR (FTIR, νmax/cm-1) 691.72, 721.47, 779.20, 992.15, 1022.66, 1142.28, 1230.90, 
1287.73, 1401.68, 1437.10, 1527.62, 1738.06, 2947.76, 3231.70; 1H NMR (400 MHz, 
CDCl3, TMS); δ 1.75 (dt, J=6.28, 6.28, 12.44 Hz,  2H), 2.33 – 2.36 (m, 6H), 2.47 (t, J=6.32 
Hz, 2H), 3.48 – 3.50 (m, 2H), 3.80 (s, 1H), 3.96 (s, 3H), 6.58 (d, J=1.77 Hz, 1H), 6.70 (dd, 
J=0.88, 7.71 Hz, 1H), 6.72 (d, J=3.54 Hz, 1H),  7.06 (s, 1H), 7.14 (d, J=8.08 Hz, 1H), 7.20 
(d, J=1.52 Hz, 1H), 7.23 (d, J=8.08 Hz, 1H), 7.25 (d, J=3.54 Hz, 1H), 7.51 – 7.53 (m, 1H), 
7.68 – 7.70 (m, 1H), 7.94 (s, 1H); 13C NMR (100 MHz, CDCl3); δ 25.56, 36.35, 40.81, 45.08, 
47.1, 58.4, 108.2, 108.9, 109.49, 114.7, 115.41, 120.29, 120.8, 123.20, 129.4, 130.22, 131.0, 
146.81, 150.0, 155.76, 160.5, 162.31; m/z (+EI) calc. For C22H27N5O3 (M+) 409.48, found 
410.39 (M+H)+; Yield: 73%. 
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The following compounds (4.52 to 4.55) were synthesised adopting the amide coupling 
reaction from 4.48 and 4.50.  
Procedure for the synthesis of N-(3-(dimethylamino)propyl)-4-(5-(4-(furan-2-
carboxamido)phenyl)furan-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamide (4.52) 
2.0 eq of HOBT (46 mg) and 1.75 eq. of DIC (46 µl) were added to a solution of 4.48 (1 eq., 
70 mg) in DCM. After 30 minutes, 1.20 eq. (23 mg) of 4.51 was added and the reaction 
mixture was allowed to stir for 3 hours. The reaction mixture was initially purified using a 
SCX cartridge (2.0 gm). Final purification was achieved using a silica column and a 
DCM:MeOH:2MNH3 solvent system. Various concentration gradients were used for 
releasing the impurities and the desired product 4.52, which was dried in vacuo; 53 mg light 
brown oil was obtained as the product.  
N-(3-(dimethylamino)propyl)-4-(5-(4-(furan-2-carboxamido)phenyl)furan-2-
carboxamido)-1-methyl-1H-pyrrole-2-carboxamide (4.52):  
 
Light brown oil. IR (FTIR, νmax/cm-1) 667.93, 739.40, 785.55, 804.16, 873.54, 971.00, 
1019.28, 1161.79, 1279.29, 1328.22, 1413.69, 1435.76, 1483.73, 1522.50, 1596.01, 1633.62, 
1736.91, 2357.91, 2939.40; 1H NMR (400 MHz, CDCl3, TMS); δ 1.73 – 1.75 (m, 2H), 2.30 
(s, 6H), 2.46 (t, J=6.06 Hz, 2H), 3.47 – 3.50 (m, 2H), 3.94 (s, 3H), 6.70 (d, J=3.54 Hz, 1H), 
6.81 (s, 1H), 7.24 (d, J=3.79 Hz, 1H), 7.42 (dd, J=4.29, 8.34 Hz, 1H), 7.49 (s, 1H), 7.57 (ddd, 
J=1.26, 7.01, 8.15 Hz, 1H), 7.68 (s, 1H), 7.74 (ddd, J=1.52, 6.95, 8.46 Hz, 1H), 7.84 – 7.86 
(m, 1H), 8.12 (d, J=7.83 Hz, 1H), 8.18 (d, J=8.34 Hz, 1H), 8.29 (br.s, 1H), 8.94 (d, J=1.7 Hz, 
1H); 13C NMR (100 MHz, CDCl3); δ 25.41, 36.40, 40.12, 45.02, 47.0, 58.49, 106.76, 108.13, 
108.17, 118.58, 119.96, 120.76, 122.61, 125.1, 125.3, 126.0, 126.23, 129.15, 131.0, 137.98, 
145.08, 146.32, 150.09, 155.26, 160.49, 162.7, 164.7; m/z (+EI) calc. For C27H29N5O5 (M+) 
503.55, found 504.02 (M+H)+; Yield: 76%. 
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Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((5-((3-
(dimethylamino)propyl)carbamoyl)-1-methyl-1H-pyrrol-3-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.54) 
2.0 eq of HOBT  and 1.75 eq. of DIC were added to a solution of 4.50 (1 eq., 50 mg) in 
DCM. After 30 minutes, 2 eq. (60 mg) of 4.53 was added and the reaction mixture was 
allowed to stir for 3 hours. The reaction mixture was initially purified using a SCX cartridge 
(2.0 gm). Final purification was achieved using a silica column and a DCM:MeOH:2MNH3 
solvent system of various concentration gradients for releasing the impurities and the desired 
product 4.54. This was dried in vacuo and 39 mg colourless oil was obtained as the product. 
2-(2,3-Dihydrobenzofuran-5-yl)-N-(3-(5-((5-((3-(dimethylamino)propyl)carbamoyl)-1-
methyl-1H-pyrrol-3-yl)carbamoyl)furan-2-yl)phenyl)thiazole-4-carboxamide (4.54):  
 
Colourless oil. IR (FTIR, νmax/cm-1)  640.06, 738.23, 866.73, 980.83, 1097.45, 1167.89, 
1216.56, 1365.34, 1537.77, 1737.23, 2969.37, 3335.36; 1H NMR (400 MHz, CDCl3, TMS); δ 
1.73 – 1.75 (m, 2H), 2.30 (s, 6H), 2.45 (t, J=6.19 Hz, 2H), 3.31 – 3.35 (m, 2H), 3.47 – 3.49 
(m, 2H), 3.84 – 3.87 (m, 2H), 3.95 (s, 3H), 4.68 (t, J=8.72 Hz, 2H), 6.63 (d, J=2.02 Hz, 1H), 
6.82 (d, J=2.02 Hz, 1H),  6.88 (d, J=8.34 Hz, 1H), 7.22 (d, J=1.77 Hz, 1H), 7.43 (t, J=8.34 
Hz, 1H),  7.51 (dt, J=1.2, 7.96 Hz, 1H), 7.63 – 7.65 (m, 1H), 7.68 – 7.69 (m, 1H), 7.78 (dd, 
J=1.7, 8.34 Hz, 1H), 7.86 (d, J=1.52 Hz, 1H), 8.11 (s, 1H), 8.26 – 8.27 (m, 1H), 9.38 (s, 1H); 
13C NMR (100 MHz, CDCl3); δ 25.56, 28.95, 29.8, 36.35, 41.81, 45.08, 58.48, 79.0, 107.82, 
108.2, 108.7, 109.49, 115.41, 119.63, 120.29, 120.8, 121.7, 122.56, 123.20, 125.15, 127.28, 
128.00, 129.20, 129.4, 130.22, 130.8, 137.95, 146.81, 150.0, 154.76, 160.1, 162.31, 169.0, 
184.4;  m/z (+EI) calc. For C34H34N6O5S (M+) 638.74, found 639.33 (M+H)
+; Yield: 78%. 
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Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(4-(5-((5-((3-
(dimethylamino)propyl)carbamoyl)-1-methyl-1H-pyrrol-3-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.55) 
2.0 eq of HOBT  and 1.75 eq. of DIC were added to a solution of 4.48 (1 eq., 80 mg) in 
DCM. After 30 minutes, 2 eq. (97 mg) of 4.53 was added and the reaction mixture was 
allowed to stir for 3 hours. The reaction mixture was initially purified using a SCX cartridge 
(2.0 gm). Final purification was achieved using a silica column and a DCM:MeOH:2MNH3 
solvent system of various concentration gradients for releasing the impurities and the desired 
product 4.55. This was dried in vacuo and 78 mg cream solid was obtained. 
2-(2,3-Dihydrobenzofuran-5-yl)-N-(4-(5-((5-((3-(dimethylamino)propyl)carbamoyl)-1-




Cream solid. IR (FTIR, νmax/cm-1)  635.73, 781.12, 981.00, 1027.27, 1142.76, 1240.76, 
1279.65, 1415.36, 1466.26, 1530.61, 1592.28, 1638.34, 2945.61, 3345.31; 1H NMR (400 
MHz, CDCl3, TMS); δ 1.74 – 1.79 (m, 2H), 2.32 (s, 6H), 2.47 (t, J=6,15 Hz, 2H), 3.32 (t, 
J=8.67 Hz, 2H), 3.47 – 3.49 (m, 2H), 3.96 (s, 3H), 4.69 (t, J=8.67 Hz, 2H), 6.61 (d, J=1.89 
Hz, 1H), 6.73 (d, J=3.47 Hz, 1H), 6.88 (d, J=8.15 Hz, 1H),  7.23 (d, J=1.89 Hz, 1H), 7.26 (d, 
J=3.47 Hz, 1H), 7.75 – 7.78 (m, 2H), 7.78 (dd, J=2.0, 8.35 Hz, 1H), 7.84 – 7.85 (m, 1H), 
7.85 – 7.90 (m, 2H), 8.09 (s, 1H), 8.12(s, 1H), 9.39 (s, 1H); 13C NMR (100 MHz, CDCl3); δ 
25.70, 29.09, 36.39, 39.15, 45.23, 47.1, 58.75, 79.1, 106.87, 109.60, 114.7, 116.62, 118.46, 
119,74, 120.37, 122.59, 123.31, 125.15, 125.35, 125.48, 126.0, 127.39, 127.5, 129.4, 131.7, 
138.02, 146.55, 149.99, 155.10, 161.41, 162.45, 162.7, 168.59, 206.42; m/z (+EI) calc. For 
C34H34N6O5S (M+) 638.74, found 639.32 (M+H)
+; Yield: 70%. 
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General procedure for the synthesis of 5-(4-bromothiophene-2-
carboxamido)benzo[b]thiophene-2-carboxylic acid (4.56) from methyl 5-(4-
bromothiophene-2-carboxamido)benzo[b]thiophene-2-carboxylate (4.46) by hydrolysis:  
A 0.5 M solution of NaOH (6.0 ml) was added to a solution of 4.46 (1 eq., 150 mg) in 6.0 ml 
dioxane at room temperature. The reaction mixture was allowed to stir for 2 hours at which 
point TLC showed completion of the reaction. Dioxane was evaporated under high vacuum 
and the residue was diluted with water. The resulting solution was acidified with 1.0 M citric 
acid solution followed by extraction with ethyl acetate (3 X 50 ml). The combined organic 
layer was washed with water (60X2 ml) and brine (60X2 ml), dried over MgSO4 and finally 
concentrated using a rotary evaporator under reduced pressure to obtain 143 mg light green, 
oily product 4.56. 
5-(4-Bromothiophene-2-carboxamido)benzo[b]thiophene-2-carboxylic acid (4.56):  
 
Light green oil. IR (FTIR, νmax/cm-1) 629.01, 785.97, 1216.44, 1364.57, 1737.71, 2041.34, 
2335.91, 2359.65, 2925.06, 3260.98, 3390.18; 1H NMR (400 MHz, CDCl3, TMS); δ 7.50 (d, 
J=1.6 Hz, 1H), 7.56 – 7.58 (m, 1H), 7.73 (d, J=1.6 Hz, 1H), 7.86 (d, J=8.0 Hz, 1H), 8.05 (s, 
1H), 8.09 (s, 1H), 8.32 (d, J=2.0 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 109.60, 115.6, 
116.62, 118.46, 123.37, 131.7, 133.9, 135.2, 138.02, 139.1, 140.1, 141.55, 161.41, 162.45 
m/z (+EI) calc. For C14H8BrNO3S2 (M+) 382.25, found 384.00 (M+H)
+; Yield: 95%. 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)benzo[b]thiophene-2-
carboxylic acid (4.57) 
A 0.5 M solution of NaOH (6.0 ml) was added to a solution of 4.46 (1 eq., 249 mg) in 6.0 ml 
dioxane at room temperature. The reaction mixture was allowed to stir for 2 hours at which 
point TLC showed completion of the reaction. Dioxane was evaporated under high vacuum 
and the residue was diluted with water. The resulting solution was acidified with 1.0 M citric 
acid solution followed by extraction with ethyl acetate (3 X 50 ml). The combined organic 
layer was washed with water (60X2 ml) and brine (60X2 ml), dried over MgSO4 and finally 
concentrated using a rotary evaporator under reduced pressure to obtain 177 mg light yellow, 




5-(5-Bromofuran-2-carboxamido)benzo[b]thiophene-2-carboxylic acid (4.57):  
 
 
Light yellow oil. IR (FTIR, νmax/cm-1) 615.89, 714.22, 798.11, 953.73, 1073.01, 1163.08, 
1217.34, 1304.72, 1415.21, 1467.52, 1586.44, 1676.74, 1736.53, 2930.23, 2968.38; 1H NMR 
(400 MHz, DMSO, TMS); δ 6.86 (d, J=3.54 Hz, 1H), 7.41 (d, J=3.54 Hz, 1H), 7.79 (dd, 
J=2.0, 8.84 Hz, 1H), 8.0 (d, J=8.59 Hz, 1H), 8.09 (s, 1H), 8.41 (d, J=1.77 Hz, 1H), 10.41 (s, 
1H); 13C NMR (100 MHz, DMSO); δ 110.7, 115.2, 115.7, 116.9, 118.2, 121.9, 123.0, 135.04, 
139.5, 140.1, 142.0, 148.99, 161.8, 162.3;  m/z (+EI) calc. For C14H8BrNO4S (M+) 366.19, 
found 368.01 (M+H)+; Yield: 74%. 
 
Compounds 4.58 to 4.61 were synthesised by the amide coupling reaction from 4.56 and 4.57 
using N,N-dimethylpropane-1,3-diamine (1 eq.) (4.38 as the amine).   
Procedure for the synthesis of 5-(4-bromothiophene-2-carboxamido)-N-(3-
(dimethylamino)propyl)benzo[b]thiophene-2-carboxamide (4.58) 
2.0 eq of HOBT (67 mg) and 1.75 eq. of DIC (67 µl) were added to a solution of 4.56 (1 eq., 
150 mg) in DCM. After 30 minutes, 1.2 eq. (48 µl) of 4.38 was added and the reaction 
mixture was allowed to stir for 3 hours. Completion of the reaction was confirmed using 
LCMS and TLC. The reaction mixture was then purified using a SCX cartridge (2.0 gm), 
which was washed using DCM (3x), DMF (3x) twice and finally MeOH (2x). The product 
4.58 was released from the cartridge using 10.0 ml 2M NH3 in MeOH and concentrated in 
vacuo to obtain yellow oil (126 mg). 
5-(4-Bromothiophene-2-carboxamido)-N-(3-(dimethylamino)propyl)benzo[b]thiophene-





Yellow oil. IR (FTIR, νmax/cm-1) 629.66, 674.90, 785.97, 1230.25, 1343.91, 1444.64, 
1631.65, 1723.61, 1739.11, 2196.38, 2930.23, 3261.50; 1H NMR (400 MHz, CDCl3, TMS); δ 
1.78 – 1.79 (m, 2H), 2.26 (s, 3H), 2.36 (s, 3H), 2.40 (t, J=8.0, Hz, 2H), 3.59 – 3.62 (m, 2H), 
7.21 – 7.23 (m, 1H), 7.47 (d, J=3.0, Hz, 1H), 7.55(dd, J=2.0, 8.59 Hz, 1H),  7.70 (d, J=3.0 
Hz, 1H), 7.79 (d, J=8.84 Hz, 1H), 8.31(d, J=2.02 Hz, 1H), 8.51 (br.s, 1H), 8.98 (br.s, 1H); 
13C NMR (100 MHz, CDCl3); δ 25.70, 39.15, 45.23, 47.0, 58.75, 109.60, 110.2, 116.62, 
118.46, 120.37, 131.7, 133.9, 135.2, 138.02, 139.0, 141.1, 146.55, 161.41, 162.45; m/z (+EI) 
calc. For C19H20BrN3O2S2 (M+) 466.42, found 466.06 (M+H)
+; Yield 69%. 
Procedure for the synthesis of 5-bromo-N-(2-((3-
(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-yl)furan-2-carboxamide (4.59) 
2.0 eq of HOBT (83 mg) and 1.75 eq. of DIC (83 µl) were added to a solution of 4.57 (1 eq., 
177 mg) in DCM. After 30 minutes, 1.2 eq. (59 µl) of 4.38 was added and the reaction 
mixture was allowed to stir for 3 hours. Completion of the reaction was confirmed using 
LCMS and TLC. The reaction mixture was then purified using a SCX cartridge (2.0 gm), 
which was washed using DCM (3x), DMF (3x) twice and finally MeOH (2x). The product 
4.59 was released from the cartridge using 10.0 ml 2M NH3 in MeOH and concentrated in 
vacuo to obtain colourless oil (129 mg). 
5-Bromo-N-(2-((3-(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-yl)furan-2-
carboxamide (4.59):  
 
Colourless oil. IR (FTIR, νmax/cm-1) 716.07, 742.51, 799.66, 924.57, 1035.56, 1098.33, 
1167.83, 1229.76, 1304.84, 1445.18, 1464.00, 1527.30, 1553.13, 1617.66, 1737.39, 2967.50, 
3339.26; 1H NMR (400 MHz, DMSO, TMS); δ 1.67 – 1.69 (m, 2H), 2.14 (s, 6H), 2.25 – 2.27 
(m, 2H), 3.63 – 3.65 (m, 2H), 6.86 (d, J=3.79 Hz,  1H), 6.96 – 6.98 (m, 1H), 7.42 (d, J=3.54 
Hz, 1H), 7.75 – 7.77 (m, 1H), 7.97 – 8.00 (m, 1H), 8.02 (s, 1H), 8.35 (d, J=2.02Hz, 1H), 8.78 
(t, J=5.43Hz, 1H); 13C NMR (100 MHz, DMSO); δ 25.70, 39.15, 45.23, 47.1, 58.75, 112.7, 
115.2, 116.62, 118.46, 120.0, 121.9, 123.0, 133.9, 139.2, 141.1, 146.05, 148.99, 161.8, 162.3; 
m/z (+EI) calc. For C19H20BrN3O3S (M+) 450.35, found 450.20 (M+H)
+; Yield: 73%. 
253 
 
Procedure for the synthesis of 5-amino-N-(3-(dimethylamino)propyl)benzofuran-2-
carboxamide (4.61) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.60 (1 eq., 100 mg) in 
DCM. After 30 minutes, 1.2 eq. (58 µl) of 4.38 was added and the reaction mixture was 
allowed to stir for 3 hours. Completion of the reaction was confirmed using LCMS and TLC. 
The reaction mixture was then purified using a SCX cartridge (2.0 gm), which was washed 
using DCM (3x), DMF (3x) twice and finally MeOH (2x). The product 4.61 was released 
from the cartridge using 10.0 ml 2M NH3 in MeOH and concentrated in vacuo to obtain light 
yellow oil (120 mg). 
5-Amino-N-(3-(dimethylamino)propyl)benzofuran-2-carboxamide (4.61):  
 
Light yellow oil. IR (FTIR, νmax/cm-1) 739.34, 767.68, 820.64, 876.90, 942.88, 1022.41, 
1047.88, 1151.02, 1233.66, 1292.49, 1365.79, 1477.38, 1540.42, 1702.25, 2360.07, 2974.76, 
3278.68; 1H NMR (400 MHz, DMSO, TMS); δ 1.68 – 1.70 (m, 2H), 2.24 (s, 6H), 2.36 – 3.39 
(m, 2H), 3.31 – 3.32 (m, 2H), 7.77 (d, J=2.27 Hz, 1H), 8.02 (s, 1H), 8.14 (s, 1H), 8.20 (d, 
J=2.02Hz, 1H), 8.67 (d, J=5.68 Hz, 1H);13C NMR (100 MHz, DMSO); δ 26.63, 38.60, 45.9, 
47.1, 58.2, 110.60, 119.24, 123.97, 126.82, 127.5, 135.42, 146.79, 152.75, 159.91; m/z (+EI) 
calc. For C14H19N3O2 (M+) 261.32, found 262.38 (M+H)
+; Yield: 81%. 
Suzuki coupling was used for the synthesis of compounds 4.62 to 4.70 following the usual 
procedure and conditions for the reaction. 
Procedure for the synthesis of 5-(4-(4-aminophenyl)thiophene-2-carboxamido)-N-(3-
(dimethylamino)propyl)benzo[b] thiophene-2-carboxamide (4.62) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq) was added to 
a solution of 4.58 (1.0 eq., 126 mg) and 4.47 (1.2 eq., 71 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
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100 °C for 15 minutes. LCMS analysis showed that the reaction was not completed after 15 
minutes and it was again microwaved for another 10 minutes and then for a final 5 minutes. 
After LCMS analysis revealed completion of the reaction, the cooled reaction mixture was 
passed through an IsoluteTM SCX-2 cartridge (2 gm) and washed with DCM (3x), DMF (3x) 
twice and finally MeOH (2x). The product 4.62 was released from the cartridge using 10.0 ml 
2M NH3 in MeOH and concentrated in vacuo (121 mg). 
5-(4-(4-Aminophenyl)thiophene-2-carboxamido)-N-(3-(dimethylamino)propyl)benzo[b] 




Colourless oil. IR (FTIR, νmax/cm-1) 629.78, 785.97, 1116.60, 1230.25, 1511.80, 1630.62, 
1736.53, 1873.43, 1969.00, 2175.71, 2334.48, 3266.14, 3333.33; 1H NMR (400 MHz, 
DMSO, TMS); δ 1.68 – 1.69 (m, 2H), 2.16 (s, 6H), 2.29 (t, J=7.07 Hz, 2H), 3.30 – 3.32 (m, 
2H), 6.41 – 6.43 (m, 1H), 6.45 – 6.48 (m,1H), 6.64 (d, J=8.59 Hz, 2H),7.43 (d, J=8.59 Hz, 
2H), 7.75(dd, J=2.0, 8.84 Hz, 1H),  7.85 (d, J=1.26 Hz, 1H), 7.99 (d, J=8.84 Hz, 1H), 8.02 (s, 
1H), 8.32 (s, 1H), 8.38 (s, 1H), 8.79 (s, 1H), 10.37 (s, 1H); 13C NMR (100 MHz, DMSO); δ 
26.70, 39.15, 46.23, 47.0, 58.75, 115.6, 116.62, 118.46, 119.34, 120.37, 123.0, 125.35, 
127.39, 127.5, 129.4, 131.7, 133.9, 135.2, 138.02, 140.8, 141.2, 145.0, 146.55, 161.41, 
162.45;  m/z (+EI) calc. For C25H26N4O2S2 (M+) 478.63, found 479.12 (M+H)
+; Yield: 94%. 
 
Procedure for the synthesis of 5-(4-aminophenyl)-N-(2-((3-
(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-yl)furan-2-carboxamide (4.63) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq) was added to 
a solution of 4.59 (1.0 eq., 105 mg) and 4.47 (1.2 eq., 72 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
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addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. LCMS analysis showed that the reaction was not completed after 15 
minutes and it was again microwaved for another 10 minutes and then for a final 5 minutes. 
After LCMS analysis revealed completion of the reaction, the cooled reaction mixture was 
passed through an IsoluteTM SCX-2 cartridge (2 gm) and washed with DCM (3x), DMF (3x) 
twice and finally MeOH (2x). The product 4.63 was released from the cartridge using 10.0 ml 
2M NH3 in MeOH and concentrated in vacuo (79 mg). 
5-(4-Aminophenyl)-N-(2-((3-(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-
yl)furan-2-carboxamide (4.63):  
 
Colourless oil. IR (FTIR, νmax/cm-1) 628.41, 720.28, 1120.85, 1177.78, 1302.75, 1444.86, 
1483.39, 1538.39, 1610.21, 2821.70, 2967.27, 3336.67; 1H NMR (400 MHz, DMSO, TMS); 
δ 1.67 – 1.69 (m, 2H), 2.14 (s, 6H), 2.25 – 2.28 (m, 2H), 3.04 – 3.07 (m, 2H), 6.41 – 6.42 (m, 
2H), 6.86 (d, J=3.79 Hz,  1H), 7.42 (d, J=3.79 Hz, 1H), 7.75 – 7.77 (m, 1H), 7.97 – 8.00 (m, 
1H), 8.0 – 8.01 (m, 2H), 8.02 (s, 1H), 8.35 (d, J=2.02Hz, 1H), 8.78 (t, J=5.43Hz, 1H), 10.41 
(s, 1H); 13C NMR (100 MHz, DMSO); δ 26.70, 39.15, 46.23, 47.1, 58.75, 108.9, 109.3, 
115.2, 115.6, 115.8, 116.62, 119.34, 120.37, 123.9, 125.35, 135.2, 138.02, 140.8, 141.2, 
145.0, 146.3, 146.55, 156.0, 161.41, 162.45;  m/z (+EI) calc. For C25H26N4O3S (M+) 462.56, 
found 463.23 (M+H)+; Yield: 73%. 
Procedure for the synthesis of 5-(4-(3-aminophenyl)thiophene-2-carboxamido)-N-(3-
(dimethylamino)propyl)benzo [b]thiophene-2-carboxamide (4.64) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq) was added to 
a solution of 4.58 (1.0 eq., 350 mg) and 4.49 (1.5 eq., 154 mg) in a 9:3:1 combination of 
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EtOH, toluene and water in the presence of K2CO3 (3.0 eq) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 20 minutes. LCMS analysis showed that the reaction was not completed after 20 
minutes and it was again microwaved for another 10 minutes. After LCMS analysis revealed 
completion of the reaction, the cooled reaction mixture was passed through an IsoluteTM 
SCX-2 cartridge (5 gm) and washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.64 was released from the cartridge using 10.0 ml 2M NH3 in MeOH and 
concentrated in vacuo (300 mg). 
5-(4-(3-Aminophenyl)thiophene-2-carboxamido)-N-(3-(dimethylamino)propyl)benzo 
[b]thiophene-2-carboxamide (4.64):  
 
Colourless oily mass. IR (FTIR, νmax/cm-1) 664.84, 684.11, 719.47, 762.73, 816.52, 848.36, 
893.97, 968.15, 1119.89, 1162.92, 1222.91, 1272.50, 1309.31, 1337.48, 1365.79, 1428.76, 
1529.61, 1574.16, 1619.90, 1738.57, 2832.04, 3251.64; 1H NMR (400 MHz, DMSO-d6, 
TMS); δ 1.71 – 1.73 (m, 2H), 2.18 (s, 6H), 2.32 (t, J=7.07 Hz, 2H), 3.39 – 3.42 (m, 2H), 6.59 
– 6.60 (m, 2H), 6.95 – 6.97 (m,  1H), 6.98 – 7.00 (m, 2H), 7.11 (t, J=8.0 Hz, 1H), 7.57 – 7.59 
(m, 1H), 7.64 – 7.65 (m, 1H), 7. 65 – 7.68 (m, 1H), 7.72 (br.s, 1H), 7.98 – 8.00 (m, 1H), 8.02 
(s, 1H), 8.39 – 8.41 (m, 1H), 10.44 (s,1H); 13C NMR (100 MHz, DMSO-d6); δ 26.92, 39.72, 
45.04, 47.1, 56.73, 111.27, 115.67, 116.3, 117.5, 119.92, 121.84, 122.92, 124.38, 129.45, 
131.39, 134.97, 136.05, 139.50, 140.14, 142.86, 144.5, 147.50, 149.16, 159.93, 163.4; m/z 
(+EI) calc. For C25H26N4O2S2 (M+) 478.63, found 479.12 (M+H)





Procedure for the synthesis of 5-(4-(6-aminopyridin-3-yl)thiophene-2-carboxamido)-N-
(3-(dimethylamino)propyl)benzo[b]thiophene-2-carboxamide (4.66) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq) was added to 
a solution of 4.58 (1.0 eq., 413 mg) and 4.65 (1.5 eq., 292 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 20 minutes. LCMS analysis showed that the reaction was not completed after 20 
minutes and it was again microwaved for another 10 minutes. After LCMS analysis revealed 
completion of the reaction, the cooled reaction mixture was passed through an IsoluteTM 
SCX-2 cartridge (5 gm) and washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.66 was released from the cartridge using 10.0 ml 2M NH3 in MeOH and 
concentrated in vacuo (374 mg). 
5-(4-(6-Aminopyridin-3-yl)thiophene-2-carboxamido)-N-(3-
(dimethylamino)propyl)benzo[b]thiophene-2-carboxamide (4.66):  
 
Light yellow oil. IR (FTIR, νmax/cm-1) 630.82, 722.61, 777.76, 1119.83, 1168.50, 1360.87, 
1436.62, 1501.95, 1553.57, 1626.46, 2362.18, 2969.51, 3332.28; 1H NMR (400 MHz, 
DMSO-d6, TMS); δ 1.68 (t, J=7.07 Hz, 2H), 2.16 (s, 6H), 2.30 (t, J=7.33Hz, 2H), 3.01 – 3.02 
(m, 2H), 6.10 (s, 2H), 6.53 (dd, J=0.51, 8.59 Hz, 1H), 7.55 – 7.57 (m, 1H), 7.61 – 7.62 (m, 
1H),  7.62 (d, J=1.52 Hz, 1H), 7.95 (d, J=1.52Hz, 1H), 7.99 (d, J=8.59 Hz, 1H), 8.02 (s, 1H), 
8.35 – 8.36 (m, 1H), 8.37 (d, J=2.02Hz, 1H), 8.40 (d, J=1.26Hz, 1H), 10.36 (s, 1H); 13C 
NMR (100 MHz, DMSO-d6); δ 26.46, 39.10, 45.14, 47.1, 56.97, 108.16, 115.73, 116.3, 
121.84, 122.92, 125.73, 128.86, 132.42, 134.96, 135.63, 139.71, 140.46, 141.42, 142.74, 
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146.2, f4r159.35, 160.11, 161.02, 161.47;  m/z (+EI) calc. For C24H25N5O2S2 (M+) 479.62, 
found 480.17 (M+H)+; Yield: 88%. 
Procedure for the synthesis of 5-(3-aminophenyl)-N-(2-((3-
(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-yl)furan-2-carboxamide (4.67) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq) was added to 
a solution of 4.59 (1.0 eq., 280 mg) and 4.49 (1.5 eq., 128 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 20 minutes. LCMS analysis showed that the reaction was not completed after 20 
minutes and it was microwaved for another 10 minutes. After LCMS analysis revealed 
completion of the reaction, the cooled reaction mixture was passed through an IsoluteTM 
SCX-2 cartridge (5 gm) and washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.67 was released from the cartridge using 10.0 ml 2M NH3 in MeOH and 
concentrated in vacuo (230 mg). 
5-(3-Aminophenyl)-N-(2-((3-(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-
yl)furan-2-carboxamide (4.67):  
 
Colourless oil. IR (FTIR, νmax/cm-1) 690.56, 743.45, 768.52, 1018.27, 1120.38, 1179.90, 
1225.59, 1298.48, 1439.92, 1522.89, 1576.95, 1614.31, 2339.42, 2360.70, 2945.12, 3339.84; 
1H NMR (400 MHz, DMSO-d6, TMS); δ 1.67 – 1.69 (m, 2H), 2.14 (s, 6H), 2.28 – 2.30 (m, 
2H), 3.39 – 3.41 (m, 2H), 6.60 – 6.63 (m, 2H), 6.97 – 7.00 (m, 2H), 7.02 – 7.03 (m, 1H), 7.10 
– 7.11 (m, 1H),7.11 (d, J=1.52 Hz, 1H), 7.43 (d, J=3.79 Hz, 1H), 7.63 (d, J=1.52 Hz, 1H), 
7.78 (dd, J=2.02, 8.84 Hz, 1H), 7.98 (d, J=8.84 Hz, 1H), 8.02 (s, 1H), 8.38 (d, J=2.01.77 Hz, 
1H), 10.28 (s, 1H); 13C NMR (100 MHz, DMSO-d6); δ 27.67, 39.72, 47.3, 49.50, 57.02, 
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103.81, 109.81, 112.66, 115.88, 117.02, 118.28, 120.13, 122.05, 123.03, 124.56, 129.96, 
131.60, 131.70, 133.43, 135.63, 136.08, 147.70, 149.26, 156.52, 161.47;  m/z (+EI) calc. For 
C25H26N4O3 (M+) 462.56, found 463.30 (M+H)
+; Yield: 80%. 
Procedure for the synthesis of 5-(6-aminopyridin-3-yl)-N-(2-((3-
(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-yl)furan-2-carboxamide (4.68) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq) was added to 
a solution of 4.59 (1.0 eq., 131 mg) and 4.65 (1.5 eq., 96 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 20 minutes. LCMS analysis showed that the reaction was not completed after 20 
minutes and it was microwaved for another 10 minutes. After LCMS analysis revealed 
completion of the reaction, the cooled reaction mixture was passed through an IsoluteTM 
SCX-2 cartridge (5 gm) and washed with DCM (3x) and DMF (3x) twice and finally MeOH 
(2x). The product 4.68 was released from the cartridge using 10.0 ml 2M NH3 in MeOH and 
concentrated in vacuo (105 mg). 
5-(6-Aminopyridin-3-yl)-N-(2-((3-(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-
5-yl)furan-2-carboxamide (4.68):   
 
Yellow oil. IR (FTIR, νmax/cm-1) 691.10, 737.63, 1017.76, 1177.00, 1265.07, 1304.85, 
1409.00, 1477.65, 1583.94, 1617.69, 2362.23, 3322.29; 1H NMR (400 MHz, DMSO-d6, 
TMS); δ 1.68 – 1.70 (m, 2H), 2.15 (s, 6H), 2.28 – 2.31 (m, 2H), 3.12 – 3.15 (m, 2H), 6.36 (s, 
2H), 6.54 – 6.55 (m, 1H), 6.90 (d, J=3.54 Hz, 1H), 7.36 (d, J=3.54 Hz, 1H), 7.56 – 7.58 (m, 
1H), 7.78 (dd, J=2.0, 8.84 Hz, 1H),  7.92 (dd, J=2.40, 8.72 Hz, 1H), 7.98 (d, J=8.84 Hz, 1H), 
8.02 (s, 1H), 8.38 (d, J=1.77 Hz, 1H), 8.59 (d, J=2.27 Hz, 1H), 10.19 (s, 1H); 13C NMR (100 
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MHz, DMSO-d6); δ 27.67, 39.72, 47.1, 49.50, 57.02, 103.81, 109.81, 112.66, 115.88, 117.02, 
118.28, 120.13, 122.05, 123.03, 129.96, 131.60, 131.70, 133.43, 135.63, 136.08, 147.70, 
149.26, 156.52, 161.47;  m/z (+EI) calc. For C24H25N5O3S (M+) 463.55, found 464.49 
(M+H)+; Yield: 78%. 
Procedure for the synthesis of 3-(5-(3-aminophenyl)furan-2-carboxamido)-N-(3-
(dimethylamino)propyl)benzofuran-6-carboxamide (4.69) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq) was added to 
a solution of 4.71 (1.0 eq., 61 mg) and 4.49 (1.2 eq., 23 mg) in a 9:3:1 combination of EtOH, 
toluene and water in the presence of K2CO3 (3.0 eq) in a 10 ml microwave vial containing a 
magnetic stirrer. The reaction vessel was flushed with nitrogen during each addition. The 
reaction mixture was sealed in an inert nitrogen environment and heated with microwave 
radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 100 °C for 
20 minutes. LCMS analysis showed that the reaction was not completed after 20 minutes and 
it was microwaved for another 10 minutes. After LCMS analysis revealed completion of the 
reaction, the cooled reaction mixture was passed through an IsoluteTM SCX-2 cartridge (5 
gm) and washed with DCM (3x), DMF (3x) twice and finally MeOH (2x). The product 4.69 
was released from the cartridge using 10.0 ml 2M NH3 in MeOH and concentrated in vacuo 
(54 mg). 
3-(5-(3-Aminophenyl)furan-2-carboxamido)-N-(3-(dimethylamino)propyl)benzofuran-
6-carboxamide (4.69):  
 
Light yellow oil. IR (FTIR, νmax/cm-1) 722.40, 785.89, 992.82, 1021.62, 1114.11, 1233.37, 
1297.16, 1441.25, 1468.87, 1540.61, 1578.87, 1643.60, 3229.50, 3336.67; 1H NMR (400 
MHz, DMSO-d6, TMS); δ 1.69 (t, J=6.95 Hz, 2H), 2.20 (s, 6H), 2.35 – 2.38 (m, 2H), 3.32 (s, 
2H), 6.60 (d, J=2.02 Hz,  1H), 6.61 (dd, J=1.26, 3.28 Hz,  1H), 6.96 (d, J=1.26 Hz,  1H), 6.97 
(d, J=2.27 Hz,  1H), 7.10 (d, J=0.76 Hz, 1H), 7.41 (d, J=3.54 Hz, 1H), 7.55 – 7.57 (m, 1H), 
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7.63 – 7.64 (m, 1H), 7.66 (s, 1H), 7.73 (s, 2H), 7.75 (d, J=2.27 Hz, 1H), 8.19 (d, J=2.02 Hz, 
1H), 10.23 (s, 1H); 13C NMR (100 MHz, DMSO-d6); δ 26.62, 37.09, 44.81, 47.1, 56.60, 
106.75, 109.11, 109.21, 114.36, 115.48, 119.72, 120.50, 121.65, 127.04, 127.51, 129.57, 
131.19, 131.28, 145.99, 147.29, 148.83, 156.03, 157.70, 162.07, 167.77; m/z (+EI) calc. For 
C25H26N4O4 (M+) 446.50, found 447.25 (M+H)
+; Yield: 86%. 
Procedure for the synthesis of 3-(5-(4-aminophenyl)furan-2-carboxamido)-N-(3-
(dimethylamino)propyl)benzofuran-6-carboxamide (4.70) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq) was added to 
a solution of 4.71 (1.0 eq., 54 mg) and 4.47 (1.2 eq., 33 mg) in a 9:3:1 combination of EtOH, 
toluene and water in the presence of K2CO3 (3.0 eq) in a 10 ml microwave vial containing a 
magnetic stirrer. The reaction vessel was flushed with nitrogen during each addition. The 
reaction mixture was sealed in an inert nitrogen environment and heated with microwave 
radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 100 °C for 
20 minutes. LCMS analysis showed that the reaction was not completed after 20 minutes and 
it was microwaved for another 10 minutes. After LCMS analysis revealed completion of the 
reaction, the cooled reaction mixture was passed through an IsoluteTM SCX-2 cartridge (5 
gm) and washed with DCM (3x), DMF (3x) twice and finally MeOH (2x). The product 4.70 
was released from the cartridge using 10.0 ml 2M NH3 in MeOH and concentrated in vacuo 
(42 mg). 
3-(5-(4-Aminophenyl)furan-2-carboxamido)-N-(3-(dimethylamino)propyl)benzofuran-
6-carboxamide (4.70):  
 
Greenish yellow oil. IR (FTIR, νmax/cm-1) 668.24, 802.47, 1021.34, 1177.83, 1203.07, 
1234.29, 1297.91, 1434.74, 1469.38, 1548.02, 1608.16, 1644.05, 2359.97, 3237.45, 3336.06; 
1H NMR (400 MHz, DMSO-d6, TMS); δ 1.68 (t, J=7.07 Hz, 2H), 2.18 (s, 6H), 2.32 – 2.34 
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(m, 2H), 3.31 – 3.32 (m, 2H), 6.46 – 6.48 (m, 2H), 6.64 – 6.65 (m, 1H), 6.66 – 6.68 (m, 1H), 
6.78 (d, J=3.54 Hz, 1H), 7.33 (d, J=3.79 Hz, 1H), 7.53 (d, J=1.01 Hz, 1H), 7.63 – 7.64 (m, 
2H), 7.65 – 7.67 (m, 1H), 7.76 (dd, J=2.1,8.97 Hz, 1H), 8.18 (d, J=2.02Hz, 1H), 10.10 (s, 
1H); 13C NMR (100 MHz, DMSO-d6); δ 26.85, 37.31, 45.05, 47.3, 56.82, 109.31, 111.57, 
112.71, 115.18, 115.49, 117.01, 120.78, 121.3, 125.94, 127.22, 128.66, 128.74, 135.47, 
140.1, 144.84, 148.56, 156.26, 157.00, 157.93, 167.7; m/z (+EI) calc. For C25H26N4O4 (M+) 
446.50, found 447.18 (M+H)+; Yield: 78%. 
The amide coupling reaction was carried out for the synthesis of compounds 4.71 to 4.81 
following the usual procedure and conditions for the reaction. 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(3-
(dimethylamino)propyl)benzofuran-2-carboxamide (4.71) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.61 (1 eq., 71 mg) in DCM. 
Then 1.2 eq. (62 mg) of 4.41 was added to the reaction mixture, which was allowed to stir for 
3 hours. Completion of the reaction was confirmed using LCMS. The reaction mixture was 
then purified by SCX cartridge (2.0 gm), which was washed using DCM (3x), DMF (3x) 
twice and finally MeOH (2x). The product 4.71 was released from the cartridge using 10.0 ml 
2M NH3 in MeOH and concentrated in vacuo to obtain yellow oil (51 mg). 
5-(5-Bromofuran-2-carboxamido)-N-(3-(dimethylamino)propyl)benzofuran-2-
carboxamide (4.71):  
 
Yellowish oil. IR (FTIR, νmax/cm-1) 739.32, 813.63, 963.39, 1028.10, 1179.59, 1235.62, 
1283.62, 1343.33, 1457.14, 1537.87, 1566.39, 1590.85, 1651.30, 2819.67, 2944.27, 3319.83; 
1H NMR (400 MHz, DMSO-d6, TMS); δ 1.67 (t, J=7.07 Hz, 2H), 2.14 (s, 6H), 2.26 (t, 
J=6.95 Hz, 2H), 3.30 – 3.32 (m, 2H), 6.84 (d, J=3.54 Hz, 1H), 7.38 (d, J=3.54 Hz, 1H), 7.51 
(d, J=1.01 Hz, 1H), 7.70 (d, J=2.27 Hz, 1H), 8.17 (d, J=2.02 Hz, 1H), 8.17 (d, J=2.02Hz, 
1H), 8.76 (d, J=5.68 Hz, 1H), 10.31 (s, 1H); 13C NMR (100 MHz, DMSO-d6); δ 27.13, 37.56, 
45.33, 47.1, 57.09, 109.52, 111.89, 114.45, 117.24, 120.83, 125.44, 134.35, 146.9, 149.50, 
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150.22, 155.34, 158.09, 162.1, 167.0;  m/z (+EI) calc. For C19H20BrN3O4 (M+) 434.28, found 
435.95 (M+H)+; Yield: 82%. 
Procedure for the synthesis of 2-(1,3-dihydroisobenzofuran-5-yl)-N-(4-(5-((2-((3-
(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.72) 
1 eq. of 4.63 (27 mg), 1.7 eq. of 4.53 (25 mg), 2 eq. HOBT and 1.75 eq. DIC were measured 
into a round bottom flask and dissolved in a minimum amount of DMF. The reaction mixture 
was allowed to stir for 3 hours at room temperature. After 3 hours the reaction mixture was 
checked by LCMS to identify completion of the reaction. LCMS analysis indicated 
completion of the reaction and the reaction mixture was poured onto an Isolute SCX (500 
mg) column for purification. The cartridge was washed using DCM (3x), DMF (3x) twice 
and finally MeOH (2x). The product 4.72 was released from the cartridge using 10.0 ml 2M 
NH3 in MeOH and concentrated in vacuo. Further purification was achieved using a silica 
column with DCM:MeOH:2MNH3 (18:1:1) as the solvent system. 21 mg colourless oil was 
obtained as the final compound. 
2-(1,3-Dihydroisobenzofuran-5-yl)-N-(4-(5-((2-((3-
(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.72):  
 
 
Colourless oil. IR (FTIR, νmax/cm-1) 640.14, 729.94, 798.27, 980.55, 1015.93, 1099.83, 
1230.74, 1294.34, 1365.13, 1413.76, 1447.00, 1482.14, 1522.14, 1637.74, 2969.08, 3307.49; 
1H NMR (400 MHz, CDCl3, TMS); δ 1.80 – 1.82 (m, 2H), 2.37 (s, 6H), 2.57 – 2.60 (m, 2H), 
3.33 (t, J=8.59 Hz, 2H), 3.60 – 3.62 (m, 2H), 4.69 – 4.71 (m, 2H), 6.78 (d, J=3.54 Hz, 1H), 
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6.89 (m, 1H), 7.36 (d, J=3.54 Hz, 1H), 7.59 (dd, J=2.02,8.84 Hz, 1H), 7.69 (s, 1H), 7.79 – 
7.82 (m, 2H),  7.84 (d, J=8.84 Hz, 1H), 7.86 – 7.88 (m, 2H), 8.02 (s, 1H), 8.13 – 8.15 (m, 
1H), 8.27 (s, 1H), 8.40 (d, J=2.02Hz, 1H), 8.85 (br.s,  1H), 9.41 – 9.42 (m, 1H), 10.37 (br.s, 
1H); 13C NMR (100 MHz, CDCl3); δ 24.74, 36.48, 45.29, 47.1, 59.40, 71.96, 76.69, 107.32, 
108.5, 109.83, 115.75, 117.79, 119.52, 119.97, 122.93, 123.09, 123.54, 124.56, 125.44, 
125.47, 125.50, 125.57, 127.60, 128.7, 129.6, 134.66, 136.79, 138.38, 139.91, 141.1, 141.7, 
146.4, 150.09, 156.26, 159.06, 162.63, 170.3;  m/z (+EI) calc. For C37H33N5O5S2 (M+) 
691.82, found 692.55 (M+H)+; Yield: 76%. 
Procedure for the synthesis of 5-(4-(4-((1H-benzo[d]imidazol-1-
yl)methyl)benzamido)phenyl)-N-(2-((3-
(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-yl)furan-2-carboxamide (4.74) 
1 eq. of 4.63 (39 mg), 1.7 eq. of 4.73 (30 mg), 2 eq. HOBT and 1.75 eq. DIC were measured 
into a round bottom flask and dissolved in a minimum amount of DMF. The reaction mixture 
was allowed to stir for 3 hours at room temperature. After 3 hours the reaction mixture was 
checked by LCMS to identify completion of the reaction. LCMS analysis indicated 
completion of the reaction and the reaction mixture was poured onto an Isolute SCX (500 
mg) column for purification. The cartridge was washed using DCM (3x), DMF (3x) twice 
and finally MeOH (2x). The product 4.74 was released from the cartridge using 10.0 ml 2M 
NH3 in MeOH and concentrated in vacuo. Further purification was achieved using a silica 
column and DCM:MeOH:2MNH3 (18:1:1) as the solvent system. 55 mg colourless, oily mass 


















Colourless oily mass. IR (FTIR, νmax/cm-1) 665.26, 736.90, 798.66, 831.62, 1019.70, 1097.66, 
1217.81, 1260.68, 1286.13, 1324.16, 1445.96, 1491.83, 1541.96, 1645.86, 1737.17, 2359.90, 
2922.19, 3339.00;  1H NMR (400 MHz, DMSO-d6, TMS); δ 1.73 – 1.75 (m, 2H), 2.20 (s, 
6H), 2.36 – 3.39 (m, 2H), 3.39 (s, 2H), 6.72 – 6.74 (m, 2H), 6.75 (d, J=3.54 Hz, 1H), 7.20 – 
7.21 (m, 2H), 7.38 (d, J=3.54 Hz, 1H), 7.39 – 7.42 (m, 2H), 7.49 – 7.51 (m, 2H), 7.62 (dd, 
J=2.0, 8.84 Hz, 1H), 7.77 – 7.79 (m, 2H),  7.80 – 7.81 (m, 2H), 7.93 (d, J=8.84 Hz, 1H), 8.05 
(s, 1H), 8.07 (s, 1H), 8.30 (s, 1H), 8.35 (d, J=2.0 Hz, 1H), 10.37 (br.s, 1H); 13C NMR (100 
MHz, DMSO-d6); δ 25.74, 38.48, 47.29, 47.5, 51.0, 59.40, 108.1, 108.6, 115.0, 116.75, 
118.79, 119.52, 119.97, 120.93, 123.09, 123.54, 125.50, 125.57, 127.60, 129.1, 131.7, 134.2, 
134.66, 136.79, 140.91, 141.1, 143.0, 144.4, 146.7, 146.9, 147.8, 150.09, 156.26, 159.06, 
161.3, 162.63, 164.1, 164.7, 170.3, 176.1;  m/z (+EI) calc. For C40H36N6O4S (M+) 696.82, 
found 697.81 (M+H)+; Yield: 93%. 
 
Procedure for the synthesis of 5-(4-(3-(4-((1H-benzo[d]imidazol-1-
yl)methyl)benzamido)phenyl)thiophene-2-carboxamido)-N-(3-
(dimethylamino)propyl)benzo[b]thiophene-2-carboxamide (4.75) 
1 eq. of 4.64 (77 mg), 1.4 eq. of 4.73 (57 mg), 2 eq. HOBT and 1.75 eq. DIC were measured 
into a round bottom flask and dissolved in a minimum amount of DMF. The reaction mixture 
was allowed to stir for 3 hours at room temperature. After 3 hours the reaction mixture was 
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checked by LCMS to identify completion of the reaction. LCMS analysis indicated the 
completion of the reaction and the reaction mixture was poured onto an Isolute SCX (500 
mg) column for purification. The cartridge was washed using DCM (3x), DMF (3x) twice 
and finally MeOH (2x). The product 4.75 was released from the cartridge using 10.0 ml 2M 
NH3 in MeOH and concentrated in vacuo. Further purification was achieved using a silica 
column and DCM:MeOH:2MNH3 (18:1:1) as the solvent system. 70 mg colourless oil was 
obtained as the final compound. 
5-(4-(3-(4-((1H-benzo[d]imidazol-1-yl)methyl)benzamido)phenyl)thiophene-2-
carboxamido)-N-(3-(dimethylamino)propyl)benzo[b]thiophene-2-carboxamide (4.75):  
 
 
Colourless oil. IR (FTIR, νmax/cm-1) 739.69, 888.50, 1110.67, 1180.04, 1260.22, 1286.33, 
1434.06, 1494.42, 1538.07, 1613.68, 1644.08, 1714.53, 2358.40, 3073.17, 3303.99; 1H NMR 
(400 MHz, DMSO-d6, TMS); δ 1.68 – 1.70 (m, 2H), 2.16 (s, 6H), 2.31 – 2.34 (m, 2H), 3.39 
(s, 2H),  5.56 (s, 2H), 7.19 – 7.21 (m, 1H), 7.22 – 7.25 (m, 2H), 7.29 – 7.31 (m, 1H), 7.35 (d, 
J=8.59 Hz, 1H), 7.41(d, J=3.79 Hz, 1H), 7.46 – 7.49 (m, 2H),  7.52 – 7.53 (m, 2H), 7.67 – 
7.68 (m, 1H),  7.73 – 7.75 (m, 1H), 7.91 – 7.92 (m, 1H), 7.98 – 8.00 (m, 2H), 8.02 (s, 1H), 
8.11 (d, J=1.5 Hz, 1H), 8.20 (s, 1H), 8.35 (s, 1H),  8.38 (s, 1H); 13C NMR (100 MHz, 
DMSO-d6); δ 26.46, 39.10, 47.70, 47.9, 52.50, 56.97,110.96, 111.06, 115.6, 116.0, 119.92, 
119.94, 122.02, 122.82, 123.1, 123.7, 123.8, 126.97, 127.50, 127.65, 127.89, 128.24, 128.43, 
128.47, 129.38, 129.96, 133.99, 136.4, 138.56, 140.1, 141.1, 142.73, 143.99, 144.71, 146.3, 
161.3, 164.7, 165.37, 166.24, 206.82; m/z (+EI) calc. For C40H36N6O3S2 (M+) 712.88, found 
713.39 (M+H)+; Yield: 61%. 
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Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((3-
(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.76) 
1 eq. of 4.69 (111 mg), 1.4 eq. of 4.53 (80 mg), 2 eq. HOBT and 1.75 eq. DIC were measured 
into a round bottom flask and dissolved in a minimum amount of DMF. The reaction mixture 
was allowed to stir for 3 hours at room temperature. After 3 hours, the reaction mixture was 
checked by LCMS to identify completion of the reaction. LCMS analysis indicated the 
completion of the reaction and the reaction mixture was poured onto an Isolute SCX (500 
mg) column for purification. The cartridge was washed using DCM (3x), DMF (3x) twice 
and finally MeOH (2x). The product 4.76 was released from the cartridge using 10.0 ml 2M 
NH3 in MeOH and concentrated in vacuo. Further purification was achieved using a silica 
column and DCM:MeOH:2MNH3 (18:1:1) as the solvent system. 77 mg cream powder was 
obtained as the final compound. 
2-(2,3-Dihydrobenzofuran-5-yl)-N-(3-(5-((2-((3-
(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.76):  
 
 
Cream powder. IR (FTIR, νmax/cm-1) 633.40, 741.29, 787.78, 1019.08, 1110.19, 1228.04, 
1304.55, 1422.99, 1447.00, 1535.35, 1586.59, 1651.93, 2357.64, 2951.21, 3115.85, 3348.21; 
1H NMR (400 MHz, CDCl3, TMS); δ 1.78(t, J=5.68 Hz, 2H), 2.35 (s, 6H), 2.54 – 2.56 (m, 
2H), 3.31 (t, J=8.72 Hz, 2H), 3.59 – 3.61 (m, 2H), 4.68 (t, J=8.72 Hz, 2H), 6.86 (d, J=3.79 
Hz,  1H), 6.88 (d, J=8.34 Hz, 1H), 7.35 (d, J=3.54 Hz, 1H), 7.46 (t, J=7.83 Hz,  1H), 7.54 (dt, 
J=1.33, 7.54 Hz, 1H), 7.60 (dd, J=2.0, 8.84 Hz, 1H), 7.65 (s, 1H), 7.67 (ddd, J=1.01, 2.15, 
7.96 Hz,  1H), 7.77 (d, J=2.02 Hz, 1H), 7.80 – 7.82 (m, 1H), 7.86 (d, J=1.26 Hz, 1H), 8.13 (s, 
1H), 8.27 (t, J=1.77 Hz, 1H), 8.36 (s, 1H), 8.40 (d, J=2.02Hz, 1H), 8.85 (t, J=4.55 Hz, 1H), 
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9.38 (s, 1H); 13C NMR (100 MHz, CDCl3); δ 24.83, 29.31, 41,15, 47.1, 47.3, 59.70, 77.30, 
108.38, 109.84, 115.91,115.94, 117.60, 119.69, 120.28, 120.66, 122.91, 123.02, 123.55, 
124.64, 125.54, 127.64, 128.35, 129.64, 130.38, 134.67, 136.82, 138.44, 139.89, 140.88, 
146.91, 150.16, 155.60, 156.27, 159.24, 161.88, 162.68, 168.85; m/z (+EI) calc. For 
C37H33N5O5S2 (M+) 691.82, found 692.72 (M+H)
+; Yield: 69%. 
Procedure for the synthesis of 5-(3-(4-((1H-benzo[d]imidazol-1-
yl)methyl)benzamido)phenyl)-N-(2-((3-
(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-yl)furan-2-carboxamide (4.77) 
1 eq. of 4.67 (97 mg), 1.4 eq. of 4.73 (74 mg), 2 eq. HOBT and 1.75 eq. DIC were measured 
into a round bottom flask and dissolved in a minimum amount of DMF. The reaction mixture 
was allowed to stir for 3 hours at room temperature. After 3hours the reaction mixture was 
checked by LCMS to identify completion of the reaction. LCMS analysis indicated the 
completion of the reaction and the reaction mixture was poured onto an Isolute SCX (500 
mg) column for purification. The cartridge was washed using DCM (3x), DMF (3x) twice 
and finally MeOH (2x). The product 4.77 was released from the cartridge using 10.0 ml 2M 
NH3 in MeOH and concentrated in vacuo. Further purification was achieved using a silica 
column and DCM:MeOH:2MNH3 (18:1:1) as the solvent system. 71 mg colourless oil was 
obtained as the final compound. 
5-(3-(4-((1H-benzo[d]imidazol-1-yl)methyl)benzamido)phenyl)-N-(2-((3-
(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-yl)furan-2-carboxamide (4.77):  
 
Colourless oil. IR (FTIR, νmax/cm-1) 634.22, 686.48, 742.14, 783.28, 884.53, 967.28, 1030.00, 
1221.88, 1264.20, 1288.49, 1365.41, 1439.46, 1497.81, 1525.18, 1547.87, 1584.65, 1641.64,  
1708.81, 2358.16, 3310.12; 1H NMR (400 MHz, CDCl3, TMS); δ 1.78 – 1.80 (m, 2H), 2.30 
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(s, 6H), 2.53 – 2.55 (m, 2H), 3.57 (dd, J=5.43, 11.49 Hz, 2H), 5.42 (s, 2H), 6.85 (d, J=3.79 
Hz, 1H), 7.23 (d, J=8.34 Hz, 2H), 7.26 – 7.29 (m, 1H), 7.30 (d, J=3.54 Hz, 1H), 7.32 – 7.34 
(m, 1H), 7.35 (d, J=3.79 Hz, 1H), 7.47 (d, J=8.08 Hz, 1H), 7.54 (d, J=9.1 Hz, 1H), 7.59 (d, 
J=8.34 Hz, 1H), 7.76 (d, J=8.34 Hz, 2H), 7.81 (d, J=8.59 Hz, 1H), 7.85 – 7.89 (m, 1H),  7.89 
– 7.91 (m, 1H), 7.98 (s, 1H), 8.02 (s, 1H), 8.20 (s, 1H), 8.28 (s, 1H), 8.37 (s, 1H), 8.52 (br.s, 
1H),  13C NMR (100 MHz, CDCl3); δ 24.83, 29.31, 41,15, 47.1, 47.6, 59.70, 77.30, 108.38, 
108.5, 109.84, 110.0, 115.91, 115.94, 117.60, 119.69, 120.28, 120.66, 122.91, 123.02, 
123.55, 124.64, 125.54, 127.64, 128.35, 129.64, 130.38, 134.67, 136.82, 138.44, 139.89, 
140.88, 146.91, 150.16, 155.60, 156.27, 159.24, 161.88, 162.68, 164.8, 168.85; m/z (+EI) 
calc. For C40H36N6O4S (M+) 696.82, found 697.57 (M+H)
+; Yield: 73%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(5-(5-((2-((3-
(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-yl)carbamoyl)furan-2-
yl)pyridin-2-yl)thiazole-4-carboxamide (4.78) 
1 eq. of 4.68 (32 mg), 1.4 eq. of 4.53 (24 mg), 2 eq. HOBT and 1.75 eq. DIC were measured 
into a round bottom flask and dissolved in a minimum amount of DMF. The reaction mixture 
was allowed to stir for 3 hours at room temperature. After 3 hours, the reaction mixture was 
checked by LCMS to identify completion of the reaction. LCMS analysis indicated the 
completion of the reaction and the reaction mixture was poured onto an Isolute SCX (500 
mg) column for purification. The cartridge was washed using DCM (3x), DMF (3x) twice 
and finally MeOH (2x). The product 4.78 was released from the cartridge using 10.0 ml 2M 
NH3 in MeOH and concentrated in vacuo. Further purification was achieved using a silica 
column and DCM:MeOH:2MNH3 (18:1:1) as the solvent system. 24 mg colourless oil was 













yl)pyridin-2-yl)thiazole-4-carboxamide (4.78):  
 
Colourless oil. IR (FTIR, νmax/cm-1) 638.77, 792.06, 940.13, 982.64, 1016.05, 1101.08, 
1230.41, 1295.44, 1397.26, 1444.25, 1485.48, 1520.17, 1583.94, 1611.27, 1647.72, 1741.86, 
2362.36, 2933.66, 3115.85, 3341.46;  1H NMR (400 MHz, CDCl3, TMS); δ 1.79 (t, J=6.44 
Hz, 2H), 2.37 (s, 6H), 2.57 – 2.59 (m, 2H), 3.34 (t, J=8.84 Hz, 2H), 3.61 – 3.64 (m, 2H), 4.70 
(t, J=8.84 Hz, 2H), 6.87 (d, J=3.79 Hz, 1H), 6.90 (d, J=8.59 Hz, 1H),  7.39 (d, J=3.54 Hz, 
1H), 7.58 (dd, J=2.1, 8.72 Hz, 1H), 7.68 (s, 1H), 7.80 (d, J=6.06 Hz, 1H),  7.86  (d, J=8.59 
Hz, 1H),  7.95 (s, 1H), 8.13 (dd, J=2.4, 8.72 Hz, 1H), 8.18 – 8.20 (m, 1H), 8.41 (d, J=1.52 
Hz, 1H), 8.57 (d, J=8.84 Hz, 1H), 8.79 (d, J=3.28 Hz, 1H), 8.88 (br s, 1H), 10.0 (s, 1H); 13C 
NMR (100 MHz, CDCl3); δ 24.73, 39.31, 47.15, 47.2, 51.0, 59.0, 78.4, 108.38, 108.7, 
110.84, 115.01, 116.94, 119.60, 120.67, 121.66, 122.81, 123.02, 123.55, 124.00, 125.54, 
127.64, 128.35, 129.64, 130.38, 135.67, 136.22, 138.65, 139.89, 141.88, 146.91, 150.16, 
155.60, 156.27, 161.88, 162.68, 168.85; m/z (+EI) calc. For C36H32N6O5S2 (M+) 692.81, 
found 693.30 (M+H)+; Yield: 74%. 
Procedure for the synthesis of 5-(6-(4-((1H-benzo[d]imidazol-1-
yl)methyl)benzamido)pyridin-3-yl)-N-(2-((3-
(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-yl)furan-2-carboxamide (4.79) 
1 eq. of 4.68 (46 mg), 1.4 eq. of 4.73 (35 mg), 2 eq. HOBT and 1.75 eq. DIC were measured 
into a round bottom flask and dissolved in a minimum amount of DMF. The reaction mixture 
was allowed to stir for 3 hours at room temperature. After 3 hours the reaction mixture was 
checked by LCMS to identify completion of the reaction. LCMS analysis indicated the 
completion of the reaction and the reaction mixture was poured onto an Isolute SCX (500 
mg) column for purification. The cartridge was washed using DCM (3x), DMF (3x) twice 
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and finally MeOH (2x). The product 4.79 was released from the cartridge using 10.0 ml 2M 
NH3 in MeOH and concentrated in vacuo. Further purification was achieved using a silica 
column and DCM:MeOH:2MNH3 (18:1:1) as the solvent system. 34 mg colourless oil was 
obtained as the final compound. 
5-(6-(4-((1H-benzo[d]imidazol-1-yl)methyl)benzamido)pyridin-3-yl)-N-(2-((3-
(dimethylamino)propyl)carbamoyl)benzo[b]thiophen-5-yl)furan-2-carboxamide (4.79):  
 
Colourless oil. IR (FTIR, νmax/cm-1) 740.95, 795.26, 1039.37, 1213.44, 1365.59, 1445.88, 
1494.87, 1538.39, 1633.71, 1737.22, 2361.96, 2969.45, 3018.29, 3341.46; 1H NMR (400 
MHz, CDCl3, TMS); δ 1.80 – 1.82 (m, 2H), 2.39 (s, 6H), 2.59 – 2.62 (m, 2H), 3.60 – 3.62 (m, 
2H), 5.49 (s, 2H), 6.86 (d, J=3.54 Hz, 1H),   7.01 – 7.02 (m, 1H), 7.17 – 7.19 (m, 1H), 7.32 – 
7.35 (m, 2H),  7.35 – 7.37 (m, 1H), 7.38 (d, J=3.54 Hz, 1H),  7.56 – 7.60 (m, 2H), 7.70 (s, 
1H), 7.86 – 7.89 (m, 2H), 7.93 – 7.95 (m, 2H), 8.02 (s, 1H), 8.11 – 8.13 (m, 1H), 8.16 (s, 1H), 
8.39 (s, 1H), 8.59 (s, 1H), 8.74 (d, J=2.3 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 25.83, 
30.31, 41,11, 47.1, 47.4, 59.50, 109.38, 109.94, 110.1, 115.38, 115.94, 116.0, 117.10, 119.70, 
120.35, 121.66, 122.34, 123.02, 123.75, 124.34, 125.84, 127.34, 129.35, 129.64, 130.38, 
134.07, 136.45, 138.14, 139.69, 141.88, 143.3, 147.91, 150.16, 155.80, 156.48, 159.24, 
161.18, 162.86, 168.85; m/z (+EI) calc. For C39H35N7O4S (M+) 697.80, found 698.53 
(M+H)+; Yield: 73%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((3-
(dimethylamino)propyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.80) 
1 eq. of 4.69 (66 mg), 1.5 eq. of 4.53 (55 mg), 2 eq. HOBT and 1.75 eq. DIC were measured 
into a round bottom flask and dissolved in a minimum amount of DMF. The reaction mixture 
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was allowed to stir for 3 hours at room temperature. After 3 hours the reaction mixture was 
checked by LCMS to identify completion of the reaction. LCMS analysis indicated the 
completion of the reaction and the reaction mixture was poured onto an Isolute SCX (500 
mg) column for purification. The cartridge was washed using DCM (3x), DMF (3x) twice 
and finally MeOH (2x). The product 4.80 was released from the cartridge using 10.0 ml 2M 
NH3 in MeOH and concentrated in vacuo. Further purification was achieved using a silica 
column and DCM:MeOH:2MNH3 (18:1:1) as the solvent system. 50 mg colourless oil was 
obtained as the final compound. 
2-(2,3-Dihydrobenzofuran-5-yl)-N-(3-(5-((2-((3-
(dimethylamino)propyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.80):  
 
Colourless oil. IR (FTIR, νmax/cm-1) 677.55, 778.73, 869.38, 938.77, 1000.0, 1102.16, 
1231.56, 1302.04, 1465.30, 1537.96, 1555.10, 1587.75, 1644.23, 1738.77, 2967.21, 3284.85; 
1H NMR (400 MHz, DMSO-d6, TMS); δ 1.67 – 1.69 (m, 2H), 2.14 (s, 6H), 2.27 (t, J=7.07 
Hz, 2H), 3.30 – 3.32 (m, 4H), 4.64 (t, J=8.72 Hz, 2H), 6.92 (d, J=8.34 Hz, 1H), 7.15 (d, 
J=3.54 Hz, 1H), 7.48 (d, J=3.54 Hz, 1H), 7.51 – 7.53 (m, 1H), 7.54 (d, J=0.76 Hz, 1H), 7.66 
(d, J=9.09 Hz, 1H), 7.77 (d, J=2.02 Hz, 1H), 7.93 – 7.94 (m, 1H), 7.96 – 7.98 (m, 1H), 8.07 – 
8.09 (m, 1H), 8.20 (d, J=2.02 Hz, 1H), 8.32 (t, J=1.89 Hz, 1H), 8.38 (s, 1H), 8.78 (t, J=5.68 
Hz, 1H), 10.33 (d, J=2.53Hz, 1H); 13C NMR (100 MHz, DMSO-d6); δ 26.93, 28.62, 37.37, 
45.12, 47.5, 56.89, 77.5, 107.99, 109.32, 109.38, 114.12, 116.69, 116.81, 120,34, 120.84, 
121.04, 123.72, 124.70, 125.20, 127.28, 127.41, 128.74, 129.33, 129.72, 134.32, 138.91, 
146.77, 149.86, 150.03, 155.10, 156.16, 157.91, 159.21, 162.08, 162.28, 167.76, 170.1; m/z 
(+EI) calc. For C37H33N5O6S (M+) 675.75, found 676.13 (M+H)
+; Yield: 75%. 
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Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(4-(5-((2-((3-
(dimethylamino)propyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.81) 
1 eq. of 4.70 (76 mg), 1.5 eq. of 4.53 (63 mg), 2 eq. HOBT and 1.75 eq. DIC were measured 
into a round bottom flask and dissolved in a minimum amount of DMF. The reaction mixture 
was allowed to stir for 3 hours at room temperature. After 3 hours the reaction mixture was 
checked by LCMS to identify completion of the reaction. LCMS analysis indicated the 
completion of the reaction and the reaction mixture was poured onto an Isolute SCX (500 
mg) column for purification. The cartridge was washed using DCM (3x), DMF (3x) twice 
and finally MeOH (2x). The product 4.81 was released from the cartridge using 10.0 ml 2M 
NH3 in MeOH and concentrated in vacuo. Further purification was achieved using a silica 
column and DCM:MeOH:2MNH3 (18:1:1) as the solvent system. 53 mg colourless oil was 





Colourless oil. IR (FTIR, νmax/cm-1) 730.61, 808.16, 1032.65, 1106.12, 1204.08, 1234.28, 
1314.28, 1359.18, 1465.30, 1528.09, 1575.51, 1591.83, 1640.81, 1738.77, 2360.05, 3081.96, 
3292.02; 1H NMR (400 MHz, DMSO-d6, TMS); δ 1.68 (t, J=7.07 Hz, 2H), 2.15 (s, 6H), 2.28 
(t, J=6.95 Hz, 2H), 3.33 – 3.35 (m, 4H), 4.65 (t, J=8.84 Hz, 2H), 6.93 (d, J=8.59 Hz, 1H), 
7.13 (d, J=3.54 Hz, 1H), 7.42 (d, J=3.54 Hz, 1H), 7.55 (d, J=0.76 Hz, 1H), 7.67 (d, J=9.09 
Hz, 1H), 7.79 (dd, J=2.1,8.97 Hz, 1H), 7.93 (dd, J=2.0, 8.34  Hz,  1H), 8.00 – 8.01 (m, 1H), 
8.02 (s, 1H), 8.04 – 8.06 (m, 1H), 8.07 – 8.10 (m, 1H), 8.20 (d, J=2.27 Hz, 1H), 8.39 (s, 1H), 
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8.78 (t, J=5.68 Hz, 1H), 10.27 (s, 1H), 10.34 (s, 1H); 13C NMR (100 MHz, DMSO-d6); δ 
26.92, 28.61, 37.36, 45.11, 47.4, 56.89, 71.75, 107.11, 109.29, 109.37, 114.18, 117.06, 
120.51, 120.90, 123.73, 125.04, 125.18, 126.7, 127.25, 127.41, 128.72,  134.29, 137.5, 
138.87, 146.32, 146.7, 149.88, 150.01, 155.19, 156.11, 156.8, 157.90, 159.14, 160.9, 162.07, 
167.77, 169.39; m/z (+EI) calc. For C37H33N5O6S (M+) 675.75, found 676.21 (M+H)
+; Yield: 
72%. 
4.1.6 Type-2 Library synthesis 
4.1.6.1 Sub type 2 Library synthesis 
General procedure for the synthesis of 2-amino-N-(3-
(dimethylamino)propyl)benzo[d]thiazole-6-carboxamide (4.83). (Amide coupling). 
2.0 eq of HOBT (108 mg) and 1.75 eq. of DIC (108 µl) were added to a solution of 4.82 in 
DMF. After 30 minutes 1.0 eq. (50 µl) of 4.38 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion the reaction mixture was passed through a 
SCX-2 cartridge (2.0 gm), which was washed with DCM (3x), DMF (3x) twice and finally 
MeOH (2x). The product 4.83 was released from the cartridge using 5.0 ml 2M NH3 in 
MeOH and concentrated in vacuo to obtain a colourless oily mass (126.0 mg). 
2-Amino-N-(3-(dimethylamino)propyl)benzo[d]thiazole-6-carboxamide (4.83) 
 
Colouless oil. IR (FTIR, νmax/cm-1) 659.93, 692.43, 732.58, 828.26, 884.35, 915.91, 1024.61, 
1098.55, 1125.22, 1284.94, 1308.01, 1459.16, 1524.72, 1628.24, 2775.91, 2932.94, 2976.39, 
3073.91, 3276.48; 1H NMR (400 MHz, DMSO-d6, TMS); 1.64 (quin, J=7.14 Hz, 2H), 2.12 
(s, 6H), 2.22 - 2.28 (m, 2H), 3.24 - 3.28 (m, 2H), 5.74 (s, 2H), 7.33 (d, J=8.34 Hz, 1H), 7.71 
(dd, J=8.34, 1.77 Hz, 1H), 8.14 (d, J=1.77 Hz, 1H); 13C NMR (100 MHz, DMSO-d6); δ 
26.95, 37.54, 44.79, 44.94, 56.73, 121.03, 121.79, 124.67, 127.01, 130.55, 154.83, 165.58, 
168.12; m/z (+EI) calc. For C13H18N4OS (M+) 278.37, found 278.62 (M+H)
+; Yield: 97%. 
The following compounds (4.85 to 4.88) were synthesised by the amide coupling reaction 
using N,N-dimethylpropane-1,3-diamine (1 eq.) (4.38) as the amine from 4.84 and 4.86. 
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Procedure for the synthesis of N-(3-(dimethylamino)propyl)-7-nitro-1H-indole-2-
carboxamide (4.85) 
2.0 eq of HOBT (131 mg) and 1.75 eq. of DIC (120 µl) were added to a solution of 4.84 (100 
mg) in DMF. After 30 minutes 1.0 eq. (50 µl) of 4.38 was added and the reaction mixture 
was allowed to stand for 3 hours. After completion, the reaction mixture was passed through 
a SCX-2 cartridge (2.0 gm), which  was washed with DCM (3x), DMF (3x) twice and finally 
MeOH (2x). The product 4.85 was released from the cartridge using 5.0 ml 2M NH3 in 
MeOH and concentrated in vacuo to obtain a dark brown oil (95 mg). 
N-(3-(dimethylamino)propyl)-7-nitro-1H-indole-2-carboxamide (4.85): 
 
Dark brown oil. IR (FTIR, νmax/cm-1) 632.65, 732.11, 831.16, 1037.47, 1098.41, 1156.32, 
1222.05, 1291.79, 1403.50, 1483.21, 1560.37, 1636.15, 2818.52,2976.72, 3281.36; 1H NMR 
(400 MHz, DMSO-d6, TMS); 2.08 - 2.11 (m, 2H), 2.14 (s, 6H), 2.27 (t, J=7.07 Hz, 2H), 
3.30 -3.37 (m, 2H), 7.32 (t, J=7.83 Hz, 1H), 7.36 (s, 1H), 8.19 (dd, J=7.83, 1.01 Hz, 1H), 
8.22 (dd, J=8.08, 1.01 Hz, 1H); 13C NMR (100 MHz, DMSO-d6); δ 27.01, 40.14, 44.97, 
45.13, 56.71, 105.93, 111.65, 120.84, 128.61, 130.47, 130.96, 132.99, 134.81, 159.32; m/z 
(+EI) calc. For C14H18N4O3 (M+) 290.32, found 292.01 (M+H)
+; Yield: 95%. 
Procedure for the synthesis of N-(3-(dimethylamino)propyl)-5-nitro-3-phenyl-1H-
indole-2-carboxamide (4.87) 
2.0 eq of HOBT (96 mg) and 1.75 eq. of DIC (87 µl) were added to a solution of 4.86 (100 
mg) in DMF. After 30 minutes 1.0 eq. (36 µl) of 4.38 was added and the reaction mixture 
was allowed to stand for 3 hours. After completion, the reaction mixture was passed through 
a SCX-2 cartridge (2.0 gm), which was washed with DCM (3x), DMF (3x) twice and finally 
MeOH (2x). The product 4.87 was released from the cartridge using 5.0 ml 2M NH3 in 








Light brown powder. IR (FTIR, νmax/cm-1) 626.07, 663.89, 718.36, 769.98, 839.66, 893.01, 
1037.09, 1064.64, 1172.34, 1257.60, 1291.25, 1327.17, 1474.81, 1520.20, 1551.31, 1634.11, 
2771.79, 2822.83, 3203.26; 1H NMR (400 MHz, DMSO-d6, TMS); δ 1.49-1.56 (m, 2H), 2.03 
(s, 6H), 2.10 (s, 2H), 3.20-3.26 (m, 2H), 7.43-7.47 (m, 1H), 7.54 (br s, 2H), 7.55 (br s, 2H), 
7.63 (d, J=9.09 Hz, 1H), 8.11 (dd, J=9.09, 2.27 Hz, 1H), 8.36 (d, J=2.02 Hz, 1H); 13C NMR 
(100 MHz, DMSO-d6); δ 26.69, 40.35, 45.24, 46.3, 56.98, 113.21, 117.13, 118.66, 126.32, 
127.65, 127.9, 128.98, 129.3, 129.5, 130.0, 132.47, 132.62, 138.71, 141.57, 161.06; m/z (+EI) 
calc. For C20H22N4O3 (M+) 366.41, found 368.07 (M+H)
+; Yield: 93%. 
Procedure for the synthesis of 5-amino-N-(3-(dimethylamino)propyl)benzofuran-2-
carboxamide (4.61) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.60 (100 mg) in DMF. 
After 30 minutes 1.0 eq. (58 µl) of 4.38 was added and the reaction mixture was allowed to 
stand for 3 hours. After completion, the reaction mixture was passed through a SCX-2 
cartridge (2.0 gm), which was washed with DCM (3x) and DMF (3x) twice and finally 
MeOH (2x). The product 4.61 was released from the cartridge using 5.0 ml 2M NH3 in 
MeOH and concentrated in vacuo to obtain brown oil (100 mg). 
5-amino-N-(3-(dimethylamino)propyl)benzofuran-2-carboxamide (4.61): 
 
Brown oil. IR (FTIR, νmax/cm-1) 616.66, 657.70, 809.89, 842.95, 943.42, 1037.48, 1097.11, 
1159.69, 1209.08, 1244.28, 1302.57, 1383.71, 1455.82, 1580.91, 1649.71, 2774.39, 2817.07, 
2859.75, 2938.85, 3231.44, 3341.46; 1H NMR (400 MHz, DMSO-d6) 1.65 (t, J=7.07 Hz, 
2H), 2.13 (s, 6H), 2.21 (t, J=7.07 Hz, 2H), 3.25 - 3.30 (m, 2H), 6.74 (dd, J=8.84, 2.27 Hz, 
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1H), 6.78 (d, J=1.77 Hz, 1H), 7.24 (d, J=1.01 Hz, 1H), 7.29 (d, J=8.59 Hz, 1H), 8.60 (t, 
J=5.56 Hz, 1H); 13C NMR (100 MHz, DMSO-d6) δ 26.98, 37.23, 45.12, 45.12, 56.89, 
104.22, 108.60, 111.50, 115.48, 127.84, 145.14, 147.53, 149.12, 158.19; m/z (+EI) calc. For 
C14H19N3O2 (M+) 261.32, found 262.0 (M+H)
+; Yield: 68%. 
General procedure for the synthesis of 7-amino-N-(3-(dimethylamino)propyl)-1H-
indole-2-carboxamide (4.88) by hydrogenation. 
N-(3-(dimethylamino)propyl)-7-nitro-1H-indole-2-carboxamide (1.0 eq., 200 mg) (4.85) was 
dissolved in a minimum amount of ethanol (30 ml) and a catalytic amount of 10% Pd/C (20 
mg) was added as a slurry in ethyl acetate. The reaction mixture was shaken overnight at 45 
psi in a Parr hydrogenator. After completion of the reduction, the suspension was filtered 
through a layer of celite, with caution, using a Buchner flask and the filtrate concentrated to 
obtain 150 mg colourless product (4.88).  
7-Amino-N-(3-(dimethylamino)propyl)-1H-indole-2-carboxamide (4.88): 
 
Colourless oil. IR (FTIR, νmax/cm-1) 732.66, 781.76, 822.48, 882.42, 1048.76, 1094.60, 
1229.15, 1256.07, 1290.85, 1380.02, 1421.18, 1556.24, 1622.31, 1737.52, 2856.85, 2969.34, 
3271.90; 1H NMR (400 MHz, DMSO-d6)  1.63 - 1.73 (m, 2H), 2.12 - 2.20 (m, 6H), 2.30 (t, 
J=7.20 Hz, 2H), 3.27 - 3.35 (m, 2H), 6.35 (dd, J=7.20, 1.14 Hz, 1H), 6.73 - 6.78 (m, 1H), 
6.78 - 6.83 (m, 1H), 6.96 (d, J=2.02 Hz, 1H), 8.43 (t, J=5.68 Hz, 1H), 11.19 (br. s., 1H); 13C 
NMR (100 MHz, DMSO-d6) δ 27.15, 37.20, 44.88, 45.07, 56.82, 102.40, 105.54, 109.00, 
120.88, 126.03, 127.88, 130.75, 134.40, 161.19; m/z (+EI) calc. For C14H20N4O (M+) 260.16, 
found 262.00 (M+H)+; Yield: 75%. 






Procedure for the synthesis of 5-amino-N-(3-(dimethylamino)propyl)-3-phenyl-1H-
indole-2-carboxamide (4.89) 
1.0 eq. (156 mg) 4.87 was dissolved in a minimum amount of ethanol (30 ml) and a catalytic 
amount of 10% Pd/C (16 mg) was added as a slurry in ethyl acetate. The reaction mixture 
was shaken for 2 hours at 45 psi in a Parr hydrogenator. After completion of the reduction the 
suspension was filtered through a layer of celite, with caution, using a Buchner flask and the 
filtrate was concentrated to obtain 140 mg colourless oil (4.89).  
5-Amino-N-(3-(dimethylamino)propyl)-3-phenyl-1H-indole-2-carboxamide (4.89) 
 
Colourless oil. IR (FTIR, νmax/cm-1) 616.02, 633.72, 665.50, 757.87, 773.73, 801.97, 840.74, 
1041.73, 1097.56, 1128.33, 1228.46, 1248.38, 1321.62, 1383.03, 1454.88, 1498.74, 1542.27, 
1600.24, 1630.62, 2950.02, 3253.14, 3406.64; 1H NMR (400 MHz, DMSO-d6)  1.48 (t, 
J=6.95 Hz, 2H), 2.03 (s,6H), 2.11 - 2.13 (m, 2H), 3.15 - 3.20 (m, 2H), 6.61 (d, J=1.52 Hz, 
1H), 6.62 - 6.66 (m, 1H), 7.11 (t, J=5.68 Hz, 1H), 7.14 - 7.18 (m, 1H), 7.32 - 7.37 (m, 1H), 
7.44 (d, J=2.27 Hz, 2H), 7.46 - 7.47 (m, 1H), 11.22 (s, 1H); 13C NMR (100 MHz, DMSO-d6) 
δ 26.56, 37.31, 45.00, 45.00, 56.76, 101.34, 112.36, 115.02, 115.29, 126.41, 127.85, 127.94, 
128.38, 129.05, 129.90, 130.13, 130.63, 135.85, 142.37, 161.62; m/z (+EI) calc. For 
C20H24N4O (M+) 336.43, found 336.86 (M+H)
+; Yield: 98%. 
The following compounds (4.90 to 4.95) were synthesized following the same procedure for 
amide coupling.  
Procedure for the synthesis of 2-(5-bromofuran-2-carboxamido)-N-(3-
(dimethylamino)propyl)benzo[d]thiazole-6-carboxamide (4.90) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.83 (98 mg) in DMF. After 
30 minutes, 1.2 eq. (81 mg) of 4.49 was added and the reaction mixture was allowed to stand 
for 3 hours. After completion, the reaction mixture was passed through a SCX-2 cartridge 
(2.0 gm), which was washed with DCM (3x), DMF (3x) twice and finally MeOH (2x). The 
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product 4.90 was released from the cartridge using 5.0 ml 2M NH3 in MeOH and 




Dark brown, oily mass. IR (FTIR, νmax/cm-1) 659.34, 765.92, 839.20, 922.33, 960.31, 
1060.22, 1092.58, 1216.41, 1279.33, 1381.64, 1406.04, 1428.31, 1524.33, 1596.51, 1659.91, 
1736.89, 2775.19, 2863.04, 2938.27, 3312.15; 1H NMR (400 MHz, DMSO-d6, TMS); 1.68 
- 1.76 (m, 2H), 2.24 - 2.27 (m, 3H), 2.30 (s, 3H), 2.41 (t, J=7.20 Hz, 2H), 3.28 - 3.33(m, 2H), 
6.79 (d, J=3.54 Hz, 1H), 7.31 - 7.38 (m, 1H), 7.62 (d, J=8.34 Hz, 1H), 7.83 (dd, J=8.59, 1.77 
Hz, 1H), 8.32 (d, J=1.52 Hz, 1H); 13C NMR (100 MHz, DMSO-d6); δ 26.3, 36.8, 45.03, 
45.85, 57.73, 110.8, 113.9, 120.0, 120.7, 121.9, 123.1, 128.9, 130.6, 145.7, 155.13, 163.82, 
166.9, 175.32; m/z (+EI) calc. For C18H19BrN4O3S (M+) 451.34, found 452.58 (M+H)
+; 
Yield: 73%. 
Procedure for the synthesis of 7-(5-bromofuran-2-carboxamido)-N-(3-
(dimethylamino)propyl)-1H-indole-2-carboxamide (4.91) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.88 (135 mg) in DMF. 
After 30 minutes, 2.0 eq. (198 mg) of 4.49 was added and the reaction mixture allowed to 
stand for 3 hours. After completion, the reaction mixture was passed through a SCX-2 
cartridge (2.0 gm), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.91 was released from the cartridge using 5.0 ml 2M NH3 in MeOH and 










Dark brown oil.  IR (FTIR, νmax/cm-1) 661.40, 736.65, 783.32, 924.20, 953.68, 1010.79, 
1097.99, 1174.27, 1256.67, 1285.10, 1384.52, 1432.87, 1464.95, 1537.21, 1631.97, 2774.39, 
2817.07, 2859.75, 2935.48, 3283.45; 1H NMR (400 MHz, DMSO-d6, TMS);  1.68 (t, J=7.07 
Hz, 2H), 2.15 (s, 6H), 2.29 (t, J=7.07 Hz, 2H), 3.34 (d, J=6.82 Hz, 2H), 6.87 (d, J=3.79 Hz, 
1H), 7.05 (t, J=7.83 Hz, 1H), 7.14 (d, J=2.02 Hz, 1H), 7.42 (d, J=3.54 Hz, 1H), 7.46 (d, 
J=7.83 Hz, 1H), 7.70 (dd, J=7.71, 0.88 Hz, 1H), 7.95 (s, 1H), 10.11 (s, 1H), 11.57 (s, 1H); 
13C NMR (100 MHz, DMSO-d6); δ 27.33, 37.47, 45.23, 45.29, 57.00, 114.05, 114.36, 
115.62, 116.63, 117.45, 120.02, 123.18, 125.41, 128.99, 132.15, 149.65, 150.10, 161.02, 
162.46; m/z (+EI) calc. For C19H21BrN4O3 (M+) 433.30, found 434.59 (M+H)
+; Yield: 58%. 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(3-
(dimethylamino)propyl)-3-phenyl-1H-indole-2-carboxamide (4.92) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.89 (140 mg) in DMF. 
After 30 minutes, 2.0 eq. (159 mg) of 4.49 was added and the reaction mixture was allowed 
to stand for 3 hours. After completion, the reaction mixture was passed through a SCX-2 
cartridge (5.0 gm), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.92 was released from the cartridge using 5.0 ml 2M NH3 in MeOH and 






Brown oily mass. IR (FTIR, νmax/cm-1) 619.84, 636.40, 663.05, 705.39, 727.16, 744.00, 
762.96, 809.18, 883.86, 921.78, 945.20, 1018.25, 1037.90, 1100.26, 1199.68, 1246.29, 
1272.54, 1304.51, 1338.43, 1386.13, 1424.24, 1474.28, 1540.25, 1590.25, 1638.61, 1737.52, 
2779.91, 2947.48, 3244.75, 3419.67; 1H NMR (400 MHz, DMSO-d6, TMS); 1.50 (t, J=6.95 
Hz, 2H), 2.04 (s, 6H), 2.08 - 2.13 (m, 2H), 3.19 - 3.23 (m, 2H), 6.80 (d, J=3.79 Hz, 1H), 7.31 
(d, J=3.54 Hz, 1H), 7.33 (br. s., 1H), 7.43 (d, J=9.09 Hz, 1H), 7.49 (s, 2H), 7.50 (d, J=1.52 
Hz, 1H), 7.60 (dd, J=8.97, 1.89 Hz, 1H), 7.89 (d, J=1.77 Hz, 1H), 7.95 (s, 1H), 10.09 (s, 1H), 
11.68 (s, 1H); 13C NMR (100 MHz, DMSO-d6); δ 26.50, 35.73, 44.99, 45.03, 56.76, 111.28, 
112.04, 114.08, 115.42, 116.41, 116.57, 118.53, 124.80, 126.61, 126.84, 128.56, 129.04, 
129.89, 131.30, 132.39, 133.87, 149.61, 154.84, 161.41, 162.26; m/z (+EI) calc. For 
C25H25BrN4O3 (M+) 509.39, found 510.61 (M+H)
+; Yield: 61%. 
Procedure for the synthesis of 5-bromo-N-(2-((3-
(dimethylamino)propyl)carbamoyl)benzofuran-5-yl)benzofuran-2-carboxamide (4.94) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.61 (71 mg) in DMF. After 
30 minutes, 2.0 eq. (131 mg) of 4.93 was added and the reaction mixture was allowed to 
stand for 3 hours. After completion, the reaction mixture was passed through a SCX-2 
cartridge (2.0 gm), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.94 was released from the cartridge using 5.0 ml 2M NH3 in MeOH. 
Further purification of the product was achieved using a silica column and 
DCM:MeOH:2MNH3 as solvent system; the polarity of the system was changed from 18:1:1 
to 17:2:1 gradually until the product was obtained in pure form. It was then concentrated in 




Colourless powder. IR (FTIR, νmax/cm-1) 621.55, 669.97, 751.69, 803.47, 889.49, 941.00, 
971.80, 1039.37, 1098.23, 1154.24, 1175.62, 1198.44, 1231.11, 1259.30, 1295.39, 1371.05, 
1438.21, 1458.15, 1475.57, 1521.26, 1540.45, 1588.93, 1636.36, 1654.06, 1736.55, 2754.04, 
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2812.03, 2938.35, 3344.11; 1H NMR (400 MHz, DMSO-d6)  1.67 (t, J=7.07 Hz, 2H), 2.14 
(s, 6H), 2.27 (t, J=6.95 Hz, 2H), 3.29 (br. s., 2H), 7.54 (d, J=0.76 Hz, 1H), 7.64 - 7.65 (m, 
1H), 7.66 (d, J=5.56 Hz, 1H), 7.70 - 7.74 (m, 1H), 7.76 - 7.78 (m, 2H), 8.08 (d, J=2.02 Hz, 
1H), 8.27 (d, J=2.02 Hz, 1H), 8.77 (t, J=5.68 Hz, 1H), 10.69 (s, 1H); 13C NMR (100 MHz, 
DMSO-d6) δ 26.92, 37.35, 45.11, 45.11, 56.87, 109.33, 109.88, 111.75, 113.80, 114.00, 
116.03, 120.62, 125.28, 127.26, 129.32, 129.67, 134.09, 149.93, 150.06, 151.02, 153.23, 
156.24, 157.85; m/z (+EI) calc. For C23H22BrN3O4 (M+) 484.34, found 486.66 (M+H)
+; 
Yield: 76%. 
General procedure for the synthesis of 2-(5-(3-aminophenyl)furan-2-carboxamido)-N-
(3-(dimethylamino)propyl)benzo[d]thiazole-6-carboxamide (4.95) using 2-(5-
bromofuran-2-carboxamido)-N-(3-(dimethylamino)propyl)benzo[d]thiazole-6-
carboxamide (4.90) and (3-aminophenyl)boronic acid (4.49). (Suzuki coupling).  
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq., 28 mg) was 
added to a solution of 4.90 (1.0 eq., 108 mg) and 4.49 (1.2 eq., 39 mg) in a 9:3:1 combination 
of EtOH, toluene and water in the presence of K2CO3 (3.0 eq., 99 mg) in a 10 ml microwave 
vial containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 82 minutes (20 minutes +10 minutes + 20 minutes + 20 minutes + 12 minutes). 
After LCMS analysis revealed complete reaction, the cooled reaction mixture was passed 
through an IsoluteTM SCX-2 cartridge (2.0 gm) and washed with DCM (3x), DMF (3x) twice 
and finally MeOH (2x). The product was released from the cartridge using 5.0 ml 2M NH3 in 
MeOH and concentrated in vacuo to obtain a crude product. This was further purified by 
flash chromatography using DCM/2M NH3 in methanol/MeOH at a ratio 9:0.5:0.5 to obtain a 










Light yellow powder. IR (FTIR, νmax/cm-1) 616.20, 660.42, 693.22, 723.03, 768.10, 839.48, 
1025.14, 1096.30, 1119.84, 1154.60, 1233.46, 1282.66, 1383.33, 1407.90, 1435.14, 1523.57, 
1578.38, 1658.54, 1737.42, 2945.12, 3225.60, 3333.93; 1H NMR (400 MHz, METHANOL-
d4, TMS);  1.83 - 1.93 (m, 2H), 2.39 (s, 6H), 2.54 - 2.61 (m, 2H), 3.46 (t, J=6.95 Hz, 2H), 
6.76 (d, J=7.83 Hz, 1H), 6.93 (d, J=3.79 Hz, 1H), 7.19 (t, J=7.71 Hz, 1H), 7.25 (d, J=7.83 
Hz, 1H), 7.28 (d, J=1.77 Hz, 1H), 7.52 (d, J=3.54 Hz, 1H), 7.80 (d, J=8.34 Hz, 1H), 7.89 (dd, 
J=8.34, 1.77 Hz, 1H), 8.36 (d, J=1.77 Hz, 1H); 13C NMR (100 MHz, METHANOL-d4); δ 
27.12, 36.39, 45.87, 46.18, 57.62, 107.35, 108.13, 113.93, 115.43, 118.27, 119.27, 120.10, 
122.19, 129.86, 130.15, 130.63, 131.98, 145.6, 147.9, 155.16, 156.1, 160.3, 165.8, 175.3; m/z 
(+EI) calc. For C24H25N5O3S (M+) 463.55, found 463.80 (M+H)
+; Yield: 81%. 
A similar procedure was followed for the following molecules, but the microwave irradiation 
time was 20 minutes. 
Procedure for the synthesis of 7-(5-(3-aminophenyl)furan-2-carboxamido)-N-(3-
(dimethylamino)propyl)-1H-indole-2-carboxamide (4.96) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.91 (1.0 eq., 130 mg) and 4.49 (2 eq., 82 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 20 minutes. After LCMS analysis revealed complete reaction, the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (2.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product was released from the cartridge 
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using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo to obtain a crude product. The 
product was further purified by flash chromatography using DCM/2M NH3 in 




Dark brown oil. IR (FTIR, νmax/cm-1) 636.44, 692.88, 723.99, 782.50, 1025.16, 1154.19, 
1233.04, 1290.02, 1412.22, 1438.43, 1540.62, 1577.71, 1626.28, 2823.17, 2937.80, 3231.70, 
3342.25; 1H NMR (400 MHz, DMSO-d6, TMS);  1.69 (quin, J=6.88 Hz, 2H), 2.15 (s, 6H), 
2.29 (t, J=7.07 Hz, 2H), 3.33 (br. s., 2H), 6.57 - 6.60 (m, 1H), 6.95 - 6.96 (m, 1H), 6.97 - 6.99 
(m, 1H), 7.00 (d, J=3.54 Hz, 1H), 7.04 - 7.07 (m, 1H), 7.08 - 7.10 (m, 1H), 7.10 - 7.11 (m, 
1H), 7.13 (d, J=7.83 Hz, 1H), 7.15 (d, J=2.02 Hz, 1H), 7.47 (d, J=3.79 Hz, 1H), 7.70 - 7.73 
(m, 1H), 7.73 (s, 1H), 10.06 (s, 1H), 11.59 (s, 1H); 13C NMR (100 MHz, DMSO-d6); δ 26.96, 
37.07, 44.91, 48.35, 56.61, 106.68, 109.14, 112.18, 114.31, 115.47, 116.66, 117.81, 119.73, 
121.65, 123.14, 127.50, 128.56, 129.20, 129.62,  146.09, 147.29, 148.88, 155.99, 160,61, 
162.06; m/z (+EI) calc. For C25H27N5O3 (M+) 445.51, found 445.61 (M+H)
+; Yield: 90%. 
Procedure for the synthesis of 5-(5-(3-aminophenyl)furan-2-carboxamido)-N-(3-
(dimethylamino)propyl)-3-phenyl-1H-indole-2-carboxamide (4.97) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.92 (1.0 eq., 129 mg) and 4.49 (2 eq., 69 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
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100 °C for 20 minutes. After LCMS analysis revealed complete reaction, the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (2.0 gm) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product was released from the cartridge 
using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo to obtain a crude product. The 
product was further purified by flash chromatography using DCM/2M NH3 in 




Light brown oil. IR (FTIR, νmax/cm-1) 694.14, 723.10, 783.14, 1023.36, 1095.15, 1119.04, 
1156.21, 1232.16, 1317.96, 1443.85, 1474.62, 1543.70, 1633.71, 1738.02, 2361.04, 2939.06, 
3225.60, 3327.85; 1H NMR (400 MHz, DMSO-d6, TMS);  1.51 (t, J=6.82 Hz, 2H), 2.04 (s, 
6H), 2.10 - 2.13 (m, 2H), 3.20 - 3.25 (m, 2H), 6.57 - 6.59 (m, 1H), 6.59 - 6.61 (m, 1H), 6.92 
(d, J=3.54 Hz, 1H), 7.06 - 7.08 (m, 1H), 7.08 - 7.09 (m, 1H), 7.09 - 7.12 (m, 1H), 7.33 (d, 
J=3.54 Hz, 1H), 7.38 - 7.42 (m, 1H), 7.44 (d, J=9.09 Hz, 1H), 7.51 (s, 2H), 7.52 (s, 1H), 7.54 
- 7.58 (m, 1H), 7.62 - 7.65 (m, 2H), 7.73 (s, 1H), 7.92 (d, J=1.52 Hz, 1H), 10.03 (s, 1H), 
11.68 (s, 1H); 13C NMR (100 MHz, DMSO-d6); δ 26.50, 37.44, 45.01, 48.55, 56.76, 106.83, 
109.38, 112.01, 114.46, 115.68, 116.07, 118.74, 119.93, 126.66, 126.85, 127.70, 128.58, 
128.77, 129.92, 131.39, 131.49, 131.56, 131.97, 132.34, 133.92, 146.54, 147.49, 148.99, 







Procedure for the synthesis of 5-(3-aminophenyl)-N-(2-((3-
(dimethylamino)propyl)carbamoyl)benzofuran-5-yl)benzofuran-2-carboxamide (4.98) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.94 (1.0 eq., 40 mg) and 4.49 (2 eq., 23 mg) in a 9:3:1 combination of EtOH, 
toluene and water in the presence of K2CO3 (3.0 eq., 99 mg) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 20 minutes. After LCMS analysis revealed complete reaction, the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (500 mg) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product was released from the cartridge 
using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo to obtain a crude product. The 
product was further purified by flash chromatography using DCM/2M NH3 in 




Brown oily mass.  IR (FTIR, νmax/cm-1) 612.14, 659.04, 697.55, 723.53, 869.62, 949.83, 
993.81, 1093.22, 1153.36, 1259.61, 1301.05, 1384.90, 1436.08, 1469.27, 1580.46, 1656.83, 
2358.18, 2927.52, 3342.83, 3439.02; 1H NMR (400 MHz, DMSO-d6, TMS); 1.68 (t, J=7.07 
Hz, 2H), 2.14 - 2.17 (m, 6H), 2.25 - 2.30 (m, 2H), 2.89 (s, 2H), 6.57 - 6.61 (m, 1H), 6.94 - 
6.97 (m, 1H), 6.97 - 7.00 (m, 1H), 7.10 - 7.16 (m, 1H), 7.54 - 7.56 (m, 1H), 7.65 (d, J=2.27 
Hz, 1H), 7.66 - 7.69 (m, 1H), 7.70 (d, J=1.77 Hz, 1H), 7.79 (dd, J=1.89, 0.88 Hz, 1H), 7.82 - 
7.84 (m, 1H), 7.96 (s, 1H), 7.97 (dd, J=1.89, 0.63 Hz, 1H), 8.27 - 8.30 (m, 1H), 8.78 (t, 
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J=5.68 Hz, 1H); 13C NMR (100 MHz, DMSO-d6); δ 26.75, 40.35, 45.15, 46.13, 57.83, 
108.30, 109.58, 111.70, 112.0, 113.50, 114.06, 115.08, 116.03, 117.89, 119.62, 123.28, 
128.26, 129.96, 130.67, 133.09, 136.75, 142,12, 148.93, 150.64, 151.21, 152.23, 156.40, 
158.54, 163.92; m/z (+EI) calc. For C29H28N4O4 (M+) 496.56, found 496.77 (M+H)
+; Yield: 
98%. 
Amide coupling was used for synthesizing compounds 4.99 to 4.104 to obtain the final 
molecules. 
Procedure for the synthesis of 2-(5-(3-(2-(2,3-dihydrobenzofuran-5-yl)thiazole-4-
carboxamido)phenyl)furan-2-carboxamido)-N-(3-
(dimethylamino)propyl)benzo[d]thiazole-6-carboxamide (4.99) from 2-(5-(3-
aminophenyl)furan-2-carboxamido)-N-(3-(dimethylamino)propyl)benzo[d]thiazole-6-
carboxamide (4.95) and 2-(2,3-dihydrobenzofuran-5-yl) thiazole-4-carboxylic acid (4.53) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.95 (1 eq., 40 mg) in DMF. 
After 30 minutes, 2.0 eq. (43 mg) of 4.53 was added and the reaction mixture was allowed to 
stand for 3 hours. After completion, the reaction mixture was passed through a SCX-2 
cartridge (500 mg), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.99 was released from the cartridge using 5.0 ml 2M NH3 in MeOH. 
Further purification of the product was achieved using a silica column and 
DCM:MeOH:2MNH3 as solvent system where the polarity of the system was changed from 
18:1:1 to 17:2:1 gradually until the product was obtained in pure form. It was then 






 Light yellow oil. IR (FTIR, νmax/cm-1) 616.50, 659.44, 694.73, 768.88, 941.23, 979.75, 
1092.84, 1229.68, 1280.00, 1302.19, 1383.51, 1434.83, 1540.07, 1654.83, 1736.49, 2927.74, 
3314.12, 3432.92; 1H NMR (400 MHz, DMSO-d6, TMS);  1.67 - 1.74 (m, 2H), 2.22 (s, 6H), 
2.37 (t, J=7.20 Hz, 2H), 3.29 (d, J=3.03 Hz, 2H), 3.32 - 3.34 (m, 2H), 4.64 - 4.69 (m, 2H), 
6.94 (d, J=8.34 Hz, 1H), 7.17 (d, J=3.54 Hz, 1H), 7.48 - 7.54 (m, 1H), 7.59 (d, J=3.54 Hz, 
1H), 7.71 (d, J=8.34 Hz, 1H), 7.72 - 7.76 (m, 1H), 7.85 - 7.90(m, 1H), 7.93 (d, J=3.79 Hz, 
2H), 7.95 (s, 1H), 8.08 - 8.11 (m, 1H), 8.36 (t, J=1.77 Hz, 1H), 8.39 (s, 1H), 8.40 (d, J=1.52 
Hz, 1H), 8.49 (t, J=5.68 Hz, 1H), 10.36 (s, 1H); 13C NMR (100 MHz, DMSO-d6); δ 26.85, 
28.61, 38.88, 44.85, 44.92, 56.71, 71.75, 108.53, 109.45, 114.32,  119.64, 120.80, 121.0, 
121.32, 121.50, 121.97,123.45, 125.0, 127.3, 128.88, 129.49, 129.86, 130.51, 130.83, 131.43, 
135.6,149.89, 152.16, 156.18, 156.73,159.21, 162.02, 167.73,169.91, 174.03, 185.49; m/z 
(+EI) calc. For C36H32N6O5S2 (M+) 692.81, found 692.56 (M+H)
+; Yield: 59%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((3-
(dimethylamino)propyl)carbamoyl)-1H-indol-7-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.100) from 7-(5-(3-aminophenyl)furan-2-
carboxamido)-N-(3-(dimethylamino)propyl)-1H-indole-2-carboxamide (4.96) and 2-(2,3-
dihydrobenzofuran-5-yl) thiazole-4-carboxylic acid (4.53) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.96 (1 eq., 60 mg) in DMF. 
After 30 minutes, 2.0 eq. (128 mg) of 4.53 was added and the reaction mixture was allowed 
to stand for 3 hours. After completion, the reaction mixture was passed through a SCX-2 
cartridge (2.0 gm), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.100 was released from the cartridge using 5.0 ml 2M NH3 in MeOH. 
Further purification of the product was achieved by passage through a silica column with 
DCM:MeOH:2MNH3 as solvent system, where the polarity of the system was changed from 
18:1:1 to 17:2:1, gradually, until the product was obtained in pure form. It was then 










Brown oily mass. IR (FTIR, νmax/cm-1) 638.74, 690.84, 734.16, 782.45, 821.24, 939.73, 
1032.41, 1100.05, 1230.25, 1287.08, 1418.81, 1454.32, 1540.21, 1648.27, 1735.40, 2935.86, 
3291.98; 1H NMR (400 MHz, DMSO-d6 TMS); 1.68 (t, J=7.07 Hz, 2H), 2.13 - 2.16 (m, 
6H), 2.25 - 2.30 (m, 2H), 3.28 (br. s., 2H), 3.33 (br. s., 2H), 4.61 - 4.68 (m, 2H), 6.92 (d, 
J=8.34 Hz, 1H), 7.08 (t, J=7.83 Hz, 1H), 7.15 - 7.17 (m, 1H), 7.18 (d, J=3.54 Hz, 1H), 7.48 
(d, J=8.08 Hz, 1H), 7.53 (d, J=3.54 Hz, 1H), 7.70 (d, J=7.58 Hz, 1H), 7.74 (d, J=8.08 Hz, 
1H), 7.92 (dd, J=8.34, 2.02 Hz, 1H), 7.94 - 7.98 (m, 1H), 8.07 (s, 1H), 8.35 (t, J=1.77 Hz, 
1H), 8.38 (s, 1H), 8.58 (t, J=5.81 Hz, 1H), 10.14 (s, 1H), 10.35 (s, 1H), 11.57 (s, 1H); 13C 
NMR (100 MHz, DMSO-d6); δ 27.36, 28.78, 37.47, 45.31, 45.31, 57.01, 82.78, 104.91, 
109.56, 114.20, 114.96, 116.73, 120.04, 123.41, 123.91, 124.31, 125.39, 126.28, 127.59, 
128.90, 129.01, 129.18, 130.01, 131.21, 133.76, 139.18, 145.76,  149.41, 150.43, 155.28, 
156.66, 160.99, 162.01, 162.60, 167.92, 169.54, 186.31; m/z (+EI) calc. For C37H34N6O5S 







Procedure for the synthesis of 7-(5-(3-(4-((1H-benzo[d]imidazol-1-
yl)methyl)benzamido)phenyl)furan-2-carboxamido)-N-(3-(dimethylamino)propyl)-1H-
indole-2-carboxamide (4.101) from 7-(5-(3-aminophenyl)furan-2-carboxamido)-N-(3-
(dimethylamino)propyl)-1H-indole-2-carboxamide (4.96) and 4-((1H-benzo[d]imidazol-
1-yl)methyl)benzoic acid (4.73) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.96 (1 eq., 115 mg) in 
DMF. After 30 minutes 2.0 eq. (131 mg) of 4.73 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was passed through a 
SCX-2 cartridge (2.0 gm), which was washed with DCM (3x), and DMF (3x) twice and 
finally MeOH (2x). The product 4.101 was released from the cartridge using 5.0 ml 2M NH3 
in MeOH. Further purification of the product was achieved by silica column chromatography 
using DCM:MeOH:2MNH3 (18:1:1) as the solvent system until the product was obtained in 





Yellow viscous material. IR (FTIR, νmax/cm-1) 690.64, 734.31, 783.63, 963.41, 1020.59, 
1088.21, 1145.61, 1176.84, 1258.75, 1287.39, 1415.61, 1496.78, 1549.21, 1633.90, 2941.34, 
3279.15; 1H NMR (400 MHz, DMSO-d6, TMS);  1.71 (t, J=7.07 Hz, 2H), 2.23 (s, 6H), 2.40 
(t, J=7.07 Hz, 2H), 3.40 (br. s., 2H), 5.61 (s, 2H), 7.07 (t, J=7.83 Hz, 1H), 7.13 (d, J=3.54 Hz, 
1H), 7.16 (d, J=2.02 Hz, 1H), 7.19 - 7.22 (m, 2H), 7.44 (s, 1H), 7.46 (s, 2H), 7.48 (s, 1H), 
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7.49 - 7.50 (m, 1H), 7.53 (d, J=3.54 Hz, 1H), 7.65 - 7.68 (m, 1H), 7.69 (d, J=2.53 Hz, 1H), 
7.71 (s, 1H), 7.81 (d, J=8.08 Hz, 1H), 7.95 (d, J=8.34 Hz, 2H), 8.25 (t, J=1.77 Hz, 1H), 8.45 
(s, 1H), 8.60 (t, J=5.56 Hz, 1H), 10.11 (s, 1H), 10.38 (s, 1H), 11.57 (s, 1H); 13C NMR (100 
MHz, DMSO-d6); δ 18.51, 44.72, 48.56, 55.99, 56.54, 62.77, 107.75, 110.64, 112.46, 116.15, 
116.50, 116.88, 118.16, 119.51, 119.87, 120.04, 120.70, 121.62, 122.42, 123.24, 127.30, 
128.10, 128.79, 128.92, 129.32, 129.67, 131.88, 133.58, 134.18, 139.70, 140.53, 143.58, 
144.30, 146.82, 155.12, 156.48, 160.85, 163.08, 165.30, 171.20;  m/z (+EI) calc. For 
C40H37N7O4 (M+) 679.77, found 679.74 (M+H)
+; Yield: 89%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((3-
(dimethylamino)propyl)carbamoyl)-3-phenyl-1H-indol-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.102) from 5-(5-(3-aminophenyl)furan-2-
carboxamido)-N-(3-(dimethylamino)propyl)-3-phenyl-1H-indole-2-carboxamide (4.97) 
and 2-(2,3-dihydrobenzofuran-5-yl) thiazole-4-carboxylic acid (4.53) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.97 (1 eq., 60 mg) in DMF. 
After 30 minutes, 2.0 eq. (57 mg) of 4.53 was added and the reaction mixture was allowed to 
stand for 3 hours. After completion, the reaction mixture was passed through a SCX-2 
cartridge (2.0 gm), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.102 was released from the cartridge using 5.0 ml 2M NH3 in MeOH. 
Further purification of the product was made using a silica column and a 
DCM:MeOH:2MNH3 solvent system where the polarity of the system was changed from 
18:1:1 to 17:2:1, gradually, until the product was obtained in pure form. It was then 













Light brown oil. IR (FTIR, νmax/cm-1) 639.37, 659.92, 692.71, 786.69, 864.70, 939.80, 
980.47, 1029.99, 1093.93, 1228.84, 1310.09, 1385.26, 1455.01, 1537.63, 1654.16, 2934.13, 
3277.47; 1H NMR (400 MHz, DMSO-d6, TMS);  1.51 (quin, J=6.88 Hz, 2H), 2.04 (s, 6H), 
2.10 - 2.12 (m, 2H), 2.13 - 2.17 (m, 2H), 3.19 - 3.25 (m, 2H), 4.65 (t, J=8.84 Hz, 2H), 6.93 
(d, J=8.34 Hz, 1H), 7.11 (d, J=3.54 Hz, 1H), 7.31 (t, J=5.56 Hz, 1H), 7.37 - 7.41 (m, 2H), 
7.46 (d, J=8.59 Hz, 1H), 7.50 - 7.51 (m, 2H), 7.52 (s, 2H), 7.63 (dd, J=8.97, 1.89 Hz, 1H), 
7.72 - 7.76 (m, 1H), 7.92 (dd, J=2.27, 1.26 Hz, 1H), 7.93 - 7.94 (m, 1H), 7.95 (br. s., 1H), 
8.08 (d, J=1.52 Hz, 1H), 8.29 (t, J=1.77 Hz, 1H), 8.38 (s, 1H), 10.11 (s, 1H), 10.31 (s, 1H), 
11.70 (s, 1H); 13C NMR (100 MHz, DMSO-d6); δ 26.51, 30.73, 35.73, 45.02, 45.11, 56.78, 
79.46, 180.34, 108.96, 109.39, 111.47, 112.07, 116.22, 116.61, 116.67, 118.85, 120.96, 
123.74, 124.11, 125.22, 126.68, 126.86, 127.42, 128.60, 128.63, 128.75, 129.05, 129.29, 
129.79, 129.93, 131.45, 132.42, 133.92, 138.87, 147.11, 149.87, 154.81, 155.89, 159.20, 
161.44, 162.09, 162.28, 167.76; m/z (+EI) calc. For C43H38N6O5S (M+) 750.86, found 751.25 







Procedure for the synthesis of 5-(5-(3-(4-((1H-benzo[d]imidazol-1-
yl)methyl)benzamido)phenyl)furan-2-carboxamido)-N-(3-(dimethylamino)propyl)-3-
phenyl-1H-indole-2-carboxamide (4.103) from 5-(5-(3-aminophenyl)furan-2-
carboxamido)-N-(3-(dimethylamino)propyl)-3-phenyl-1H-indole-2-carboxamide (4.97) 
and 4-((1H-benzo[d]imidazol-1-yl)methyl)benzoic acid (4.73) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.97 (1 eq., 75 mg) in DMF. 
After 30 minutes, 2.0 eq. (73 mg) of 4.73 was added and the reaction mixture was allowed to 
stand for 3 hours. After completion, the reaction mixture was passed through a SCX-2 
cartridge (500 mg), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.103 was released from the cartridge using 5.0 ml 2M NH3 in MeOH. 
Further purification of the product was achieved using a silica column and 
DCM:MeOH:2MNH3 as solvent system in which the polarity of the system was changed 
from 18:1:1 to 17:2:1, gradually, until the product was obtained in pure form. It was then 




Colourless, fluffy material. IR (FTIR, νmax/cm-1) 612.91, 692.98, 736.90, 788.56, 1018.45, 
1214.76, 1256.08, 1306.23, 1372.32, 1426.56, 1472.01, 1538.07, 1643.54, 1744.28, 2956.07, 
3250.64; 1H NMR (400 MHz, DMSO-d6, TMS);  1.50 (t, J=6.82 Hz, 2H), 2.03 (s, 6H), 2.11 
(t, J=6.95 Hz, 2H), 3.20 - 3.26 (m, 2H), 5.62 (s, 2H), 7.05 (d, J=3.54 Hz, 1H), 7.19 - 7.23 (m, 
2H), 7.31 (t, J=5.68 Hz, 1H), 7.37 - 7.39 (m, 1H), 7.39 - 7.40 (m, 1H), 7.43 - 7.46 (m, 2H), 
7.46 - 7.48 (m, 2H), 7.50 (s, 2H), 7.51 - 7.52 (m, 2H), 7.53 (dd, J=2.78, 0.76 Hz, 1H), 7.63 
(dd, J=8.84, 2.02 Hz, 1H), 7.66 - 7.71 (m, 2H), 7.75 - 7.78 (m, 1H), 7.92 (d, J=1.77 Hz, 1H), 
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7.93 - 7.96 (m, 2H), 8.20 (t, J=1.77 Hz, 1H), 8.46 (s, 1H), 10.08 (s, 1H), 10.34 (s, 1H); 13C 
NMR (100 MHz, DMSO-d6); δ 26.76, 37.67, 45.26, 47.50, 56.19, 57.01, 110.84, 111.56, 
112.24, 116.27, 116.31, 116.49, 116.76, 118.94, 119.72, 120.23, 120.95, 121.82, 122.61, 
126.85, 127.04, 127.49, 128.28, 128.77, 129.22, 129.43, 129.83, 129.89, 130.10, 131.67, 
132.57, 133.78, 134.10, 134.31, 134.37, 137.73, 139.78, 140.74, 143.79, 144.35, 144.47, 
147.24, 155.01, 156.06, 161.61, 165.44; m/z (+EI) calc. For C46H41N7O4 (M+) 755.86, found 
756.07 (M+H)+; Yield: 60%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(2-((2-((3-
(dimethylamino)propyl)carbamoyl)benzofuran-5-yl)carbamoyl)benzofuran-5-
yl)phenyl)thiazole-4-carboxamide (4.104) from 5-(3-aminophenyl)-N-(2-((3-
(dimethylamino)propyl)carbamoyl)benzofuran-5-yl)benzofuran-2-carboxamide (4.98) 
and 2-(2,3-dihydrobenzofuran-5-yl) thiazole-4-carboxylic acid (4.53) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.98 (1 eq., 38 mg) in DMF. 
After 30 minutes, 2.0 eq. (38 mg) of 4.53 was added and the reaction mixture was allowed to 
stand for 3 hours. After completion, the reaction mixture was passed through a SCX-2 
cartridge (500 mg), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.104 was released from the cartridge using 5.0 ml 2M NH3 in MeOH. 
Further purification of the product was achieved using a silica column and 
DCM:MeOH:2MNH3 (18:1:1) as solvent system to obtain the product in pure form. It was 







Colourless oil.  IR (FTIR, νmax/cm-1) 636.44, 691.10, 721.457, 785.24, 811.00, 870.28, 
940.13, 1034.27, 1101.08, 1149.67, 1198.26, 1229.04, 1292.40, 1460.92, 1536.21, 1649.19, 
2323.17, 2357.81, 2939.02, 3286.58; 1H NMR (400 MHz, DMSO-d6)  1.68 (t, J=6.95 Hz, 
2H), 2.15 - 2.17 (m, 6H), 2.28 (t, J=6.95 Hz, 2H), 3.17 (s, 2H), 3.30 (br. s., 2H), 4.65 (t, 
J=8.72 Hz, 2H), 6.93 (d, J=8.59 Hz, 1H), 7.49 - 7.52 (m, 2H), 7.55 (d, J=0.76 Hz, 1H), 7.67 
(d, J=8.84 Hz, 1H), 7.81 (d, J=2.27 Hz, 1H), 7.83 (d, J=1.77 Hz, 1H), 7.84 (s, 1H), 7.86 - 
7.88 (m, 1H), 7.92 - 7.95 (m, 1H), 8.07 (d, J=1.52 Hz, 1H), 8.11 - 8.13 (m, 1H), 8.22 - 8.24 
(m, 1H), 8.30 (d, J=2.27 Hz, 1H), 8.38 (s, 1H), 8.78 (t, J=5.68 Hz, 1H), 10.28 (s, 1H), 10.69 
(s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 26.91, 28.63, 37.36, 45.10, 45.10, 56.87, 71.76, 
109.38, 110.85, 111.76, 112.32, 114.04, 119.16, 120.70, 120.81, 122.59, 123.73, 124.00, 
125.22, 126.36, 127.28, 127.42, 127.85, 128.72, 128.84, 129.29, 131.49, 131.59, 134.24, 
136.28, 138.97, 140.57, 149.51, 150.07, 151.03, 154.15, 156.60, 157.90, 159.17, 162.09, 
167.78; m/z (+EI) calc. For C41H35N5O6S (M+) 725.81, found 726.98 (M+H)
+; Yield: 72%. 
4.1.6.2 Sub type 3 Library synthesis 
General procedure for the synthesis of N-(3-(dimethylamino)propyl)-5-nitrobenzofuran-
2-carboxamide (4.106) from 5-nitrobenzofuran-2-carboxylic acid (4.105) and N,N-
dimethylpropane-1,3-diamine (4.38) (Amide coupling) 
2.0 eq of HOBT (522 mg) and 1.75 eq. of DIC (525 µl) were added to a solution of 4.105 (1 
eq., 400 mg) in DMF. After 30 minutes, 1.0 eq. (242 µl) of 4.38 was added and the reaction 
mixture was allowed to stand for 3 hours. After completion, the reaction mixture was passed 
through a SCX-2 cartridge (5.0 gm), which was washed with DCM (3x), DMF (3x) twice and 
finally MeOH (2x). The product 4.106 was released from the cartridge using 5.0 ml 2M NH3 
in MeOH and concentrated in vacuo to obtain a bright yellow oil (336 mg). 
N-(3-(dimethylamino)propyl)-5-nitrobenzofuran-2-carboxamide (4.106): 
 
Bright yellow oil. IR (FTIR, νmax/cm-1) 682.50, 737.70, 766.18, 827.94, 861.61, 889.94, 
916.66, 939.92, 955.81, 990.36, 1038.20, 1060.33, 1097.24, 1132.03, 1162.55, 1247.81, 
1270.14, 1301.05, 1338.74, 1453.72, 1521.19, 1600.55, 1660.00, 2360.22, 2779.28, 2819.37, 
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2856.77, 2952.05; 1H NMR (400 MHz, CDCl3, TMS); δ 1.80 (quin, J=6.13 Hz, 2H), 2.34 (s, 
6H), 2.49 - 2.55 (m, 2H), 3.61 (td, J=6.06, 5.31 Hz, 2H), 7.53 (d, J=1.01 Hz, 1H), 7.58 (d, 
J=9.09 Hz, 1H), 8.33 (dd, J=9.09, 2.27 Hz, 1H), 8.61 - 8.63 (m, 1H); 13C NMR (100 MHz, 
CDCl3); δ 25.11, 39.64, 44.50, 45.10, 58.62, 109.59, 111.83, 118.84, 121.73, 127.76, 144.37, 
152.20, 156.91, 157.31; m/z (+EI) calc. For C14H17N3O4 (M+) 291.30, found 292.29 (M+H)
+; 
Yield: 84%. 
General procedure for the synthesis of 5-amino-N-(3-
(dimethylamino)propyl)benzofuran-2-carboxamide (4.61) from N-(3-
(dimethylamino)propyl)-5-nitrobenzofuran-2-carboxamide (4.106) by hydrogenation. 
N-(3-(Dimethylamino)propyl)-5-nitrobenzofuran-2-carboxamide (1.0 eq., 336 mg,) (4.106) 
was dissolved in a minimum amount of ethanol (30 ml) and a catalytic amount of 10% Pd/C 
(34 mg) was added as a slurry, also in ethanol. The reaction mixture was shaken for 2 hours 
at 45 psi in a Parr hydrogenator. After completion of the reduction, the suspension was 
filtered through a layer of celite, with caution, using a Buchner flask and the filtrate was 
concentrated to obtain light yellow oil (4.61) (242 mg). 
5-Amino-N-(3-(dimethylamino)propyl)benzofuran-2-carboxamide (4.61) 
 
Light yellow oily mass. IR (FTIR, νmax/cm-1) 630.65, 732.57, 809.43, 853.13, 1038.19, 
1097.61, 1160.32, 1208.16, 1243.22, 1298.70, 1385.67, 1454.19, 1477.56, 1526.06, 1584.13, 
1650.06, 2780.36, 2821.70, 2863.04, 2940.10, 3240.31, 3333.30; 1H NMR (400 MHz, 
CDCl3, TMS);  1.73 - 1.81 (m, 2H), 2.29 (s, 6H), 2.46 (t, J=6.44 Hz, 2H), 3.50 - 3.53 (m, 
2H), 6.76 (dd, J=8.84, 2.53 Hz, 1H), 6.87 (d, J=2.27 Hz, 1H), 7.21 - 7.25 (m, 2H), 8.11 (br. 
s., 1H); 13C NMR (100 MHz, CDCl3); δ 25.70, 38.51, 44.80, 44.83, 57.80, 106.06, 108.84, 
111.46, 115.76, 128.08, 142.39, 148.87, 149.19, 158.63; m/z (+EI) calc. For C14H19N3O2 
(M+) 261.32, found 261.76 (M+H)+; Yield: 72%. 





Procedure for the synthesis of 5-(5-bromothiophene-2-carboxamido)-N-(3-
(dimethylamino)propyl)benzofuran-2-carboxamide (4.108) from 5-amino-N-(3-
(dimethylamino)propyl)benzofuran-2-carboxamide (4.61) and 5-bromothiophene-2-
carboxylic acid (4.107) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.61 (1eq., 23 mg) in DMF. 
After 30 minutes, 2.0 eq. (46 mg) of 4.107 was added and the reaction mixture was allowed 
to stand for 3 hours. After completion, the reaction mixture was passed through a SCX-2 
cartridge (500 mg), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.108 was released from the cartridge using 5.0 ml 2M NH3 in MeOH and 




Colourless oil. IR (FTIR, νmax/cm-1) 613.47, 626.39, 731.75, 765.13, 802.99, 815.89, 831.82, 
850.11, 874.64, 947.04, 976.41, 1003.66, 1036.05, 1064.10, 1084.09, 1125.55, 1166.82, 
1205.36, 1273.79, 1315.82, 1326.04, 1345.86, 1413.10, 1434.02, 1462.30, 1513.71, 1548.17, 
1591.92, 1636.09, 2361.33, 2764.52, 2813.65, 2939.02, 2968.56, 3316.76, 3358.41; 1H NMR 
(400 MHz, DMSO-d6, TMS); 1.67 (t, J=6.95 Hz, 2H), 2.16 (s, 6H), 2.29 (t, J=6.95 Hz, 2H), 
3.26 - 3.29 (m, 2H), 7.38 (d, J=4.04 Hz, 1H), 7.52 (s, 1H), 7.61 - 7.65 (m, 1H), 7.66 - 7.70 
(m, 1H), 7.87 (d, J=4.04 Hz, 1H), 8.14 (d, J=2.02 Hz, 1H), 8.77 (t, J=5.81 Hz, 1H), 10.38 (s, 
1H); 13C NMR (100 MHz, DMSO-d6); δ 26.84, 37.29, 45.03, 45.06, 56.81, 109.32, 111.74, 
113.91, 117.70, 120.52, 123.45, 127.29, 129.78, 131.68, 134.24, 150.92, 157.86, 158.74, 
162.41; m/z (+EI) calc. For C19H20BrN3O3S (M+) 450.35, found 449.60 (M+H)







General procedure for Suzuki coupling for the synthesis of 5-(5-(3-
aminophenyl)thiophene-2-carboxamido)-N-(3-(dimethylamino)propyl)benzofuran-2-
carboxamide (4.109) from 5-(5-bromothiophene-2-carboxamido)-N-(3-
(dimethylamino)propyl)benzofuran-2-carboxamide (4.108) and (3-aminophenyl)boronic 
acid (4.49) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq., 6 mg) was 
added to a solution of 4.108 (1.0 eq., 25 mg) and 4.49 (1.2 eq., 26 mg) in a 9:3:1 combination 
of EtOH, toluene and water in the presence of K2CO3 (3.0 eq., 23 mg) in a 10 ml microwave 
vial containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was passed through an IsoluteTM SCX-2 cartridge (500 mg) and washed with DCM 
(3x), DMF (3x) twice and finally MeOH (2x). The product was released from the cartridge 




 Dark brown, oily mass. IR (FTIR, νmax/cm-1) 660.50, 709.32, 721.47, 779.45, 867.24, 993.11, 
1094.01, 1159.72, 1239.43, 1298.48, 1343.95, 1385.70, 1440.55, 1548.38, 1598.54, 1653, 
2341.46, 2363.08, 2859.75, 2932.92, 3342.51; 1H NMR (400 MHz, DMSO-d6, TMS);  1.68 
(t, J=6.82 Hz, 2H), 2.18 (s, 6H), 2.31 (t, J=6.82 Hz, 2H), 2.89 (s, 2H), 6.57 - 6.59 (m, 1H), 
6.95 - 6.96 (m, 1H), 7.10 (t, J=7.83 Hz, 1H), 7.45 (d, J=3.79 Hz, 1H), 7.52 - 7.54 (m, 1H), 
7.64 (d, J=9.09 Hz, 1H), 7.70 (d, J=2.02 Hz, 1H), 7.73 (s, 1H), 7.95 (s, 1H), 8.00 (d, J=4.04 
Hz, 1H), 8.19 (d, J=2.27 Hz, 1H), 8.78 (d, J=2.78 Hz, 1H), 10.32 (s, 1H); 13C NMR (100 
MHz, DMSO-d6); δ 26.60, 35.53, 44.78, 44.81, 56.57, 111.47, 113.54, 114.16, 115.47, 
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119.72, 121.63, 123.30, 127.06, 127.50, 129.49, 129.83, 133.22, 137.74, 147.29, 149.12, 
149.35, 149.76, 157.70, 159.54, 162.05; m/z (+EI) calc. For C25H26N4O3S (M+) 462.56, 
found 462.81 (M+H)+; Yield: 86%. 
A similar Suzuki coupling condition was followed for the following reaction. 
Procedure for the synthesis of 5-(benzofuran-5-yl)furan-2-carboxylic acid (4.111) from 
2-(benzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4.110) and 5-bromofuran-
2-carboxylic acid (4.41) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.110 (1.0 eq., 100 mg) and 4.41 (1.5 eq., 117 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. After LCMS analysis revealed complete reaction the cooled reaction 
mixture was dried over vacuum. A silica column was used to purify the product 4.111. 
Initially the Palladium catalyst was trapped over a silica bed, which was washed with ethyl 
acetate to obtain the crude reaction mixture. This was then dried and purified using column 
chromatography, with ethyl acetate as the solvent system. Purification was very tricky, but a 
reasonable amount (89 mg) of pure product was obtained. 
5-(Benzofuran-5-yl)furan-2-carboxylic acid (4.111): 
 
Colourless oily mass. IR (FTIR, νmax/cm-1) 690.47, 789.10, 881.54, 1021.07, 1204.42, 
1263.83, 2361.94; 1H NMR (400 MHz, DMSO-d6, TMS);  7.05 (dd, J=2.15, 0.88 Hz, 1H), 
7.12 (d, J=3.54 Hz, 1H), 7.32 (d, J=3.54 Hz, 1H), 7.70 (d, J=8.84 Hz, 1H), 7.78 (dd, J=8.59, 
1.77 Hz, 1H) 8.06 (d, J=2.27 Hz, 1H), 8.11 (d, J=1.52 Hz, 1H); 13C NMR (100 MHz, DMSO-
d6); δ 107.01, 107.08, 111.98, 117.40, 121.33, 127.51, 128.64, 128.76, 131.38, 131.48, 





Amide coupling was used for synthesising compounds 4.112 to 4.117. 
Procedure for the synthesis of 5-(5-(3-(5-(benzofuran-5-yl)furan-2-
carboxamido)phenyl)furan-2-carboxamido)-N-(3-(dimethylamino)propyl)benzofuran-2-
carboxamide (4.112) from 5-(5-(3-aminophenyl)furan-2-carboxamido)-N-(3-
(dimethylamino)propyl)benzofuran-2-carboxamide (4.69) and-(benzofuran-5-yl)furan-
2-carboxylic acid (4.111) 
2.0 eq of HOBT, 1.75 eq. of DIC, 2eq.of 4.69 (78 mg) and 1.0 eq. (20 mg) of 4.111 were 
added to DMF and the reaction mixture was allowed to stand for 3 hours. After completion, 
the reaction mixture was passed through a SCX-2 cartridge (500 mg), which was washed 
with DCM (3x), DMF (3x) twice and finally MeOH (2x). The product 4.112 was released 
from the cartridge using 5.0 ml 2M NH3 in MeOH and concentrated in vacuo to obtain a 
crude product. The product was purified using a silica column and 18:1:1 DCM:MeOH:2M 





Colourless, viscous material. IR (FTIR, νmax/cm-1) 734.63, 864.86, 881.54, 956.09, 1021.07, 
1111.18, 1129.52, 1168.32, 1204.42, 1233.90, 1263.83, 1297.11, 1343.91, 1434.31, 1467.89, 
1546.23, 1584.18, 1648.75, 2361.94, 2780.36, 2816.53, 2857.88, 2932.13, 3121.44, 3278.35; 
1H NMR (400 MHz, Acetone-d4, TMS);  1.78 (quin, J=6.63 Hz, 2H), 2.24 (d, J=1.01 Hz, 
6H), 2.42 (td, J=6.51, 1.39 Hz, 2H), 3.46 - 3.50 (m, 2H), 6.98 (dd, J=2.02, 1.01 Hz, 1H), 7.04 
(d, J=3.54 Hz, 1H), 7.06 (d, J=3.79 Hz, 1H), 7.35 (d, J=3.54 Hz, 1H), 7.39 (d, J=3.79 Hz, 
1H), 7.42 - 7.43 (m, 1H), 7.47 (t, J=8.08 Hz, 1H), 7.53 (d, J=8.84 Hz, 1H), 7.64 (dt, J=8.59, 
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0.76 Hz, 1H), 7.67 - 7.70 (m, 1H), 7.82 - 7.86 (m, 1H), 7.90 (d, J=2.02 Hz, 1H), 7.91 (d, 
J=2.27 Hz, 1H), 7.92 (d, J=1.77 Hz, 1H), 8.24 (d, J=1.52 Hz, 1H), 8.28 - 8.30 (m, 1H), 8.33 
(s, 1H), 9.76 (d, J=11.37 Hz, 1H); 13C NMR (100 MHz, Acetone-d4); δ 35.78, 48.88, 97.94, 
97.98, 98.83, 100.19, 102.56, 102.81, 104.78, 104.89, 107.50, 107.60, 107.68, 108.26, 
108.81, 111.20, 111.53, 111.71, 111.80, 112.70, 116.23, 118.98, 119.26, 120.42, 121.39, 
125.85, 130.40, 137.83, 138.61, 142.56, 146.16, 146.67, 147.48, 196.11, 196.30, 196.32, 
196.49, 196.70; m/z (+EI) calc. For C38H32N4O7 (M+) 656.68, found 656.87 (M+H)
+; Yield: 
51%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((3-
(dimethylamino)propyl) 
carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-yl)phenyl)-5-methylthiazole-4-
carboxamide (4.114) from 4.69 and 2-(2,3-dihydrobenzofuran-5-yl)- 
5-methylthiazole-4-carboxylic acid (4.113) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.69 (1eq., 31 mg) in DMF. 
After 30 minutes, 2.0 eq. (36 mg) of 4.113 was added and the reaction mixture was allowed 
to stand for 3 hours. After completion, the reaction mixture was passed through a SCX-2 
cartridge (500 mg), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.114 was released from the cartridge using 5.0 ml 2M NH3 in MeOH and 








Colourless oil. IR (FTIR, νmax/cm-1) 689.85, 736.01, 786.86, 861.17, 939.68, 1020.63, 
1101.77, 1231.67, 1301.82, 1432.25, 1460.44, 1529.72, 1584.25, 1649.65, 2357.05, 2780.48, 
2817.07, 2943.15, 3280.48; 1H NMR (400 MHz, DMSO-d6, TMS);  1.67 (t, J=7.07 Hz, 2H), 
2.15 (s, 6H), 2.28 (t, J=6.95 Hz, 2H), 2.66 (s, 3H), 3.25 - 3.29 (m, 2H), 3.33 (br. s., 2H), 4.63 
(t, J=8.84 Hz, 2H), 6.90 (d, J=8.34 Hz, 1H), 7.13 (d, J=3.54 Hz, 1H), 7.47 (d, J=3.54 Hz, 
1H), 7.50 (d, J=8.08 Hz, 1H), 7.53 (d, J=0.76 Hz, 1H), 7.65 (d, J=9.09 Hz, 1H), 7.69 - 7.70 
(m, 1H), 7.71 - 7.73 (m, 1H), 7.75 (d, J=2.02 Hz, 1H), 7.76 - 7.78 (m, 1H), 7.88 (d, J=1.52 
Hz, 1H), 8.18 (d, J=2.02 Hz, 2H), 8.77 (t, J=5.68 Hz, 1H), 10.30 (s, 1H), 10.31 (s, 1H); 13C 
NMR (100 MHz, DMSO-d6); δ 17.21, 26.90, 28.58, 37.34, 40.14, 45.10, 56.87, 71.81, 
108.01, 109.29, 109.55, 111.67, 114.04, 116.86, 120.76, 121.09, 123.33, 124.45, 125.14, 
127.07, 127.25, 128.96, 129.36, 129.69, 134.32, 139.21, 140.0, 146.76, 148.72, 150.01, 
150.90, 155.01, 155.93, 156.13, 157.88, 160.16, 162.26, 166.85; m/z (+EI) calc. For 
C38H35N5O6S (M+) 689.78, found 690.93 (M+H)
+; Yield: 54%. 
Procedure for the synthesis of N-(3-(5-((2-((3-
(dimethylamino)propyl)carbamoyl)benzofuran-5-yl) 
carbamoyl)furan-2-yl)phenyl)-4-methyl-2-(pyrazin-2-yl)thiazole-5-carboxamide (4.116) 
from 4.69 and 4-methyl-2-(pyrazin-2-yl)thiazole-5-carboxylic acid (4.115) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.69 (1eq., 35 mg) in DMF. 
After 30 minutes, 2.0 eq. (35 mg) of 4.115 was added and the reaction mixture was allowed 
to stand for 3 hours. After completion, the reaction mixture was passed through a SCX-2 
cartridge (500 mg), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.116 was released from the cartridge using 5.0 ml 2M NH3 in MeOH and 












Colourless viscous mass. IR (FTIR, νmax/cm-1) 685.21, 781.11, 880.83, 1013.16, 1104.28, 
1166.05, 1203.46, 1234.17, 1300.57, 1348.24, 1434.26, 1469.72, 1513.77, 1557.36, 1584.31, 
1644.68, 2356.80, 2936.00, 3266.89; 1H NMR (400 MHz, DMSO-d6, TMS);  1.70 (t, J=6.95 
Hz, 2H), 2.22 (s, 6H), 2.37 (t, J=7.07 Hz, 2H), 2.73 (s, 3H), 3.30 (br. s., 2H), 7.14 (d, J=3.54 
Hz, 1H), 7.48 (d, J=3.54 Hz, 1H), 7.51 (t, J=7.96 Hz, 1H), 7.54 (d, J=0.76 Hz, 1H), 7.65 (d, 
J=9.09 Hz, 1H), 7.72 (d, J=2.02 Hz, 1H), 7.74 - 7.76 (m, 1H), 7.77 (t, J=1.64 Hz, 1H), 8.19 
(d, J=2.02 Hz, 1H), 8.21 (t, J=1.77 Hz, 1H), 8.76 - 8.80 (m, 2H), 8.82 (d, J=2.53 Hz, 1H), 
9.36 (d, J=1.52 Hz, 1H), 10.30 (s, 1H), 10.52 (s, 1H); 13C NMR (100 MHz, DMSO-d6); δ 
17.17, 26.60, 37.17, 40.14, 44.77, 56.60, 109.35, 111.67, 113.53, 114.03, 116.55, 116.72, 
120.77, 127.25, 128.61, 129.73, 134.33, 136.43, 139.05, 140.65, 144.75, 145.28, 146.48, 
146.78, 149.96, 150.90, 154.95, 156.13, 156.88, 157.92, 159.86, 161.32, 162.54, 164.90; m/z 
(+EI) calc. For C34H31N7O5S (M+) 649.72, found 649.61 (M+H)
+; Yield: 78%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((3-
(dimethylamino)propyl)carbamoyl)benzofuran-5-yl)carbamoyl)thiophen-2-
yl)phenyl)thiazole-4-carboxamide (4.117) from 5-(5-(3-aminophenyl)thiophene-2-
carboxamido)-N-(3-(dimethylamino)propyl)benzofuran-2-carboxamide (4.109) and 2-
(2,3-dihydrobenzofuran-5-yl)thiazole-4-carboxylic acid (4.53) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.109 (1eq., 28 mg) in 
DMF. After 30 minutes, 2.0 eq. (30 mg) of 4.53 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was passed through a 
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SCX-2 cartridge (500 mg), which was washed with DCM (3x), DMF (3x) twice and finally 
MeOH (2x). The product 4.117 was released from the cartridge using 5.0 ml 2M NH3 in 





Light green powder. IR (FTIR, νmax/cm-1) 622.10, 641.49, 677.69, 732.92, 747.39, 771.95, 
804.76, 877.07, 941.35, 981.10, 103.92, 1112.12, 1163.00, 1194.23, 1237.39, 1255.95, 
1276.28, 1299.08, 1347.58, 1415.86, 1434.30, 1454.00, 1550.54, 1590.48, 1638.51, 2361.62, 
2768.29, 2815.15, 2941.68, 3318.34, 3353.65; 1H NMR (400 MHz, DMSO-d6, TMS);  1.68 
(t, J=7.20 Hz, 2H), 2.16 (s, 6H), 2.29 (t, J=6.82 Hz, 2H), 3.28 (br. s., 4H), 4.65 (t, J=8.84 Hz, 
2H), 6.94 (d, J=8.34 Hz, 1H), 7.45 - 7.51 (m, 1H), 7.53 - 7.55 (m, 1H), 7.63 - 7.65 (m, 1H), 
7.66 (s, 1H), 7.71 - 7.75 (m, 1H), 7.92 - 7.93 (m, 1H), 7.93 - 7.97 (m, 2H), 8.06 - 8.09 (m, 
2H), 8.21 (d, J=2.02 Hz, 1H), 8.29 (t, J=1.89 Hz, 1H), 8.39 (s, 1H), 8.78 (t, J=5.68 Hz, 1H), 
10.32 (s, 1H), 10.39 (s, 1H); 13C NMR (100 MHz, DMSO-d6); δ 26.88, 28.61, 37.33, 45.07, 
45.10, 56.84, 71.76, 109.37, 111.71, 112.47, 113.80, 114.96, 116.29, 117.60, 120.50, 120.53, 
122.75, 123.74, 124.21, 125.19, 126.28, 127.30, 127.44, 128.74, 130.18, 133.36, 137.25, 
138.91, 139.23, 149.85, 150.00, 150.86, 157.91, 159.27, 162.09, 169.30, 187.84; m/z (+EI) 
calc. For C37H33N5O5S2 (M+) 691.82, found 691.87 (M+H)
+; Yield: 71%. 
Again, intermediates 4.118 to 4.121 were synthesized by amide coupling reaction between 5-
(5-(3-aminophenyl)furan-2-carboxamido)-N-(3-(dimethylamino)propyl)benzofuran-2-
carboxamide (4.69) and 5-bromofuran-2-carboxylic acid (4.41),5-bromothiophene-2-
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carboxylic acid (4.107) and 2-bromo-4-methylthiazole-5-carboxylic acid (4.120), 
respectively. 
Procedure for the synthesis of 5-(5-(3-(5-bromofuran-2-carboxamido)phenyl)furan-2-
carboxamido)-N-(3-(dimethylamino)propyl)benzofuran-2-carboxamide (4.118) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.69 (1eq., 196 mg) in 
DMF. After 30 minutes, 2.2 eq. (184 mg) of 4.41 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was passed through a 
SCX-2 cartridge (5 gm), which was washed with DCM (3x), DMF (3x) twice and finally 
MeOH (2x). The product 4.118 was released from the cartridge using 5.0 ml 2M NH3 in 




Yellow oil. IR (FTIR, νmax/cm-1) 630.99, 682.65, 736.90, 863.46, 925.46, 959.04, 1108.85, 
1168.26, 1204.42, 1295.06, 1431.73, 1462.73, 1514.39, 1585.91, 1644.03, 2356.58, 2940.56, 
3278.85; 1H NMR (400 MHz, DMSO-d6, TMS);  1.67 (t, J=7.07 Hz, 2H), 2.15 (s, 6H), 2.28 
(t, J=7.07 Hz, 2H), 3.27 - 3.31 (m, 2H), 6.86 (d, J=3.54 Hz, 1H), 7.12 (d, J=3.54 Hz, 1H), 
7.42 (d, J=3.54 Hz, 1H), 7.46 - 7.48 (m, 1H), 7.48 - 7.51 (m, 1H), 7.54 (d, J=0.76 Hz, 1H), 
7.66 (d, J=8.84 Hz, 1H), 7.73 (dt, J=8.02, 1.17 Hz, 1H), 7.74 - 7.78 (m, 1H), 7.80 (ddd, 
J=8.21, 2.02, 0.88 Hz, 1H), 8.17 - 8.19 (m, 2H), 8.77 (t, J=5.68 Hz, 1H), 10.29 (s, 1H), 10.38 
(s, 1H); 13C NMR (100 MHz, DMSO-d6); δ 26.68, 37.12, 39.62, 44.88, 56.65, 107.70, 
109.08, 111.46, 113.83, 114.10, 116.28, 116.50, 117.08, 120.11, 120.55, 120.77, 125.25, 
127.04, 129.14, 129.46, 134.11, 138.61, 146.55, 148.92, 149.80, 150.70, 154.79, 154.99, 
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Procedure for the synthesis of 5-(5-(3-(5-bromothiophene-2-carboxamido)phenyl)furan-
2-carboxamido)-N-(3-(dimethylamino)propyl)benzofuran-2-carboxamide (4.119) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.69 (1eq., 231 mg) in 
DMF. After 30 minutes, 2.0 eq. (214 mg) of 4.107 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was passed through a 
SCX-2 cartridge (500 mg), which was washed with DCM (3x), DMF (3x) twice and finally 
MeOH (2x). The product 4.119 was released from the cartridge using 5.0 ml 2M NH3 in 




Colourless, oily mass. IR (FTIR, νmax/cm-1) 680.07, 734.02, 779.57, 801.47, 878.72, 976.56, 
1027.73, 1099.49, 1170.07, 1201.84, 1234.21, 1262.43, 1293.07, 1352.23, 1425.53, 1469.49, 
1513.61, 1555.87, 1585.63, 1638.76, 2346.25, 2775.19, 2816.53, 2857.88, 2934.17, 3279.67; 
1H NMR (400 MHz, DMSO-d6, TMS);  1.70 (t, J=7.07 Hz, 2H), 2.21 (s, 6H), 2.36 (t, 
J=7.07 Hz, 2H), 3.31 - 3.34 (m, 2H), 7.13 (d, J=3.54 Hz, 1H), 7.39 (d, J=4.04 Hz, 1H), 7.47 - 
7.48 (m, 1H), 7.51 (d, J=7.83 Hz, 1H), 7.54 (d, J=0.76 Hz, 1H), 7.66 (d, J=8.84 Hz, 1H), 7.72 
(d, J=1.52 Hz, 1H), 7.74 - 7.76 (m, 1H), 7.77 - 7.78 (m, 1H), 7.92 (d, J=4.04 Hz, 1H), 8.17 - 
8.18 (m, 1H), 8.18 (d, J=2.27 Hz, 1H), 8.78 (t, J=5.81 Hz, 1H), 10.30 (s, 1H), 10.47 (s, 1H); 
13C NMR (100 MHz, DMSO-d6); δ 26.66, 37.20, 41.12, 44.83, 56.66, 107.96, 109.34, 
111.67, 114.03, 116.36, 116.69, 118.00, 119.45, 120.38, 120.77, 127.25, 129.73, 130.03, 
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131.75, 134.32, 138.94, 141.59, 145.27, 146.77, 149.97, 150.90, 154.97, 156.13, 157.91, 
158.90; m/z (+EI) calc. For C30H27BrN4O5S (M+) 635.53, found 636.38 (M+H)
+; Yield: 76%. 
Procedure for the synthesis of 2-bromo-N-(3-(5-((2-((3-
(dimethylamino)propyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-yl)phenyl)-4-
methylthiazole-5-carboxamide (4.121) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.69 (1eq., 100 mg) in 
DMF. After 30 minutes, 2.0 eq. (94 mg) of 4.120 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was passed through a 
SCX-2 cartridge (500 mg), which was washed with DCM (3x), DMF (3x) twice and finally 
MeOH (2x). The product 4.121 was released from the cartridge using 5.0 ml 2M NH3 in 




Colourless oil. IR (FTIR, νmax/cm-1) 630.65, 682.65, 785.93, 925.46, 1019.68, 1126.93, 
1225.09, 1349.07, 1535.05, 1555.71, 1644.86, 1981.63, 2345.61, 2903.67, 3215.53; 1H NMR 
(400 MHz, CDCl3, TMS); δ 1.70 - 1.73 (m, 2H), 2.28 (br. s., 6H), 2.40 - 2.46 (m, 2H), 2.50 
(s, 3H), 3.50 - 3.52 (m, 2H), 7.13 - 7.15 (m, 1H), 7.35 (d, J=3.03 Hz, 1H), 7.53 (br. s., 1H), 
7.57 - 7.59 (m, 1H), 7.60 - 7.65 (m, 1H), 7.70 - 7.73 (m, 1H), 7.83 – 7.93 (m, 1H), 8.23 - 8.36 
(m, 2H), 8.44 (br. s., 1H); 13C NMR (100 MHz, CDCl3); δ 15.3, 26.54, 36.15, 43.02, 46.94, 
56.80, 106.39, 109.45, 109.59, 113.24, 115.89, 118.09, 120.93, 121.55, 122.69, 126.67, 
129.54, 131.12, 131.32, 138.12, 145.87, 150.32, 151.94, 156.38, 158.14, 159.33, 160.94, 
161.57, 162.39, 168.49; m/z (+EI) calc. For C30H28BrN5O5S (M+) 650.54, found 651.59 
(M+H)+; Yield: 63%. 
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From 4.118, 4.119 and 4.121 intermediates final compounds 4.123 to 4.133 were synthesized 
by following the general conditions for the Suzuki coupling reaction.  
Procedure for the synthesis of 5-(5-(3-(5-(benzo[b]thiophen-5-yl)furan-2-
carboxamido)phenyl)furan-2-carboxamido)-N-(3-(dimethylamino)propyl)benzofuran-2-
carboxamide (4.123) from 4.118 and (2-(benzo[b]thiophen-5-yl)-4,5,5-trimethyl-1,3,2-
dioxaborolan-4-yl)methylium (4.122) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.118 (1.0 eq., 53 mg) and 4.122 (2.2 eq., 49 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. After completion, the reaction mixture was passed through a SCX-2 
cartridge (1 gm), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.123 was released from the cartridge using 5.0 ml 2M NH3 in MeOH and 




Colourless, oily mass. IR (FTIR, νmax/cm-1) 694.15, 748.85, 794.36, 890.65, 954.96, 1020.00, 
1120.48, 1203.74, 1265.07, 1297.37, 1348.72, 1434.80, 1469.53, 1523.97, 1586.29, 1643.98, 
1738.82, 2360.24, 2768.29, 2938.91, 3279.54; 1H NMR (400 MHz, DMSO-d6, TMS); 1.68 
(quin, J=7.07 Hz, 2H), 2.16 (s, 6H), 2.29 (t, J=7.07 Hz, 2H), 3.28 - 3.31 (m, 2H), 7.16 (d, 
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J=3.54 Hz, 1H), 7.25 (d, J=3.54 Hz, 1H), 7.48 (d, J=2.27 Hz, 1H), 7.49 (d, J=2.27 Hz, 1H), 
7.50 - 7.53 (m, 1H), 7.54 (d, J=1.01 Hz, 1H), 7.55 - 7.57 (m, 1H), 7.59 - 7.63 (m, 1H), 7.66 
(d, J=9.09 Hz, 1H), 7.76 (d, J=2.02 Hz, 1H), 7.86 (s, 1H), 7.87 - 7.88 (m, 1H), 7.99 (dd, 
J=8.46, 1.64 Hz, 1H), 8.15 (d, J=8.59 Hz, 1H), 8.20 (d, J=2.02 Hz, 1H), 8.25 (t, J=1.77 Hz, 
1H), 8.52 (d, J=1.52 Hz, 1H), 8.78 (t, J=5.81 Hz, 1H), 10.31 (s, 1H), 10.39 (s, 1H); 13C NMR 
(100 MHz, DMSO-d6); δ 26.85, 37.31, 40.14, 45.04, 56.81, 107.74, 107.93, 109.31, 111.67, 
114.07, 116.74, 116.78, 117.32, 119.20, 120.79, 121.31, 123.17, 125.76, 127.26, 128.64, 
128.76, 129.33, 129.70, 131.48, 131.98, 132.20, 134.22, 138.99, 139.39, 146.37, 146.77, 
150.01, 150.92, 155.08, 155.66, 156.15, 156.20, 157.90; m/z (+EI) calc. For C38H32N4O6S 
(M+) 672.75, found 672.61 (M+H)+; Yield: 97%. 
Procedure for the synthesis of N-(3-(dimethylamino)propyl)-5-(5-(3-(5-(4-methyl-3,4-
dihydro-2H-benzo[b][1,4]oxazin-7-yl)furan-2-carboxamido)phenyl)furan-2-
carboxamido)benzofuran-2-carboxamide (4.125) from 4.118 and 4-methyl-7-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (4.124) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.118 (1.0 eq., 58 mg) and 4.124 (2.2 eq., 57 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. After completion the reaction mixture was passed through a SCX-2 
cartridge (1 gm), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.125 was released from the cartridge using 5.0 ml 2M NH3 in MeOH and 


















Dark orange oil. IR (FTIR, νmax/cm-1) 631.52, 660.45, 693.76, 792.66, 865.52, 955.41, 
1031.36, 1095.60, 1201.31, 1258.85, 1309.42, 13378.86, 1385.91, 1435.80, 1469.53, 
1490.38, 1555.83, 1585.97, 1653.79, 2360.47, 2823.17, 2938.24, 3273.12; 1H NMR (400 
MHz, Acetone-d4, TMS);  1.77 (t, J=6.69 Hz, 2H), 2.22 (d, J=0.76 Hz, 6H), 2.39 (td, 
J=6.44, 1.26 Hz, 2H), 2.94 (s, 3H), 3.34 - 3.37 (m, 2H), 3.46 - 3.50 (m, 2H), 4.27 - 4.30 (m, 
2H), 6.74 (d, J=8.59 Hz, 1H), 6.78 (d, J=3.54 Hz, 1H), 7.02 (d, J=3.54 Hz, 1H), 7.23 (d, 
J=2.02 Hz, 1H), 7.32 (d, J=3.54 Hz, 1H), 7.34 (t, J=0.88 Hz, 1H), 7.42 (s, 1H), 7.43 - 7.46 
(m, 1H), 7.50 - 7.52 (m, 1H), 7.52 - 7.54 (m, 1H), 7.57 - 7.63 (m, 1H), 7.64 - 7.65 (m, 1H), 
7.66 (d, J=1.52 Hz, 1H), 7.67 - 7.72 (m, 1H), 7.84 (d, J=8.84 Hz, 1H), 7.91 (d, J=8.08 Hz, 
1H), 7.95 (s, 1H), 8.28 (t, J=1.89 Hz, 1H); 13C NMR (100 MHz, Acetone-d4); δ 26.68, 36.23, 
40.06, 49.31, 49.34, 56.01, 96.37, 99.15, 102.91, 103.30, 103.51, 105.16, 105.26, 108.05, 
108.83, 109.92, 110.70, 111.39, 111.92, 112.12, 119.33, 119.92, 120.04, 120.71, 121.65, 
121.71, 123.19,  123.27, 129.08, 135.69, 137.36, 138.93, 142.24, 142.92, 147.09, 148.38, 






Procedure for the synthesis of 5-(5-(3-(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)furan-2-
carboxamido)phenyl)furan-2-carboxamido)-N-(3-(dimethylamino)propyl)benzofuran-2-
carboxamide (4.127) from 4.118 and (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)boronic acid 
(4.126) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.118 (1.0 eq., 50 mg) and 4.126 (2.2 eq., 30 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. After completion, the reaction mixture was passed through a SCX-2 
cartridge (1 gm), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.127 was released from the cartridge using 5.0 ml 2M NH3 in MeOH and 




Light green oil. IR (FTIR, νmax/cm-1) 689.88, 745.63, 789.78, 853.87, 890.10, 926.25, 954.27, 
1020.45, 1067.83, 1126.25, 1226.86, 1243.88, 1280.53, 1308.81, 1352.43, 1435.54, 1468.54, 
1547.72, 1582.32, 1650.68, 1705.46, 2357.65, 2938.77, 3293.76; 1H NMR (400 MHz, 
Acetone-d4, TMS);  1.75 - 1.82 (m, 2H), 2.24 (d, J=3.54 Hz, 6H), 2.39 - 2.43 (m, 2H), 3.47 - 
3.51 (m, 2H), 4.32 (d, J=4.29 Hz, 4H), 6.92 (br. s., 1H), 7.03 (t, J=3.92 Hz, 1H), 7.31 - 7.35 
(m, 2H), 7.37 - 7.39 (m, 1H), 7.41 - 7.43 (m, 2H), 7.52 - 7.55 (m, 2H), 7.68 (d, J=7.07 Hz, 
2H), 7.79 - 7.85 (m, 1H), 7.88 (br. s., 1H), 7.95 (br. s., 1H), 8.25 - 8.29 (m, 2H), 8.43 (br. s., 
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1H), 9.72 (br. s., 1H); 13C NMR (100 MHz, Acetone-d4); δ 29.38, 35.80, 48.88, 48.90, 55.61, 
97.50, 98.83, 107.45, 107.66, 108.29, 108.71, 109.16, 111.38, 111.83, 114.33, 118.97, 
119.53, 119.66, 120.39, 121.35, 122.80, 122.86, 125.72, 135.16, 135.68, 137.67, 138.55, 
138.58, 142.54, 146.65, 146.91, 147.17, 147.23, 147.31, 153.74, 158.12, 160.14, 162.35; m/z 
(+EI) calc. For C38H34N4O8 (M+) 674.70, found 675.04 (M+H)
+; Yield: 84%. 
Procedure for the synthesis of 5-(5-(3-(5-(benzofuran-5-yl)thiophene-2-
carboxamido)phenyl)furan-2-carboxamido)-N-(3-(dimethylamino)propyl)benzofuran-2-
carboxamide (4.129) from 4.119 and 2-(benzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane (4.128) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.119 (1.0 eq., 45 mg) and 4.128 (2.2 eq., 38 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. After completion the reaction mixture was passed through a SCX-2 
cartridge (1 gm), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.129 was released from the cartridge using 5.0 ml 2M NH3 in MeOH and 




Colourless oil. IR (FTIR, νmax/cm-1) 630.11, 681.17, 733.86, 777.78, 864.26, 955.93, 1027.61, 
1109.57, 1129.86, 1170.41, 1234.15, 1259.95, 1294.38, 1350.84, 1438.17, 1469.68, 1513.19, 
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1539.15, 1585.07, 1640.35, 2361.40, 27774.39, 2817.07, 2853.65, 2931.22, 3286.35; 1H 
NMR (400 MHz, DMSO-d6, TMS);  1.68 (t, J=7.07 Hz, 2H), 2.16 (s, 6H), 2.29 (t, J=7.07 
Hz, 2H), 3.34 - 3.37 (m, 2H), 7.04 (dd, J=2.02, 0.76 Hz, 1H), 7.14 (d, J=3.54 Hz, 1H), 7.48 
(d, J=3.79 Hz, 1H), 7.50 - 7.53 (m, 1H), 7.54 (d, J=0.76 Hz, 1H), 7.63 (d, J=3.79 Hz, 1H), 
7.66 (d, J=8.84 Hz, 1H), 7.70 (s, 1H), 7.71 (d, J=1.77 Hz, 1H), 7.72 - 7.75 (m, 1H), 7.75 - 
7.79 (m, 1H), 7.80 - 7.84 (m, 1H), 8.06 (dd, J=1.64, 0.88 Hz, 1H), 8.07 (d, J=2.02 Hz, 1H), 
8.09 (d, J=4.04 Hz, 1H), 8.19 (d, J=2.27 Hz, 1H), 8.22 (t, J=1.89 Hz, 1H), 8.78 (t, J=5.81 Hz, 
1H), 10.31 (s, 1H), 10.42 (s, 1H); 13C NMR (100 MHz, DMSO-d6); δ 26.86, 37.31, 45.05, 
45.07, 56.83, 106.95, 109.29, 111.67, 112.03, 112.59, 116.29, 116.31, 116.70, 118.63, 
120.76, 122.66, 124.09, 127.25, 127.89, 128.09, 128.24, 128.71, 129.37, 129.70, 130.42, 
134.32, 138.11, 139.28, 146.75, 147.21, 150.00, 150.90, 154.38, 156.14, 157.88, 158.31, 
159.86, 162.02; m/z (+EI) calc. For C38H32N4O6S(M+) 672.75, found 673.20 (M+H)
+; Yield: 
67%. 
Procedure for the synthesis of 5-(5-(3-(5-(benzo[b]thiophen-5-yl)thiophene-2-
carboxamido)phenyl)furan-2-carboxamido)-N-(3-(dimethylamino)propyl)benzofuran-2-
carboxamide (4.130) from 4.119 and 4.122 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.119 (1.0 eq., 44 mg) and 4.122 (2.2 eq., 40 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 20 minutes. After completion, the reaction mixture was passed through a SCX-2 
cartridge (1 gm), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.130 was released from the cartridge using 5.0 ml 2M NH3 in MeOH and 












Colourless oily mass. IR (FTIR, νmax/cm-1) 631.79, 680.33, 736.93, 774.51, 804/07, 854.27, 
945.48, 1028.05, 1111.35, 1168.64, 1202.06, 1235.43, 1263.17, 1310.00, 1345.85, 1435.41, 
1458.06, 1514.29, 1552.21, 1586.46, 1635.57, 2359.64, 2823.17, 2939.93, 3286.55; 1H NMR 
(400 MHz, DMSO-d6, TMS);  1.68 (t, J=7.07 Hz, 2H), 2.16 (s, 6H), 2.29 (t, J=7.07 Hz, 2H), 
3.33 (br. s., 2H), 7.14 (d, J=3.79 Hz, 1H), 7.48 (d, J=3.79 Hz, 1H), 7.53 - 7.54 (m, 1H), 7.54 
(d, J=1.01 Hz, 1H), 7.55 (s, 1H), 7.66 (d, J=9.09 Hz, 1H), 7.71 (d, J=4.04 Hz, 1H), 7.72 - 
7.75 (m, 1H), 7.76 (d, J=2.02 Hz, 1H), 7.78 (d, J=1.26 Hz, 1H), 7.80 - 7.84 (m, 1H), 7.85 (d, 
J=5.31 Hz, 1H), 8.10 (d, J=2.78 Hz, 1H), 8.11 (d, J=1.52 Hz, 1H), 8.19 (d, J=2.02 Hz, 1H), 
8.22 (t, J=1.77 Hz, 1H), 8.29 (d, J=1.77 Hz, 1H), 8.77 (t, J=5.68 Hz, 1H), 10.30 (s, 1H), 
10.44 (s, 1H); 13C NMR (100 MHz, DMSO-d6); δ 26.87, 37.31, 45.06, 45.77, 56.84, 105.43, 
107.57, 109.02, 109.30, 111.67, 114.03, 116.33, 116.71, 120.45, 122.12, 123.40, 124.16, 
124.40, 127.26, 128.64, 128.76, 129.71, 130.45, 131.48, 134.33, 136.56, 138.32, 140.11, 
142.84, 143.83, 146.76, 148.34, 150.01, 150.91, 155.08, 157.88, 166.59, 178.25; m/z (+EI) 
calc. For C38H32N4O5S (M+) 688.81, found 689.14 (M+H)
+; Yield: 46%. 
Procedure for the synthesis of N-(3-(dimethylamino)propyl)-5-(5-(3-(5-(4-methyl-3,4-
dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiophene-2-carboxamido)phenyl)furan-2-
carboxamido)benzofuran-2-carboxamide (4.131) from 4.119 and 4.124 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.119 (1.0 eq., 58 mg) and 4.124 (2.2 eq., 55 mg) in a 9:3:1 combination of 
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EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. After completion the reaction mixture was passed through a SCX-2 
cartridge (1 gm), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.131 was released from the cartridge using 5.0 ml 2M NH3 in MeOH and 






Fluorescent yellow oil. IR (FTIR, νmax/cm-1) 692.14, 721.77, 791.11, 863.36, 959.84, 
1028.48, 1119.25, 1161.63, 1224.86, 1253.39, 1301.41, 1444.25, 1510.52, 1539.91, 1584.90, 
1651.50, 2341.46, 2358.62, 2817.07, 2871.95, 2941.73.3255.86; 1H NMR (400 MHz, 
Acetone-d6’ TMS);  1.71 - 1.85 (m, 2H), 2.23 (d, J=4.55 Hz, 6H), 2.38 - 2.44 (m, 2H), 2.93 
- 2.94 (m, 3H), 3.32 - 3.37 (m, 2H), 3.46 - 3.51 (m, 2H), 4.28 (d, J=4.29 Hz, 2H), 6.50 - 6.61 
(m, 1H), 6.73 (dd, J=8.46, 4.93 Hz, 1H), 7.01 - 7.04 (m, 1H), 7.15 - 7.20 (m, 1H), 7.27 (t, 
J=4.04 Hz, 1H), 7.34 (t, J=4.29 Hz, 1H), 7.42 (d, J=4.80 Hz, 1H), 7.52 (br. s., 1H), 7.54 (br. 
s., 1H), 7.60 (d, J=6.06 Hz, 1H), 7.65 - 7.67 (m, 1H), 7.69 (d, J=4.80 Hz, 1H), 7.83 - 7.85 (m, 
1H), 7.92 - 7.95 (m, 1H), 8.28 (br. s., 1H), 8.31 (br. s., 1H), 9.69 (br. s., 1H), 9.76 (br. s., 1H); 
13C NMR (100 MHz, Acetone-d6); δ 27.61, 38.63, 39.91, 45.70, 49.57, 58.76, 58.78, 65.63, 
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108.41, 108.70, 110.03, 110.14, 112.46, 113.31, 113.82, 114.70, 114.81, 114.94, 115.74, 
117.23, 117.61, 120.31, 121.37, 121.48, 122.65, 123.98, 128.87, 129.48, 129.59, 130.28, 
130.83, 132.73, 132.82, 145.39, 151.60, 152.47, 156.63, 159.02, 161.15; m/z (+EI) calc. For 
C39H37N5O6S (M+) 703.81, found 704.13 (M+H)
+; Yield: 70%. 
Procedure for the synthesis of 5-(5-(3-(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-
yl)thiophene-2-carboxamido)phenyl)furan-2-carboxamido)-N-(3-
(dimethylamino)propyl)benzofuran-2-carboxamide (4.132) from 4.119 and 4.126 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.119 (1.0 eq., 32 mg) and 4.126 (2.0 eq., 18 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. After completion the reaction mixture was passed through a SCX-2 
cartridge (1 gm), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.132 was released from the cartridge using 5.0 ml 2M NH3 in MeOH and 






Light brown oil. IR (FTIR, νmax/cm-1) 663.77, 733.62, 793.48, 890.92, 1025.56, 1065.97, 
1103.01, 1126.89, 1216.44, 1231.67, 1282.71, 1364.46, 1447.19, 1505.06, 1557.75, 1584.44, 
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1644.87, 1737.79, 2043.77, 2329.26, 2356.54, 2969.32, 3300.04, 3414.63; 1H NMR (400 
MHz, DMSO-d6, TMS);  1.67 (quin, J=7.07 Hz, 2H), 2.15 (s, 6H), 2.27 (t, J=6.95 Hz, 2H), 
3.27 - 3.32 (m, 2H), 4.30 (s, 4H), 6.95 (d, J=8.34 Hz, 1H), 7.14 (d, J=3.54 Hz, 1H), 7.20 - 
7.24 (m, 1H), 7.26 (d, J=2.27 Hz, 1H), 7.49 (d, J=3.79 Hz, 1H), 7.50 - 7.52 (m, 1H), 7.52 - 
7.53 (m, 1H), 7.55 (d, J=0.76 Hz, 1H), 7.67 (d, J=9.09 Hz, 1H), 7.71 - 7.75 (m, 1H), 7.75 - 
7.79 (m, 1H), 7.79 - 7.83 (m, 1H), 8.03 - 8.06 (m, 1H), 8.19 - 8.20 (m, 1H), 8.21 (d, J=1.77 
Hz, 1H), 8.80 (t, J=5.68 Hz, 1H), 10.33 (s, 1H), 10.41 (s, 1H); 13C NMR (100 MHz, DMSO-
d6); δ 26.96, 37.36, 45.16, 45.27, 56.90, 64.12, 64.24, 106.38, 109.34, 110.40, 111.71, 
114.06, 114.26, 116.31, 116.76, 117.81, 119.04, 120.15, 120.39, 120.79, 123.64, 126.41, 
127.28, 127.70, 130.42, 137.63, 143.76, 144.09, 146.76, 148.49, 150.02, 150.92, 155.09, 
156.17, 157.90, 159.87, 161.49, 162.00; m/z (+EI) calc. For C38H34N4O7S (M+) 690.76, 
found 690.98 (M+H)+; Yield: 94%. 
Procedure for the synthesis of 2-(benzofuran-5-yl)-N-(3-(5-((2-((3-
(dimethylamino)propyl)carbamoyl) benzofuran-5-yl)carbamoyl)furan-2-yl)phenyl)-4-
methylthiazole-5-carboxamide (4.133) from 4.121 and 4.128 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.121 (1.0 eq., 50 mg) and 4.128 (2.0 eq., 38 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 20 minutes. After completion, the reaction mixture was passed through a SCX-2 
cartridge (1 gm), which was washed with DCM (3x), DMF (3x) twice and finally MeOH 
(2x). The product 4.133 was released from the cartridge using 5.0 ml 2M NH3 in MeOH and 
concentrated in vacuo to obtain the crude material. The crude was purified using a silica 
column and a DCM:MeOH:2M NH3 (18:1:1)  solvent system to obtain the pure product. The 










Light yellow oil. IR (FTIR, νmax/cm-1) 630.02, 691.10, 733.62, 784.05, 1028.19, 1107.94, 
1207.37, 1237.47, 1305.91, 1435.14, 1465.50, 1540.09, 1585.10, 1651.37, 2329.26, 2358.05, 
2774.39, 2823.17, 2859.75, 2945.12, 3276.00; 1H NMR (400 MHz, Acetone-d6, TMS);  
1.75 - 1.81 (m, 2H), 2.08 - 2.15 (m, 2H), 2.24 (br. s., 6H), 2.34 - 2.50 (m, 3H), 3.47 - 3.52 (m, 
2H), 5.58 - 5.66 (m, 1H), 7.03 - 7.07 (m, 1H), 7.35 (d, J=3.03 Hz, 1H), 7.43 (br. s., 1H), 7.47 
- 7.50 (m, 1H), 7.55 (d, J=3.79 Hz, 2H), 7.61 - 7.71 (m, 1H), 7.72 - 7.78 (m, 1H), 7.83 (br. s., 
2H), 7.93 - 8.03 (m, 1H), 8.23 - 8.36 (m, 2H), 8.44 (br. s., 1H), 9.73 (d, J=13.89 Hz, 1H); 13C 
NMR (100 MHz, Acetone-d6); δ 16.32, 27.64, 37.51, 40.30, 45.73, 58.80, 106.63, 107.93, 
108.44, 108.95, 110.98, 112.14, 112.97, 117.18, 117.90, 120.13, 120.98, 121.45, 121.99, 
127.49, 129.22, 129.40, 130.23, 131.47, 136.72, 143.54, 146.94, 147.38, 150.78, 151.04, 
156.10, 156.88, 158.94, 159.11, 161.04, 161.87, 162.31, 168.07; m/z (+EI) calc. For 
C38H33N5O6S (M+) 687.76, found 687.59 (M+H)
+; Yield: 16%. 
4.1.7 Type 3 Library synthesis 
General procedure for the synthesis of 5-nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-
2-carboxamide (4.135) from 5-nitrobenzofuran-2-carboxylic acid (4.105) and 4-
(piperidin-1-yl)phenyl)methanamine (4.134) (Amide coupling) 
2.0 eq of HOBT (113 mg) and 1.75 eq. of DIC (114 µl) were added to a solution of 4.105 (1.2 
eq., 104 mg) in DCM. After 30 minutes, 1.0 eq. (80.0 mg) of 4.134 was added and the 
reaction mixture was allowed to stand for 3 hours. After completion, the reaction mixture was 
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dried using a rotary evaporator to obtain the crude product. The product 4.135 was purified 
by flash chromatography using 100% DCM as mobile phase. The pure product was 
concentrated in vacuo to obtain a bright yellow powder (140 mg). 
5-Nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (4.135): 
 
Bright yellow powder. IR (FTIR, νmax/cm-1) 608.00, 674.43, 731.49, 749.75, 767.98, 821.84, 
848.42, 900.34, 915.96, 986.39, 1040.69, 1067.76, 1125.60, 1173.83, 1227.49, 1275.81, 
1303.14, 1339.96, 1385.92, 1442.03, 1516.97, 1598.47, 1647.69, 2361.37, 2857.53, 2941.60, 
3096.52, 3316.04; 1H NMR (400 MHz, CDCl3, TMS); δ 1.55 - 1.63 (m, 2H), 1.69 - 1.73 (m, 
4H), 3.15 - 3.19 (m, 4H), 4.59 (d, J=5.81 Hz, 2H), 6.91 - 6.93 (m, 1H), 6.93 - 6.95 (m, 1H), 
7.24 - 7.26 (m, 1H), 7.27 - 7.29 (m, 1H), 7.55 - 7.58 (m, 1H), 7.60 (d, J=1.01 Hz, 1H), 8.30 - 
8.34 (m, 1H), 8.62 (dd, J=2.27, 0.51 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 24.24, 25.70, 
25.70, 43.24, 50.36, 50.36, 110.24, 112.26, 116.43, 116.43, 119.23, 122.30, 127.16, 127.95, 
129.13, 129.13, 144.75, 151.72, 151.91, 157.11, 157.40; m/z (+EI) calc. For C21H21N3O4 
(M+) 379.41, found 379.90 (M+H)+; Yield: 88%. 
 
A similar amide coupling reaction was used for synthesizing compounds 4.137 to 4.163. 
Procedure for the synthesis of 5-nitro-N-(3-(piperidin-1-yl)benzyl)benzofuran-2-
carboxamide (4.137) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.105 (1.2 eq., 196 mg) in 
DCM. After 30 minutes, 1.0 eq. (150 mg) of 4.136 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was dried using a rotary 
evaporator to obtain the crude product. The product 4.137 was purified by flash 
chromatography using 100% DCM as mobile phase. The pure product was concentrated in 







Light yellow powder. IR (FTIR, νmax/cm-1) 681.96, 718.53, 749.00, 762.53, 819.63, 862.93, 
906.60, 948.72, 992.73, 1004.41, 1027.84, 1070.65, 1118.06, 1192.30, 1244.35, 1279.61, 
1323.54, 1343.91, 1421.23, 1442.23, 1492.39, 1525.67, 1571.32, 1596.17, 1621.56, 1736.85, 
2335.91, 2359.63, 2801.03, 2857.88, 2932.70, 3095.60, 3268.47; 1H NMR (400 MHz, 
CDCl3, TMS); δ 1.57 - 1.62 (m, 2H), 1.71 (dt, J=11.18, 5.65 Hz, 4H), 3.17 - 3.21 (m, 4H), 
4.63 (d, J=5.56 Hz, 2H), 6.83 (d, J=7.58 Hz, 1H), 6.90 (dd, J=8.34, 2.53 Hz, 1H), 6.94 - 6.96 
(m, 1H), 7.24 - 7.29 (m, 2H), 7.59 (d, J=9.09 Hz, 1H), 7.63 (d, J=0.76 Hz, 1H), 8.34 (dd, 
J=9.09, 2.53 Hz, 1H), 8.63 (d, J=2.27 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 24.24, 25.79, 
25.79, 44.15, 50.42, 50.42, 110.89, 112.33, 115.75, 116.15, 118.64, 119.28, 123.37, 127.97, 
129.63, 137.98, 144.80, 151.64, 152.71, 157.15, 157.48; m/z (+EI) calc. For C21H21N3O4 
(M+) 379.41, found 380.00 (M+H)+; Yield: 67%. 
Procedure for the synthesis of 5-nitro-N-(3-(piperidin-1-ylmethyl)benzyl)benzofuran-2-
carboxamide (4.139) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.105 (1.2 eq., 195 mg) in 
DCM. After 30 minutes, 1.0 eq. (160 mg) of 4.138 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was dried using a rotary 
evaporator to obtain the crude product. The product 4.139 was purified by flash 
chromatography using 100% DCM as mobile phase. The pure product was concentrated in 






Light yellow oil. IR (FTIR, νmax/cm-1) 631.71, 683.83, 705.86, 730.93, 750.39, 821.62, 
898.70, 991.70, 1039.18, 1068.48, 1111.10, 1174.95, 1224.97, 1275.17, 1300.54, 1344.03, 
1444.32, 1521.46, 1569.73, 1600.27, 1659.35, 1711.16, 2355.29, 2756.09, 2792.68, 2835.65, 
2931.81, 3103.65, 3299.95; 1H NMR (400 MHz, CDCl3, TMS); δ 1.40 - 1.46 (m, 2H), 1.57 
(quin, J=5.62 Hz, 4H), 2.38 (br. s., 4H), 3.47 (s, 2H), 4.67 (d, J=5.81 Hz, 2H), 7.25 - 7.26 (m, 
1H), 7.28 (d, J=7.83 Hz, 2H), 7.30 - 7.33 (m, 1H), 7.34 (s, 1H), 7.57 (dt, J=9.09, 0.76 Hz, 
1H), 7.61 (d, J=1.01 Hz, 1H), 8.31 (dd, J=9.09, 2.27 Hz, 1H), 8.59 - 8.61 (m, 1H); 13C NMR 
(100 MHz, CDCl3); δ 24.20, 25.77, 30.82, 43.50, 54.47, 63.52, 110.84, 112.27, 119.20, 
122.29, 126.53, 127.87, 128.60, 128.71, 128.75, 137.15, 139.27, 144.69, 151.53, 157.09, 
157.55, 206.85; m/z (+EI) calc. For C22H23N3O4 (M+) 393.44 found 393.33 (M+H)
+; Yield: 
89%. 
Procedure for the synthesis of 5-nitro-N-(2-(piperidin-1-yl)ethyl)benzofuran-2-
carboxamide (4.141) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.105 (1.0 eq., 100 mg) in 
DCM. After 30 minutes 1.0 eq. (62 mg) of 4.140 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was dried using a rotary 
evaporator to obtain the crude product. The product 4.141 was purified by flash 
chromatography using 100% DCM as mobile phase. The pure product was concentrated in 
vacuo to obtain a yellow, viscous oil (150 mg). 
5-Nitro-N-(2-(piperidin-1-yl)ethyl)benzofuran-2-carboxamide (4.141): 
 
Yellow, viscous oil. IR (FTIR, νmax/cm-1) 631.40, 683.60, 747.94, 822.76, 897.61, 940.13, 
1069.98, 1096.85, 1127.98, 1176.98, 1275.81, 1342.86, 1445.64, 1523.21, 1599.61, 1651.54, 
2329.26, 2359.18, 2935.23, 3241.62; 1H NMR (500 MHz, CDCl3, TMS); δ 1.51 (br. s., 2H), 
1.67 (quin, J=5.60 Hz, 4H), 2.60 (br. s., 4H), 2.69 - 2.76 (m, 2H), 3.66 (q, J=5.36 Hz, 2H), 
7.25 - 7.27 (m, 1H), 7.55 (d, J=0.95 Hz, 1H), 8.28 (dd, J=9.14, 2.52 Hz, 1H), 8.58 (d, J=2.21 
Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 23.46, 23.89, 25.42, 35.66, 42.12, 54.22, 56.91, 
110.42, 112.37, 112.38, 119.11, 122.11, 127.85, 151.82, 157.18, 157.85; m/z (+EI) calc. For 
C16H19N3O4 (M+) 317.34, found 317.99 (M+H)
+; Yield: 98%. 
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Procedure for the synthesis of 5-nitro-N-(2-(pyrrolidin-1-yl)ethyl)benzofuran-2-
carboxamide (4.143) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.105 (1.0 eq., 60 mg) in 
DCM. After 30 minutes, 1.0 eq. (33 mg) of 4.142 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was dried using a rotary 
evaporator to obtain the crude product. The product 4.143 was purified by flash 
chromatography using 100% DCM as mobile phase. The pure product was concentrated in 




Yellow, viscous oil. IR (FTIR, νmax/cm-1) 631.54, 683.84, 749.27, 822.30, 1034.27, 1069.66, 
1095.59, 1170.90, 1275.71, 1342.93, 1445.92, 1523.21, 1573.61, 1599.68, 1614.31, 1653.96, 
2804.87, 2965.94, 3097.56, 3337.71, 3647.90, 3734.74; 1H NMR (500 MHz, CDCl3, TMS); δ 
1.85 - 1.90 (m, 4H), 2.72 (br. s., 4H), 2.85 (t, J=5.67 Hz, 2H), 3.67 (q, J=5.46 Hz, 2H), 7.52 
(d, J=8.83 Hz, 1H), 7.56 - 7.57 (m, 1H), 8.30 (dd, J=9.14, 2.52 Hz, 1H), 8.60 (d, J=2.21 Hz, 
1H); 13C NMR (100 MHz, CDCl3); δ 23.47, 37.82, 42.18, 50.77, 53.98, 54.60, 110.51, 
111.07, 112.42, 119.15, 122.17, 127.89, 151.78, 157.19, 157.93; m/z (+EI) calc. For 
C15H17N3O4 (M+) 303.31, found 304.04 (M+H)
+; Yield: 97%. 
Procedure for the synthesis of N-(2-morpholinoethyl)-5-nitrobenzofuran-2-carboxamide 
(4.145) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.105 (1.0 eq., 60 mg) in 
DCM. After 30 minutes, 1.0 eq. (38 mg) of 4.144 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was dried using a rotary 
evaporator to obtain the crude product. The product 4.145 was purified by flash 
chromatography using 100% DCM as mobile phase. The pure product was concentrated in 









Light yellow oil. IR (FTIR, νmax/cm-1) 637.26, 683.21, 748.84, 824.00, 860.39, 936.56, 
1034.88, 1068.93, 1113.89, 1172.89, 1234.95, 1272.65, 1304.39, 1341.33, 1445.57, 1520.17, 
1597.68, 1651.80, 2810.97, 2859.75, 2939.35, 3103.65, 3298.78, 3647.93, 3734.18; 1H NMR 
(500 MHz, CDCl3, TMS); δ 2.56 (br. s., 4H), 2.66 (t, J=5.99 Hz, 2H), 3.62 (q, J=5.88 Hz, 
2H), 3.76 - 3.80 (m, 4H), 7.23 (br. s., 1H), 7.58 - 7.61 (m, 1H), 7.64 (d, J=9.14 Hz, 1H), 8.35 
(dd, J=8.98, 2.36 Hz, 1H), 8.63 (d, J=2.21 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 23.47, 
35.59, 42.18, 53.32, 56.73, 66.91, 110.66, 112.39, 119.24, 122.28, 127.93, 144.69, 151.73, 
157.18, 157.72; m/z (+EI) calc. For C15H17N3O5 (M+) 319.31, found 319.93 (M+H)
+; Yield: 
97%. 
Procedure for the synthesis of N-(3-morpholinopropyl)-5-nitrobenzofuran-2-
carboxamide (4.147) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.105 (1.0 eq., 100 mg) in 
DCM. After 30 minutes, 1.0 eq. (70 mg) of 4.146 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was dried using a rotary 
evaporator to obtain the crude product. The product 4.147 was purified by flash 
chromatography using 100% DCM as mobile phase. The pure product was concentrated in 
vacuo to obtain a light green oil (160 mg). 
N-(3-morpholinopropyl)-5-nitrobenzofuran-2-carboxamide (4.147): 
 
Light green oil. IR (FTIR, νmax/cm-1) 608.40, 681.75, 731.38, 751.03, 767.71, 818.07, 829.06, 
864.26, 887.58, 953.91, 988.10, 1029.56, 1061.79, 1089.81, 1170.75, 1223.50, 1274.25, 
1302.82, 1338.89, 1359.75, 1439.24, 1455.69, 1516.01, 1601.22, 1659.76, 1980.26, 2354.22, 
2821.99, 2856.04, 2946.05, 3201.74; 1H NMR (400 MHz, CDCl3, TMS); δ 1.83 (dt, J=11.77, 
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5.82 Hz, 2H), 2.59 (br. s., 4H), 2.62 - 2.66 (m, 2H), 3.59 - 3.66 (m, 2H), 3.90 (t, J=4.66 Hz, 
4H), 7.58 (d, J=1.01 Hz, 1H), 7.60 (d, J=9.32 Hz, 1H), 8.34 (dd, J=9.06, 2.52 Hz, 1H), 8.63 
(d, J=2.27 Hz, 1H), 8.97 (br. s., 1H); 13C NMR (100 MHz, CDCl3); δ 23.47, 23.71, 35.10, 
40.44, 53.78, 58.77, 66.84, 110.34, 111.96, 119.26, 122.26, 128.07, 144.71, 152.34, 157.09, 
157.55; m/z (+EI) calc. For C16H19N3O5 (M+) 333.34, found 334.18 (M+H)
+; Yield: 99%. 
Procedure for the synthesis of N-(4-(dimethylamino)butyl)-5-nitrobenzofuran-2-
carboxamide (4.149) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.105 (1.0 eq., 100 mg) in 
DMF. After 30 minutes, 0.88 eq. (45 mg) of 4.148 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was purified using the 
‘catch and release’ method over a SCX cartridge. The product 4.149 was released from the 
cartridge using 10 ml 2M NH3. The pure product was concentrated in vacuo to obtain a 
colourless oil (100 mg). 
N-(4-(dimethylamino)butyl)-5-nitrobenzofuran-2-carboxamide (4.149): 
 
Colourless oil. IR (FTIR, νmax/cm-1) 425.03, 681.97, 737.24, 771.79, 814.53, 853.40, 889.80, 
956.24, 1023.76, 1065.00, 1155.70, 1170.81, 1231.20, 1264.50, 1338.62, 1441.72, 1461.00, 
1519.75, 1651.97, 2778.8, 2821.20, 2857.40, 2924.00, 3108.30; 1H NMR (400 MHz, CDCl3) 
δ 1.69 (q, J=6.13 Hz, 2H), 1.72 - 1.79 (m, 2H), 2.35 (s, 6H), 2.42 (t, J=6.42 Hz, 2H), 3.50 (q, 
J=5.79 Hz, 2H), 7.56 - 7.57 (m, 1H), 7.59 (d, J=9.06 Hz, 1H), 8.33 (dd, J=9.06, 2.52 Hz, 1H), 
8.55 (br. s., 1H), 8.62 (d, J=2.27 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 25.39, 287.40, 
39.45, 45.18, 45.29, 59.06, 110.24, 112.11, 119.19, 122.08, 128.07, 144.64, 152.41, 157.18, 
157.81; m/z (+EI) calc. For C15H19N3O4 (M+) 305.33, found (M+H)
+ 306.1; Yield: 68%. 
Procedure for the synthesis of 5-nitro-N-(3-(pyrrolidin-1-yl)propyl)benzofuran-2-
carboxamide (4.151) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.105 (1.0 eq., 100 mg) in 
DMF. After 30 minutes, 0.80 eq. (50 mg) of 4.150 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was purified using the 
‘catch and release’ method over a SCX cartridge (1 gm). The product 4.151 was released 
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from the cartridge using 10 ml 2M NH3. The pure product was concentrated in vacuo to 




Light yellow powder.  IR (FTIR, νmax/cm-1) 423.90, 566.25, 682.16, 731.76, 818.48, 895.49, 
913.85, 1004.50, 1064.83, 1143.60, 1170.77, 1261.08, 1272.24, 1292.89, 1338.73, 1439.80, 
1521.94, 1594.00, 1665.27, 2788.00, 2812.00, 2872.50, 2945.00, 2966.20, 3111.30; 1H NMR 
(400 MHz, CDCl3) δ 1.84 (dt, J=11.71, 5.98 Hz, 2H), 1.94 (dt, J=6.74, 3.30 Hz, 4H), 2.66 
(br. s., 4H), 2.74 - 2.81 (m, 2H), 3.60 - 3.67 (m, 2H), 7.52 (s, 1H), 7.54 (s, 1H), 8.32 (dd, 
J=9.19, 2.39 Hz, 1H), 8.62 (d, J=2.27 Hz, 1H), 9.35 (br. s., 1H); 13C NMR (100 MHz, 
CDCl3) δ 23.48, 23.58, 25.98, 40.42, 54.02, 54.12, 55.71, 109.96, 111.95, 119.17, 122.06, 
128.12, 144.60, 152.64, 157.20, 157.61; m/z (+EI) calc. For C16H19N3O4 (M+) 317.34, found 
(M+H)+ 318.10; Yield: 69%. 
Procedure for the synthesis of 5-nitro-N-(4-(pyrrolidin-1-yl)butyl)benzofuran-2-
carboxamide (4.153) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.105 (1.0 eq., 100 mg) in 
DMF. After 30 minutes, 0.9 eq. (62 mg) of 4.152 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was purified using the 
‘catch and release’ method over a SCX cartridge (1 gm). The product 4.153 was released 
from the cartridge using 10 ml 2M NH3. The pure product was concentrated in vacuo to 
obtain colourless solid (110 mg). 
5-Nitro-N-(4-(pyrrolidin-1-yl)butyl)benzofuran-2-carboxamide (4.153): 
 
Colourless solid. IR (FTIR, νmax/cm-1) 415.30, 487.31, 553.01, 587.97, 619.20, 687.12, 
754.24, 806.37, 892.17, 1009.24, 1056.87, 1125.38, 1289.37, 1497.32, 1505.67, 1543.02, 
1668.23, 2821.48, 2859.00, 3211.10, 3330.28; 1H NMR (400 MHz, CDCl3) δ 1.52 – 1.62 (m, 
2H), 1.68 – 1.72 (m, 4H), 1.84 – 1.95 (m, 2H), 2.50 – 2.64 (m, 4H), 3.12 (br. s., 2H), 3.60 - 
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3.67 (m, 2H), 7.57 (s, 1H), 7.84 (d, J=9.0 Hz, 1H), 8.20 (d, J=9.0 Hz, 1H), 8.56 (s, 1H); 13C 
NMR (100 MHz, CDCl3) δ 23.00, 23.51, 24.98, 27.56, 40.10, 54.58, 55.12, 56.27, 108.47, 
112.30, 116.04, 120.37, 130.56, 145.62, 150.14, 158.07, 163.30; m/z (+EI) calc. For 
C17H21N3O (M+) 331.37, found (M+H)
+ 332.10; Yield: 69%. 
Procedure for the synthesis of 5-nitro-N-(3-(piperidin-1-yl)propyl)benzofuran-2-
carboxamide (4.155) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.105 (1.0 eq., 100 mg) in 
DMF. After 30 minutes, 0.80 eq. (55 mg) of 4.154 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was purified using the 
‘catch and release’ method over a SCX cartridge (1 gm). The product 4.155 was released 
from the cartridge using 10 ml 2M NH3. The pure product was concentrated in vacuo to 
obtain light yellow powder (136g). 
5-Nitro-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide (4.155): 
 
Light yellow powder. IR (FTIR, νmax/cm-1) 422.91, 517.88, 681.44, 751.75, 819.17, 890.08, 
1062.13, 1118.69, 1170.78, 1251.20, 1340.48, 1436.80, 1515.88, 1599.37, 166151, 2760.70, 
2806.00, 2857.40, 2921.00, 3111.30; 1H NMR (400 MHz, CDCl3) δ 1.60 (br. s., 2H), 1.73 - 
1.79 (m, 4H), 1.79 - 1.84 (m, 2H), 2.54 (br. s., 4H), 2.59 - 2.63 (m, 2H), 3.57 - 3.66 (m, 2H), 
7.50 (d, J=9.06 Hz, 1H), 7.56 (d, J=1.01 Hz, 1H), 8.32 (dd, J=9.06, 2.52 Hz, 1H), 8.62 (d, 
J=2.27 Hz, 1H), 9.48 (br. s., 1 H);  13C NMR (100 MHz, CDCl3) δ 22.89, 23.47, 23.71, 24.27, 
25.71, 40.70, 42.13, 54.67, 110.00, 111.82, 119.19, 122.07, 128.13, 144.60, 152.63, 157.16, 
157.63; m/z (+EI) calc. For C17H21N3O4 (M+) 331.37, found (M+H)
+ 332.0; Yield: 85%. 
Procedure for the synthesis of N-(2-(4-methylpiperazin-1-yl)ethyl)-5-nitrobenzofuran-2-
carboxamide (4.157) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.105 (1.0 eq., 100 mg) in 
DMF. After 30 minutes, 0.9 eq. (62 mg) of 4.156 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was purified using the 
‘catch and release’ method over a SCX cartridge (1 gm). The product 4.157 was released 
from the cartridge using 10 ml 2M NH3. The pure product was concentrated in vacuo to 





Light yellow oil. IR (FTIR, νmax/cm-1) 424.01, 587.40, 681.92, 731.18, 751.55, 819.27, 
890.27, 913.85, 953.15, 977.33, 1068.00, 1119.38, 1171.27, 1255.40, 1305.30, 1339.75, 
1439.80, 1516.34, 1600.21, 1662.08, 2739.50, 2766.80, 2812.00, 2851.40, 2921.00, 3108.30, 
3223.20, 3335.00; 1H NMR (400 MHz, CDCl3) δ 2.32 - 2.35 (m, 2H), 2.52 (br. s., 4H), 2.58 
(br. s., 3H), 2.64 (br. s., 2H), 2.64 - 2.67 (m, 2H), 3.60 (q, J=5.62 Hz, 2H), 7.21 - 7.26 (m, 
1H), 7.55 - 7.60 (m, 1H), 7.65 (d, J=9.32 Hz, 1H), 8.35 (dd, J=9.06, 2.52 Hz, 1H), 8.63 (d, 
J=2.52 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 23.47, 26.68, 35.95, 45.98, 52.78, 55.10, 
56.14, 110.54, 112.39, 119.22, 122.23, 127.97, 144.70, 151.86, 157.20, 157.69; m/z (+EI) 
calc. For C16H20N4O4 (M+) 332.35, found (M+H)
+ 333.1; Yield: 88%. 
Procedure for the synthesis of ethyl 5-(5-bromofuran-2-carboxamido)benzofuran-2-
carboxylate (4.159) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.158 (1.0 eq., 200 mg) in 
DCM. After 30 minutes, 2.0 eq. (186 mg) of 4.41 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was dried using a rotary 
evaporator to obtain the crude product. The product 4.159 was purified by flash 
chromatography using 100% DCM as mobile phase. The pure product was concentrated in 
vacuo to obtain brown oil (267 mg). 
Ethyl 5-(5-bromofuran-2-carboxamido)benzofuran-2-carboxylate (4.159): 
 
Brown oil. IR (FTIR, νmax/cm-1) 439.30, 493.68, 545.09, 662.97, 736.31, 806.02, 816.02, 
880.60, 919.90, 950.13, 1009.50, 1095.20, 1110.30, 1179.71, 1213.00, 1313.29, 1394.59, 
1478.40, 1560.00, 1665.48, 1712.46, 2470.50, 2497.70, 2902.80, 2969.30, 2987.40, 3117.40, 
3350.10; 1H NMR (400 MHz, Methanol-d4) δ 1.40 (t, J=7.05 Hz, 3H), 4.40 (q, J=7.05 Hz, 
2H), 6.65 (d, J=3.53 Hz, 1H), 7.25 (d, J=3.53 Hz, 1H), 7.57 (s, 2H), 7.68 (dd, J=8.94, 2.14 
Hz, 1H), 8.12 (d, J=2.27 Hz, 1H); 13C NMR (100 MHz, Methanol-d4) δ 14.92, 62.99, 113.42, 
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115.30, 115.84, 116.63, 118.88, 123.82, 127.36, 128.87, 135.57, 148.14, 151.05, 154.59, 
158.09, 161.17; m/z (+EI) calc. For C16H12BrNO5 (M+) 378.12, found (M+H)
+ 380.10; Yield: 
72%. 
Procedure for the synthesis of N-(2-(2-methylthiazol-4-yl)ethyl)-5-nitrobenzofuran-2-
carboxamide (4.161) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.105 (1.0 eq., 100 mg) in 
DCM. After 30 minutes, 0.9 eq. (62 mg) of 4.160 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was purified using the 
‘catch and release’ method over a SCX cartridge (1 gm). The product 4.161 was released 
from the cartridge using 10 ml 2M NH3. The pure product was concentrated in vacuo to 
obtain light yellow powder (159 mg). 
N-(2-(2-methylthiazol-4-yl)ethyl)-5-nitrobenzofuran-2-carboxamide (4.161): 
 
Light yellow powder. IR (FTIR, νmax/cm-1) 402.67, 428.73, 568.70, 683.67, 737.32, 767.53, 
820.50, 891.05, 960.33, 1067.35, 1132.00, 1179.91, 1234.50, 1274.45, 1311.33, 1340.26, 
1445.40, 1516.52, 1531.93, 1578.00, 1599.00, 1651.48, 1620.00, 1689.40, 3042.00, 3114.30, 
3216.70, 3349.30; 1H NMR (400 MHz, CDCl3) δ 2.76 (s, 3H), 3.05 (t, J=6.42 Hz, 2H), 3.81 - 
3.86 (m, 2H), 6.88 (d, J=0.76 Hz, 1H), 7.58 (d, J=0.76 Hz, 1H), 7.59 - 7.63 (m, 1H), 8.31 - 
8.35 (m, 1H), 8.61 - 8.62 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 19.16, 23.40, 42.07, 
110.42, 112.28, 114.16, 119.21, 122.21, 127.94, 151.90, 153.43, 157.17, 157.23, 157.72, 
166.53; m/z (+EI) calc. For C15H13N3O4S (M+) 331.35, found (M+H)
+ 331.90; Yield: 99%. 
Procedure for the synthesis of N-(2-(dimethylamino)ethyl)-5-nitrobenzofuran-2-
carboxamide (4.163) 
2.0 eq of HOBT and 1.75 eq. of DIC were added to a solution of 4.105 (1.0 eq., 100 mg) in 
DCM. After 30 minutes, 0.9 eq. (38 mg) of 4.162 was added and the reaction mixture was 
allowed to stand for 3 hours. After completion, the reaction mixture was purified using the 
‘catch and release’ method over a SCX cartridge (1 gm). The product 4.163 was released 
from the cartridge using 10 ml 2M NH3. The pure product was concentrated in vacuo to 






Light yellow powder. IR (FTIR, νmax/cm-1) 423.63, 496.73, 551.13, 569.27, 611.59, 682.93, 
726.45, 745.91, 825.92, 889.67, 944.08, 965.24, 1041.04, 1104.30, 1122.40, 1167.80, 
1237.30, 1262.99, 1292.44, 1340.72, 1437.17, 1497.13, 1523.40, 1599.14, 1670.85, 2772.80, 
2784.9, 2824.20, 2857.40, 2942.00, 2969.30, 3114.40, 3392.40; 1H NMR (400 MHz, CDCl3) 
δ 2.33 (s, 6H), 2.59 (t, J=5.92 Hz, 2H), 3.59 (q, J=5.37 Hz, 2H), 7.57 (d, J=1.01 Hz, 1H), 
7.62 (d, J=9.06 Hz, 1H), 8.33 (dd, J=9.19, 2.39 Hz, 1H), 8.61 (d, J=2.52 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δ 36.70, 45.16, 45.16, 57.54, 110.49, 112.41, 119.17, 122.19, 127.94, 
144.64, 151.84, 157.20, 157.78; m/z (+EI) calc. For C13H15N3O4 (M+) 277.28, found (M+H)
+ 
278.10; Yield: 97%. 
General procedure for the synthesis of 5-amino-N-(4-(piperidin-1-yl)benzyl)benzofuran-
2-carboxamide (4.164) from 5-nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-
carboxamide (4.135) by hydrogenation. 
5-Nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (1.0 eq., 113 mg) (4.135) was 
dissolved in a minimum amount of ethanol (25 ml) and a catalytic amount of 10% Pd/C (20 
mg) was added as a slurry, also in ethanol. The reaction mixture was shaken for 1.5-2.5 hours 
at 45 psi in a Parr hydrogenator. After completion of the reduction, the suspension was 
filtered through a layer of celite, with caution, using a Buchner flask and the filtrate was 
concentrated to obtain a light brown viscous oil (4.164) (104 mg). Pd/C waste was discarded 





Light brown oil. IR (FTIR, νmax/cm-1) 732.74, 804.97, 857.88, 919.38, 1026.00, 1044.26, 
1128.77, 1158.02, 1231.67, 1298.26, 1327.23, 1383.60, 1452.22, 1474.74, 1512.93, 1583.30, 
1646.33, 1731.49, 2359.93, 2804.87, 2847.56, 2930.66, 3336.41; 1H NMR (400 MHz, 
CDCl3, TMS); δ 1.57 - 1.62 (m, 2H), 1.71 (quin, J=5.62 Hz, 4H), 3.14 - 3.19 (m, 4H), 4.56 
(d, J=5.56 Hz, 2H), 6.78 (dd, J=8.84, 2.27 Hz, 2H), 6.88 - 6.91 (m, 1H), 6.93 (d, J=8.59 Hz, 
2H), 7.21 - 7.24 (m, 1H), 7.26 (d, J=7.07 Hz, 2H), 7.33 (d, J=1.01 Hz, 1H); 13C NMR (100 
MHz, CDCl3); δ 24.56, 26.03, 26.03, 39.58, 43.30, 50.89, 103.16, 106.88, 110.26, 112.29, 
115.78, 116.69, 116.87, 128.83, 129.36, 143.07, 149.21, 149.48, 149.62, 152.04, 159.04; m/z 
(+EI) calc. For C21H23N3O2 (M+) 349.43, found 349.23 (M+H)
+; Yield: 100%. 
A similar hydrogenation process was followed for the synthesis of compounds 4.165 to 4.177 
as mentioned below. 
Procedure for the synthesis of 5-amino-N-(3-(piperidin-1-yl)benzyl)benzofuran-2-
carboxamide (4.165) 
5-Nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (1.0 eq., 170 mg) (4.137) was 
dissolved in a minimum amount of ethanol (35 ml) and a catalytic amount of 10% Pd/C (17 
mg) was added as a slurry, also in ethanol. The reaction mixture was shaken for 1.5-2.5 hours 
at 45 psi in a Parr hydrogenator. After completion of the reduction, the suspension was 
filtered through a layer of celite, with caution, using a Buchner flask and the filtrate was 
concentrated to obtain a light brown, viscous oil (4.165) (120 mg). Pd/C waste was discarded 
following the standard procedure of the university described earlier in the chapter. 
5-Amino-N-(3-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (4.165): 
 
Light brown viscous mass. IR (FTIR, νmax/cm-1) 630.11, 694.14, 733.75, 776.13, 855.09, 
921.90, 952.27, 994.79, 1128.18, 1158.78, 1243.33, 1301.51, 1353.14, 1450.99, 1476.87, 
1519.98, 1586.98, 1651.21, 2363.94, 2804.87, 2847.56, 2931.97, 3325.96; 1H NMR (400 
MHz, CDCl3, TMS); δ 1.56 - 1.62 (m, 2H), 1.71 (dt, J=11.24, 5.75 Hz,4H), 3.15 - 3.21 (m, 
4H), 4.60 (d, J=5.81 Hz, 2H), 6.79 (dd, J=8.72, 2.40 Hz, 1H), 6.83 (d, J=7.33 Hz, 1H), 6.87 - 
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6.90 (m, 1H), 6.91 (dd, J=2.53, 0.51 Hz, 1H), 6.95 (s, 1H), 7.22 - 7.24 (m, 1H), 7.24 - 7.27 
(m, 1H), 7.34 (d, J=0.76 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 24.26, 25.80, 25.81, 43.87, 
50.51, 50.52, 106.57, 110.03, 112.02, 115.83, 116.13, 116.42, 118.71, 128.51, 129.48, 
138.52, 142.78, 145.39, 149.09, 149.33, 158.78; m/z (+EI) calc. For C21H23N3O2 (M+) 
349.43, found 349.01 (M+H)+; Yield: 77%. 
Procedure for the synthesis of 5-amino-N-(3-(piperidin-1-ylmethyl)benzyl)benzofuran-
2-carboxamide (4.166) 
5-Nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (1.0 eq., 100 mg) (4.139) was 
dissolved in a minimum amount of ethanol (25 ml) and a catalytic amount of 10% Pd/C (10 
mg) was added as a slurry, also in ethanol. The reaction mixture was shaken for 1.5-2.5 hours 
at 45 psi in a Parr hydrogenator. After completion of the reduction, the suspension was 
filtered through a layer of celite, with caution, using a Buchner flask and the filtrate was 
concentrated to obtain a colourless, viscous mass (4.166) (63 mg). Pd/C waste was discarded 
following the standard procedure of the university described earlier in the chapter. 
5-Amino-N-(3-(piperidin-1-ylmethyl)benzyl)benzofuran-2-carboxamide (4.166): 
 
Colourless, viscous mass. IR (FTIR, νmax/cm-1) 631.85, 702.51, 802.98, 858.45, 993.18, 
1039.03, 1112.04, 1160.99, 1239.43, 1299.10, 1361.23, 1477.42, 1520.42, 1580.91, 1649.95, 
1708.38, 2798.78, 2847.56, 2933.49, 3331.44; 1H NMR (400 MHz, CDCl3, TMS); δ 1.41 - 
1.48 (m, 2H), 1.60 (quin, J=5.62 Hz, 4H), 2.41 (br. s., 4H), 3.50 (s, 2H), 4.65 (d, J=6.06 Hz, 
2H), 6.79 (dd, J=8.84, 2.27 Hz, 1H), 6.90 - 6.92 (m, 2H), 7.25 (d, J=8.84 Hz, 1H), 7.29 (d, 
J=7.58 Hz, 2H), 7.34 (br. s., 1H), 7.35 (d, J=0.76 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 
24.21, 25.71, 30.88, 43.32, 54.47, 63.55, 77.20, 106.60, 110.17, 112.00, 116.50, 126.65, 
128.49, 128.61, 128.72, 128.88, 137.73, 138.78, 142.78, 148.98, 149.35, 158.91; m/z (+EI) 
calc. For C22H25N3O2 (M+) 363.45, found 364.12 (M+H)





Procedure for the synthesis of 5-amino-N-(2-(piperidin-1-yl)ethyl)benzofuran-2-
carboxamide (4.167) 
5-Nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (1.0 eq., 150 mg) (4.141) was 
dissolved in a minimum amount of ethanol (25 ml) and a catalytic amount of 10% Pd/C (15 
mg) was added as a slurry, also in ethanol. The reaction mixture was shaken for 1.5-2.5 hours 
at 45 psi in a Parr hydrogenator. After completion of the reduction, the suspension was 
filtered through a layer of celite, with caution, using a Buchner flask and the filtrate was 
concentrated to obtain a light brown oil (4.167) (134 mg). Pd/C waste was discarded 
following the standard procedure of the university described earlier in the chapter. 
5-Amino-N-(2-(piperidin-1-yl)ethyl)benzofuran-2-carboxamide (4.167): 
 
Light brown oil. IR (FTIR, νmax/cm-1) 745.15, 809.54, 865.62, 957.87, 1043.72, 1090.91, 
1129.07, 1165.74, 1242.60, 1303.60, 1325.43, 1360.35, 1383.35, 1456.02, 1577.87, 1615.12, 
1647.72, 1709.67, 1732.75, 2358.94, 2931.49, 2966.59, 3336.21; 1H NMR (500 MHz, 
CDCl3, TMS); δ 1.50 (br. s., 2H), 1.67 (quin, J=5.60 Hz, 4H), 2.61 (br. s., 4H), 2.72 (t, 
J=5.67 Hz, 2H), 3.64 (q, J=5.88 Hz, 2H), 6.76 (dd, J=8.83, 2.21 Hz, 1H), 6.87 (d, J=2.21 Hz, 
1H), 7.18 (d, J=8.51 Hz, 1H), 7.25 - 7.30 (m, 2H); 13C NMR (100 MHz, CDCl3); δ 23.47, 
23.85, 25.26, 35.56, 42.12, 54.23, 57.13, 106.45, 109.66, 112.10, 116.29, 128.38, 142.60, 
149.16, 149.36, 159.18; m/z (+EI) calc. For C16H21N3O2 (M+) 287.36, found 287.87 (M+H)
+; 
Yield: 99%. 
Procedure for the synthesis of 5-amino-N-(2-(pyrrolidin-1-yl)ethyl)benzofuran-2-
carboxamide (4.168) 
5-Nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (1.0 eq., 80 mg) (4.143) was 
dissolved in a minimum amount of ethanol (25 ml) and a catalytic amount of 10% Pd/C (10 
mg) was added as a slurry, also in ethanol. The reaction mixture was shaken for 1.5-2.5 hours 
at 45 psi in a Parr hydrogenator. After completion of the reduction, the suspension was 
filtered through a layer of celite, with caution, using a Buchner flask and the filtrate was 
concentrated to obtain a light brown oil (4.168) (70 mg). Pd/C waste was discarded following 






Light brown oil. IR (FTIR, νmax/cm-1) 639.47, 745.76, 851.20, 936.02, 1045.22, 1093.04, 
1164.42, 1208.19, 1242.12, 1301.53, 1382.70, 1453.88, 1475.18, 1522.15, 1583.94, 1617.35, 
1646.12, 1733.50, 2329.26, 2360.62, 2798.78, 2871.95, 2932.92, 2966.50, 3337.73; 1H NMR 
(500 MHz, CDCl3, TMS); δ 1.86 (dt, J=6.46, 3.39 Hz, 4H), 2.70 (br. s., 4H), 2.82 (t, J=5.99 
Hz, 2H), 3.63 (q, J=5.89 Hz, 2H), 6.77 (dd, J=8.67, 2.36 Hz, 1H), 6.88 (d, J=2.21 Hz, 1H), 
7.21 - 7.26 (m, 2H), 7.29 (d, J=0.95 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 23.71, 23.73, 
37.96, 42.41, 54.26, 55.06, 106.74, 109.99, 112.36, 116.56, 128.67, 142.89, 149.43, 149.60, 
159.45; m/z (+EI) calc. For C15H19N3O2 (M+) 273.33, found 273.01 (M+H)
+; Yield: 97%. 
Procedure for the synthesis of 5-amino-N-(2-morpholinoethyl)benzofuran-2-
carboxamide (4.169) 
5-Nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (1.0 eq., 85 mg) (4.145) was 
dissolved in a minimum amount of ethanol (25 ml) and a catalytic amount of 10% Pd/C (10 
mg) was added as a slurry, also in ethanol. The reaction mixture was shaken for 1.5-2.5 hours 
at 45 psi in a Parr hydrogenator. After completion of the reduction. the suspension was 
filtered through a layer of celite, with caution, using a Buchner flask and the filtrate was 
concentrated to obtain a brown oil (4.169) (70 mg). Pd/C waste was discarded following the 
standard procedure of the university described earlier in the chapter. 
5-Amino-N-(2-morpholinoethyl)benzofuran-2-carboxamide (4.169): 
 
Brown oil. IR (FTIR, νmax/cm-1) 632.69, 747.19, 807.52, 857.95, 935.17, 1045.39, 1114.07, 
1146.63, 1163.00, 1208.45, 1301.96, 1361.11, 1454.23, 1476.05, 1522.16, 1583.94, 1645.97, 
1732.90, 2335.36, 2810.97, 2859.75, 2967.14, 3334.37; 1H NMR (500 MHz, CDCl3, TMS); δ 
2.57 (br. s., 4H), 2.65 (t, J=6.15 Hz, 2H), 3.57 - 3.63 (m, 2H), 3.75 - 3.79 (m, 4H), 6.79 (dd, 
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J=8.67, 2.36 Hz, 1H), 6.89 (dd, J=2.21, 0.63 Hz, 1H), 7.26 - 7.28 (m, 2H), 7.29 (d, J=0.95 
Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 23.45, 35.39, 42.12, 53.29, 56.97, 66.76, 106.50, 
109.82, 112.03, 116.36, 128.41, 142.72, 149.09, 149.30, 159.06; m/z (+EI) calc. For 
C15H19N3O3 (M+) 289.33, found 289.02 (M+H)
+; Yield: 91%. 
Procedure for the synthesis of 5-amino-N-(3-morpholinopropyl)benzofuran-2-
carboxamide (4.170) 
5-Nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (1.0 eq., 180 mg) (4.147) was 
dissolved in a minimum amount of ethanol (25 ml) and a catalytic amount of 10% Pd/C (20 
mg) was added as a slurry, also in ethanol. The reaction mixture was shaken for 1.5-2.5 hours 
at 45 psi in a Parr hydrogenator. After completion of the reduction, the suspension was 
filtered through a layer of celite, with caution, using a Buchner flask and the filtrate was 
concentrated to obtain a light brown viscous oil (4.170) (160 mg). Pd/C waste was discarded 
following the standard procedure of the university described earlier in the chapter. 
5-Amino-N-(3-morpholinopropyl)benzofuran-2-carboxamide (4.170): 
 
Light yellow oil. IR (FTIR, νmax/cm-1) 690.95, 800.41, 832.64, 859.99, 896.24, 911.72, 
919.67, 961.36, 983.85, 1029.91, 1072.11, 1129.99, 1153.90, 1208.56, 1242.79, 1266.55, 
1292.30, 1360.10, 1342.03, 1455.24, 1474.70, 1522.95, 1582.71, 1618.43, 1654.22, 2013.55, 
2357.79, 2818.34, 2951.52, 3340.12, 3434.10; 1H NMR (400 MHz, CDCl3, TMS); δ 1.78 (dt, 
J=11.90, 6.01 Hz, 2H), 2.54 (br. s., 4H), 2.56 - 2.60 (m, 2H), 3.54 - 3.60 (m, 2H), 3.86 (t, 
J=4.66 Hz, 4H), 6.77 (dd, J=8.69, 2.39 Hz, 1H), 6.89 (d, J=2.27 Hz, 1H), 7.25 (d, J=2.52 Hz, 
1H), 8.65 (br. s., 1H); 13C NMR (100 MHz, CDCl3); δ 23.45, 24.04, 39.97, 42.12, 53.76, 
58.64, 66.75, 106.62, 109.49, 111.72, 116.22, 128.56, 142.74, 149.20, 149.66, 158.90; m/z 
(+EI) calc. For C16H21N3O3 (M+) 303.36, found 303.45 (M+H)
+; Yield: 98%. 
Procedure for the synthesis of 5-amino-N-(4-(dimethylamino)butyl)benzofuran-2-
carboxamide (4.171) 
5-Nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (1.0 eq., 100 mg) (4.149) was 
dissolved in a minimum amount of ethanol (25 ml) and a catalytic amount of 10% Pd/C (10 
mg) was added as a slurry, also in ethanol. The reaction mixture was shaken for 1.5-2.5 hours 
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at 45 psi in a Parr hydrogenator. After completion of the reduction, the suspension was 
filtered through a layer of celite, with caution, using a Buchner flask and the filtrate was 
concentrated to obtain a light brown oil (4.171) (81 mg). Pd/C waste was discarded following 
the standard procedure of the university described earlier in the chapter. 
5-Amino-N-(4-(dimethylamino)butyl)benzofuran-2-carboxamide (4.171): 
 
Light brown oil. IR (FTIR, νmax/cm-1) 429.04, 518.60, 562.05, 615.46, 732.61, 807.58, 
1019.6, 1164.70, 1206.97, 1241.29, 1306.80, 1454.78, 1478.58, 1531.65, 1584.87, 1639.00, 
2778.8, 2824.2, 2863.50, 2939.00, 3332.00; 1H NMR (400 MHz, CDCl3) δ; 1.63 - 1.68 (m, 
2H), 1.68 - 1.74 (m, 2H), 2.33 (s, 6H), 2.42 (t, J=6.67 Hz, 2H), 3.48 (q, J=6.29 Hz, 2H), 6.79 
(dd, J=8.69, 2.39 Hz, 1H), 6.91 (d, J=2.52 Hz, 1H), 7.27 - 7.28 (m, 1H), 7.29 (d, J=0.76 Hz, 
1H), 7.84 (br. s., 1H); 13C NMR (100 MHz, CDCl3) δ 20.83, 27.76, 39.47, 45.39, 45.41, 
59.31, 106.92, 109.83, 112.21, 112.84, 116.47, 128.89, 142.99, 149.93, 159.06; m/z (+EI) 
calc. For C15H21N3O2 (M+) 275.35, found (M+H)
+ 276.1; Yield: 90%. 
Procedure for the synthesis of 5-amino-N-(3-(pyrrolidin-1-yl)propyl)benzofuran-2-
carboxamide (4.172) 
5-Nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (1.0 eq., 100 mg) (4.151) was 
dissolved in a minimum amount of ethanol (25 ml) and a catalytic amount of 10% Pd/C (10 
mg) was added as a slurry, also in ethanol. The reaction mixture was shaken for 1.5-2.5 hours 
at 45 psi in a Parr hydrogenator. After completion of the reduction, the suspension was 
filtered through a layer of celite, with caution, using a Buchner flask and the filtrate was 
concentrated to obtain a colourless oil (4.172) (90 mg). Pd/C waste was discarded following 





Colourless oil. IR (FTIR, νmax/cm-1) 428.48, 519.74, 571.26, 614.54, 731.89, 749.11, 807.30, 
859.45, 1161.70, 1210.00, 1242.62, 1300.80, 1454.31, 1475.64, 1524.20, 1583.61, 1638.63, 
2803.00, 2878.60, 2930.00, 2957.20, 3232.20, 3335.00; 1H NMR (400 MHz, CDCl3) δ 1.85 
(dt, J=12.15, 6.14 Hz, 2H), 1.89 - 1.98 (m, 4H), 2.69 (br. s., 4H), 2.77 (t, J=6.17 Hz, 2H), 
3.56 - 3.63 (m, 2H), 6.78 (dd, J=8.69, 2.39 Hz, 1H), 6.90 (d, J=2.52 Hz, 1H), 7.24 (d, J=8.81 
Hz, 1H), 8.71 (br. s., 1H); 13C NMR (100 MHz, CDCl3) δ 23.33, 23.48, 26.51, 50.91, 53.97, 
54.31, 59.11, 104.25, 106.60, 109.24, 111.82, 116.10, 128.60, 142.61, 149.34, 154.99; m/z 
(+EI) calc. For C16H21N3O (M+) 287.36, found (M+H)
+ 288.10; Yield: 99%. 
Procedure for the synthesis of 5-amino-N-(4-(pyrrolidin-1-yl)butyl)benzofuran-2-
carboxamide (4.173) 
5-Nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (1.0 eq., 100 mg) (4.153) was 
dissolved in a minimum amount of ethanol (25 ml) and a catalytic amount of 10% Pd/C (10 
mg) was added as a slurry, also in ethanol. The reaction mixture was shaken for 1.5-2.5 hours 
at 45 psi in a Parr hydrogenator. After completion of the reduction, the suspension was 
filtered through a layer of celite, with caution, using a Buchner flask and the filtrate was 
concentrated to obtain a light yellow powder (4.173) (85 mg). Pd/C waste was discarded 
following the standard procedure of the university described earlier in the chapter. 
5-Amino-N-(4-(pyrrolidin-1-yl)butyl)benzofuran-2-carboxamide (4.173): 
 
Light yellow powder. IR (FTIR, νmax/cm-1) 416.34, 564.89, 678.00, 725.24, 809.64, 946.27, 
1009.49, 1079.28, 1197.34, 1342.00, 1469.31, 1507.60, 1534.00, 1687.01, 1732.08, 
2764.058, 2834.00, 2964.32; 1H NMR (400 MHz, CDCl3) δ 1.52 – 1.62 (m, 2H), 1.68 – 1.72 
(m, 4H), 1.84 – 1.97 (m, 2H), 2.50 – 2.64 (m, 4H), 3.12 (br. s., 2H), 3.60 - 3.67 (m, 2H), 6.39 
(d, J=9.0 Hz, 1H), 7.41 (d, J=9.0 Hz, 1H), 7.59 (s, 1H), 7.65 (s, 1H); 13C NMR (100 MHz, 
CDCl3) δ 23.00, 23.51, 24.98, 27.56, 40.10, 54.58, 55.12, 56.27, 108.47, 112.30, 116.04, 
120.37, 130.56, 145.62, 150.14, 158.07, 163.30; m/z (+EI) calc. For C17H23N3O2 (M+) 




Procedure for the synthesis of 5-amino-N-(3-(piperidin-1-yl)propyl)benzofuran-2-
carboxamide (4.174) 
5-Nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (1.0 eq., 130 mg) (4.155) was 
dissolved in a minimum amount of ethanol (25 ml) and a catalytic amount of 10% Pd/C (15 
mg) was added as a slurry, also in ethanol. The reaction mixture was shaken for 1.5-2.5 hours 
at 45 psi in a Parr hydrogenator. After completion of the reduction, the suspension was 
filtered through a layer of celite, with caution, using a Buchner flask and the filtrate was 
concentrated to obtain a colourless oil (4.174) (45 mg). Pd/C waste was discarded following 
the standard procedure of the university described earlier in the chapter. 
5-Amino-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide (4.174): 
 
Colourless oil. IR (FTIR, νmax/cm-1) 429.22, 519.24, 614.89, 729.66, 805.38, 856.42, 913.85, 
962.22, 1040.80, 1089.20, 1125.40, 1159.32, 1208.82, 1243.96, 1297.70, 1453.63, 1474.84, 
1521.02, 1583.60, 1640.04, 2766.80, 2812.00, 2857.40, 2933.00, 3226.20, 3341.00; 1H NMR 
(400 MHz, CDCl3) δ ppm 1.23 - 1.29 (m, 2H), 1.55 (br. s., 2H), 1.72 - 1.77 (m, 4H), 1.78 - 
1.83 (m, 2H), 2.52 (br. s., 2H), 2.56 - 2.60 (m, 2H), 3.53 - 3.59 (m, 2H), 6.75 - 6.79 (m, 1H), 
6.90 (d, J=2.27 Hz, 1H), 7.18 - 7.22 (m, 1H), 7.28 (d, J=0.76 Hz, 1H), 8.98 (br. s., 1H); 13C 
NMR (100 MHz, CDCl3) δ 23.51, 24.21, 24.28, 25.47, 40.06, 42.11, 54.62, 58.66, 106.67, 
109.31, 111.72, 116.14, 128.65, 142.66, 149.33, 149.89, 159.07; m/z (+EI) calc. For 
C17H23N3O2 (M+) 301.38, found (M+H)
+ 302.20; Yield: 38%. 
Procedure for the synthesis of 5-amino-N-(2-(4-methylpiperazin-1-yl)ethyl)benzofuran-
2-carboxamide (4.175) 
5-Nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (1.0 eq., 130 mg) (4.157) was 
dissolved in a minimum amount of ethanol (25 ml) and a catalytic amount of 10% Pd/C (13 
mg) was added as a slurry, also in ethanol. The reaction mixture was shaken for 1.5-2.5 hours 
at 45 psi in a Parr hydrogenator. After completion of the reduction, the suspension was 
filtered through a layer of celite, with caution, using a Buchner flask and the filtrate was 
concentrated to obtain a light brown oil (4.175) (112 mg). Pd/C waste was discarded 





Light brown oil. IR (FTIR, νmax/cm-1) 428.83, 519.83, 614.36, 729.61, 753.00, 805.33, 
1038.70, 1089.90, 1123.00, 1159.20, 1208.58, 1243.81, 1300.80, 1453.79, 1474.69, 1521.54, 
1583.66, 1639.52, 2810.00, 2852.20, 2936.60, 3231.80, 3346.30; 1H NMR (400 MHz, 
CDCl3) δ 2.31 (s, 3H), 2.37 - 2.59 (m, 8H), 2.59 - 2.62 (m, 2H), 3.54 (q, J=5.96 Hz, 2H), 6.77 
(dd, J=8.94, 2.39 Hz, 1H), 6.88 (d, J=2.27 Hz, 1H), 7.08 (br. s., 1H), 7.28 - 7.30 (m, 1H); 13C 
NMR (100 MHz, CDCl3) δ 23.51, 26.78, 35.89, 45.88, 52.68, 55.00, 56.44, 106.59, 109.79, 
112.08, 116.36, 128.52, 142.76, 149.27, 149.37, 159.07; m/z (+EI) calc. For C16H22N4O (M+) 
302.37, found (M+H)+ 303.10; Yield: 95%. 
Procedure for the synthesis of 5-amino-N-(2-(2-methylthiazol-4-yl)ethyl)benzofuran-2-
carboxamide (4.176) 
5-Nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (1.0 eq., 150 mg) (4.161 was 
dissolved in a minimum amount of ethanol (25 ml) and a catalytic amount of 10% Pd/C (15 
mg) was added as a slurry, also in ethanol. The reaction mixture was shaken for 1.5-2.5 hours 
at 45 psi in a Parr hydrogenator. After completion of the reduction, the suspension was 
filtered through a layer of celite, with caution, using a Buchner flask and the filtrate was 
concentrated to obtain a colourless oil (4.176) (130 mg). Pd/C waste was discarded following 
the standard procedure of the university described earlier in the chapter. 
5-Amino-N-(2-(2-methylthiazol-4-yl)ethyl)benzofuran-2-carboxamide (4.176): 
 
Colourless oil. IR (FTIR, νmax/cm-1) 432.79, 612.62, 631.97, 755.94, 792.94, 819.88, 865.29, 
1059.70, 1129.49, 1158.79, 1235.998, 1303.80, 1321.80, 1385.10, 1453.09, 1522.15, 
1561.45, 1617.00, 1637.45, 2918.50, 2966.70, 3334.20; 1H NMR (400 MHz, CDCl3) δ 2.74 
(s, 3H), 3.04 (t, J=6.55 Hz, 2H), 3.79 - 3.82 (m, 2H), 6.79 (dd, J=8.69, 2.39 Hz, 1H), 6.86 (s, 
1H), 6.89 - 6.90 (m, 1H), 7.28 (s, 1H), 7.29 (d, J=1.01 Hz, 1H); 13C NMR (100 MHz, CDCl3) 
δ 19.17, 23.47, 42.07, 106.54, 109.68, 111.98, 114.00, 116.32, 128.47, 142.70, 149.25, 
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153.60, 156.99, 159.03, 166.14; m/z (+EI) calc. For C15H15N3O2S (M+) 301.36, found 
(M+H)+ 302.00; Yield: 95%. 
Procedure for the synthesis of 5-amino-N-(2-(dimethylamino)ethyl)benzofuran-2-
carboxamide (4.177) 
5-Nitro-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (1.0 eq., 120 mg) (4.163) was 
dissolved in a minimum amount of ethanol (25 ml) and a catalytic amount of 10% Pd/C (12 
mg) was added as a slurry, also in ethanol. The reaction mixture was shaken for 1.5-2.5 hours 
at 45 psi in a Parr hydrogenator. After completion of the reduction, the suspension was 
filtered through a layer of celite, with caution, using a Buchner flask and the filtrate was 
concentrated to obtain a light brown, viscous oil (4.177) (105 mg). Pd/C waste was discarded 
following the standard procedure of the university described earlier in the chapter. 
5-Amino-N-(2-(dimethylamino)ethyl)benzofuran-2-carboxamide (4.177): 
 
Colourless oil. IR (FTIR, νmax/cm-1) 432.79, 612.62, 631.97, 755.94, 792.94, 819.88, 865.29, 
1059.70, 1129.49, 1158.79, 1235.998, 1303.80, 1321.80, 1385.10, 1453.09, 1522.15, 
1561.45, 1617.00, 1637.45, 2918.50, 2966.70, 3334.20; 1H NMR (400 MHz, CDCl3) δ 3.04 
(t, J=6.55 Hz, 2H), 3.79 - 3.82 (m, 2H), 6.79 (dd, J=8.69, 2.39 Hz, 1H), 6.86 (s, 1H), 6.89 - 
6.90 (m, 1H), 7.28 (s, 1H), 7.29 (d, J=1.01 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 19.17, 
23.47, 42.07, 106.54, 109.68, 111.98, 114.00, 116.32, 128.47, 142.70, 149.25, 153.60, 
156.99, 159.03, 166.14; m/z (+EI) calc. For C13H17N3O2 (M+) 247.29, found (M+H)
+ 247.00; 
Yield: 98%. 
General procedure for the synthesis of (5-bromofuran-2-carboxamido)benzofuran-2-
carboxylic acid (4.178) from ethyl 5-(5-bromofuran-2-carboxamido)benzofuran-2-
carboxylate (4.159) by hydrolysis 
Ethyl 5-(5-bromofuran-2-carboxamido)benzofuran-2-carboxylate (267 mg, 1 eq.) (4.159) was 
dissolved in equal volumes of 1,4-dioxane and 0.5M NaOH (5 ml + 5 ml) in a round bottom 
flask. This reaction mixture was stirred for 3.0 hours at which point LCMS and TLC showed 
completion of the reaction. The reaction mixture was then diluted with 10.0 ml of distilled 
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water and 0.5M HCL acid solution was added drop by drop to reach a pH near 3.0. At this 
point, the product (4.178) precipitated and was collected by filtering on a sintered funnel. The 
pink powder was scraped from the funnel and dried overnight in a vacuum oven at 40 ºC. The 
final weight of the dried product was 208 mg.  
(5-Bromofuran-2-carboxamido)benzofuran-2-carboxylic acid (4.178): 
 
Light pink powder. IR (FTIR, νmax/cm-1) 420.58, 457.43, 543.29, 611.59, 740.94, 790.56, 
876.66, 942.62, 1034.80, 1110.30, 1182.71, 1227.81, 1340.00, 1406.70, 1473.32, 1565.30, 
1593.81, 1655.13, 2491.70, 2917.90, 3093, 3365.20; 1H NMR (400 MHz, Methanol-d4) δ 
6.65 - 6.68 (m, 1H), 7.27 (d, J=3.53 Hz, 1H), 7.53 (s, 1H), 7.57 (d, J=9.06 Hz, 1H), 7.69 (dd, 
J=8.94, 2.14 Hz, 1H), 8.11 (d, J=2.27 Hz, 1H); 13C NMR (100 MHz, Methanol-d4) δ 113.15, 
114.35, 115.62, 116.46, 118.64, 123.30, 135.14, 137.23, 146.06, 149.47, 154.36, 157.96, 
161.67, 165.32; m/z (+EI) calc. For C14H8BrNO5 (M+) 350.12, found (M+H)
+ 351.90; Yield: 
84%. 
Amide coupling was used to obtain the following intermediates (4.179 to 4.194). 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(4-(piperidin-1-
yl)benzyl)benzofuran-2-carboxamide (4.179) from 5-amino-N-(4-(piperidin-1-
yl)benzyl)benzofuran-2-carboxamide (4.164) and 5-bromofuran-2-carboxylic acid (4.41) 
97 mg (1.0 eq.) 4.164, 80 mg (1.50 eq.) 4.41, 2.0 eq. HOBt and 1.75 eq. DIC were mixed in a 
round bottomed flask to which a minimum amount of DCM was added to make a clear 
solution. The reaction mixture was then stirred for 3 hours. In between, the progress of the 
reaction was checked using LCMS. When the reaction was completed after 3 hours the 
mixture was dried using a rotary evaporator and the product dried in a vacuum. The product 
4.179 was then purified using a silica column with a DCM:ethylacetate solvent systems of 









Bright yellow oil. IR (FTIR, νmax/cm-1) 630.36, 700.21, 733.62, 781.24, 802.60, 865.75, 
922.28, 946.81, 1010.97, 1100.52, 1125.37, 1167.24, 1201.39, 1234.31, 1359.23, 1466.33, 
1514.09, 1567.77, 1614.10, 1657.00, 1710.07, 2329.26, 2359.13, 2935.98, 2963.41, 3339.21; 
1H NMR (400 MHz, CDCl3, TMS); δ 1.61 (q, J=5.89 Hz, 2H), 1.78 (dt, J=11.37, 5.68 Hz, 
4H), 3.20 - 3.24 (m, 4H), 3.77 (dt, J=13.01, 6.38 Hz, 2H), 4.59 (d, J=5.56 Hz, 2H), 6.43 (d, 
J=3.54 Hz, 1H), 6.51 (d, J=3.54 Hz, 1H), 7.04 - 7.07 (m, 2H), 7.13 (d, J=3.54 Hz, 1H), 7.22 
(d, J=3.54 Hz, 1H), 7.41 (d, J=8.84 Hz, 1H), 7.47 (d, J=1.01 Hz, 1H), 7.57 (dd, J=8.97, 2.15 
Hz, 1H), 8.06 (d, J=2.02 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 23.23, 23.60, 25.09, 42.49, 
42.97, 52.06, 110.69, 112.02, 113.80, 114.17, 114.61, 117.66, 117.82, 119.65, 120.47, 
124.98, 126.29, 126.83, 128.01, 129.16, 149.18, 149.48, 151.87, 157.88, 158.63, 160.79; m/z 
(+EI) calc. For C26H24BrN3O4 (M+) 522.39, found 523.87 (M+H)
+; Yield: 90%. 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(3-(piperidin-1-
yl)benzyl)benzofuran-2-carboxamide (3.180) from 5-amino-N-(3-(piperidin-1-
yl)benzyl)benzofuran-2-carboxamide (3.165) and 5-bromofuran-2-carboxylic acid (3.41) 
112 mg (1.0 eq.) 4.165, 92 mg (1.50 eq.) 4.41, 2.0 eq. HOBt and 1.75 eq. DIC were mixed in 
a round bottomed flask to which a minimum amount of DCM was added to make a clear 
solution. The reaction mixture was then stirred for 3 hours. In between, the progress of the 
reaction was checked using LCMS. When the reaction was completed after 3 hours the 
mixture was dried using a rotary evaporator and the product dried in a vacuum. The product 
4.180 was then purified using a silica column and DCM:ethylacetate solvent systems of 









Orange, viscous mass. IR (FTIR, νmax/cm-1) 630.60, 747.98, 865.74, 923.99, 1045.20, 
1129.01, 1166.98, 1243.73, 1324.91, 1360.25, 1383.75, 1462.31, 1521.54, 1559.65, 1613.65, 
2358.91, 2929.33.2966.77, 3337.38; 1H NMR (400 MHz, CDCl3, TMS); δ 1.56 - 1.62 (m, 
2H), 1.71 (dt, J=11.18, 5.65 Hz, 4H), 3.15 - 3.21 (m, 4H), 4.62 (d, J=5.56 Hz, 2H), 6.53 (dd, 
J=3.54, 0.51 Hz, 1H), 6.84 (d, J=7.83 Hz, 1H), 6.88 - 6.92 (m, 1H), 6.95 (s, 1H), 7.22 (dd, 
J=3.54, 0.51 Hz, 1H), 7.44 - 7.47 (m, 1H), 7.49 (s, 1H), 7.57 (dd, J=8.84, 2.27 Hz, 1H), 7.69 
(d, J=8.84 Hz, 1H), 7.91 (d, J=8.59 Hz, 1H), 8.09 (d, J=2.27 Hz, 1H), 8.11 (s, 1H); 13C NMR 
(100 MHz, CDCl3); δ 23.45, 24.24, 25.78, 42.23, 50.51, 50.54, 112.07, 114.08, 114.67, 
117.65, 120.30, 124.47, 124.91, 129.54, 133.24, 135.47, 137.29, 137.62, 138.34, 139.83, 
140.94, 147.50, 149.68, 155.00, 157.03, 158.44; m/z (+EI) calc. For C26H24BrN3O4 (M+) 
522.39, found 523.74 (M+H)+; Yield: 89.58%. 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(3-(piperidin-1-
ylmethyl)benzyl)benzofuran-2-carboxamide (4.181) from 5-amino-N-(3-(piperidin-1-
ylmethyl)benzyl)benzofuran-2-carboxamide (4.166) and 5-bromofuran-2-carboxylic 
acid (4.41) 
59 mg (1.0 eq.) 4.166, 46 mg (1.50 eq.) 4.41, 2.0 eq. HOBt and 1.75 eq. DIC were mixed in a 
round bottomed flask to which a minimum amount of DCM was added to make a clear 
solution. The reaction mixture was then stirred for 3 hours. In between, the progress of the 
reaction was checked using LCMS. When the reaction was completed after 3 hours the 
mixture was dried using a rotary evaporator and the product dried in a vacuum. The product 
4.181 was then purified using a silica column and DCM:ethylacetate solvent systems of 







Brown, viscous mass. IR (FTIR, νmax/cm-1) 632.88, 744.08, 806.50, 865.66, 923.54, 944.49, 
1012.57, 1098.86, 1129.15, 1167.57, 1245.67, 1324.92, 1360.04, 1383.64, 1463.05, 1565.72, 
1614.10, 1659.33, 2926.82, 2967.03, 3338.39; 1H NMR (400 MHz, CDCl3, TMS); δ 2.89 (m, 
2H), 2.96 (s, 2H), 3.49 (s, 4H), 3.80 (dt, J=12.95, 6.54 Hz, 4H), 4.55 (d, J=6.06 Hz, 1H), 6.46 
- 6.52 (m, 1H), 7.17 - 7.19 (m, 1H), 7.29 - 7.31 (m, 1H), 7.32 - 7.33 (m, 1H), 7.35 (dd, 
J=5.81, 1.26 Hz, 1H), 7.37 - 7.40 (m, 1H), 7.45 (d, J=0.76 Hz, 1H), 7.49 (dd, J=8.97, 2.15 
Hz, 1H), 7.64 - 7.68 (m, 2H), 7.80 - 7.84 (m, 2H), 8.01 - 8.04 (m, 1H); 13C NMR (100 MHz, 
CDCl3); δ 22.72, 23.36, 31.48, 36.51, 42.33, 50.78, 55.25, 110.60, 112.13, 113.67, 114.35, 
118.21, 122.11, 126.24, 127.95, 128.21, 128.83, 129.18, 130.03, 133.01, 139.45, 142.27, 
149.26, 151.93, 155.06, 157.32, 158.98; m/z (+EI) calc. For C27H26BrN3O4 (M+) 536.42, 
found 537.58 (M+H)+; Yield: 63%. 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(2-(piperidin-1-
yl)ethyl)benzofuran-2-carboxamide (4.182) from 5-amino-N-(2-(piperidin-1-
yl)ethyl)benzofuran-2-carboxamide (4.167) and 5-bromofuran-2-carboxylic acid (4.41) 
130 mg (1.0 eq.) 4.167, 129 mg (1.50 eq.) 4.41, 2.0 eq. HOBt and 1.75 eq. DIC were mixed 
in a round bottomed flask in which a minimum amount of DCM was added to make a clear 
solution. The reaction mixture was then stirred for 3 hours. In between, the progress of the 
reaction was checked using LCMS. When the reaction was completed after 3 hours it was 
dried using a rotary evaporator and the residue dried in a vacuum. The product 4.182 was 
then purified using a silica column and DCM:ethyl acetate as the solvent system of different 







Brown, viscous oil. IR (FTIR, νmax/cm-1) 631.14, 740.72, 807.85, 925.21, 1029.33, 1105.98, 
1203.85, 1237.87, 1301.03, 1350.38, 1462.47, 1541.35, 1586.51, 1651.73, 2201.22, 2323.17, 
2359.75, 2810.97, 2934.03, 3290.65; 1H NMR (500 MHz, CDCl3, TMS); δ 1.47 - 1.52 (m, 
2H), 1.64 (quin, J=5.60 Hz, 4H), 2.47 (br. s., 4H), 2.56 - 2.61 (m, 2H), 3.57 (q, J=5.88 Hz, 
2H), 6.53 (d, J=3.78 Hz, 1H), 7.22 (d, J=3.78 Hz, 1H), 7.44 (d, J=0.95 Hz, 1H), 7.52 (d, 
J=8.83 Hz, 1H), 7.58 (dd, J=8.83, 2.21 Hz, 1H), 8.08 (d, J=1.89 Hz, 2H); 13C NMR (100 
MHz, CDCl3); δ 23.46, 24.35, 26.00, 30.94, 35.99, 54.32, 56.97, 110.14, 112.14, 113.95, 
114.68, 117.64, 120.03, 124.86, 128.16, 132.98, 149.21, 150.04, 151.89, 154.95, 158.63; m/z 
(+EI) calc. For C21H22BrN3O4 (M+) 460.32, found 461.49 (M+H)
+; Yield: 66%. 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(2-(pyrrolidin-1-
yl)ethyl)benzofuran-2-carboxamide (4.183) from 5-amino-N-(2-(pyrrolidin-1-
yl)ethyl)benzofuran-2-carboxamide (4.168) and 5-bromofuran-2-carboxylic acid (4.41) 
70 mg (1.0 eq.) 4.168, 73 mg (1.50 eq.) 4.41, 2.0 eq. HOBt and 1.75 eq. DIC were mixed in a 
round bottomed flask in which a minimum amount of DCM was added to make a clear 
solution. The reaction mixture was then stirred for 3 hours. In between, the progress of the 
reaction was checked using LCMS. When the reaction was completed after 3 hours it was 
dried using a rotary evaporator and the residue dried in a vacuum. The product 4.183 was 
then purified using a silica column and DCM:ethylacetate solvent systems of different 






Light yellow viscous oil. IR (FTIR, νmax/cm-1)658.41, 739.93, 747.93, 757.97, 791.79, 
810.73, 849.88, 864.54, 882.30, 925.33, 938.77, 960.55, 1031.30, 1105.85, 1135.00, 1169.21, 
1205.89, 1223.16, 1240.07, 1279.43, 1308.79, 1337.97, 1354.97, 1436.07, 1460.66, 1569.95, 
1593.26, 1638.43, 1650.22, 2335.36, 2357.05, 2803.26, 2871.95, 2939.62, 3311.23; 1H NMR 
(500 MHz, CDCl3, TMS); δ 1.84 (dt, J=7.01, 3.27 Hz, 4H), 2.57 - 2.63 (m, 4H), 2.74 (t, 
J=6.15 Hz, 2H), 3.58 - 3.63 (m, 2H), 6.53 (d, J=3.47 Hz, 1H), 7.15 (t, J=5.04 Hz, 1H), 7.22 
(d, J=3.47 Hz, 1H), 7.45 (d, J=0.95 Hz, 1H), 7.50 - 7.53 (m, 1H), 7.56 - 7.60 (m, 1H), 8.07 
(br. s., 1H), 8.08 (d, J=1.89 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 23.80, 24.40, 38.33, 
40.75, 54.23, 54.86, 110.48, 112.42, 114.22, 114.94, 117.91, 120.31, 125.12, 128.43, 133.24, 
149.47, 150.24, 152.13, 155.20, 158.95; m/z (+EI) calc. For C20H20BrN3O4 (M+) 446.29, 
found 445.98 (M+H)+; Yield: 98%. 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(2-
morpholinoethyl)benzofuran-2-carboxamide (4.184) from 5-amino-N-(2-
morpholinoethyl)benzofuran-2-carboxamide (4.169) and 5-bromofuran-2-carboxylic 
acid (4.41) 
70 mg (1.0 eq.) 4.169, 69 mg (1.50 eq.) 4.41, 2.0 eq. HOBt and 1.75 eq. DIC were mixed in a 
round bottomed flask in which a minimum amount of DCM was added to make a clear 
solution. The reaction mixture was then stirred for 3 hours. In between, the progress of the 
reaction was checked using LCMS. When the reaction was completed after 3 hours it was 
dried using a rotary evaporator and dried in a vacuum. The product 4.184 was then purified 
using a silica column and DCM:ethylacetate solvent systems of different polarities. Finally, 




Light yellow oil. IR (FTIR, νmax/cm-1) 615.82, 657.68, 750.47, 792.38, 807.91, 866.04, 
912.80, 965.19, 1006.70, 1067.97, 1112.31, 1172.63, 1217.73, 1287.83, 1311.12, 1342.18, 
1459.43, 1519.63, 1537.85, 1592.94, 149.90, 2335.36, 2356.42, 2810.97, 2859.75, 2947.35, 
3316.47; 1H NMR (500 MHz, CDCl3, TMS); δ 2.54 (br. s., 4H), 2.63 (t, J=6.15 Hz, 2H), 3.57 
- 3.63 (m, 2H), 3.78 (t, J=4.57 Hz, 4H), 6.53 (d, J=3.78 Hz, 1H), 7.23 (d, J=3.47 Hz, 1H), 
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7.46 (d, J=0.95 Hz, 1H), 7.52 (d, J=8.83 Hz, 1H), 7.59 (dd, J=8.83, 2.21 Hz, 1H), 8.10 (d, 
J=2.21 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 35.56, 35.60, 53.36, 56.89, 66.99, 67.01, 
110.37, 112.12, 114.00, 114.69, 117.68, 120.15, 124.89, 128.14, 133.06, 149.18, 149.84, 
151.86, 154.96, 158.63; m/z (+EI) calc. For C20H20BrN3O5 (M+) 462.29, found 461.96 
(M+H)+; Yield: 94%. 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(3-
morpholinopropyl)benzofuran-2-carboxamide (4.185) from 5-amino-N-(3-
morpholinopropyl)benzofuran-2-carboxamide (4.170) 5-bromofuran-2-carboxylic acid 
(4.41) 
160 mg (1.0 eq.) 4.170, 201 mg (2.0 eq.) 4.41, 2.0 eq. HOBt and 1.75 eq. DIC were mixed in 
a round bottomed flask in which a minimum amount of DCM was added to make a clear 
solution. The reaction mixture was then stirred for 3 hours. In between, the progress of the 
reaction was checked using LCMS. When the reaction was completed after 3 hours it was 
dried using a rotary evaporator and the residue dried in a vacuum. The product 4.185 was 
then purified using a silica column and DCM:MeOH solvent systems of different polarities. 




 Light brown oil. IR (FTIR, νmax/cm-1) 627.74, 711.22, 746.50, 761.76, 791.89, 806.52, 
861.61, 913.75, 927.07, 956.92, 987.27, 1028.60, 1067.84, 1104.38, 1132.80, 1171.94, 
1204.03, 1223.18, 1276.02, 1301.46, 1359.58, 1465.78, 1551.11, 1572.36, 1587.57, 1667.37, 
1755.58, 2361.59, 2809.69, 2875.54, 2923.38, 3316.40, 3537.21; 1H NMR (400 MHz, 
CDCl3, TMS); δ 1.82 (dt, J=11.83, 5.92 Hz, 2H), 2.58 (br. s., 4H), 2.60 - 2.64 (m, 2H), 3.57 - 
3.65 (m, 2H), 3.90 (t, J=4.53 Hz, 4H), 6.52 (d, J=3.53 Hz, 1H), 7.22 (d, J=3.53 Hz, 1H), 7.44 
(d, J=1.01 Hz, 1H), 7.47 (d, J=9.06 Hz, 1H), 7.56 (dd, J=8.94, 2.14 Hz, 1H), 8.11 (d, J=2.01 
Hz, 1H), 8.14 (s, 1H), 8.78 (t, J=4.28 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 23.47, 23.96, 
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40.16, 53.80, 58.73, 66.82, 74.41, 110.08, 111.14, 114.17, 114.66, 117.65, 120.14, 124.87, 
128.24, 133.06, 150.35, 151.35, 151.77, 155.00, 158.52; m/z (+EI) calc. For C21H22BrN3O5 
(M+) 476.32, found 475.77 (M+H)+; Yield: 48%. 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(4-
(dimethylamino)butyl)benzofuran-2-carboxamide (4.186) from 5-amino-N-(4-
(dimethylamino)butyl)benzofuran-2-carboxamide (4.171) and 5-bromofuran-2-
carboxylic acid (4.41) 
71 mg (1.0 eq.) 4.171, 123 mg (2.50 eq.) 4.41, 2.0 eq. HOBt and 1.75 eq. DIC were mixed in 
a round bottomed flask in which a minimum amount of DMF was added to make a clear 
solution. The reaction mixture was then stirred for 3 hours. In between, the progress of the 
reaction was checked using LCMS. When the reaction was completed after 3 hours it was 
poured over an Isolute SCX (2 gm) cartridge for purification. The product 4.186 was then 
purified using the ‘catch and release’ method and the product was released from the cartridge 




Light brown oil. IR (FTIR, νmax/cm-1) 428.84, 569.57, 735.64, 803.56, 924.18, 957.32, 
1014.6, 1102.0, 1235.18, 1298.54, 1436.96, 1462.23, 1536.26, 1569.04, 1586.57,  1645.55, 
2780.0, 2825.1, 2855.2, 2924.5, 3265.0; 1H NMR (400 MHz, CDCl3) δ 1.66 (q, J=6.55 Hz, 
2H), 1.69 - 1.76 (m, 2H), 2.29 - 2.32 (m, 6H), 2.37 (t, J=6.55 Hz, 2H), 3.49 (q, J=6.04 Hz, 
2H), 6.53 (dd, J=3.53, 0.50 Hz, 1H), 7.22 (dd, J=3.53, 0.50 Hz, 1H), 7.43 (d, J=1.01 Hz, 1H), 
7.44 - 7.48 (m, 1H), 7.58 (dd, J=8.94, 2.14 Hz, 1H), 8.07 (d, J=2.27 Hz, 1H), 8.11 (s, 1H), 
8.18 (br. s., 1H); 13C NMR (100 MHz, CDCl3) δ 25.51, 27.51, 39.39, 45.31, 45.32, 59.19, 
109.98,111.88, 114.03, 114.66, 117.63, 119.98, 124.86, 129.37, 132.24, 132.98, 149.23, 
150.36, 151.84, 158.71; m/z (+EI) calc. For C20H22BrN3O4 (M+) 448.31, found (M+H)
+ 
449.8; Yield: 66%. 
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Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(3-(pyrrolidin-1-
yl)propyl)benzofuran-2-carboxamide (4.187) from 5-amino-N-(3-(pyrrolidin-1-
yl)propyl)benzofuran-2-carboxamide (4.172) and 5-bromofuran-2-carboxylic acid (4.41) 
85 mg (1.0 eq.) 4.172, 141 mg (2.50 eq.) 4.41, 2.0 eq. HOBt and 1.75 eq. DIC were mixed in 
a round bottomed flask in which a minimum amount of DMF was added to make a clear 
solution. The reaction mixture was then stirred for 3 hours. In between, the progress of the 
reaction was checked using LCMS. When the reaction was completed after 3 hours it was 
poured over an Isolute SCX (2 gm) cartridge for purification. The product 4.187 was then 
purified using the ‘catch and release’ method and the product was released from the cartridge 




Light brown oil. IR (FTIR, νmax/cm-1) 431.07, 431.07, 569.50, 729.72, 801.71, 865.50, 
925.94, 1010.60, 1101.30, 1167.81,m 1202.57, 1237.55, 1296.87, 1346.00, 1460.34, 1528.14, 
1568.46, 1645.86, 1742.00, 2851.40, 2918.83, 3271.50; 1H NMR (400 MHz, CDCl3) δ 1.82 
(dt, J=11.71, 5.98 Hz, 2H), 1.89 - 1.96 (m, 4H), 2.63 (br. s., 4H), 2.71 - 2.77 (m, 2H), 3.58 - 
3.64 (m, 2H), 6.52 (d, J=3.53 Hz, 1H), 7.22 (d, J=3.53 Hz, 1H), 7.40 (d, J=1.01 Hz, 1H), 7.41 
- 7.44 (m, 1H), 7.57 (dd, J=8.94, 2.14 Hz, 1H), 8.06 (d, J=2.27 Hz, 1H), 8.12 (s, 1H) 9.04 (br. 
s., 1H); 13C NMR (100 MHz, CDCl3) δ 23.56, 23.59, 26.39, 40.19, 54.07, 54.09, 55.71, 
109.71, 111.79, 114.07, 114.68, 117.64, 119.98, 124.88, 128.30, 132.96, 150.67, 151.91, 
153.82, 155.03, 158.58; m/z (+EI) calc. For C21H22BrN3O4 (M+) 460.32, found (M+H)
+ 
460.10; Yield: 66%. 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(4-(pyrrolidin-1-
yl)butyl)benzofuran-2-carboxamide (4.188) from 5-amino-N-(4-(pyrrolidin-1-
yl)butyl)benzofuran-2-carboxamide (4.173) and 5-bromofuran-2-carboxylic acid (4.41)  
112 mg (1.0 eq.) 4.173, 177 mg (2.50 eq.) 4.41, 2.0 eq. HOBt and 1.75 eq. DIC were mixed 
in a round bottomed flask in which a minimum amount of DMF was added to make a clear 
solution. The reaction mixture was then stirred for 3 hours. In between, the progress of the 
reaction was checked using LCMS. When the reaction was completed after 3 hours it was 
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poured over an Isolute SCX (2 gm) cartridge for purification. The product 4.188 was then 
purified using the ‘catch and release’ method and the product was released from the cartridge 




Dark brown oil. IR (FTIR, νmax/cm-1) 429.14, 629.22, 728.10, 798.84, 909.12, 921.17, 
1011.50, 1102.00, 1123.00, 1168.20, 1202.05, 1240.14, 1295.68, 1349.00, 1435.83, 1460.78, 
1525.87, 1569.04, 1585.54, 16454.16, 1737.60, 2855.20, 2924.50, 3274.00; 1H NMR (400 
MHz, CDCl3) δ 1.60 – 1.69 (m, 2H), 1.75 – 1.85 (m, 4H), 1.90 – 2.10 (m, 2H), 2.30 – 2.44 
(m, 4H), 3.12 – 3.25 (m, 2H), 3.60 - 3.67 (br. s., 2H), 6.74 (d, J=3.9 Hz, 1H), 7.29 (d, J=3.9 
Hz, 1H), 7.59 (s, 1H), 7.57 (d, J=9.0 Hz, 1H), 7.65 (d, J=9.0 Hz, 1H), 8.03 (s, 1H), 8.83 (s, 
1H), 9.03 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 23.0, 23.08, 25.27, 27.34, 40.12, 54.36, 
56.07, 57.34, 107.89, 111.23, 112.56, 113.37, 117.54, 118.01, 122.45, 130.0, 132.28, 149.67, 
150.27, 152.64, 158.37, 162.45; m/z (+EI) calc. For C22H24BrN3O4 (M+) 474.35, found 
(M+H)+ 474.00; Yield: 76%. 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(3-(piperidin-1-
yl)propyl)benzofuran-2-carboxamide (4.189) from 5-amino-N-(3-(piperidin-1-
yl)propyl)benzofuran-2-carboxamide (4.174) and 5-bromofuran-2-carboxylic acid (4.41) 
39 mg (1.0 eq.) 4.174, 62 mg (2.50 eq.) 4.41, 2.0 eq. HOBt and 1.75 eq. DIC were mixed in a 
round bottomed flask in which a minimum amount of DMF was added to make a clear 
solution. The reaction mixture was then stirred for 3 hours. In between, the progress of the 
reaction was checked using LCMS. When the reaction was completed after 3 hours it was 
poured over an Isolute SCX (2 gm) cartridge for purification. The product 4.189 was then 
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purified using the ‘catch and release’ method and the product was released from the cartridge 




Brown oil. IR (FTIR, νmax/cm-1) 429.52, 692.22, 795.86, 862.67, 963.35, 1011.50, 1039.92, 
1099.00, 1165.20, 1201.67, 1237.50, 1296.17, 1346.00, 1462.51, 1531.25, 1585.34, 1645.39, 
2770.9, 2810.00, 2855.20, 2933.05, 3274.00; 1H NMR (400 MHz, Methanol-d4) δ 1.50 (br. s., 
2H), 1.65 (quin, J=5.67 Hz, 4H), 1.84 (quin, J=7.05 Hz, 2H), 2.12 - 2.14 (m, 2H), 2.45 - 2.50 
(m, 4H), 3.45 (t, J=6.67 Hz, 2H), 6.66 (d, J=3.53 Hz, 1H), 7.26 (d, J=3.53 Hz, 1H), 7.44 (d, 
J=0.76 Hz, 1H), 7.53 (d, J=8.81 Hz, 1H), 7.69 (dd, J=8.94, 2.14 Hz, 1H), 8.08 (d, J=2.01 Hz, 
1H); 13C NMR (100 MHz, Methanol-d4) δ 25.54, 26.88, 27.18, 31.04, 39.80, 40.83, 55.89, 
58.67, 111.60, 113.09, 115.84, 116.54, 118.87, 123.16, 124.67, 129.38, 134.57, 135.48, 
151.35, 153.87, 158.13, 161.28; m/z (+EI) calc. For C22H24BrN3O4 (M+) 474.35, found 
(M+H)+ 475.70; Yield: 81%. 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(2-(4-
methylpiperazin-1-yl)ethyl)benzofuran-2-carboxamide (4.190) from 5-amino-N-(2-(4-
methylpiperazin-1-yl)ethyl)benzofuran-2-carboxamide (4.175) and 5-bromofuran-2-
carboxylic acid (4.41) 
102 mg (1.0 eq.) 4.175, 161 mg (2.50 eq.) 4.41, 2.0 eq. HOBt and 1.75 eq. DIC were mixed 
in a round bottomed flask in which a minimum amount of DMF was added to make a clear 
solution. The reaction mixture was then stirred for 3 hours. In between, the progress of the 
reaction was checked using LCMS. When the reaction was completed after 3 hours it was 
poured over an Isolute SCX (2 gm) cartridge for purification. The product 4.190 was then 
purified using the ‘catch and release’ method and the product was released from the cartridge 








Light brown oil. IR (FTIR, νmax/cm-1) 418.60, 427.81, 569.76, 594.81, 609.96, 628.54, 
738.59, 801.50, 919.90, 1007.60, 1104.30, 1149.60, 1167.80, 1204.00, 1237.30, 1283.72, 
1349.10, 1460.03, 1536.50, 1569.16, 1586.01, 1644.98, 2809.00, 2945.00, 3283.60; 1H NMR 
(400 MHz, Methanol-d4) δ 2.12 - 2.19 (m, 4H), 2.32 (s, 3H), 2.54 (m,  4H), 2.64 (t, J=6.67 
Hz, 2H), 3.54 - 3.59 (m, 2H), 6.67 (d, J=3.53 Hz, 1H), 7.27 (d, J=3.53 Hz, 1H), 7.46 (d, 
J=1.01 Hz, 1H), 7.55 - 7.60 (m, 1H), 7.68 - 7.73 (m, 1H), 8.08 (d, J=2.01 Hz, 1H); 13C NMR 
(100 MHz, Methanol-d4) δ 31.05, 34.01, 37.72, 46.32, 54.01, 56.00, 58.39, 111.68, 113.20, 
115.84, 116.55, 118.31, 118.88, 120.07, 123.21, 127.37, 129.35, 137.88, 151.10, 151.27, 
153.92; m/z (+EI) calc. For C21H23BrN4O4 (M+) 475.34, found (M+H)
+ 475.00; Yield: 81%. 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(4-
(morpholinomethyl)phenyl)benzofuran-2-carboxamide (4.192) from 5-(5-bromofuran-2-
carboxamido)benzofuran-2-carboxylic acid (4.178) and 4-(morpholinomethyl)aniline 
(4.191) 
70 mg (1.0 eq.) 4.178, 35 mg (0.90 eq.) 4.191, 2.0 eq. HOBt and 1.75 eq. DIC were mixed in 
a round bottomed flask in which a minimum amount of DMF was added to make a clear 
solution. The reaction mixture was then stirred for 3 hours. In between, the progress of the 
reaction was checked using LCMS. When the reaction was completed after 3 hours it was 
poured over an Isolute SCX (2 gm) cartridge for purification. The product 4.192 was then 
purified using the ‘catch and release’ method and the product was released from the cartridge 









Light yellow oil. IR (FTIR, νmax/cm-1) 443.01, 463.23, 496.31, 561.57, 580.52, 598.99, 
614.15, 737.42, 746.84, 793.63, 805.50, 827.54, 913.85, 953.15, 998.49, 1034.80, 1104.30, 
1240.30, 1325.00, 1400.50, 1436.80, 1470.00, 1515.40, 1584.90, 1606.00, 1651.40, 2464.50, 
2803.00, 2917.90, 2957.20, 3335.00; 1H NMR (400 MHz, METHANOL-d4) δ 2.47 (br. s., 
4H), 3.51 - 3.56 (m, 2H), 3.67 - 3.70 (m, 4H), 6.69 (d, J=8.06 Hz, 1H), 7.07 (d, J=8.56 Hz, 
1H), 7.20 (m, J=8.56 Hz, 2H), 7.24 - 7.28 (m, 2H), 7.43 (m, J=8.56 Hz, 2H) 8.83 (s, 1H); 13C 
NMR (100 MHz, METHANOL-d4) δ 54.52, 55.71, 64.50, 67.21, 67.34, 108.54, 110.27, 
112.38, 113.25, 115.97, 117.64, 120.31, 121.13, 122.65, 129.67, 129.84, 130.04, 132.58, 
134.09, 136.27, 149.08, 150.70, 152.38, 160.38, 162.13; m/z (+EI) calc. For C25H22BrN3O5 
(M+) 524.36, found (M+H)+ 525.80; Yield: 34%. 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(2-(2-methylthiazol-
4-yl)ethyl)benzofuran-2-carboxamide (4.193) from 5-amino-N-(2-(2-methylthiazol-4-
yl)ethyl)benzofuran-2-carboxamide (4.176) and 5-bromofuran-2-carboxylic acid (4.41) 
125 mg (1.0 eq.) 4.176, 198 mg (2.5 eq.) 4.41, 2.0 eq. HOBt and 1.75 eq. DIC were mixed in 
a round bottomed flask in which a minimum amount of DMF was added to make a clear 
solution. The reaction mixture was then stirred for 3 hours. In between, the progress of the 
reaction was checked using LCMS. When the reaction was completed after 3 hours it was 
poured over an Isolute SCX (2 gm) cartridge for purification. The product 4.193 was then 
purified using the ‘catch and release’ method and the product was released from the cartridge 









Colourless powder. IR (FTIR, νmax/cm-1) 423.83, 479.58, 625.01, 741.08, 820.62, 854.90, 
872.97, 927.20, 951.30, 1041.70, 1108.00, 1132.00, 1177.20, 1240.50, 1343.00, 1402.82, 
1426.56, 1448.26, 1466.36, 1551.25, 1567.82, 1590.64, 1638.27, 2460.60, 2502.80, 2927.50, 
2966.70, 3340.30; 1H NMR (400 MHz, CDCl3) δ 2.74 (s, 3H), 3.05 (t, J=6.55 Hz, 2H), 3.78 - 
3.82 (m, 2H), 6.52 (d, J=3.53 Hz, 1H), 6.89 (s, 1H), 7.22 (d, J=3.78 Hz, 1H), 7.42 - 7.44 (m, 
1H), 7.47 (s, 1H), 7.58 (dd, J=8.81, 2.27 Hz, 1H), 7.72 (d, J=8.56 Hz, 1H), 8.07 (d, J=2.01 
Hz, 1H), 8.18 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 19.05, 23.36, 42.42, 110.32, 112.09, 
114.11, 114.28, 114.69, 117.69, 120.28, 124.97, 126.78, 133.08, 149.22, 149.81, 151.92, 
153.31, 155.08, 158.81, 166.70; m/z (+EI) calc. For C20H16BrN3O4S (M+) 474.33, found 
(M+H)+ 476.10; Yield: 83%. 
Procedure for the synthesis of 5-(5-bromofuran-2-carboxamido)-N-(2-
(dimethylamino)ethyl)benzofuran-2-carboxamide (4.194) from 5-amino-N-(2-
(dimethylamino)ethyl)benzofuran-2-carboxamide (4.177) and 5-bromofuran-2-
carboxylic acid (4.41) 
101 mg (1.0 eq.) 4.177, 195 mg (2.5 eq.) 4.41, 2.0 eq. HOBt and 1.75 eq. DIC were mixed in 
a round bottomed flask in which a minimum amount of DMF was added to make a clear 
solution. The reaction mixture was then stirred for 3 hours. In between, the progress of the 
reaction was checked using LCMS. When the reaction was completed after 3 hours it was 
poured over an Isolute SCX (2 gm) cartridge for purification. The product 4.195 was then 
purified using the ‘catch and release’ method and the product was released from the cartridge 











Light brown oil. IR (FTIR, νmax/cm-1) 426.88, 571.60, 727.61, 798.98, 863.93, 924.18, 
1011.50, 1105.00, 1202.13, 1236.56, 1298.04, 1349.00, 1436.39, 1459.49, 1531.12, 1569.01, 
1585.74, 1647.01, 2777.00, 2825.10, 2861.30, 2936.60, 3274.00; 1H NMR (400 MHz, 
CDCl3) δ 2.31 (s, 6H), 2.54 (t, J=5.92 Hz, 2H), 3.56 (q, J=5.54 Hz, 2H), 6.52 (d, J=3.53 Hz, 
1H), 7.16 (t, J=4.28 Hz, 1H), 7.21 (d, J=3.53 Hz, 1H), 7.42 - 7.44 (m, 1H), 7.51 (s, 1H), 7.55 
- 7.60 (m, 1H), 8.07 (d, J=2.01 Hz, 1H), 8.16 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 36.72, 
45.25, 45.28, 57.74, 110.22, 112.13, 114.00, 114.63, 117.60, 120.14, 124.85, 128.11, 133.01, 
149.23, 149.89, 151.87, 154.99, 158.70; m/z (+EI) calc. For C18H18BrN3O4 (M+) 420.26, 
found (M+H)+ 421.80; Yield: 87%. 
General procedure for Suzuki coupling for the synthesis of 5-(5-(3-aminophenyl)furan-
2-carboxamido)-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (4.195) from 5-
(5-bromofuran-2-carboxamido)-N-(4-(piperidin-1-yl)benzyl)benzofuran-2-carboxamide 
(4.179) and (3-aminophenyl)boronic acid (4.49) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq., 31 mg) was 
added to a solution of 4.179 (1.0 eq., 140 mg) and 4.49 (1.5 eq., 75 mg) in a 9:3:1 
combination of EtOH, toluene and water in the presence of K2CO3 (3.0 eq., 111 mg) in a 10 
ml microwave vial containing a magnetic stirrer. The reaction vessel was flushed with 
nitrogen during each addition. The reaction mixture was sealed in an inert nitrogen 
environment and heated with microwave radiation in an EMRYSTM Optimizer Microwave 
Station (Personal Chemistry) at 100 °C for 13 minutes. LCMS analysis revealed completion 
of reaction and the cooled reaction mixture was passed through a layer of celite and dried to 
obtain the crude product. This was then purified by flash chromatography using a DCM and 
ethyl acetate solvent mixture (100% DCM, then 10% ethyl acetate in DCM and 20% ethyl 







Light green, viscous material. IR (FTIR, νmax/cm-1) 609.11, 668.16, 746.24, 781.38, 807.01, 
863.29, 919.84, 1037.30, 1116.70, 1205.66, 1237.73, 1286.79, 1338.77, 1461.79, 1517.13, 
1590.08, 1645.15, 1732.38, 2335.36, 2359.55, 2930.11, 3341.16; 1H NMR (400 MHz, 
CDCl3, TMS); δ 1.57 - 1.63 (m, 2H), 1.72 (dt, J=11.18, 5.65 Hz, 4H), 3.15 - 3.20 (m, 4H), 
4.58 (d, J=5.81 Hz, 2H), 6.68 - 6.73 (m, 1H), 6.74 (d, J=3.54 Hz, 1H), 6.81 (t, J=5.68 Hz, 
1H), 6.91 - 6.96 (m, 2H), 7.08 (s, 1H), 7.13 - 7.18 (m, 1H), 7.23 (d, J=7.83 Hz, 1H), 7.26 (s, 
1H), 7.27 - 7.29 (m, 1H), 7.32 (d, J=3.54 Hz, 1H), 7.44 (d, J=8.84 Hz, 1H), 7.47 (d, J=0.76 
Hz, 1H), 7.63 (dd, J=8.97, 2.15 Hz, 1H), 8.08 (d, J=2.02 Hz, 1H), 8.18 (s, 1H); 13C NMR 
(100 MHz, CDCl3); δ 24.27, 25.73, 25.74, 43.08, 50.48, 50.54, 107.73, 110.50, 110.79, 
111.95, 114.00, 115.09, 115.74, 116.50, 116.76, 117.49 120.36, 127.69, 128.12, 129.07, 
129.09, 129.90, 130.41, 133.42, 146.47, 146.89, 149.71, 151.76, 151.84, 156.14, 156.26, 
158.40; m/z (+EI) calc. For C32H30N4O4 (M+) 534.61, found 534.94 (M+H)
+; Yield: 70%. 
Similar Suzuki coupling reaction conditions were applied for compounds 4.196 to 4.209 
using (3-aminophenyl)boronic acid (4.49) as the boronic acid. 
Procedure for the synthesis of 5-(5-(3-aminophenyl)furan-2-carboxamido)-N-(3-
(piperidin-1-yl)benzyl)benzofuran-2-carboxamide (4.196) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.180 (1.0 eq., 146 mg) and 4.49 (1.5 eq., 57 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
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addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 20 minutes. LCMS analysis revealed completion of reaction and the cooled 
reaction mixture was passed through a layer of celite and dried to obtain the crude product. 
This was then purified by flash chromatography using DCM and ethyl acetate solvent 
mixtures (100% DCM, then 10% ethyl acetate in DCM and 20% ethyl acetate in DCM) to 




Light yellow powder. IR (FTIR, νmax/cm-1) 632.54, 749.14, 897.79, 934.00, 1050.21, 
1135.10, 1163.68, 1223.63, 1326.41, 1363.35, 1385.62, 1476.14, 1525.64, 1560.61, 
1615.655, 2359.00, 2930.31.2968.97, 3339.58; 1H NMR (400 MHz, CDCl3, TMS); δ 1.59 - 
1.63 (m, 2H), 1.80 (dt, J=11.18, 5.65 Hz, 4H), 3.45 - 3.48 (m, 4H), 4.13 (s, 2H), 6.59 (dd, 
J=3.54, 0.51 Hz, 1H), 6.89 (d, J=7.83 Hz, 1H), 6.90 - 6.92 (m, 1H), 7.05 (s, 1H), 7.34 (dd, 
J=3.54, 0.51 Hz, 1H), 7.44 (m, 1H), 7.46 (m, 1H), 7.55 - 7.57 (m, 1H), 7.60 (s, 1H), 7.63 (dd, 
J=8.84, 2.27 Hz, 1H), 7.80 (d, J=8.84 Hz, 1H), 7.93 (d, J=8.59 Hz, 1H), 8.00 (d, J=2.27 Hz, 
1H), 8.09 (s, 1H); 13C NMR (100 MHz, CDCl3) δ; 13C NMR (100 MHz, CDCl3); δ 24.0, 
25.35. 25.5, 43.12, 53.12, 55.03, 106.32, 108.9, 109.67, 110.25, 111.27, 112.54, 119.32, 
119.54, 120.48, 121.00, 123.14, 126.57, 126.58, 128.64, 129.08, 135.27, 136.58, 140.59, 
141.87, 145.69, 148.69, 150.46, 156.37, 159.02, 162.87, 170.39; m/z (+EI) calc. For 
C32H30N4O4 (M+) 534.61, found 534.98 (M+H)
+; Yield: 94%. 
Procedure for the synthesis of 5-(5-(3-aminophenyl)furan-2-carboxamido)-N-(3-
(piperidin-1-ylmethyl)benzyl)benzofuran-2-carboxamide (4.197) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.181 (1.0 eq., 49 mg) and 4.49 (1.5 eq., 19 mg) in a 9:3:1 combination of 
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EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 10 minutes. LCMS analysis revealed completion of reaction and the cooled 
reaction mixture was passed through a layer of celite and dried to obtain the crude product. 
This was then purified by flash chromatography using DCM and ethyl acetate solvent 
mixtures (100% DCM, then 10% ethyl acetate in DCM and 20% ethyl acetate in DCM) to 




Light green, viscous material. IR (FTIR, νmax/cm-1) 692.51, 740.17, 779.93, 800.43, 861.72, 
992.65, 1019.19, 1110.60, 1168.93, 1204.33, 1228.81, 1297.69, 1344.01, 1438.17, 1465.50, 
1540.23, 1581.99, 1651.88, 1711.12, 1738.82, 2358.09, 2853.65, 2922.60, 3317.71; 1H NMR 
(400 MHz, CDCl3, TMS); δ 1.43 - 1.49 (m, 2H), 1.59 (dt, J=10.80, 5.59 Hz, 4H), 2.40 (br. s., 
4H), 3.50 (s, 2H), 4.68 (d, J=5.81 Hz, 2H), 6.72 (ddd, J=7.83, 2.27, 1.01 Hz, 1H), 6.76 (d, 
J=3.79 Hz, 1H), 7.08 (t, J=1.89 Hz, 1H), 7.16 (dt, J=8.02, 1.17 Hz, 1H), 7.24 (d, J=7.83 Hz, 
1H), 7.31 (d, J=7.33 Hz, 2H), 7.33 (d, J=3.54 Hz, 1H), 7.35 (s, 1H), 7.47 (d, J=9.09 Hz, 1H), 
7.51 (d, J=1.01 Hz, 1H), 7.64 (dd, J=9.09, 2.27 Hz, 1H), 8.11 (d, J=2.02 Hz, 1H), 8.15 (s, 
1H); 13C NMR (100 MHz, CDCl3) δ 24.75, 25.87, 30.91, 43.43, 54.54, 68.74, 73.48, 105.86, 
107.78, 110.79, 112.02, 114.02, 115.12, 117.51, 119.60, 120.41, 124.58, 125.08, 126.90, 
128.16, 128.64, 128.80, 129.94, 130.43, 133.47, 136.07, 139.58, 146.89, 149.61, 151.82, 
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156.16, 156.24, 162.49; m/z (+EI) calc. For C33H32N4O4 (M+) 548.63, found 548.79 (M+H)
+; 
Yield: 70%. 
Procedure for the synthesis of 5-(5-(3-aminophenyl)furan-2-carboxamido)-N-(2-
(piperidin-1-yl)ethyl)benzofuran-2-carboxamide (4.198) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.182 (1.0 eq., 138 mg) and 4.49 (1.5 eq., 62 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. LCMS analysis revealed completion of reaction and the cooled 
reaction mixture was passed through a layer of celite and dried to obtain the crude product. 
This was then purified by flash chromatography using DCM and ethyl acetate solvent 
mixtures (100% DCM, then 10% ethyl acetate in DCM and 20% ethyl acetate in DCM) to 




Brown, viscous oil. IR (FTIR, νmax/cm-1) 688.06, 724.54, 781.76, 855.14, 925.50, 993.93, 
1026.73, 1117.67, 1168.35, 1232.38, 1302.65, 1435.04, 1467.91, 1540.30, 1582.46, 1651.53, 
2335.36, 2362.03, 2931.98, 3327.86; 1H NMR (500 MHz, CDCl3, TMS); δ 1.50 (br. s., 2H), 
1.66 (dt, J=11.19, 5.44 Hz, 4H), 2.36 (s, 2H), 2.50 (br. s., 2H), 2.59 - 2.64 (m, 2H), 3.56 - 
3.63 (m, 2H), 6.71 (ddd, J=7.88, 2.52, 0.95 Hz, 1H), 6.76 (d, J=3.47 Hz, 1H), 7.09 (t, J=1.89 
Hz, 1H), 7.17 (ddt, J=2.36, 1.50, 0.75, 0.75 Hz, 1H), 7.19 (s, 1H), 7.25 - 7.27 (m, 1H), 7.33 - 
7.34 (m, 1H), 7.45 - 7.47 (m, 1H), 7.47 - 7.48 (m, 1H), 7.53 - 7.55 (m, 1H), 7.55 - 7.58 (m, 
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1H), 7.66 (d, J=1.26 Hz, 1H) 7.67 - 7.69 (m, 1H), 8.09 (d, J=2.21 Hz, 1H); 13C NMR (100 
MHz, CDCl3); δ 21.70, 24.51, 26.12, 36.18, 51.12, 54.60, 57.31, 108.02, 110.46, 111.01, 
112.38, 115.33, 115.99, 117.79, 120.47, 125.53, 128.46, 128.70, 128.80, 129.27, 132.29, 
132.37, 147.13, 152.10, 156.35, 156.51, 159.00; m/z (+EI) calc. For C27H29N4O4 (M+) 
472.54, found 472.78 (M+H)+; Yield: 71%. 
Procedure for the synthesis of 5-(5-(3-aminophenyl)furan-2-carboxamido)-N-(2-
(pyrrolidin-1-yl)ethyl)benzofuran-2-carboxamide (4.199) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.183 (1.0 eq., 100 mg) and 4.49 (1.5 eq., 46 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 10 minutes. LCMS analysis revealed completion of reaction and the cooled 
reaction mixture was passed through a SCX (2 gm) cartridge for purification and 2M NH3 in 




Dark brown oil. IR (FTIR, νmax/cm-1) 688.09, 722.28, 782.02, 863.39, 952.05, 1021.96, 
1113.01, 1153.97, 1204.33, 1296.88, 1344.03, 1441.21, 1467.52, 1488.16, 1540.88, 1578.94, 
1648.13, 2335.36, 2357.07, 2817.07, 2932.59, 3042.68, 3225.60, 3345.79; 1H NMR (500 
MHz, CDCl3, TMS); δ 1.84 (dt, J=6.62, 3.31 Hz, 4H), 2.62 (br. s., 4H), 2.76 (t, J=5.99 Hz, 
2H), 3.59 - 3.64 (m, 2H), 6.72 (ddd, J=7.88, 2.21, 0.95 Hz, 1H), 6.76 (d, J=3.78 Hz, 1H), 
7.00 (t, J=7.88 Hz, 1H), 7.08 - 7.09 (m, 1H), 7.15 - 7.18 (m, 1H), 7.24 (d, J=7.88 Hz, 1H), 
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7.33 (d, J=3.47 Hz, 1H), 7.46 (d, J=0.95 Hz, 1H), 7.47 - 7.50 (m, 1H), 7.52 (d, J=9.14 Hz, 
1H), 7.62 - 7.66 (m, 1H), 7.67 - 7.70 (m, 1H), 8.09 (d, J=2.21 Hz, 1H), 8.17 (s, 1H); 13C 
NMR (100 MHz, CDCl3); δ 21.84, 23.53, 38.02, 48.13, 53.99, 54.67, 107.79, 110.28, 110.75, 
112.13, 113.95, 115.09, 115.75, 117.55, 120.21, 128.15, 128.46, 128.55, 129.94, 130.39, 
132.12, 133.29, 146.45, 146.86, 149.87, 156.10; m/z (+EI) calc. For C26H26N4O4 (M+) 
458.51, found 459.21 (M+H)+; Yield: 97%. 
Procedure for the synthesis of 5-(5-(3-aminophenyl)furan-2-carboxamido)-N-(2-
morpholinoethyl)benzofuran-2-carboxamide (4.200) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.184 (1.0 eq., 100 mg) and 4.49 (1.5 eq., 44 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 13 minutes. LCMS analysis revealed completion of reaction and the cooled 
reaction mixture was passed through a SCX (2 gm) cartridge for purification and 2M NH3 in 





Dark brown oil. IR (FTIR, νmax/cm-1) 630.36, 784.23, 863.10, 961.38, 1024.14, 1113.62, 
1167.89, 1204.99, 1234.37, 1309.71, 1441.21, 1540.36, 1582.62, 1651.32, 2335.36, 2356.50, 
2817.07, 2938.98, 3347.83; 1H NMR (500 MHz, CDCl3) δ 2.55 (br. s., 4H), 2.64 (t, J=5.99 
Hz, 2H), 3.58 - 3.63 (m, 2H), 3.76 - 3.80 (m, 4H), 6.71 (ddd, J=7.88, 2.52, 0.95 Hz, 1H), 6.76 
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(d, J=3.47 Hz, 1H), 7.08 (t, J=1.89 Hz, 1H), 7.14 - 7.18 (m, 2H), 7.23 - 7.27 (m, 1H), 7.33 (d, 
J=3.47 Hz, 1H), 7.46 (d, J=0.95 Hz, 1H), 7.47 - 7.50 (m, 1H), 7.51 - 7.54 (m, 1H), 7.64 - 
7.70 (m, 2H), 8.10 (d, J=1.89 Hz, 1H), 8.21 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 35.31, 
35.36, 53.11, 56.65, 66.70, 66.73, 107.52, 110.16, 110.49, 111.81, 114.82, 115.49, 117.32, 
120.07, 127.86, 128.31, 129.67, 130.12, 131.77, 133.13, 146.15, 146.62, 149.49, 151.55, 
155.88, 158.46; m/z (+EI) calc. For C26H26N4O5 (M+) 474.51, found 475.10 (M+H)
+; Yield: 
97%. 
Procedure for the synthesis of 5-(5-(3-aminophenyl)furan-2-carboxamido)-N-(3-
morpholinopropyl)benzofuran-2-carboxamide (4.201) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.185 (1.0 eq., 250 mg) and 4.49 (1.5 eq., 108 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 20 minutes. LCMS analysis revealed completion of reaction and the cooled 
reaction mixture was passed through a SCX (2 gm) cartridge for purification and 2M NH3 in 
MeOH was used to release the pure product 4.201 (181 mg) from the cartridge. 
5-(5-(3-Aminophenyl)furan-2-carboxamido)-N-(3-morpholinopropyl)benzofuran-2-
carboxamide (4.201): 
Light brown oil. IR (FTIR, νmax/cm-1) 636.84, 689.46, 782.66, 862.50, 986.84, 1028.57, 
1112.71, 1171.05, 1201.75, 1231.34, 1300.00, 1343.49, 1465.78, 1538.49, 1584.76, 1643.85, 
2011.96, 2359.98, 3329.63; 1H NMR (400 MHz, CDCl3, TMS); δ 1.81 (quin, J=5.79 Hz, 
2H), 2.57 (br. s., 4H), 2.59 - 2.64 (m, 2H), 3.58 - 3.65 (m, 2H), 3.91 (t, J=4.66 Hz, 4H), 6.71 
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(ddd, J=7.93, 2.39, 1.01 Hz, 1H), 6.75 (d, J=3.78 Hz, 1H), 7.08 - 7.10 (m, 1H), 7.15 - 7.18 
(m, 1H), 7.22 - 7.27 (m, 1H), 7.33 (d, J=3.53 Hz, 1H), 7.45 - 7.46 (m, 1H), 7.46 - 7.51 (m, 
2H), 7.61 - 7.65 (m, 1H), 7.66 - 7.71 (m, 1H), 8.11 (d, J=2.01 Hz, 1H), 8.22 (s, 1H), 8.81 (t, 
J=4.41 Hz, 1H); 13C NMR (100 MHz, CDCl3); δ 23.97, 29.69, 40.23, 50.69, 53.84, 58.79, 
66.87, 107.76, 110.12, 110.46, 110.77, 111.70, 114.16, 115.09, 115.74, 117.56, 120.28, 
128.24, 128.45, 130.39, 131.99, 132.11, 133.37, 146.43, 146.87, 150.28, 156.29; m/z (+EI) 
calc. For C27H28N4O5 (M+) 488.54, found 489.06 (M+H)
+; Yield: 71%. 
Procedure for the synthesis of 5-(5-(3-aminophenyl)furan-2-carboxamido)-N-(4-
(dimethylamino)butyl)benzofuran-2-carboxamide (4.202) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.186 (1.0 eq., 76 mg) and 4.49 (2.5 eq., 58 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 20 minutes. LCMS analysis revealed completion of reaction and the cooled 
reaction mixture was passed through a SCX (2 gm) cartridge for purification and 2M NH3 in 
MeOH was used to release the pure product 4.202 (76 mg) from the cartridge. 
5-(5-(3-Aminophenyl)furan-2-carboxamido)-N-(4-(dimethylamino)butyl)benzofuran-2-
carboxamide (4.202): 
Light brown oil. IR (FTIR, νmax/cm-1) 406.01, 416.24, 427.69, 524.08, 535.29, 600.15, 
611.67, 688.72, 777.83, 847.36, 959.20, 1019.60, 1107.30, 1152.60, 1231.20, 1300.80, 
1442.80, 1468.62, 1536.50, 1581.90, 2851.40, 2921.00, 3214.10, 3347.10; 1H NMR (400 
MHz, CDCl3) δ 1.66 – 1.67 (m, 2H), 1.69 - 1.76 (m, 2H), 2.29 (s, 6H), 2.56 (t, J=6.55 Hz, 
2H), 3.09 (m, 2H), 6.53 (dd, J=3.53, 0.50 Hz, 1H), 6.89 (dd, J=0.50, 1.50 Hz, 1H),7.22 (dd, 
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J=3.53, 0.50 Hz, 1H), 7.43 (d, J=1.01 Hz, 1H), 7.44 - 7.48 (m, 1H), 7.50 (m, 1H),7.58 (dd, 
J=8.94, 2.14 Hz, 1H), 7.64 (m, 1H), 7.57 (m, 1H), 8.07 (d, J=2.27 Hz, 1H), 8.11 (s, 1H), 8.18 
(br. s., 1H); 13C NMR (100 MHz, CDCl3) δ 24.1, 27.5, 42.3, 47.6, 47.8, 57.6, 106.8, 108.2, 
108.9, 110.12, 113.0, 114.5, 116.8, 118.4, 118.9 130.4, 130.8, 131.0, 132.3, 133.0, 145.8, 
148.2, 150.0,156.3, 158.2, 160.9; m/z (+EI) calc. For C26H28N4O4 (M+) 460.52, found 
(M+H)+ 461.20; Yield: 98%. 
Procedure for the synthesis of 5-(5-(3-aminophenyl)furan-2-carboxamido)-N-(3-
(pyrrolidin-1-yl)propyl)benzofuran-2-carboxamide (4.203) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.187 (1.0 eq., 36 mg) and 4.49 (2.5 eq., 27 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. LCMS analysis revealed completion of reaction and the cooled 
reaction mixture was passed through a SCX (1 gm) cartridge for purification and 2M NH3 in 




Brown oil. IR (FTIR, νmax/cm-1) 427.50, 568.59, 691.98, 738.15, 779.05, 863.60, 953.15, 
1022.70, 1107.30, 1170.80, 1203.76, 1233.02, 1296.69, 1469.51, 1538.84, 1581.52, 1645.17, 
2809.00, 2936.00, 2963.20, 3220.20, 3347.10; 1H NMR (400 MHz, CDCl3) δ 1.74 – 1.78 (m, 
2H), 1.80 - 1.93 (m, 4H), 2.63 – 2.75 (m, 4H), 2.81 - 2.87 (m, 2H), 3.64 - 3.84 (m, 2H), 6.52 
(dd, J=8.5, 2.1 Hz, 1H), 6.80 (d, J=2.1 Hz, 1H), 7.13 (d, J=3.53 Hz, 1H), 7.38 (d, J=3.53 Hz, 
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1H), 7.40 (d, J=1.01 Hz, 1H), 7.41 - 7.44 (m, 1H), 7.50 (dd, J=7.8, 8.5 Hz, 1H), 7.57 (dd, 
J=8.94, 2.14 Hz, 1H), 7.68 (dd, J=7.8, 8.5 Hz, 1H), 8.06 (d, J=2.27 Hz, 1H), 8.12 (s, 1H) 
9.04 (br. s., 1H); 13C NMR (100 MHz, CDCl3) δ 23.50, 23.60, 26.90, 40.10, 40.29, 56.61, 
56.68, 106.31, 108.52, 108.64, 110.92, 111.13, 113.82, 114.67, 118.54, 118.90, 130.52, 
131.12, 132.00, 132.12, 145.91, 148.23, 150.00, 152.36, 156.28, 158.37, 162.12; m/z (+EI) 
calc. For C27H28N4O4 (M+) 472.54, found (M+H)
+ 473.20; Yield: 81%. 
Procedure for the synthesis of 5-(5-(3-aminophenyl)furan-2-carboxamido)-N-(4-
(pyrrolidin-1-yl)butyl)benzofuran-2-carboxamide (4.204) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.188 (1.0 eq., 124 mg) and 4.49 (2.5 eq., 90 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. LCMS analysis revealed completion of reaction and the cooled 
reaction mixture was passed through a SCX (2 gm) cartridge for purification and 2M NH3 in 




Orange oil. IR (FTIR, νmax/cm-1) 425.46, 524.20, 568.14, 616.52, 690.36, 729.91, 778.48, 
856.42, 956.17, 1022.70, 1113.40, 1204.00, 1234.30, 1296.59, 1346.00, 1436.15, 1468.45, 
1519.98, 1542.95, 1580.42, 2812.00, 2851.40, 2936.00, 3223.20, 3350.10; 1H NMR (400 
MHz, CDCl3) δ 1.59 (br. s., 2H), 1.78 (dt, J=11.20, 5.48 Hz, 6H), 2.50 (br. s., 2H), 2.54 - 
2.59 (m, 2H), 3.57 - 3.63 (m, 2H), 3.83 (br. s., 2H), 6.26 (dd, J=8.06, 2.27 Hz, 1H), 6.67 
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(ddd, J=7.99, 2.33, 1.01 Hz, 1H), 6.71 (ddd, J=7.93, 2.39, 1.01 Hz, 1H), 6.95 - 6.99 (m, 1H), 
7.09 (t, J=1.89 Hz, 1H), 7.15 - 7.18 (m, 1H), 7.24 (d, J=8.06 Hz, 1H), 7.33 (d, J=3.53 Hz, 
1H), 7.41 (d, J=8.81 Hz, 1H), 7.44 (d, J=0.76 Hz, 1H), 7.66 (dd, J=8.81, 2.27 Hz, 1H), 8.04 
(d, J=2.01 Hz, 1H), 8.20 (s, 1H), 9.28 (br. s., 1H); 13C NMR (100 MHz, CDCl3) δ 23.96, 
24.04, 25.79, 27.57, 38.56, 54.80, 55.41, 56.61, 105.69, 107.59, 107.76, 109.75, 110.77, 
111.60, 113.89, 114.05, 115.08, 117.52, 117.64, 120.15, 129.52, 130.26, 130.40, 133.22, 
146.46, 150.58, 156.11, 158.63; m/z (+EI) calc. For C28H30N4O4 (M+) 486.56, found (M+H)
+ 
487.20; Yield: 94%. 
Procedure for the synthesis of 5-(5-(3-aminophenyl)furan-2-carboxamido)-N-(3-
(piperidin-1-yl)propyl)benzofuran-2-carboxamide (4.205) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.1889 (1.0 eq., 41 mg) and 4.49 (2.5 eq., 30 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. LCMS analysis revealed completion of reaction and the cooled 
reaction mixture was passed through a SCX (1 gm) cartridge for purification and 2M NH3 in 




Dark brown oil. IR (FTIR, νmax/cm-1) 408.82, 422.32, 533.24, 690.93, 780.86, 1022.70, 
1116.40, 1024.45, 1230.97, 1303.09, 1343.00, 1469.65, 1543.54, 1582.47, 1639.41, 2497.70, 
2936.00, 3349.01; 1H NMR (400 MHz, Methanol-d4) δ 1.52 (br. s., 2H), 1.63 - 1.70 (m, 4H), 
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1.82 - 1.90 (m, 2H), 2.13 - 2.15 (m, 2H), 2.47 - 2.51 (m, 4H), 3.43 - 3.50 (m, 2H), 6.72 - 6.76 
(m, 1H), 6.89 (d, J=3.53 Hz, 1H), 7.16 - 7.21 (m, 1H), 7.23 - 7.26 (m, 1H), 7.27 (d, J=1.76 
Hz, 1H), 7.35 (d, J=3.78 Hz, 1H), 7.47 (d, J=0.50 Hz, 1H), 7.57 (d, J=9.06 Hz, 1H), 7.75 (dd, 
J=8.94, 2.14 Hz, 1H), 8.13 (d, J=2.01 Hz, 1H); 13C NMR (100 MHz, Methanol-d4) δ 26.69, 
26.99, 28.06, 30.82, 35.21, 40.60, 55.70, 56.69, 104.44, 108.18, 111.42, 112.88, 113.75, 
116.70, 118.49, 120.09, 123.11, 127.11, 129.22, 131.77, 138.92, 142.23, 145.37, 147.63, 
150.48, 153.67, 158.90, 162.33; m/z (+EI) calc. For C28H30N4O4 (M+) 486.56, found (M+H)
+ 
487.20; Yield: 97%. 
Procedure for the synthesis of 5-(5-(3-aminophenyl)furan-2-carboxamido)-N-(2-(4-
methylpiperazin-1-yl)ethyl)benzofuran-2-carboxamide (4.206) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.190 (1.0 eq., 120 mg) and 4.49 (2.5 eq., 86 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. LCMS analysis revealed completion of reaction and the cooled 
reaction mixture was passed through a SCX (2 gm) cartridge for purification and 2M NH3 in 




Yellow oil. IR (FTIR, νmax/cm-1) 419.02, 447.53, 523.28, 572.34, 690.98, 719.37, 781.06, 
863.93, 954.30, 1008.50, 1023.60, 1108.00, 1153.10, 1204.40, 1235.08, 1285.37, 1343.00, 
1443.95, 1463.29, 1538.70, 1582.12, 1641.20, 1740.60, 2849.20, 2917.47, 3219.70, 3337.20; 
1H NMR (400 MHz, CDCl3) δ 2.31 - 2.35 (s, 3H), 2.53 (m, 8H), 2.64 (t, J=6.04 Hz, 2H), 3.55 
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- 3.63 (m, 2H), 6.75 (d, J=3.78 Hz, 1H), 7.08 (t, J=2.01 Hz, 1H), 7.16 - 7.21 (m, 2H), 7.22 - 
7.27 (m, 1H), 7.33 (d, J=3.52 Hz, 1H), 7.45 (d, J=0.76 Hz, 1H), 7.52 (d, J=8.81 Hz, 1H), 7.66 
(dd, J=8.81, 2.27 Hz, 1H), 8.08 (d, J=2.01 Hz, 1H), 8.22 (s, 1H); 13C NMR (100 MHz, 
CDCl3) δ 29.99, 31.87, 36.22, 40.54, 53.08, 55.37, 56.66, 108.08, 110.63, 111.09, 112.31, 
114.32, 114.37, 115.39, 116.07, 117.88, 117.96, 120.62, 128.43, 129.83, 130.23, 133.67, 
136.34, 147.19, 150.12, 152.14, 159.04; m/z (+EI) calc. For C27H29N5O4 (M+) 487.55, found 
(M+H)+ 488.20; Yield: 97%. 
Procedure for the synthesis of 5-(5-(3-aminophenyl)furan-2-carboxamido)-N-(4-
(morpholinomethyl)phenyl)benzofuran-2-carboxamide (4.207) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.192 (1.0 eq., 28 mg) and 4.49 (2.5 eq., 18 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. LCMS analysis revealed completion of reaction and the cooled 
reaction mixture was passed through a SCX (1 gm) cartridge for purification and 2M NH3 in 




Dark brown oil. IR (FTIR, νmax/cm-1) 418.52, 462.16, 507.35, 538.60, 623.09, 695.62, 775.43, 
862.43, 1002.08, 1071.00, 1071.00, 1111.14, 1170.80, 1261.50, 1288.70, 1328.00, 1433.80, 
1451.90, 1482.10, 1517.27, 1579.09, 1598.39, 2815.10, 2863.50, 2924.00, 2932.20, 3032.70, 
3217.10, 3344.00; 1H NMR (400 MHz, METHANOL-d4) δ 2.45 (d, J=16.37 Hz, 4H), 3.51 
(s, 2H), 3.65 - 3.72 (m, 4H), 6.67 - 6.71 (m, 2H), 6.88 - 6.92 (m, 2H), 6.94 (t, J=1.89 Hz, 
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2H), 7.06 (d, J=8.31 Hz, 2H), 7.13 (t, J=7.81 Hz, 2H), 7.33 - 7.40 (m, 2H), 7.64 - 7.69 (m, 
1H), 7.74 (d, J=8.56 Hz, 1H); 13C NMR (100 MHz, METHANOL-d4) δ 5.01, 55.64, 64.58, 
66.34, 66.89, 108.02, 108.23, 108.65, 111.08, 113.84, 114.28, 115.39, 117.13, 118.91, 
121.51, 121.67, 129.35, 129.82, 130.25, 130.56, 131.25, 132.84, 134.29, 136.19, 146.35, 
148.09, 150.00, 152.23, 156.38, 160.02, 162.34; m/z (+EI) calc. For C31H28N4O5 (M+) 
536.58, found (M+H)+ 537.30; Yield: 87%. 
Procedure for the synthesis of 5-(5-(3-aminophenyl)furan-2-carboxamido)-N-(2-(2-
methylthiazol-4-yl)ethyl)benzofuran-2-carboxamide (4.208) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.193 (1.0 eq., 120 mg) and 4.49 (2.5 eq., 86 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. LCMS analysis revealed completion of reaction and the cooled 
reaction mixture was passed through a SCX (2 gm) cartridge for purification and 2M NH3 in 






Colourless oil. IR (FTIR, νmax/cm-1) 430.17, 567.72, 691.73, 784.31, 863.97, 939.25, 1041.70, 
1110.35, 1235.58, 1297.75, 1343.75, 1459.57, 1542.11, 1584.32, 1647.94, 2852.20, 2921.50, 
3319.20; 1H NMR (400 MHz, CDCl3) δ 2.77 (s, 3H), 3.06 (t, J=6.29 Hz, 2H), 3.80 - 3.86 (m, 
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2H), 6.72 (ddd, J=7.99, 2.33, 1.01 Hz, 1H), 6.76 (d, J=3.53 Hz, 1H), 6.88 (s, 1H), 7.08 (t, 
J=1.89 Hz, 1H), 7.15 - 7.18 (m, 1H), 7.24 (d, J=7.81 Hz, 1H), 7.33 (d, J=3.78 Hz, 1H), 7.46 
(d, J=1.01 Hz, 1H), 7.49 (d, J=9.06 Hz, 1H), 7.53 (t, J=5.54 Hz, 1H), 7.65 (dd, J=8.94, 2.14 
Hz, 1H), 8.09 (d, J=2.01 Hz, 1H), 8.17 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 19.54, 25.86, 
41.44, 107.04, 110.54, 111.09, 112.33, 114.38, 115.43, 117.88, 118.71, 120.57, 124.94, 
129.53, 130.26, 132.94, 136.05, 144.96, 146.76, 147.19, 151.26, 153.96, 155.89, 159.01, 
163.10, 163.96; m/z (+EI) calc. For C26H22N4O4S (M+) 486.54, found (M+H)
+ 487.20; Yield: 
97%. 
Procedure for the synthesis of 5-(5-(3-aminophenyl)furan-2-carboxamido)-N-(2-
(dimethylamino)ethyl)benzofuran-2-carboxamide (4.209) 
A catalytic amount of tetrakis(triphenylphosphine)palladium, Pd(PPh3)4 (0.1 eq.) was added 
to a solution of 4.194 (1.0 eq., 58 mg) and 4.49 (2.5 eq., 47 mg) in a 9:3:1 combination of 
EtOH, toluene and water in the presence of K2CO3 (3.0 eq.) in a 10 ml microwave vial 
containing a magnetic stirrer. The reaction vessel was flushed with nitrogen during each 
addition. The reaction mixture was sealed in an inert nitrogen environment and heated with 
microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 
100 °C for 15 minutes. LCMS analysis revealed completion of reaction and the cooled 
reaction mixture was passed through a SCX (1 gm) cartridge for purification and 2M NH3 in 




Dark brown oil. IR (FTIR, νmax/cm-1) 403.30, 417.76, 566.25, 691.90, 725.72, 780.99, 862.93, 
1020.95, 1107.30, 1203.56, 1231.81, 1298.49, 1343.00, 1468.45, 1539.09, 1581.34, 1644.83, 
2784.90, 2827.2, 2942.00, 3223.20, 3338.00; 1H NMR (400 MHz, CDCl3) δ 2.32 (s, 6H), 
2.55 (t, J=5.92 Hz, 2H), 3.57 (q, J=5.62 Hz, 2H), 6.71 (dd, J=7.81, 1.26 Hz, 1H), 6.75 (d, 
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J=3.52 Hz, 1H), 7.08 (s, 1H), 7.16 (d, J=7.55 Hz, 2H), 7.24 (t, J=7.81 Hz, 1H), 7.33 (d, 
J=3.78 Hz, 1H), 7.45 (s, 1H), 7.52 (d, J=9.06 Hz, 1H), 7.64 (dd, J=8.81, 2.01 Hz, 1H) 8.09 
(d, J=2.01 Hz, 1H), 8.21 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 22.18, 34.99, 45.27, 57.77, 
107.75, 110.25, 112.11, 113.95, 114.65, 115.72, 117.52, 120.25, 128.13, 129.91, 133.32, 
136.06, 141.20, 146.88, 151.83, 152.84, 156.11, 158.76, 161.37, 173.26; m/z (+EI) calc. For 
C24H24N4O4 (M+) 432.47, found (M+H)
+ 433.10; Yield: 99%. 
The general procedure for the amide coupling reaction was followed for the synthesis of the 
following final compounds (4.210 to 4.224) from reactions between several heterocyclic 
amines and 2-(2,3-dihydrobenzofuran-5-yl)thiazole-4-carboxylic acid (4.53). 
General procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((4-
(piperidin-1-yl)benzyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.210) from 4.195 and 4.53 
81 mg (1.0 eq.) of 4.195 and 75 mg (2.0 eq.) of 4.53 were added to a reaction vessel. Along 
with these, 2.0 eq. of HOBt and 1.75 eq. of DIC were added and a clear solution was made by 
dissolving these reactants in a minimum amount of DMF. The reaction mixture was stirred 
for 3 hours with occasional monitoring of the progress of the reaction by LCMS. After 
completion of the reaction, it was dried using a vacuum. The crude product was purified by 
silica column chromatography using DCM and ethyl acetate solvent mixtures (100% DCM, 
then 10% ethyl acetate in DCM and 20% ethyl acetate in DCM) to obtain the pure product 















Colourless, viscous oil. IR (FTIR, νmax/cm-1) 643.91, 669.74, 692.45, 742.38, 798.55, 832.96, 
873.86, 921.32, 975.95, 1024.45, 1106.40, 1128.04, 1172.39, 1198.74, 1233.28, 1299.98, 
1345.64, 1473.61, 1550.55, 1591.58, 1645.62, 1679.74, 2361.31, 2790.69, 2852.71, 2932.16, 
3111.11, 3317.64; 1H NMR (400 MHz, CDCl3, TMS); δ 1.60 (q, J=5.89 Hz, 2H), 1.75 (dt, 
J=11.24, 5.75 Hz, 4H), 3.18 - 3.23 (m, 4H), 3.31 (t, J=8.84 Hz, 2H), 4.59 (d, J=5.81 Hz, 2H), 
4.69 (t, J=8.84 Hz, 2H), 6.86 - 6.88 (m, 1H), 6.99 - 7.02 (m, 2H), 7.26 - 7.27 (m, 1H), 7.27 - 
7.28 (m, 1H), 7.35 - 7.37 (m, 1H), 7.38 (d, J=1.77 Hz, 1H), 7.39 (s, 1H), 7.40 (d, J=1.77 Hz, 
1H), 7.41 - 7.44 (m, 2H), 7.48 (d, J=0.76 Hz, 1H), 7.52 - 7.56 (m, 1H), 7.74 - 7.76 (m, 2H), 
7.87 (d, J=1.52 Hz, 1H), 8.09 (d, J=2.27 Hz, 1H), 8.15 (s, 1H), 8.28 (t, J=1.77 Hz, 1H), 8.33 
(s, 1H); 13C NMR (100 MHz, CDCl3); δ 23.81, 25.31, 25.34, 29.31, 43.02, 44.25, 51.63, 
71.95, 108.38, 109.86, 111.42, 111.57, 111.95, 114.37, 115.97, 115.99, 116.75, 117.39, 
117.65, 120.31, 122.47, 123.01, 123.56, 123.57, 126.35, 126.48, 127.65, 128.03, 128.35, 
128.45, 129.16, 129.65, 133.36, 138.37, 141.70, 149.08, 149.47, 150.09, 151.88, 155.59, 
155.64, 158.64, 159.32, 160.31; m/z (+EI) calc. For C44H37N5O6S (M+) 763.86, found 764.15 





Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((3-(piperidin-
1-yl)benzyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-yl)phenyl)thiazole-4-
carboxamide (4.211) from 4.196 and 4.53 
55 mg (1.0 eq.) of 4.196 and 51 mg (2.0 eq.) of 4.53 were added to a reaction vessel. Along 
with these, 2.0 eq. of HOBt and 1.75 eq. of DIC were added and a clear solution was made by 
dissolving these reactants in a minimum amount of DMF. The reaction mixture was stirred 
for 3 hours with occasional monitoring of the progress of the reaction by LCMS. After 
completion of the reaction it was dried using vacuum. The crude product was purified by 
silica column chromatography using DCM and ethyl acetate solvent mixtures (100% DCM, 






Colourless mass. IR (FTIR, νmax/cm-1) 636.44, 691.10, 727.54, 785.24, 864.20, 941.37, 
979.60, 1000.86, 1016.05, 1111.68, 1167.89, 1233.44, 1295.44, 1350.10, 1468.86, 1537.87, 
1586.98, 1650.13, 1665.94, 2335.36, 2363.10, 2930.65, 3329.26; 1H NMR (400 MHz, 
CDCl3, TMS); δ 1.56 - 1.62 (m, 2H), 1.69 - 1.73 (m, 4H), 3.14 - 3.22 (m, 4H), 3.31 (t, J=8.59 
Hz, 2H), 4.62 (d, J=5.56 Hz, 2H), 4.66 - 4.70 (m, 2H), 6.84 - 6.87 (m, 2H), 6.87 - 6.89 (m, 
2H), 6.95 - 6.96 (m, 1H), 7.23 - 7.26 (m, 1H), 7.34 (d, J=3.79 Hz, 1H), 7.42 - 7.43 (m, 1H), 
7.45 (d, J=2.02 Hz, 1H), 7.48 (d, J=0.76 Hz, 1H), 7.53 (dt, J=7.83, 1.39 Hz, 1H), 7.65 - 7.66 
(m, 1H), 7.66 - 7.68 (m, 1H), 7.68 (d, J=2.02 Hz, 1H), 7.78 (dd, J=8.34, 2.02 Hz, 1H), 7.86 
(d, J=1.52 Hz, 1H), 8.11 (d, J=2.02 Hz, 1H), 8.13 (s, 1H), 8.27 (t, J=1.77 Hz, 1H), 8.37 (s, 
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1H), 9.38 (s, 1H); 13C NMR (100 MHz, CDCl3); δ 23.47, 24.25, 25.79, 29.29, 42.18, 43.94, 
50.45, 71.94, 108.31, 109.83, 110.61, 111.91, 114.23, 115.64, 115.88, 116.10, 117.52, 
118.66, 120.22, 120.65, 122.91, 123.54, 125.52, 127.63, 128.05, 128.33, 128.42, 128.54, 
129.50, 129.61, 130.39, 132.03, 132.13, 133.46, 138.38, 146.91, 149.56, 150.14, 151.80, 
152.65, 156.27, 158.48, 159.22, 162.66; m/z (+EI) calc. For C44H37N5O6S (M+) 763.86, 
found 763.79 (M+H)+; Yield: 64%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((3-(piperidin-
1-ylmethyl)benzyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-yl)phenyl)thiazole-4-
carboxamide (4.212) from 4.197 and 4.53 
27 mg (1.0 eq.) of 4.197 and 18 mg (1.5 eq.) of 4.53 were added to a reaction vessel. Along 
with these, 2.0 eq. of HOBt and 1.75 eq. of DIC were added and a clear solution was made by 
dissolving these reactants in a minimum amount of DMF. The reaction mixture was stirred 
for 3 hours with occasional monitoring of the progress of the reaction by LCMS. After 
completion of the reaction it was dried using vacuum. The crude product was purified by 
silica column chromatography using DCM and ethyl acetate solvent mixtures (100% DCM, 
then 10% ethyl acetate in DCM and 20% ethyl acetate in DCM) to obtain the pure product 







Colourless oil. IR (FTIR, νmax/cm-1) 639.47, 744.49, 865.93, 958.54, 1037.66, 1097.90, 
1129.57, 1167.45, 1243.19, 1325.31, 1360.51, 1383.56, 1462.80, 1559.65, 1612.68, 2335.36, 
2357.70, 2932.92, 2966.89, 3336.27; 1H NMR (500 MHz, DMSO-d6, TMS); δ 1.12 - 1.20 
(m, 4H), 1.45 - 1.48 (m, 2H), 3.28 - 3.31 (m, 2H), 3.63 (dquin, J=7.68, 6.59, 6.59, 6.59, 6.59 
Hz, 4H), 4.36 (s, 2H), 4.64 (t, J=8.83 Hz, 2H), 6.93 (d, J=8.20 Hz, 1H), 7.16 (d, J=3.47 Hz, 
1H), 7.19 - 7.23 (m, 1H), 7.25 - 7.28 (m, 1H), 7.46 - 7.47 (m, 1H), 7.47 - 7.50 (m, 2H), 7.52 
(t, J=7.88 Hz, 1H), 7.61 - 7.63 (m, 1H), 7.63 - 7.66 (m, 1H), 7.66 - 7.69 (m, 1H), 7.75 - 7.77 
(m, 1H), 7.85 - 7.87 (m, 1H), 7.91 - 7.93 (m, 1H), 7.94 (d, J=1.89 Hz, 1H), 8.06 - 8.09 (m, 
2H), 8.21 (d, J=2.21 Hz, 1H), 8.31 - 8.32 (m, 1H), 8.39 (s, 1H), 9.30 (t, J=6.15 Hz, 1H), 
10.33 (s, 1H), 10.35 (s, 1H); 13C NMR (100 MHz, DMSO-d6); δ 21.18, 23.51, 28.82, 29.48, 
36.35, 45.02, 51.14, 52.60, 68.40, 107.46, 107.96, 109.18, 109.44, 109.61, 109.99, 110.45, 
111.97, 113.52, 114.80, 119.12, 119.29, 119.91, 120.55, 121.11, 121.30, 121.93, 122.33, 
122.48, 123.24, 124.30, 125.23, 126.41, 128.60, 129.90, 131.80, 134.25, 138.11, 144.43, 
148.36, 151.20, 154.34, 156.98, 160.69, 162.29, 188.33; m/z (+EI) calc. For C45H39N5O5S 
(M+) 777.89, found 778.21 (M+H)+; Yield: 69%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((2-(piperidin-
1-yl)ethyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-yl)phenyl)thiazole-4-
carboxamide (4.213) from 4.198 and 4.53 
82 mg (1.0 eq.) of 4.198 and 85 mg (2.0 eq.) of 4.53 were added to a reaction vessel. Along 
with this, 2.0 eq. of HOBt and 1.75 eq. of DIC were added and a clear solution was made by 
dissolving these reactants in a minimum amount of DMF. The reaction mixture was stirred 
for 3 hours with occasional monitoring of the progress of the reaction by LCMS. After 
completion of the reaction it was dried using vacuum. The crude product was purified by 
using a SCX cartridge (2 gm) by the catch and release method, as described earlier in the 
chapter. Ten ml 2M NH3 was used to release the product from the cartridge. Purification of 
the product 4.213 (40 mg) was finally made using flash chromatography with 










Colourless oil. IR (FTIR, νmax/cm-1) 691.66, 735.84, 785.97, 863.06, 939.92, 1015.54, 
1110.70, 1231.48, 1537.77, 1584.59, 1650.61, 2175.94, 2929.57, 3300.69; 1H NMR (500 
MHz, DMSO-d6, TMS); δ 1.38 (d, J=3.47 Hz, 2H), 1.49 (quin, J=5.52 Hz, 4H), 2.38 (br. s., 
2H), 2.44 (t, J=6.94 Hz,  2H), 3.30 (t, J=8.20 Hz, 2H), 3.36 - 3.42 (m, 4H), 4.65 (t, J=8.67 
Hz, 2H), 6.93 (d, J=8.51 Hz, 1H), 7.16 (d, J=3.47 Hz, 1H), 7.47 (d, J=3.78 Hz, 1H), 7.52 (t, 
J=8.04 Hz, 1H), 7.55 (d, J=0.95 Hz, 1H), 7.67 (d, J=9.14 Hz, 1H), 7.75 - 7.78 (m, 2H), 7.92 - 
7.96 (m, 2H), 8.09 (d, J=1.58 Hz, 1H), 8.20 (d, J=2.21 Hz, 1H), 8.32 (t, J=1.89 Hz, 1H), 8.39 
(s, 1H), 8.59 (t, J=5.83 Hz, 1H), 10.32 (s, 1H), 10.35 (s, 1H); 13C NMR (100 MHz, DMSO-
d6); δ 21.15, 25.75, 28.81, 30.89, 54.22, 55.11, 57.42, 57.71, 60.64, 109.72, 111.95, 114.34, 
115.82, 117.14, 119.81, 119.95, 121.08, 123.94, 125.40, 125.81, 125.96, 126.79, 127.47, 
127.63, 128.63, 128.97, 129.57, 129.91, 138.06, 139.12, 141.33, 141.61, 146.94, 150.03, 
150.10, 151.12, 152.06, 152.78, 162.29; m/z (+EI) calc. For C39H35N5O6S (M+) 701.79, 
found 702.18 (M+H)+; Yield: 41%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((2-
(pyrrolidin-1-yl)ethyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.214) from 4.199 and 4.53 
60 mg (1.0 eq.) of 4.199 and 65 mg (2.0 eq.) of 4.53 were added to a reaction vessel. Along 
with these, 2.0 eq. of HOBt and 1.75 eq. of DIC were added and a clear solution was made by 
dissolving these reactants in a minimum amount of DMF. The reaction mixture was stirred 
for 3 hours with occasional monitoring of the progress of the reaction by LCMS. The crude 
product was purified by using a SCX cartridge (2 gm) by the catch and release method, as 
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described earlier in the chapter. Ten ml 2M NH3 was used to release the product from the 
cartridge. Purification of product 4.214 (50 mg) was finally made using flash chromatography 





Light yellow oil. IR (FTIR, νmax/cm-1) 634.44, 660.73, 691.69, 740.32, 785.58, 864.16, 
939.32, 979.60, 1022.12, 1095.97, 1167.89, 1204.33, 1232.84, 1299.84, 1347.07, 1383.51, 
1463.93, 1539.90, 1585.93, 1650.75, 2335.36, 2358.58, 2804.87, 2859.75, 2922.10, 2957.31, 
3115.85, 3286.58; 1H NMR (500 MHz, CDCl3, TMS); δ 1.88 (br. s., 4H), 2.75 (br. s., 2H), 
2.96 (s, 4H), 3.29 - 3.35 (m, 2H), 3.67 (d, J=5.36 Hz, 2H), 4.69 (t, J=8.83 Hz, 2H), 6.87 (d, 
J=3.78 Hz, 1H), 6.89 (d, J=8.20 Hz, 1H), 7.36 (d, J=3.78 Hz, 1H), 7.43 - 7.46 (m, 1H), 7.48 
(d, J=7.88 Hz, 1H), 7.54 - 7.56 (m, 1H), 7.63 (dd, J=8.67, 2.05 Hz, 1H), 7.67 - 7.70 (m, 1H), 
7.79 (dd, J=8.20, 1.89 Hz, 1H), 7.87 - 7.88 (m, 1H), 8.03 (s, 1H), 8.10 (d, J=2.21 Hz, 1H), 
8.15 (s, 1H), 8.28 (t, J=1.73 Hz, 1H), 8.32 (s, 1H), 9.40 (s, 1H); 13C NMR (100 MHz, 
CDCl3); δ 23.74, 29.54, 31.67, 36.73, 51.12, 54.29. 55.04, 72.21, 108.62, 110.10, 110.59, 
112.32, 114.38, 116.09, 117.80, 118.35, 120.47, 120.71, 120.88, 123.20, 123.79, 125.75, 
1227.88, 128.28, 128.59, 129.91, 130.64, 133.49, 138.65, 147.14, 150.36, 152.11, 155.74, 
156.47, 159.47, 162.74, 162.90, 169.10; m/z (+EI) calc. For C38H33N5O6S (M+) 687.76, 





Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((2-
morpholinoethyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-yl)phenyl)thiazole-4-
carboxamide (4.215) from 4.200 and 4.53 
77 mg (1.0 eq.) of 4.200 and 60 mg (1.5 eq.) of 4.53 were added to a reaction vessel. Along 
with these, 2.0 eq. of HOBt and 1.75 eq. of DIC were added and a clear solution was made by 
dissolving these reactants in a minimum amount of DMF. The reaction mixture was stirred 
for 3 hours with occasional monitoring of the progress of the reaction by LCMS. The crude 
product was purified by using a SCX cartridge (2 gm) by the catch and release method, as 
described earlier in the chapter. Ten ml 2M NH3 was used to release the product from the 
cartridge. Purification of the product 4.215 (37 mg) was finally achieved using flash 





Light yellow oil. IR (FTIR, νmax/cm-1) 660.03, 691.98, 740.58, 788.04, 862.95, 939.05, 
979.60, 1027.26, 1111.93, 1170.96, 1300.58, 1344.03, 1384.84, 1465.10, 1539.46, 1585.38, 
1653.79, 2335.36, 2359.56, 2817.07, 2853.65, 2929.41, 3282.17; 1H NMR (500 MHz, 
CDCl3, TMS); δ 2.55 (br. s., 4H), 2.64 (t, J=5.99 Hz, 2H), 3.33 (t, J=8.67 Hz, 2H), 3.58 - 
3.63 (m, 2H), 3.75 - 3.80 (m, 4H), 4.70 (t, J=8.67 Hz, 2H), 6.87 - 6.89 (m, 1H), 7.14 (t, 
J=5.20 Hz, 1H), 7.37 (d, J=3.78 Hz, 1H), 7.47 (d, J=0.95 Hz, 1H), 7.47 - 7.49 (m, 1H), 7.52 - 
7.57 (m, 2H), 7.66 - 7.71 (m, 2H), 7.80 (dd, J=8.51, 1.89 Hz, 1H), 7.88 (d, J=1.26 Hz, 1H), 
8.03 (s, 1H), 8.13 (d, J=2.21 Hz, 1H), 8.15 (s, 1H), 8.30 (t, J=1.73 Hz, 1H), 8.31 (s, 1H), 9.41 
(s, 1H); 13C NMR (100 MHz, CDCl3); δ 29.29, 31.42, 35.56, 36.47, 53.37, 56.91, 67.01, 
71.96, 107.59, 109.85, 110.41, 112.03, 114.22, 115.83, 117.62, 120.55, 122.96, 123.55, 
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125.49, 127.63, 128.09, 128.34, 129.66, 130.38, 133.34, 137.39, 146.85, 149.74, 150.10, 
151.85, 153.56, 155.10, 155.52, 156.24, 158.69, 159.22, 162,65, 168.86; m/z (+EI) calc. For 
C38H33N5O7S (M+) 703.76, found 703.97 (M+H)
+; Yield: 48%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((3-
morpholinopropyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-yl)phenyl)thiazole-4-
carboxamide (4.216) from 4.201 and 4.53 
181 mg (1.0 eq.) of 4.201 and 183 mg (2.0 eq.) of 4.53 were added to a reaction vessel. Along 
with these, 2.0 eq. of HOBt and 1.75 eq. of DIC were added and a clear solution was made by 
dissolving these reactants in a minimum amount of DMF. The reaction mixture was stirred 
for 3 hours with occasional monitoring of the progress of the reaction by LCMS. The crude 
product was purified by using a SCX cartridge (2 gm) by the catch and release method, as 
described earlier in the chapter. Ten ml 2M NH3 was used to release the product from the 
cartridge. Purification of the product 4.216 (200 mg) was finally achieved using flash 





Light brown oil. IR (FTIR, νmax/cm-1) 630.70, 777.26, 862.45, 930.18, 985.92, 1029.19, 
1109.90, 1173.90, 1230.17, 1299.11, 1343.38, 1435.03, 1469.44, 1503.94, 1519.59, 1557.48, 
1585.11, 1634.61, 2006.35, 2331.65, 2823.88, 3329.29; 1H NMR (400 MHz, CDCl3, TMS); δ 
1.78 - 1.84 (m, 2H), 2.57 (br. s., 4H), 2.59 - 2.63 (m, 2H), 3.31 (t, J=8.69 Hz, 2H), 3.58 - 3.65 
(m, 2H), 3.91 (t, J=4.66 Hz, 4H), 4.69 (t, J=8.69 Hz, 2H), 6.86 (d, J=3.53 Hz, 1H), 6.88 (d, 
J=8.31 Hz, 1H), 7.35 (d, J=3.78 Hz, 1H), 7.43 - 7.45 (m, 1H), 7.46 (d, J=4.53 Hz, 1H), 7.48 
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(d, J=5.29 Hz, 1H), 7.52 - 7.56 (m, 1H), 7.62 - 7.66 (m, 1H), 7.68 (dd, J=8.81, 2.27 Hz, 1H), 
7.78 (dd, J=8.31, 2.01 Hz, 1H), 7.85 - 7.87 (m, 1H), 8.13 (d, J=2.01 Hz, 1H), 8.14 (s, 1H), 
8.31 (t, J=1.76 Hz, 1H), 8.43 (s, 1H), 8.78 (t, J=5.04 Hz, 1H), 9.39 (s, 1H); 13C NMR (100 
MHz, CDCl3); δ 14.32, 24.31, 29.61, 54.16, 59.09, 66.06, 67.20, 72.27, 73.94, 110.15, 
111.94, 114.70, 116.17, 117.87, 120.86, 123.29, 123.57, 123.85, 125.82, 127.93, 128.49, 
128.65, 129.93, 130.71, 133.72, 135.05, 139.97, 142.53, 147.21, 150.40, 150.56, 155.80, 
156.42, 156.62, 158.90, 159.54, 163.84, 169.15, 185.36; m/z (+EI) calc. For C39H35N5O7S 
(M+) 717.79, found 718.25 (M+H)+; Yield: 75%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((4-
(dimethylamino)butyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.217) from 4.202 and 4.53 
73 mg (1.0 eq.) of 4.202 and 96 mg (2.5 eq.) of 4.53 were added to a reaction vessel. Along 
with these, 2.0 eq. of HOBt and 1.75 eq. of DIC were added and a clear solution was made by 
dissolving these reactants in a minimum amount of DMF. The reaction mixture was stirred 
for 3 hours with occasional monitoring of the progress of the reaction by LCMS. The crude 
product was purified by using a SCX cartridge (2 gm) by the catch and release method, as 
described earlier in the chapter. Ten ml 2M NH3 was used to release the product from the 
cartridge. Purification of the product 4.217 (82 mg) was finally achieved using flash 







Brown oil. IR (FTIR, νmax/cm-1) 420.75, 562.35, 593.45, 635.77, 690.07, 736.98, 786.44, 
863.70, 938.04, 1016.60, 1109.32, 1201.00, 1231.27, 1297.86, 1466.34, 1534.91, 1584.89, 
1654.59, 2781.90, 2821.20, 2857.4, 2930.00, 3120.40, 3286.60; 1H NMR (400 MHz, CDCl3) 
δ 1.62 - 1.68 (m, 2H), 1.69 - 1.76 (m, 2H), 2.20 - 2.22 (m, 2H), 2.28 - 2.32 (m, 6H), 2.37 (t, 
J=6.55 Hz, 2H), 3.31 (t, J=8.69 Hz, 2H), 3.46 - 3.52 (m, 2H), 4.65 - 4.71 (m, 2H), 6.86 (d, 
J=3.53 Hz, 1H), 6.88 (d, J=8.31 Hz, 1H), 7.34 (d, J=3.78 Hz, 1H), 7.42 (d, J=1.01 Hz, 1H), 
7.44 - 7.45 (m, 1H), 7.46 - 7.47 (m, 1H), 7.52 - 7.55 (m, 1H), 7.65 (ddd, J=7.99, 2.08, 1.01 
Hz, 1H), 7.69 (dd, J=9.06, 2.27 Hz, 1H), 7.78 (dd, J=8.31, 1.76 Hz, 1H), 7.85 - 7.87 (m, 1H), 
8.08 (d, J=2.27 Hz, 1H), 8.12 - 8.13 (m, 1H), 8.28 (t, J=1.76 Hz, 1H), 9.39 (s, 1H); 13C NMR 
(100 MHz, CDCl3) δ 23.56, 26.41, 40.17, 47.13, 54.07, 55.69, 60.82, 65.98, 103.11, 105.77, 
107.75, 109.70, 110.77, 111.71, 112.33, 113.87, 114.05, 114.58, 115.08, 115.72, 117.51, 
117.63, 120.11, 127.45, 128.25, 129.51, 129.91, 133.24, 137.75, 142.59, 146.46, 146.57, 
148.65, 150.55, 151.81, 152.52, 155.97, 156.11; m/z (+EI) calc. For C38H35N5O6S (M+) 
689.78, found (M+H)+ 690.30; Yield: 77%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((3-
(pyrrolidin-1-yl)propyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.218) from 4.203 and 4.53 
60 mg (1.0 eq.) of 4.203 and 78 mg (2.5 eq.) of 4.53 were added to a reaction vessel. Along 
with these, 2.0 eq. of HOBt and 1.75 eq. of DIC were added and a clear solution was made by 
dissolving these reactants in a minimum amount of DMF. The reaction mixture was stirred 
for 3 hours with occasional monitoring of the progress of the reaction by LCMS. The crude 
product was purified by using a SCX cartridge (2 gm) by the catch and release method, as 
described earlier in the chapter. Ten ml 2M NH3 was used to release the product from the 
cartridge. Purification of the product 4.218 (71 mg) was finally madee using flash 











Light yellow oil. IR (FTIR, νmax/cm-1) 417.98, 427.08, 563.79, 562.30, 642.39, 691.16, 
725.18, 786.88, 865.50, 907.80, 983.38, 1016.60, 1107.30, 1140.60, 1204.00, 1231.64, 
1291.70, 1465.31, 1538.74, 1584.76, 1648.80, 2800.00, 2927.00, 2963.20, 3277.60; 1H NMR 
(400 MHz, CDCl3) δ 1.78 - 1.84 (m, 2H), 1.88 - 1.96 (m, 4H), 2.62 (br. s., 4H), 2.73 (t, 
J=5.92 Hz, 2H), 3.21 - 3.37 (m, 2H), 3.57 - 3.64 (m, 2H), 4.60 - 4.76 (m, 2H), 6.84 - 6.87 (m, 
1H), 7.34 (d, J=3.53 Hz, 1H), 7.40 (s, 1H), 7.41 (d, J=8.31 Hz, 1H), 7.45 (d, J=8.06 Hz, 1H), 
7.51 - 7.54 (m, 1H), 7.64 (ddd, J=7.93, 2.14, 1.01 Hz, 1H), 7.69 (dd, J=8.81, 2.01 Hz, 1H), 
7.78 (dd, J=8.31, 1.76 Hz, 1H), 7.86 (d, J=1.51 Hz, 1H), 8.07 (d, J=2.01 Hz, 1H), 8.13 (s, 
1H), 8.29 (t, J=1.89 Hz, 1H), 8.45 (s, 1H), 9.02 (t, J=4.66 Hz, 1H), 9.39 (s, 1H); 13C NMR 
(100 MHz, CDCl3) δ 23.48, 23.56, 40.17, 54.07, 55.54, 55.69, 60.82, 103.11, 105.77, 106.78, 
107.75, 109.55, 109.70, 110.77, 111.71, 112.33, 113.87, 114.06, 114.58, 115.08, 115.72, 
117.51, 117.63, 118.53, 120.11, 127.45, 128.07, 128.25, 129.51, 129.91, 133.24, 137.75, 
142.59, 146.46, 146.57, 150.55, 155.97, 156.11, 160.42; m/z (+EI) calc. For C39H35N5O6S 
(M+) 701.79, found (M+H)+ 702.40; Yield: 80%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((4-
(pyrrolidin-1-yl)butyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.219) from 4.204 and 4.53 
79 mg (1.0 eq.) of 4.204 and 100 mg (2.5 eq.) of 4.53 were added to a reaction vessel. Along 
with these, 2.0 eq. of HOBt and 1.75 eq. of DIC were added and a clear solution was made by 
dissolving these reactants in a minimum amount of DMF. The reaction mixture was stirred 
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for 3 hours with occasional monitoring of the progress of the reaction by LCMS. The crude 
product was purified by using a SCX cartridge (2 gm) by the catch and release method, as 
described earlier in the chapter. Ten ml 2M NH3 was used to release the product from the 
cartridge. Purification of the product 4.219 (105 mg) was finally achieved using flash 





Light yellow oil. IR (FTIR, νmax/cm-1) 430.10, 563.16, 631.16, 690.60, 737.16, 786.28, 
863.93, 981.42, 1110.54, 1231.51, 1295.24, 1465.97, 1541.08, 1584.71, 1648.11, 2924.5; 1H 
NMR (400 MHz, CDCl3) δ 1.58 (br. s., 2H), 1.74 - 1.80 (m, 6H), 2.48 (br. s., 2H), 2.53 - 2.57 
(m, 2H), 3.30 (t, J=8.81 Hz, 2 H), 3.55 - 3.62 (m, 2H), 4.65 - 4.71 (m, 2H), 6.84 - 6.87 (m, 
1H), 6.88 (s, 1H), 7.34 (d, J=3.53 Hz, 1H), 7.39 (d, J=9.06 Hz, 1H), 7.41 - 7.43 (m, 1H), 7.44 
- 7.47 (m, 1H), 7.51 - 7.55 (m, 1H), 7.66 (d, J=7.81 Hz, 1H), 7.70 (dd, J=8.94, 2.14 Hz, 1H), 
7.77 (dd, J=8.31, 1.76 Hz, 1H), 7.84 - 7.86 (m, 1H), 8.06 (d, J=2.01 Hz, 1H), 8.12 (s, 1H), 
8.27 (s, 1H), 8.41 (s, 1H), 9.28 (br. s., 1H), 9.38 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 
22.21, 24.04, 24.47, 25.84, 29.27, 54.81, 55.40, 59.30, 68.83, 71.93, 109.69, 109.80, 111.50, 
114.27, 115.83, 117.47, 119.33, 120.18, 120.37, 120.60, 122.91, 123.51, 125.47, 127.59, 
128.21, 128.32, 129.60, 130.37, 133.24, 138.36, 146.91, 150.09, 150.56, 151.79, 155.45, 
156.28, 158.58, 159.20, 162.63, 168.80; m/z (+EI) calc. For C40H37N5O6S (M+) 715.82, 





Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((3-(piperidin-
1-yl)propyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-yl)phenyl)thiazole-4-
carboxamide (4.220) from 4.205 and 4.53 
36 mg (1.0 eq.) of 4.205 and 46 mg (2.5 eq.) of 4.53 were added to a reaction vessel. Along 
with these, 2.0 eq. of HOBt and 1.75 eq. of DIC were added and a clear solution was made by 
dissolving these reactants in a minimum amount of DMF. The reaction mixture was stirred 
for 3 hours with occasional monitoring of the progress of the reaction by LCMS. The crude 
product was purified by using a SCX cartridge (2 gm) by the catch and release method, as 
described earlier in the chapter. Ten ml 2M NH3 was used to release the product from the 
cartridge. Purification of the product 4.220 (50 mg) was finally achieved using flash 





Light yellow oil. IR (FTIR, νmax/cm-1) 414.05, 430.07, 593.93, 641.84, 690.99, 725.88, 
788.11, 859.45, 907.80, 1016.60, 1110.68, 1198.00, 1237.58, 1297.70, 1343.00, 1466.02, 
1535.68, 1584.66, 1653.61, 2854.40, 2927.00, 3295.7; 1H NMR (400 MHz, CDCl3) δ 1.60 
(br. s., 2H), 1.75 - 1.83 (m, 6H), 2.54 (br. s., 2H), 2.57 - 2.61 (m, 2H), 3.32 (t, J=8.69 Hz, 
2H), 3.57 - 3.63 (m, 2H), 3.72 (s, 2H), 4.69 (t, J=8.81 Hz, 2H), 6.86 - 6.90 (m, 2H), 7.35 (d, 
J=3.53 Hz, 1H), 7.41 (d, J=9.06 Hz, 1H), 7.43 (s, 1H), 7.47 (d, J=7.81 Hz, 1H), 7.53 - 7.57 
(m, 1H), 7.65 (dd, J=2.01, 1.01 Hz, 1H), 7.67 - 7.70 (m, 1H), 7.79 (dd, J=8.31, 2.01 Hz, 1H), 
7.86 - 7.88 (m, 1H), 8.06 - 8.09 (m, 1H), 8.14 (s, 1H), 8.29 - 8.31 (m, 1H), 8.35 (s, 1H), 9.40 
(s, 1H); 13C NMR (100 MHz, CDCl3) δ 22.83, 24.12, 24.85, 27.22, 34.49, 50.49, 53.03, 
55.99, 60.59, 64.87, 102.22, 104.51, 106.75, 108.00, 108.12, 109.82, 110.07, 110.41, 114.28, 
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115.69, 119.45, 120.62, 121.72, 122.93, 124.77, 125.31, 126.50, 131.43, 132.24, 135.26, 
143.26, 143.93, 146.89, 147.71, 150.14, 150.93, 151.19, 152.84, 154.97, 161.00; m/z (+EI) 
calc. For C40H37N5O6S (M+) 715.82, found (M+H)
+ 716.40; Yield: 94%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((2-(4-
methylpiperazin-1- yl)ethyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.221) from 4.206 and 4.53 
151 mg (1.0 eq.) of 4.206 and 192 mg (2.5 eq.) of 4.53 were added to a reaction vessel. Along 
with these, 2.0 eq. of HOBt and 1.75 eq. of DIC were added and a clear solution was made by 
dissolving these reactants in a minimum amount of DMF. The reaction mixture was stirred 
for 3 hours with occasional monitoring of the progress of the reaction by LCMS. The crude 
product was purified by using a SCX cartridge (2 gm) by the catch and release method, as 
described earlier in the chapter. Ten ml 2M NH3 was used to release the product from the 
cartridge. Purification of the product 4.221 (120 mg) was finally achieved using flash 





Light yellow oil. IR (FTIR, νmax/cm-1) 418.35, 563.04, 593.92, 630.45, 691.07, 738.46, 
786.93, 862.47, 941.06, 980.35, 1010.60, 1107.30, 1146.60, 1164.70, 1207.00, 1234.17, 
1283.68, 1346.00, 1462.59, 1538.96, 1584.71, 1648.96, 2806.00, 2851.40, 2924.00, 3120.40, 
3283.60; 1H NMR (400 MHz, CDCl3) δ 2.26 - 2.30 (m, 2H), 2.31 (s, 3H), 2.47 - 2.53 (m, 
2H), 2.53 - 2.63 (m, 6H), 3.28 (t, J=8.81 Hz, 2H), 3.56 (q, J=5.79 Hz, 2H), 4.65 (t, J=8.81 
Hz, 2H), 6.80 (d, J=3.53 Hz, 1H), 6.85 (d, J=8.31 Hz, 1H), 7.21 (t, J=4.78 Hz, 1H), 7.30 (d, 
J=3.78 Hz, 1H), 7.37 - 7.42 (m, 2H), 7.44 - 7.50 (m, 2H), 7.55 (dt, J=8.31, 1.38 Hz, 1H), 7.74 
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(dd, J=8.31, 2.01 Hz, 1H), 7.71 (dd, J=8.94, 2.14 Hz, 1H), 7.81 (s, 1H), 8.00 (s, 1H), 8.09 (s, 
1H), 8.31 (t, J=1.76 Hz, 1H), 8.74 (s, 1H), 9.38 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 29.0, 
46.57, 53.00, 55.61, 56.40, 56.47, 56.87, 56.91, 78.13, 106.32, 108.11, 108.61, 110.94, 
113.27, 114.02, 117.35, 118.94, 119.37, 120.31, 121.13, 125.01, 127.09, 127.42, 128.37, 
129.58, 130.10, 130.25, 130.50, 132.47, 135.29, 146.08, 150.07, 150.36, 152.37, 155.94, 
162.07, 162.64, 169.87, 183.91; m/z (+EI) calc. For C39H36N6O6S (M+) 716.80, found 
(M+H)+ 717.30; Yield: 54%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((4-
(morpholinomethyl)phenyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.222) from 4.207 and 4.53 
32 mg (1.0 eq.) of 4.207 and 38 mg (2.5 eq.) of 4.53 were added to a reaction vessel. Along 
with these, 2.0 eq. of HOBt and 1.75 eq. of DIC were added and a clear solution was made by 
dissolving these reactants in a minimum amount of DMF. The reaction mixture was stirred 
for 3 hours with occasional monitoring of the progress of the reaction by LCMS. The crude 
product was purified by using a SCX cartridge (2 gm) by the catch and release method, as 
described earlier in the chapter. Ten ml 2M NH3 was used to release the product from the 
cartridge. Purification of the product 4.222 (36 mg) was finally achieved using flash 





Colourless oil. IR (FTIR, νmax/cm-1) 420.21, 456.34, 658.24, 697.01, 824.12, 976.24, 1112.65, 
1112.87, 113.01, 1343.00, 1458.17, 1492.08, 1550.21, 1567.37, 1634.13, 27.14, 2824.38, 
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2954.37, 3335.25; 1H NMR (400 MHz, DMSO-d6) δ 2.30 - 2.39 (m, 4H), 3.44 (s, 2H), 3.52 - 
3.64 (m, 4H), 4.65 (t, J=8.69 Hz, 2H), 6.94 (d, J=8.56 Hz, 1H), 7.17 (d, J=3.53 Hz, 1H), 7.30 
(d, J=8.56 Hz, 2H), 7.49 (d, J=3.78 Hz, 1H), 7.53 (t, J=8.06 Hz, 1H), 7.59 (s, 1H), 7.73 - 7.76 
(m, 1H), 7.77 (d, J=8.56 Hz, 2H), 7.79 (s, 1H), 7.80 - 7.81 (m, 1H), 7.92 - 7.97 (m, 2H), 8.08 
- 8.10 (m, 1H), 8.25 (d, J=2.01 Hz, 1H), 8.33 (t, J=1.76 Hz, 1H), 8.40 (s, 1H), 10.36 (s, 1H), 
10.53 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 29.01, 56.50, 57.02, 64.00, 65.23, 66.19, 
80.10, 108.20, 108.64, 109.11, 111.84, 113.14, 114.50, 119.14, 119.26, 120.08, 121.03, 
121.34, 121.56, 121.98, 124.90, 127.54, 128.34, 129.26, 129.65, 129.81, 129.97, 130.03, 
130.13, 132.32, 134.19, 136.35, 136.52, 146.25, 150.12, 150.32, 152.69, 156.37, 160.25, 
162.23, 162.38, 168.91, 184.00; m/z (+EI) calc. For C43H35N5O7S (M+) 765.83, found 
(M+H)+ 766.40; Yield: 76%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((2-(2-
methylthiazol-4-yl)ethyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.223) from 4.208 and 4.53 
256 mg (1.0 eq.) of 4.208 and 326 mg (2.5 eq.) of 4.53 were added to a reaction vessel. Along 
with these, 2.0 eq. of HOBt and 1.75 eq. of DIC were added and a clear solution was made by 
dissolving these reactants in a minimum amount of DMF. The reaction mixture was stirred 
for 3 hours with occasional monitoring of the progress of the reaction by LCMS. The crude 
product was purified by using a SCX cartridge (5 gm) by the catch and release method, as 
described earlier in the chapter. Ten ml 2M NH3 was used to release the product from the 
cartridge. Purification of the product 4.223 (300 mg) was finally achieved using flash 







Colourless oil. IR (FTIR, νmax/cm-1) 428.54, 473.28, 498.28, 561.90, 629.13, 684.51, 743.99, 
780.18, 935.01, 980.35, 1013.60, 1104.30, 1185.90, 1239.05, 1300.80, 1393.90, 1427.26, 
1471.73, 1524.40, 1584.90, 1641.70, 1666.50, 2851.4, 2924.00, 2957.2, 3120.40, 3323.00; 1H 
NMR (400 MHz, CDCl3) δ 2.70 (s, 3H), 3.05 (t, J=7.18 Hz, 2H), 3.73 (t, J=7.05 Hz, 2H), 
4.10 (q, J=7.05 Hz, 2H), 4.64 (t, J=8.69 Hz, 2H), 6.84 (d, J=8.31 Hz, 1H), 7.03 (d, J=3.53 
Hz, 1H), 7.10 (s, 1H), 7.37 (d, J=3.53 Hz, 1H), 7.45 (d, J=1.01 Hz, 1H), 7.46 (d, J=1.01 Hz, 
1H), 7.48 - 7.49 (m, 1H), 7.52 (dd, J=8.81, 1.51 Hz, 1H), 7.58 (d, J=9.06 Hz, 1H), 7.72 (dt, 
J=2.01, 1.26 Hz, 1H), 7.74 (d, J=2.27 Hz, 1H), 7.75 - 7.78 (m, 1H), 7.80 (dd, J=8.06, 1.26 
Hz, 1H), 7.86 (d, J=8.31 Hz, 1H), 8.00 (d, J=1.51 Hz, 1H), 8.13 (d, J=2.01 Hz, 1H), 8.24 (s, 
1H), 8.34 (t, J=1.76 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 19.43, 28.80, 29.24, 40.19, 
79.25, 106.35, 108.24, 108.54, 110.58, 113.24, 114.78, 115.27, 117.45, 119.63, 120.08, 
121.31, 121.84, 125.40, 127.36, 127.60, 129.03, 129.50, 130.21, 130.32, 132.01, 136.38, 
146.28, 150.07, 150.30, 152.34, 152.36, 156.28, 158.54, 162.03, 162.35, 163.28, 169.84, 
184.50; m/z (+EI) calc. For C38H29N5O6S2 (M+) 715.80, found (M+H)
+ 716.20; Yield: 79%. 
Procedure for the synthesis of 2-(2,3-dihydrobenzofuran-5-yl)-N-(3-(5-((2-((2-
(dimethylamino)ethyl)carbamoyl)benzofuran-5-yl)carbamoyl)furan-2-
yl)phenyl)thiazole-4-carboxamide (4.224) from 4.209 and 4.53 
59 mg (1.0 eq.) of 4.209 and 84 mg (2.5 eq.) of 4.53 were added to a reaction vessel. Along 
with these, 2.0 eq. of HOBt and 1.75 eq. of DIC were added and a clear solution was made by 
dissolving these reactants in a minimum amount of DMF. The reaction mixture was stirred 
for 3 hours with occasional monitoring of the progress of the reaction by LCMS. The crude 
product was purified by using a SCX cartridge (2 gm) by the catch and release method, as 
described earlier in the chapter. Ten ml 2M NH3 was used to release the product from the 
cartridge. Purification of the product 4.224 (60 mg) was finally achieved using flash 











Light yellow oil. IR (FTIR, νmax/cm-1) 416086, 564.12, 593.27, 640.94, 690.65, 725.29, 
786.41, 826.47, 938.04, 1019.60, 1107.30, 1203.53, 1232.22, 1294.70, 1352.10, 1463.65, 
1538.72, 1585.07, 1645.88, 2921.00, 3117.4, 3298.70; 1H NMR (400 MHz, CDCl3) δ 2.32 (s, 
6H), 2.56 (t, J=5.79 Hz, 2H), 3.30 (t, J=8.69 Hz, 2H), 3.56 (q, J=5.54 Hz, 2H), 4.68 (t, 
J=8.81 Hz, 2H), 6.84 (d, J=3.78 Hz, 1H), 6.87 (d, J=8.56 Hz, 1H), 7.18 (t, J=4.66 Hz, 1H), 
7.33 (d, J=3.53 Hz, 1H), 7.41 - 7.46 (m, 2H), 7.48 - 7.53 (m, 2H), 7.64 (d, J=8.06 Hz, 1H), 
7.68 (dd, J=9.06, 2.01 Hz, 1H), 7.77 (dd, J=8.31, 1.76 Hz, 1H), 7.85 (s, 1H), 8.10 (d, J=1.76 
Hz, 1H), 8.12 (s, 1H), 8.27 (s, 1H), 8.45 (s, 1H), 9.38 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 
23.42, 29.26, 36.69, 45.24, 57.77, 71.94, 107.68, 108.29, 109.80, 110.26, 112.01, 114.18, 
115.82, 117.49, 120.17, 120.52, 120.62, 122.92, 123.51, 125.47, 127.59, 128.03, 128.32, 
129.58, 130.36, 133.35, 138.33, 146.89, 149.75, 150.07, 151.83, 155.43, 156.28, 159.21, 
162.62, 168.80; m/z (+EI) calc. For C36H31N5O6S (M+) 661.73, found (M+H)




4.2.1 Assays used for the biophysical evaluation of the ligands  
Although a large number of techniques are used for the biophysical evaluation of the G-
quadruplex ligands, this thesis focuses on high-throughput fluorescence-resonance-energy-
transfer (FRET) melting experiments and a biophysical modified telomere-repeat-
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amplification-protocol (TRAP) (discussed in chapter 2). Additionally, ultraviolet (UV), 
melting and circular dichroism (CD) experiments are discussed, as they remain the most 
experimentally feasible and informative techniques amongst isothermal/viscosimetry titration 
colorimetry, voltametric, DNA footprinting and surface plasmon resonance (SPR) techniques.  
4.2.1.1 Fluorescence resonance energy transfer (FRET) assay 
The principles and application of the FRET melting assay have been described previously in 
chapter 2. 
4.2.1.1.1 Choice of FRET sequences  
The aryl-polyamide series was screened by FRET against several oligonucleotides, as 
follows:  
 
i) F21T; telomeric DNA – For quadruplex ligands to function as telomerase-inhibitors they 
must show significant quadruplex-stabilizing ability. This sequence is indicative of telomeric-
DNA. Good-quadruplex ligands show greater than ~ΔTm25 °C [c=1 μm].  
ii) Hairpin duplex DNA – G-quadruplex ligands must demonstrate selectivity towards 
quadruplex DNA from duplex DNA. Favourable G-quadruplex ligands will, therefore, not 
bind duplex DNA and demonstrate high ΔTm[Quadruplex]: ΔTm[Duplex] ratios.  
iii) TERRA HTelo – When these non-coding telomeric repeat-containing RNA (TERRA) 
sequences are transcribed, they can regulate telomere maintenance, binding TRF1 and TRF2 
and interfere with telomere elongation.  
iv) cKit1 and cKit2 – PQS have been identified within the promoter region of the c-kit 
oncogene. cKit is a dominant oncogene in gastrointestinal-stromal (GIST) tumours and 
melanomas promoting cell survival, proliferation and differentiation.  
v) Heat shock protein 90 (HSP90a) - PQS have been identified within the promoter region 
of HSP90. HSP90 is a molecular chaperone involved in the folding of proteins. Cancer-
causing oncoproteins require HSP90 as a result of destabilizing mutant genetic aberrations. 
Tumour cells are, therefore, dependent on HSP90. 17AAG is a HSP90 inhibitor in the clinic 
highlighting proof-of-principle for HSP90 inhibition.  
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vi) k-Ras (KR32) - PQS have been identified within the promoter region of the c-kit 
oncogene. k-Ras is a dominant oncogene in pancreatic tumours, promoting cell growth.  
 
4.2.1.1.2 Materials and methods  
4.2.1.1.2.1 Compound preparation and long-term storage  
All compounds were dissolved in 10 mM stock solutions in 100% dimethyl sulfoxide 
(DMSO) and stored at -20 °C. Compounds were then diluted in 1 mM dH2O (10% DMSO) 
prior to use.  
 
4.2.1.1.2.2 Oligoneucleotide sequences used for the FRET assay  
The following oligonucleotide sequences were purchased from Eurogentec, Southampton, 
UK.  
i) F21T (Human telomeric sequence): 5'-FAM-GGG TTA GGG TTA GGG TTA GGG-
TAMRA-3' 
ii) T-Loop (Duplex DNA): 5'-FAM-TAT AGC TATA TTT TTT TATA GCT ATA-
TAMRA-3' 
iii) k-Ras F32RT (KR32): 5'-FAM- AGG GCG GTG TGG GAA GAG GGA AGA GGG 
GGA GG-TAMRA  
iv) k-Ras F33RT (KR33): 5'-FAM-AGG GCG GTG TGG GAA GAG GGA AGA GGG 
GGA GGC-TAMRA  
v) HSP90a: 5'-FAM- GGG CCA AAG GGA AGG GGT GGG-TAMRA  
vi) HSP90b: 5'-FAM- GGG CGG GCC AAA GGG AAG GGG-TAMRA  
vii) HSP90c: 5'-FAM-AGG GCG GGC CAA AGG GAA GGG GTG GGC-TAMRA  
viii) cKit-1: 5'-FAM-AGA GGG AGG GCG CTG GGA GGA GGG GCT-TAMRA  
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ix) cKit-2: 5'-FAM-CCC GGG CGG GCG CGA GGG AGG GGA GG-TAMRA  
x) DRH: TTA-GGG-TTAGGG-TTT-TTT-CCC-UAA-CCC-UAA 
xi) CDRH: TTA-GGG-TTAGGG-TTT-TTT-CCC-TAA-CCC-TAA 
xii) Cmyc: TGG-GGA-GGG-TGG-GGAGGG-TGG-GGA-AGG 
x) RNA hTelo (TERRA): 5'-FAM-d(GGG[UUAGGG]3)-TAMRA  
4.2.1.1.2.3 Preparation of FRET-buffer 
TAMRA (6-carboxytetramethylrhodamine) is an acceptor fluorophore, whereas FAM (6-
carboxyfluorescein) is a donor fluorophore. From 20 μm stock solutions, 400 nM solutions in 
FRET buffer (optimised as 50 mM potassium, 50 mM cacodylate, pH 7.4) were prepared 
prior to use.  The buffer was stored in the freezer at -20 °C.  
 
4.2.1.1.2.4 Annealing of DNA 
The fluorescence tagged sequences were diluted in two steps with sterile water (DNA Grade, 
Fisher Scientific) to obtain first 100 μm, then 20 μm solutions. These solutions were then 
further diluted to 400 nM using FRET-buffer. The sequences were annealed by heating at 85 
°C for 5 minutes, followed by cooling to room temperature over two hours (Grant Bio PCH-2 
Dry Block Heating/Cooling System).  
 
4.2.1.1.2.5 Preparation of ligand solutions  
For all the synthesized biaryl polyamides, ligand stock solutions of 20 mM were made with 
dimethyl sulfoxide (≥ 99.9%, A.C.S. spectrophotometric grade, Sigma-Aldrich). From these 
stock solutions, the following dilutions were prepared using FRET buffer: 100 μm, 50 μm, 25 
μm, 15 μm, 10 μm, 5 μm and 2 μm, for some compounds, and also 1 μm. These 






4.2.1.1.2.6 Fluorescent Resonance Energy Transfer (FRET)-Based DNA Melting Assay  
For the FRET-based DNA melting assay, 50 µl of annealed DNA was placed in each well of 
a 96-well plate (Bio-Rad Laboratories), and then 50 µl of ligand solution was added to each 
well. Different concentrations of each compound were tested, each concentration being tested 
in triplicate. Pure FRET buffer instead of ligand solution was added to all wells of the first 
line (A) of the plate to serve as blank. After 15 minutes of incubation at room-temperature, 
the well plate was processed in the DNA Engine Opticon (Continuous Fluorescence Detector, 
MJ Research) and florescence measurements were taken over a temperature range from 30 °C 
to 100 °C at intervals of 0.5 °C. Prior to each measurement, the temperature was kept 
constant for 30 seconds. The incident radiation was emitted at 450-495 nm and detection 
measured at 515-545 nm.   
4.2.1.1.2.7 Data processing 
The data were analysed using the program Origin – Scientific Graphing and Analysis 
Software (Version 7.0, OriginLab Corp.). The increases in the melting temperatures (Tm) 
were obtained by subtracting the value of the blank from the measured values of each sample. 
For each concentration of every compound the average of Tm was calculated from the three 
corresponding values. 
 
4.2.1.2 F21T Competition assay with calf thymus-DNA 
For compound KN-88 an additional competition assay was performed with F21T and duplex 
DNA of calf thymus. The aim of this experiment was to clarify whether the affinity between 
the ligand KN-88 and the DNA sequence F21T is affected by the simultaneous presence of 
duplex DNA. 
 
A 800 nM solution of F21T in FRET-buffer was annealed and a ligand solution of 2 μm from 
KN-88 was made. A solution of calf thymus-DNA (CT-DNA) was prepared by dissolving a 
small amount with unknown mass of calf thymus-DNA sodium salt (Type I, Highly 
Polymerized, fibrous preparation) in 20 ml FRET-buffer. On the following day, the solution 
was filtered (0.45 μm). To determine its purity and concentration, UV measurements at 
wavelengths of 260 nm and 280 nm were taken from 1:100 and 1:10 dilutions (Biochrom 
Libra S22 UV/Vis Spectrophotometer). Considering the determined concentration, the calf 
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thymus-DNA solution was then further diluted with FRET-buffer to obtain solutions of the 
following concentrations: 800 μm (corresponds to a concentration ratio F21T: CT-DNA = 
1:1000), 80 μm (1:100), 8 μm (1:10) and 800 nM (1:1).  
A well-plate was filled as depicted in Table 4.1. Thereby, the calf thymus-DNA-solutions 
were added 2 minutes after all other components. The well plate was processed in the DNA 
Engine Opticon and the data analysed as described above.  
Table 4.1: F21T competition assay with calf thymus-DNA: Filling of the well-plate. 
 1 2 3 
A - blank 25 µl F21T 800 nM + 75 µl FRET-buffer 
B - 1:0 25 µl F21T 800 nM + 50 µl KN-88 2 μm + 25 µl FRET-buffer 
C - 1:1 25 µl F21T 800 nM + 50 µl KN-88 2 μm + 25 µl CT-DNA 800 nM 
D - 1:10 25 µl F21T 800 nM + 50 µl KN-88 2 μm + 25 µl CT-DNA 8 μm 
E - 1:100 25 µl F21T 800 nM + 50 µl KN-88 2 μm + 25 µl CT-DNA 80 μm 
F - 1:1000 25 µl F21T 800 nM + 50 µl KN-88 2 μm + 25 µl CT-DNA 800 μm 
 
4.2.1.3 Telomere repeat amplification protocol (trap) assay  
Since it was established that quadruplex-ligands contaminate the second-stage of the 
traditional TRAP assay, a modified three-stage assay coined TRAP–LIG was proposed [240]. 
The first-stage involved TS primer elongation by telomerase in the presence of the ligand. 
The second and novel-introduction was the subsequent removal of the ligand. Finally, the 
elongated artifacts were amplified via polymerase-chain-reaction (PCR).  
 
4.2.1.4 Materials and Methods 
Telomerase-dependent elongation was carried out by preparing a master mix containing 0.1 
μg TS forward primer (5′-AAT CCG TCG AGC AGA GTT-3′), TRAP buffer (20 mM Tris–
HCl [pH 8.3], 68 mM KCl, 1.5 mM MgCl2, 1 mM EGTA, and 0.05% [v/v] Tween 20), 0.05 
μg bovine serum albumin (BSA), dNTPs (125  μm), and protein extract (500 ng/μl) diluted in 
lysis buffer (10 mM Tris–HCl [pH 7.5], 1 mM MgCl2, 1 mM EGTA, 0.5% Chaps, 10% 
glycerol, 5 mM β-mercaptoethanol, and 0.1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride 
[AEBSF]). The elongation master mix was added to freshly prepared ligands at various 
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concentrations diluted in dH2O, a negative control (no telomerase) and a positive control (no 
ligand). Elongation occurred for 30 mins at 30 °C, followed by 94 °C for 5 mins and the final 
mixture was maintained at 20 °C.  
 
The elongated TRAP products were purified to remove ligands in the QIA quick nucleotide 
purification kit (Qiagen) in accordance with the manufacturer’s instructions. The QIA quick 
kit is designed for the purification of oligonucleotides more than 17 bases in length. An initial 
high-salt buffer binds the negatively charged oligonucleotides to the positively charged spin 
tube membrane. Further centrifugation ensures all other components, including positively 
charged and neutral ligand molecules are eluted. Then, an ethanol-based buffer is washed 
through the spin-tube to wash any impurities away before the DNA is eluted using a low-salt 
concentration solution. Since the TRAP assay is sensitive to trace amounts of ethanol, the 
purified samples were dissolved in DEPC H2O and precipitated in a centrifuged vacuum at 30 
°C and then re-dissolved in 40 μL PCR-grade water at room temperature prior to the 
amplification step.  
 
The purified extended artifacts were then amplified via PCR. The amplification master-mix 
was comprised of 1 μm ACX reverse primer (5′-GCG CGG [CTTACC]3 CTA ACC-3′), 0.1 
μg TS forward primer (5′-AAT CCG TCG AGC AGA GTT-3′), TRAP buffer, 5 μg BSA, 0.5 
mM dNTPs, and 2 units of Taq polymerase (RedHot, ABgene, UK). A 10 μl aliquot of the 
5X master mix was added to the 40 μL purified telomerase extended samples and amplified 
for 35 cycles of 94 °C for 30 s, of 61 °C for 1 min, and of 72 °C for 1 min.  
 
TRAP products were separated by a 10% w/w PAGE and visualized with 1xSYBR Green I 
nucleic acid gel stain (Sigma-Aldrich, S9430). Gels were quantified using a gel scanner and 
Gene Tool software (Syngene, UK). Densitometry analysis was obtained by integrating the 
total intensity of each PCR product ladder in the denaturing gels. Drug samples were 
normalized against positive control (no ligand). Lanes were background-corrected through 
subtracting the integrated total intensity of the negative control (no telomerase). The 
biophysical TRAP-LIG data for the aryl polyamide series of ligands were collected at a range 
of concentrations to obtain dose–response curves from which EC50 values (the concentrations 
required for 50% enzyme inhibition, corresponding to a 50% decrease in total integrated 




4.3.1 Assays for the biological evaluation of G-quadruplex ligands  
Although biophysical assays (discussed in earlier section) provide relatively fast, ‘proof-of-
principle’ information in assessing G-quadruplex stabilization and acute telomerase 
inhibition, the next level of evaluation is the introduction of G-quadruplex ligands into cells. 
Initially, biophysical assays were used to screen large libraries of small molecules and 
identify potentially active small-molecules. Subsequently, this focused range of small 
molecules was examined in cell-culture studies.  
 
Prior to clinical evaluation, lead-molecules must be identified by pre-clinical studies. The 
purpose is to emphasize and consolidate the biophysical proof-of-principle studies. In anti-
cancer drug discovery, the initial paradigm of any new class of agents is to demonstrate 
significant (<1 μm) toxicity in a range of tumour cell lines while having little adverse 
effects/toxicity in a healthy fibroblast cell line. Further, we must identify and validate the 
molecular target and mechanism of action of the compound for pre-clinical investigations. 
Toxicity screens can offer preliminary insight into the mechanism of action of ligands 
through observing selectivity/potency in a range of cell lines.  
 
The principles of the biological assays used to assess the activity of the G-quadruplex binding 
ligands have been described in Chapter 2. 
 
4.3.2 Materials and methods  
4.3.2.1 Cell Culture  
The aryl polyamide series was evaluated against a varied panel of cell lines: MCF7 (human 
breast adenocarcinoma), A549 (human lung adenocarcinoma), and MIA-Pa-Ca-2 (human 
pancreatic) were obtained from the European Collection of Cell Cultures, and WI38 (healthy 
fibroblast), RCC4 (human renal) and HPAC (human pancreatic) cell lines were obtained from 
the American Type Culture Collection. All adherent cell-lines were maintained in monolayer 
culture in 75 cm2 flasks (TPP, Switzerland) under a humidified 5% CO2 atmosphere at 37ºC. 
Unless otherwise specified, all incubations were made under these conditions. For MCF7 and 
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A549, Dulbecco’s MEM medium (GIBCO 21969, Invitrogen, UK) was used, supplemented 
with L-glutamine (2 mM, GIBCO 25030, Invitrogen, UK), essential amino acids (1%, 
GIBCO 11140, Invitrogen, UK), foetal calf serum (10%, S1810, Biosera, UK) and 
hydrocortisone (0.5 μg/mL, Acros Organics, UK). For MIA-Pa-Ca-2, Dulbecco’s MEM, 
supplemented with L-glutamine (2mM) and foetal calf serum (10%) was used. For WI38 the 
medium MEM (M2279, Sigma, UK) with added L-glutamine (2mM), essential amino acids 
(1%) and foetal calf serum (10%) was used. For HPAC the medium D-MEM/F12 (1:1) 
(21331, Invitrogen, UK) supplemented with L-glutamine (2mM), insulin (0.002 mg/ml, 
GIBCO 12585-014, Invitrogen, UK), transferrin (0.005 mg/ml, 11108-016, Invitrogen, UK), 
hydrocortisone (40 ng/ml), epidermal growth factor (10 ng/ml, 53003-018, Invitrogen, UK) 
and foetal calf serum (10%) was used. For RCC4 the medium employed was RPMI 1640 
(GIBCO 31870, Invitrogen, UK), supplemented with L-glutamine (2 mM), foetal calf serum 
(10%) and cultured in G418 (0.5 mg/ml) (10131-027, Invitrogen, UK). For passaging, cells 
were washed with PBS (GIBCO 14040, Invitrogen, UK), incubated with trypsine (GIBCO 
25300, Invitrogen, UK), and re-seeded into fresh medium. For seeding, cells were counted 
using a Neubauer haemocytometer (Assistant, Germany) by microscopy on a non-adherent 
suspension of cells that was washed in PBS, trypsinised, centrifuged at 8 °C at 8000 rpm for 
3 mins and re-suspended in fresh medium.  
 
4.3.2.2 Sulfhorhodamine B assay (SRB)  
MCF7, A549, MIA-Pa-Ca-2, WI38, RCC4 and HPAC were counted and diluted to the 
required concentration in 20 mL medium, as 160 μL medium (containing a pre-determined 
number of cells) was seeded into each well of a 96 well plate (Nunc, Denmark). After 24 h 
incubation, the polyamide series was subjected to a series of dilutions as 40 μL of medium 
containing variant drug concentrations was added and the cells incubated for 96 h. The 
medium was then removed and the cells fixed by incubation with TCA (10%, Sigma-Aldrich, 
UK) in water for 30 mins at 4 °C. After the TCA was removed, cells were washed 5 times 
with deionised water and dried at 60 °C for 1 h. Sulforhodamine B (80 μL, 0.4% in 1% acetic 
acid, Acros Organics, UK) was then added to the cells for 15 mins at RT. The SRB was then 
removed as the wells were washed with 1% acetic acid (200 μL), and dried at 60ºC for 1 h. 
Tris-base (100 μL, 10 mM, Acros Organics, UK) solution was then added, and the plates 
shaken for 5 mins. The absorbance at 540 nm was then measured with a plate reader 
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(Spectrostar Omega, BMG Labtech, Germany). All data were normalized to the value of 100 
for the control experiment (untreated cells), and the IC50 values were obtained as the 
concentration leading to an absorbance intensity of 50%. Individual data sets were averaged 
in quadruplicate with the assay performed on three independent occasions.  
 
4.3.2.3 Long-term treatment profiles and population doublings studies  
In initial experiments, varying numbers of cells were seeded in T25 and T75 flasks to 
predetermine the optimum number of cells required for the following experiments. Long-term 
cell studies occurred using the MIA-PaCa 2 cell line. Several treatment profiles were utilized; 
(*re-treatment involved discarding the medium, washing the cells with PBS and applying the 
drug in fresh medium).  
 
i) 0.6 x IC50 for a total of 7 days. Cells were re-treated* with the drug on day 3 and day 5.  
ii) 1 x IC50 for 1, 3 and 5 days. The 5-day study was re-treated* on day 3.  
iii) Varying concentrations of drug for 4-days with re-treatment on day 2; the 4-day treatment 
cycle was repeated to observe the long-term effect on cell population.  
 
Treatment profile iii) was utilized in a long-term pd study. Cells were counted on day 4, as 
described, and re-seeded (1 x 104 cells in T25 flasks and 1x105 cells in T75 flasks to ensure 
~80% confluency after 4-days) in their respective treatment profiles for the duration of the 
experiment. Two-seeding densities were used, and each condition repeated in triplicate and 




5; Nf is the number of cells at time of counting; pd is number of population 
doubling  
4.3.2.4 Modified telomere repeat amplification protocol (TRAP)  
The materials and methods performed were as previously described in 4.2.1.4. Protein 
extracts were a result of treatment profiles i) and ii) outlined in 4.3.2.3.  




4.3.2.5 β-Galactosidase senescence studies  
Senescence was detected and quantified using a commercially available kit (β-galactosidase 
senescence staining kit, Cell Signalling Technology, MA, USA) in accordance with the 
manufacturers’ instructions. Following appropriate treatment of the cells, 1x105 cells were 
seeded in a 35 mm well within 6-well plates in 2 ml of medium and incubated for 24 h. 
Afterwards, the medium was removed and the cells washed with 2 ml of PBS, and then 
treated with 1 ml of fixative solution (2% formaldehyde and 2% glutaraldehyde in PBS) for 
15 mins at room temperature. The fixative was then removed and the cells washed with PBS. 
Afterwards, freshly prepared staining solution (930 μL of 500 mM potassium ferrocyanide, 
10 μL 500 mM potassium ferricyanide and 50 μl of 20 mg/ml 5-bromo-4-chloro-3-indolyl-β-
D-galactopyranoside in DMF, final volume of 1 ml) was added to the cells and incubated 
overnight. The number of senescent cells, as indicated by blue pigmentation, was quantified 
by microscopy.  
 
4.3.2.6 Western blots; protein expression studies  
Western blots were conducted to investigate the relative expression of telomerase (hTERT) 
and k-Ras. Whole cell nuclear extracts were extracted using the RIPA lysis buffer system (sc-
24948, Santa-Cruz Biotechnology, USA) and quantified using the BCA protein assay (23225, 
Pierce, Thermo Scientific, USA). Prior to gel-loading, ~150 μg of protein sample was 
vortexed in a 1:1 mixture with 2 x Laemmli samples buffer and heated to 90 °C for 5 mins. 
Samples were run on Mini-Protean TGX Any kD Precast Gels (456-9033, BioRad, USA) at 
200v for 40 mins, and subsequently transferred onto nitrocellulose membranes at 40 mV for 
120 mins at room-temperature. The nitrocellulose membrane was then blocked with 3% (w/v) 
non-fat dried milk in Tris buffered saline (TBS) buffer (50 mM tris, pH 7.2, 150 mM NaCl). 
Incubation with primary antibody, 1/200 anti-k-Ras (F234; sc-30, Santa-Cruz Biotechnology, 
USA; Mouse), 1/200 anti-hTERT (600401252, Rockland Immunochemicals, USA; Rabbit) 
and 1/100 anti-actin (AC-15, ab6276, Abcam, USA; mouse) was conducted overnight at 4 
°C. After incubation with the primary antibody, the membrane was washed twice for 5 mins 
with TBS, and treated with secondary antibody for 2 h. Proteins were detected using Super-




5.0 Conclusion and Future Work 
 
After careful modification of the first generation biaryl polyamides, a total of 66 molecules 
containing novel benzofused biaryl moiety were synthesized using a solution phase 
combinatorial approach. Most molecules were obtained in good yield and purity utilizing 
established synthetic procedures. The structures of these compounds were unambiguously 
confirmed using a range of spectroscopic techniques. Initial assessment of the G-quadruplex 
binding ligands was carried out using a FRET melting assay. KN-242, which is a hybrid 
benzofused compound containing biaryl building blocks, provided significant G-quadruplex 
stabilization of human telomeric G-quadruplex by 34.43 ºC at 1 μm concentration, while 
showing no binding affinity towards duplex DNA. Analysis of the molecules with other 
oligonucleotide sequences such as ckit-1, ckit-2, cmyc, DRH and CDRH by FRET melting 
further confirmed their ability to selectivly stabilize telomeric quadruplexes. Biophysical 
studies of some of the molecules by TRAP and modified-TRAP assays showed some degree 
of telomerase inhibition, while short term growth inhibitory assays against six different 
cancer cell lines (MiaPaCa2, A549, MCF7, HeLa, U87MG and A431) provided low 
micromolar IC50 values, and between 5-8 fold selectivity for cancer cell lines compared to the 
non-tumor cell line. Molecules such as these, with good G-quadruplex stabilizing potential, 
binding selectivity, cytotoxicity and drug like properties have potential as therapeutic agents 
in the oncology area. 
 
As these initial results have demonstrated significant activity against a panel of pancreatic 
tumour cell lines, future biological investigations will be undertaken against the promoter 
kRAS G-quadruplex sequences. Biological evaluation of some of the ligands is presently 
underway at the University of Missisipy (USA) in which they are being studied in a kras 
model. Although a limited SAR has already been established based on available data, a 
complete SAR has yet to be established by compiling all the biological results. Future work 
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Table AP1: ΔTm values for Duplex at 5 μm, 2 μm, and 1 μm concentration with standard deviations 
 
ΔTm values for Control Duplex DNA sequence 
Code Structure MW 5µm 2 μm 1 μm 
KN-24 
 
504.02 0.07 ± 0.20 0.00 ± 0.00 0.20 ± 0.00 
KN-39 
 
491.11 0.00 ± 0.00 0.13 ± 0.15 0.37 ± 0.58 
KN-40 
 
507.38 0.20 ± 0.10 0.07 ± 0.08 0.17 ± 0.13 
KN-41 
 
507.15 0.40 ± 0.00 0.30 ± 0.00 0.23 ± 0.05 
KN-45 
 
543.00 0.23 ± 0.11 0.47 ± 0.08 -1.53 ± 0.05 
KN-46 
 
527.10 0.23 ± 0.08 0.33 ± 0.15 0.533 ± 0.08 
KN-47 
 
543.05 -1.53 ± 0.58 -1.533 ± 0.15 -1.50 ± 0.10 
KN-48 
 
529.96 -1.33 ± 0.08 0.33 ± 0.05 0.13 ± 0.05 
KN-49 
 
528.94 -0.43 ± 0.92 -1.40 ± 0.00 0.27 ± 0.05 
KN-50 
 
512.99 0.17 ± 0.05 0.23 ± 0.08 0.43 ± 0.58 
KN-51 
 
489.17 0.00 ± 0.20 0.30 ± 0.08 0.17 ± 0.0 
KN-52 
 
490.14 0.00 ± 0.58 0.13 ± 0.13 0.37 ± 0.00 
KN-53 
 
473.13 -1.33 ± 0.13 -1.63 ± 0.00 -1.33 ± 0.10 
421 
 
Table AP1: ΔTm values for Duplex at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
 
ΔTm values for Control Duplex DNA sequence 
Code Structure MW 5µm 2 μm 1 μm 
KN-54 
 
499.85 -1.37 ± 0.08 -1.50 ± 0.05 -1.50 ± 0.40 
KN-55 
 
499.92 -1.53 ± 0.20 -1.30 ± 0.11 -1.27 ± 0.29 
KN-56 
 
483.88 -1.60 ± 0.05 -1.33 ± 0.10 -1.33 ± 0.00 
KN-57 
 
539.09 -1.50 ± 0.05 -1.70 ± 0.20 -1.53 ± 0.10 
KN-58 
 
539.09 -1.33 ± 0.17 -1.53 ± 0.00 -1.60 ± 0.08 
KN-59 
 
523.12 -1.53 ± 0.10 -1.33 ± 0.00 -1.40 ± 0.21 
KN-60 
 
554.99 -1.67 ± 0.58 -1.57 ± 0.08 -1.26 ± 0.13 
KN-61 
 
554.99 -1.67 ± 0.10 -1.67 ± 0.10 -1.50 ± 0.05 
KN-62 
 
539.05 -1.63 ± 0.13 -1.57 ± 0.10 -1.33 ± 0.08 
KN-78 
 
692.55 -1.20 ± 0.15 -1.07 ± 0.00 -1.26 ± 0.00 
KN-79 
 
697.81 -1.40 ± 0.58 -1.37 ± 0.10 -1.13 ± 0.08 
422 
 
Table AP1: ΔTm values for Duplex at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
 
ΔTm values for Control Duplex DNA sequence 
Code Structure MW 5µm 2 μm 1 μm 
KN-83 
 
713.39 -1.37 ± 0.00 -1.40 ± 0.58 -1.56 ± 0.26 
KN-88 
 
692.72 0.71 ± 0.08 0.40 ± 0.08 0.40 ± 0.05 
KN-89 
 
697.57 0.40 ± 0.08 -0.80 ± 0.97 -1.17 ± 0.00 
KN-90 
 
693.30 0.12 ± 0.11 0.08 ± 0.12 0.06 ± 0.13 
KN-91 
 
698.53 0.07 ± 0.15 0.26 ± 0.05 0.30 ± 0.11 
KN-110 
 
639.33 0.10 ± 0.00 0.09 ± 0.00 0.03 ± 0.00 
KN-112 
 
639.32 0.43 ± 0.05 0.34 ± 0.00 0.15 ± 0.10 
KN-119 
 
676.13 -0.33 ± 0.08 0.20 ± 0.15 0.33 ± 0.00 
KN-120 
 
676.21 0.33 ± 0.00 0.67 ± 0.08 0.17 ± 0.05 
KN-136 
 
725.81 0.24 ± 0.00 0.19 ± 0.08 0.02 ± 0.00 
423 
 
Table AP1: ΔTm values for Duplex at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
ΔTm values for Control Duplex DNA sequence 
Code Structure MW 5µm 2 μm 1 μm 
KN-130 
 
692.81 0.33 ± 0.00 0.36 ± 0.05 0.267 ± 0.05 
KN-143 
 
674.77 0.33 ± 0.10 0.67 ± 0.58 0.37 ± 0.08 
KN-144 
 
679.77 0.83 ± 0.10 0.37 ± 0.08 0.47 ± 0.15 
KN-145 
 
750.86 0.53 ± 0.00 0.43 ± 0.00 0.433 ± 0.10 
KN-146 
 
755.86 0.67 ± 0.15 0.40 ± 0.58 0.30 ± 0.58 
KN-148 
 
656.68 1.47 ± 0.05 1.83 ± 0.00 0.40 ± 0.58 
KN-149 
 
689.78 0.33 ± 0.10 0.53 ± 0.00 0.33 ± 0.10 
KN-150 
 
649.72 0.50 ± 0.08 0.33 ± 0.10 0.53 ± 0.00 
KN-154 
 








Table AP1: ΔTm values for Duplex at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
ΔTm values for Control Duplex DNA sequence 
Code Structure MW 5µm 2 μm 1 μm 
KN-155 
 
687.74 0.23 ± 0.00 0.19 ± 0.00 0.02 ± 0.08 
KN-156 
 
672.75 0.27 ± 0.53 0.33 ± 0.00 0.21 ± 0.08 
KN-157 
 
688.81 0.52 ± 0.15 0.32 ± 0.10 0.13 ± 0.08 
KN-158 
 
687.76 0.93 ± 0.00 0.01 ± 0.05 0.09 ± 0.12 
KN-159 
 
674.70 0.52 ± 0.00 0.41 ± 0.10 0.24 ± 0.00 
KN-160 
 
703.81 0.27 ± 0.08 0.27 ± 0.58 0.33 ± 0.00 
KN-161 
 
690.76 0.38 ± 0.00 -0.67 ± 0.10 0.17 ± 0.15 
KN-164 
 
703.19 0.00 ±0.08 0.03 ± 0.00 0.06 ± 0.10 
KN-176 
 
691.82 0.57 ± 0.58 -0.47 ± 0.00 0.27 ± 0.08 
KN-200 
 
763.86 0.00 ± 0.13 0.23 ± 0.00 0.23 ± 0.00 
KN-202 
 






Table AP1: ΔTm values for Duplex at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
 
ΔTm values for Control Duplex DNA sequence 
Code Structure MW 5µm 2 μm 1 μm 
KN-207 
 
777.89 0.23 ± 0.00 0.10 ± 0.08 0.31 ± 0.08 
KN-212 
 
701.79 0.50 ± 0.08 0.30 ± 0.58 0.37 ± 0.58 
KN-217 
 
687.76 0.43 ± 0.10 0.67 ± 0.05 0.41 ± 0.15 
KN-222 
 
703.76 0.31 ± 0.08 0.45 ± 0.15 0.60 ± 0.08 
KN-227 
 
717.79 0.35 ± 0.05 0.45 ± 0.05 0.48 ± 0.10 
KN-232 
 
689.78 0.350 ± 0.265 0.883 ± 0.603 0.217 ± 0.702 
KN-237 
 
701.79 0.98 ± 0.41 0.33 ± 0.61 0.58 ± 0.76 
KN-242 
 
715.82 1.57 ± 1.20 0.50 ± 0.64 0.20 ± 0.63 
KN-247 
 
715.25 0.60 ± 1.48 0.03 ± 1.26 -0.07 ± 0.51 
KN-252 
 
716.80 1.30 ± 0.48 0.13 ± 0.05 -0.17 ± 0.47 
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Table AP1: ΔTm values for Duplex at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
ΔTm values for Control Duplex DNA sequence 
Code Structure MW 5µm 2 μm 1 μm 
KN-257 
 
765.83 0.10 ± 0.46 -0.17 ± 0.66 -0.05 ± 0.61 
KN-267 
 
715.80 -0.37 ± 0.53 -0.83 ± 1.26 0.27 ± 0.51 
KN-272 
 
661.73 -0.17 ± 1.09 0.13 ± 0.75 0.83 ± 0.28 
 
Table AP2: ΔTm values for C-Kit1 at 5 μm, 2 μm, and 1 μm concentration with standard deviations 
ΔTm values for C-kit1 
Code Structure MW 5µm 2 μm 1 μm 
KN-24 
 
504.02 0.48 ± 0.00 0.00 ± 0.10 0.14 ± 0.05 
KN-40 
 
507.38 0.00 ± 0.05 0.00 ± 0.11 0.00 ± 0.22 
KN-41 
 
507.15 0.00 ± 0.17 0.00 ± 0.00 0.00 ± 0.26 
KN-45 
 
543.00 0.00 ± 0.12 0.00 ± 0.52 0.00 ± 0.100 
KN-46 
 
527.10 0.00 ± 0.05 0.00 ± 0.10 0.00± 0.36 
KN-47 
 
543.05 0.00 ± 0.20 0.00 ± 0.00 0.00 ± 0.59 
KN-48 
 
529.96 0.00 ± 0.05 0.00 ± 0.17 0.00 ± 0.12 
KN-49 
 
528.94 0.00 ± 0.10 0.00 ± 0.16 0.00 ± 0.36 
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Table AP2: ΔTm values for C-Kit1 at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
ΔTm values for C-kit1 
Code Structure MW 5µm 2 μm 1 μm 
KN-50 
 
512.99 0.01 ± 0.00 0.00 ± 0.05 0.00 ± 0.52 
KN-51 
 
489.17 0.00 ± 0.25 0.00 ± 0.15 0.00 ± 0.30 
KN-52 
 
490.14 0.00 ± 0.25 0.00 ± 0.20 0.00 ± 0.00 
KN-53 
 
473.13 0.00 ± 0.10 0.00± 0.36 0.00 ± 0.01 
KN-54 
 
499.85 0.00 ± 0.00 0.00 ± 0.17 0.00 ± 0.12 
KN-55 
 
499.92 0.00 ± 0.11 0.00 ± 0.05 0.00 ± 0.10 
KN-56 
 
483.88 0.06 ± 0.10 0.20 ± 0.20 0.00 ± 0.22 
KN-57 
 
539.09 0.00 ± 0.12 0.00 ± 0.00 0.00 ± 0.26 
KN-58 
 
539.09 0.00 ± 0.08 0.00 ± 0.35 0.00 ± 0.19 
KN-59 
 
523.12 0.00 ± 0.20 0.00 ± 0.11 0.00 ± 0.10 
KN-60 
 






Table AP2: ΔTm values for C-Kit1 at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
ΔTm values for C-kit1 
Code Structure MW 5µm 2 μm 1 μm 
KN-61 
 
554.99 0.00 ± 0.26 0.00 ± 0.15 0.00 ± 0.23 
KN-62 
 
539.05 0.05 ± 0.52 0.00 ± 0.00 0.00± 0.36 
KN-79 
 
697.81 1.27 ± 0.20 0.90 ± 0.22 0.52 ± 0.51 
KN-83 
 
713.39 2.54 ± 0.52 0.00 ± 0.10 0.00 ± 0.08 
KN-90 
 
693.30 0.21 ± 0.08 0.00 ± 0.25 0.00 ± 0.65 
KN-91 
 
698.53 0.34 ± 0.17 0.00 ± 0.22 0.00 ± 0.00 
KN-110 
 
639.33 0.00 ± 0.10 0.22 ± 0.11 0.00 ± 0.05 
KN-112 
 
639.32 2.43  ± 0.00 1.133 ± 0.08 0.92 ± 0.10 
KN-157 
 
688.81 4.03 ± 0.71 1.41 ± 0.11 0.68 ± 0.36 
KN-158 
 
687.76 1.17 ± 0.52 1.33 ± 1.02 0.83 ± 0.36 
KN-200 
 
763.86 1.93 ± 0.25 0.92 ± 0.73 0.43 ± 0.15 
KN-202 
 
763.86 2.22 ± 0.08 1.06 ± 0.26 0.54 ± 0.61 
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Table AP2: ΔTm values for C-Kit1 at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
Tm values for C-kit1 
Code Structure MW 5µm 2 μm 1 μm 
KN-207 
 
777.89 1.51 ± 0.00 1.22 ± 0.15 0.59 ± 0.10 
KN-222 
 
703.76 1.62 ± 0.56 1.06 ± 0.29 0.61 ± 0.63 
KN-257 
 





Table AP3: ΔTm values for C-Kit2 at 5 μm, 2 μm, and 1 μm concentration with standard deviations 
ΔTm values for C-kit2 
Code Structure MW 5µm 2 μm 1 μm 
KN-24 
 
504.02 0.00 ± 0.05 0.00 ± 0.00 0.00 ± 0.27 
KN-39 
 
491.11 0.00 ± 0.65 0.00 ± 0.15 0.00 ± 0.50 
KN-40 
 
507.38 0.42 ± 0.15 0.35 ± 0.71 0.40 ± 0.63 
KN-41 
 
507.15 0.00 ± 0.16 0.00 ± 0.93 0.00 ± 0.13 
KN-45 
 
543.00 0.46 ± 0.30 0.30 ± 0.00 0.10 ± 0.12 
KN-46 
 





Table AP3: ΔTm values for C-Kit2 at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
ΔTm values for C-kit2 
Code Structure MW 5µm 2 μm 1 μm 
KN-47 
 
543.05 0.00 ± 0.92 0.00 ± 0.08 0.00 ± 0.15 
KN-48 
 
529.96 0.00 ± 0.08 0.00 ± 0.15 0.00 ± 0.16 
KN-49 
 
528.94 0.00 ± 0.65 0.00 ± 0.62 0.00 ± 0.51 
KN-50 
 
512.99 0.00 ± 0.10 0.00 ± 0.00 0.00 ± 0.08 
KN-51 
 
489.17 0.00 ± 0.52 0.00 ± 0.32 0.00 ± 0.33 
KN-52 
 
490.14 0.00 ± 0.15 0.00 ± 0.40 0.00 ± 0.08 
KN-53 
 
473.13 0.00 ± 0.15 0.00 ± 0.10 0.00 ± 0.58 
KN-54 
 
499.85 0.30 ± 0.38 0.00 ± 0.16 0.00 ± 0.32 
KN-55 
 
499.92 0.00 ± 0.05 0.00 ± 0.22 0.00 ± 0.39 
KN-56 
 
483.88 0.00 ± 0.21 0.00 ± 0.15 0.00 ± 0.06 
KN-57 
 




Table AP3: ΔTm values for C-Kit2 at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
ΔTm values for C-kit2 
Code Structure MW 5µm 2 μm 1 μm 
KN-59 
 
523.12 0.12 ± 0.13 0.00 ± 0.15 0.00 ± 0.90 
KN-60 
 
554.99 0.03 ± 0.11 0.00 ± 0.34 0.00 ± 0.00 
KN-61 
 
554.99 0.02 ± 0.13 0.00 ± 0.08 0.00 ± 0.23 
KN-62 
 
539.05 0.00 ± 0.10 0.00 ± 0.90 0.00 ± 0.05 
KN-78 
 
692.55 0.52 ± 0.00 2.72 ± 0.15 0.40 ± 0.15 
KN-79 
 
697.81 0.46 ± 0.80 0.00 ± 0.03 0.00 ± 0.06 
KN-83 
 
713.39 2.98 ± 0.05 2.01 ± 0.15 0.91 ± 0.25 
KN-91 
 
698.53 1.34 ± 0.15 0.18 ± 0.17 0.44 ± 0.12 
KN-110 
 
639.33 2.27 ± 0.00 0.44 ± 0.25 0.16 ± 0.13 
KN-112 
 








Table AP3: ΔTm values for C-Kit2 at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
ΔTm values for C-kit2 
Code Structure MW 5µm 2 μm 1 μm 
KN-136 
 
725.81 4.01 ± 0.00 1.42 ± 0.06 0.36 ± 0.13 
KN-146 
 
755.86 5.83 ± 0.01 1.39 ± 0.11 0.31 ± 0.12 
KN-149 
 
689.78 2.30 ± 0.28 1.92 ± 0.00 0.41 ± 0.10 
KN-150 
 
649.72 3.13 ± 0.71 1.10 ± 0.10 1.34 ± 0.13 
KN-156 
 
672.75 2.83  ± 0.20 1.02 ± 0.19 0.62 ± 0.39 
KN-157 
 
688.81 2.43 ± 0.65 0.86 ± 0.04 0.35 ± 0.15 
KN-158 
 
687.76 2.58 ± 0.70 0.98 ± 0.15 0.53 ± 0.00 
KN-200 
 
763.86 0.60 ± 0.20 -0.10 ± 0.20 0.50 ± 0.26 
KN-202 
 
763.86 1.43 ± 0.31 0.70 ± 0.0 0.60 ± 0.26 
433 
 
Table AP4: ΔTm values for DRH at 5 μm, 2 μm, and 1 μm concentration with standard deviations 
ΔTm values for DRH 
Code Structure MW 5µm 2 μm 1 μm 
KN-24 
 
504.02 0.07 ± 0.15 0.25 ± 0.00 0.05 ± 0.73 
KN-39 
 
491.11 -0.03 ± 0.15 0.03 ± 0.08 0.37 ± 0.08 
KN-40 
 
507.38 0.21 ± 0.08 0.03 ± 0.08 0.11 ± 0.08 
KN-41 
 
507.15 0.30 ± 0.00 0.27 ± 0.58 0.03 ± 0.08 
KN-45 
 
543.00 0.08 ± 0.28 0.35 ± 0.00 0.25 ± 0.00 
KN-46 
 
527.10 0.25 ± 0.00 0.23 ± 0.05 0.28 ± 0.05 
KN-47 
 
543.05 0.23 ± 0.08 0.17 ± 0.08 0.10 ± 0.00 
KN-48 
 
529.96 0.17 ± 0.21 0.27 ± 0.08 0.20 ± 0.00 
KN-49 
 
528.94 0.13 ± 0.15 0.83 ± 0.58 0.20 ± 0.00 
KN-50 
 
512.99 0.27 ± 0.08 0.11 ± 0.13 -0.10 ± 0.25 
KN-51 
 
489.17 -0.37 ± 0.00 -0.17 ± 0.00 -0.13 ± 0.05 
KN-52 
 
490.14 -0.07 ± 0.20 -0.23 ± 0.11 -0.13 ± 0.05 
KN-54 
 





Table AP4: ΔTm values for DRH at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
 
ΔTm values for DRH 
Code Structure MW 5µm 2 μm 1 μm 
KN-55 
 
499.92 -0.07 ± 0.00 -0.03 ± 0.08 0.10 ± 0.08 
KN-56 
 
483.88 0.10 ± 0.13 -0.67 ± 0.00 0.03 ± 0.100 
KN-57 
 
539.09 0.23 ± 0.00 0.20 ± 0.15 0.00 ± 0.05 
KN-58 
 
539.09 0.33 ± 0.00 0.17 ± 0.53 0.20 ± 0.15 
KN-59 
 
523.12 -0.03 ± 0.08 0.17 ± 0.13 0.07 ± 0.13 
KN-60 
 
554.99 0.07 ± 0.15 0.00 ± 0.15 0.10 ± 0.15 
KN-61 
 
554.99 0.20 ± 0.20 -0.03 ± 0.00 0.26 ± 0.00 
KN-62 
 
539.05 -0.07 ± 0.25 -0.20 ± 0.58 0.30 ± 0.05 
KN-78 
 
692.55 0.67 ± 0.13 0.47 ± 0.10 0.43 ± 0.08 
KN-79 
 
697.81 0.37 ± 0.00 0.67 ± 0.10 0.47 ± 0.10 
KN-88 
 
692.72 0.57 ± 0.08 0.37 ± 0.13 0.31 ± 0.58 
435 
 
Table AP4: ΔTm values for DRH at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
 
ΔTm values for DRH 
Code Structure MW 5µm 2 μm 1 μm 
KN-89 
 
697.57 0.33 ± 0.53 0.33 ± 0.15 0.50 ± 0.08 
KN-90 
 
693.30 0.23 ± 0.15 0.18 ± 0.08 0.14 ± 0.15 
KN-91 
 
698.53 0.33 ± 0.15 0.37 ± 0.05 0.00 ± 0.00 
KN-110 
 
639.33 0.33 ± 0.08 0.90 ± 0.00 0.16 ± 0.13 
KN-112 
 
639.32 0.43 ± 0.15 0.93 ± 0.58 0.06 ± 0.00 
KN-119 
 
676.13 -0.67 ± 0.58 0.03 ± 0.13 0.67 ± 0.08 
KN-120 
 
676.21 0.30 ± 0.00 0.00 ± 0.00 0.00 ± 0.10 
KN-130 
 
692.81 0.30 ± 0.00 0.20 ± 0.00 0.33 ± 0.58 
KN-136 
 
725.81 0.43 ± 0.58 0.36 ± 0.15 0.10 ± 0.00 
KN-143 
 
674.77 0.37 ± 0.53 0.33 ± 0.08 0.23 ± 0.08 
KN-144 
 
679.77 0.87 ± 0.08 0.67 ± 0.08 0.23 ± 0.58 
436 
 
Table AP4: ΔTm values for DRH at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
ΔTm values for DRH 
Code Structure MW 5µm 2 μm 1 μm 
KN-145 
 
750.86 0.63 ± 0.08 0.30 ± 0.08 0.30 ± 0.00 
KN-146 
 
755.86 0.60 ± 0.10 0.33 ± 0.08 0.17 ± 0.08 
KN-148 
 
656.68 2.93 ± 0.00 1.50 ± 0.51 0.17 ± 0.13 
KN-149 
 
689.78 0.47 ± 0.08 0.23 ± 0.08 0.1 ± 0.05 
KN-150 
 
649.72 0.57 ± 0.58 0.33 ± 0.08 0.27 ± 0.15 
KN-154 
 
672.75 0.30 ± 0.08 0.20 ± 0.58 0.10 ± 0.08 
KN-155 
 
687.74 0.67 ± 0.00 0.17 ± 0.00 0.17 ± 0.13 
KN-156 
 
672.75 0.33 ± 0.15 0.37 ± 0.00 0.26 ± 0.10 
KN-157 
 
688.81 0.43 ± 0.05 0.40 ± 0.08 0.23 ± 0.08 
KN-158 
 
687.76 0.40 ± 0.08 0.67 ± 0.10 0.33 ± 0.11 
KN-159 
 





Table AP4: ΔTm values for DRH at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
ΔTm values for DRH 
Code Structure MW 5µm 2 μm 1 μm 
KN-160 
 
703.81 0.66 ± 0.10 0.60 ± 0.08 0.40 ± 0.05 
KN-161 
 
690.76 0.73 ± 0.28 0.50 ± 0.05 0.37 ± 0.00 
KN-176 
 
691.82 1.20 ± 0.11 0.76 ± 0.00 0.27 ± 0.00 
KN-200 
 
763.86 0.25 ± 0.11 0.18 ± 0.00 -0.17 ± 0.20 
KN-202 
 
763.86 0.01 ± 0.05 -0.05 ± 0.31 0.30 ± 0.11 
KN-207 
 
777.89 0.38 ± 0.10 -0.01 ± 0.26 0.13 ± 0.10 
KN-212 
 
701.79 0.23 ± 0.00 0.27 ± 0.58 0.10 ± 0.05 
KN-217 
 
687.76 0.31 ± 0.08 0.28 ± 0.10 0.28 ± 0.00 
KN-222 
 
703.76 0.33 ± 0.10 0.20 ± 0.15 0.20 ± 0.05 
KN-227 
 
717.79 0.31 ± 0.08 0.23 ± 0.00 0.250 ± 0.08 
KN-232 
 
689.78 0.78 ± 0.40 -0.17 ± 0.00 -0.37 ± 0.14 
KN-237 
 
701.79 0.08 ± 0.28 -0.61 ± 0.00 -1.07 ± 0.35 
438 
 
Table AP4: ΔTm values for DRH at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
ΔTm values for DRH 
Code Structure MW 5µm 2 μm 1 μm 
KN-242 
 
715.82 16.43 ± 1.14 -0.96 ± 0.34 -0.67 ± 0.14 
KN-247 
 
715.25 -3.31 ± 1.41 -0.16 ± 0.35 -1.21 ± 0.42 
KN-252 
 
716.80 11.98 ± 2.54 -0.36 ± 0.35 -0.67 ± 0.00 
KN-257 
 
765.83 -1.07 ± 0.14 -0.47 ± 0.00 -0.71 ± 0.00 
KN-267 
 
715.80 -0.36 ± 0.07 -0.67 ± 0.23 0.13 ± 0.35 
KN-272 
 

















Table AP5: ΔTm values for CDRH at 5 μm, 2 μm, and 1 μm concentration with standard deviations 
ΔTm values for CDRH 
Code Structure MW 5µm 2 μm 1 μm 
KN-24 
 
504.02 0.71 ± 0.08 0.83 ± 0.58 0.60 ± 0.10 
KN-39 
 
491.11 0.83 ± 0.08 0.17 ± 0.13 1.11 ± 0.05 
KN-40 
 
507.38 1.00 ± 0.10 0.73 ± 0.08 0.90 ± 0.00 
KN-41 
 
507.15 1.07 ± 0.05 1.28 ± 0.13 0.70 ± 0.10 
KN-45 
 
543.00 0.87 ± 0.58 0.50 ± 0.10 0.83 ± 0.08 
KN-46 
 
527.10 0.88 ± 0.05 0.90 ± 0.10 1.18 ± 0.05 
KN-47 
 
543.05 1.11 ± 0.05 1.01 ± 0.08 1.50 ± 0.10 
KN-48 
 
529.96 1.10 ± 0.10 0.91 ± 0.08 0.83 ±0.05 
KN-49 
 
528.94 0.30 ± 0.94 0.90 ± 0.00 0.83 ± 0.08 
KN-50 
 
512.99 1.05 ± 0.36 1.51 ± 0.11 1.63 ± 0.05 
KN-51 
 
489.17 -0.23 ± 0.10 0.15 ± 0.08 0.17 ± 0.00 
KN-52 
 
490.14 -0.00 ± 0.08 -0.07 ± 0.13 0.50 ± 0.05 
KN-53 
 
473.13 -0.10 ± 0.15 0.07 ± 0.00 0.01 ± 0.10 
440 
 
Table AP5: ΔTm values for CDRH at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
 
ΔTm values for CDRH 
Code Structure MW 5µm 2 μm 1 μm 
KN-53 
 
473.13 -0.15 ± 0.15 0.07 ± 0.00 0.07 ± 0.10 
KN-54 
 
499.85 0.15 ± 0.08 0.27 ± 0.48 -0.21 ± 0.08  
KN-55 
 
499.92 -0.20 ± 0.08 -0.05 ± 0.08 -0.05 ± 0.05 
KN-56 
 
483.88 -0.15 ± 0.05 -0.15 ± 0.05 -0.01 ± 0.05 
KN-57 
 
539.09 -0.03 ± 0.00 -0.03 ± 0.00 -0.03 ± 0.10 
KN-58 
 
539.09 -0.01  ± 0.05 -0.11 ± 0.08 -0.17 ± 0.05 
KN-59 
 
523.12 -0.20 ± 0.05 -0.00 ± 0.08 -0.17 ± 0.11 
KN-60 
 
554.99 -0.21 ± 0.05 -0.15 ± 0.05 -0.01 ± 0.15 
KN-61 
 
554.99 -1.15 ± 0.10 0.15 ± 0.00 -0.07 ± 0.08 
KN-62 
 
539.05 -0.18 ± 0.11 -0.05 ± 0.10 0.15 ± 0.10 
441 
 
Table AP5: ΔTm values for CDRH at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
 
ΔTm values for CDRH 
Code Structure MW 5µm 2 μm 1 μm 
KN-78 
 
692.55 0.20 ± 0.20 0.23 ± 0.08 0.08 ± 0.05 
KN-79 
 
697.81 -0.28 ± 0.2 0.01 ± 0.05 0.15 ± 0.10 
KN-83 
 
713.39 0.11 ± 0.05 0.07 ± 0.05 0.08 ± 0.05 
KN-88 
 
692.72 3.50 ± 0.05 1.96 ± 0.05 3.16 ± 0.05 
KN-89 
 
697.57 0.11 ± 0.08 0.28 ± 0.28 0.48 ± 0.05 
KN-90 
 
693.30 0.35 ± 0.05 0.13 ± 0.23 0.10 ± 0.00 
KN-91 
 
698.53 0.24 ± 0.05 0.13 ± 0.10 0.02 ± 0.05 
KN-110 
 
639.33 0.27 ± 0.05 0.83 ± 0.23 0.80 ± 0.00 
KN-112 
 
639.32 0.16 ± 0.05 0.03 ± 0.03 0.00 ± 0.00 
KN-119 
 
676.13 3.55 ± 0.05 2.47 ± 0.23 1.11 ± 0.11 
442 
 
Table AP5: ΔTm values for CDRH at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
ΔTm values for CDRH 
Code Structure MW 5µm 2 μm 1 μm 
KN-120 
 
676.21 1.21 ± 0.10 0.92 ± 0.05 0.46 ± 0.23 
KN-130 
 
692.81 0.25 ± 0.10 0.31 ± 0.05 0.14 ± 0.10 
KN-136 
 
725.81 0.27 ± 0.05 0.13 ± 0.231 0. 08 ± 0.00 
KN-143 
 
674.77 0.21 ± 0.45 0.18 ± 0.08 0.20 ± 0.11 
KN-144 
 
679.77 0.11 ± 0.05 0.10 ± 0.10 0.11 ± 0.05 
KN-145 
 
750.86 0.56 ± 0.23 0.23 ± 0.15 0.13 ± 0.00 
KN-146 
 
755.86 0.47 ± 0.11 0.36 ± 0.10 0.13 ± 0.05 
KN-148 
 
656.68 1.30 ± 0.05 2.93 ± 0.26 3.30 ± 0.32 
KN-149 
 





Table AP5: ΔTm values for CDRH at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
ΔTm values for CDRH 
Code Structure MW 5µm 2 μm 1 μm 
KN-150 
 
649.72 0.28 ± 0.23 0.11 ± 0.05 0.19 ± 0.08 
KN-154 
 
672.75 -0.03 ± 0.15 -0.03 ± 0.05 -0.20 ± 0.10 
KN-155 
 
687.74 0.03 ± 0.11 -0.33 ± 0.05 -0.10 ± 0.10 
KN-156 
 
672.75 -0.23 ± 0.37 -0.30 ± 0.26 -0.50 ± 0.10 
KN-157 
 
688.81 -0.20 ± 0.10 -0.36 ± 0.05 -0.33 ± 0.05 
KN-158 
 
687.76 -0.13 ± 0.25 -0.53 ± 0.25 -0.70 ± 0.26 
KN-159 
 
674.70 0.20 ± 0.00 0.00 ± 0.28 0.20 ± 0.00 
KN-160 
 
703.81 0.30 ± 0.11 0.30 ± 0.00 0.66 ± 0.23 
KN-161 
 
690.76 0.26 ± 0.05 0.83 ± 0.23 0.80 ± 0.00 
KN-176 
 




Table AP5: ΔTm values for CDRH at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
ΔTm values for CDRH 
Code Structure MW 5µm 2 μm 1 μm 
KN-200 
 
763.86 2.53 ± 0.10 1.30 ± 0.05 3.03 ± 0.08 
KN-202 
 
763.86 2.90 ± 0.05 1.60 ± 0.15 3.17 ± 0.05 
KN-207 
 
777.89 3.33 ± 0.00 1.77 ± 0.08 2.97 ± 0.08 
KN-212 
 
701.79 4.33 ± 0.25 2.53 ± 0.10 3.30 ± 0.11 
KN-217 
 
687.76 3.40 ± 0.08 2.07 ± 0.05 3.20 ± 0.08 
KN-222 
 
703.76 3.00 ± 0.08 1.80 ± 0.58 3.23 ± 0.00 
KN-227 
 
717.79 3.10 ± 0.05 1.76 ± 0.05 3.13 ± 0.10 
KN-232 
 
689.78 0. 83 ± 0.20 0. 35 ± 0.63 0.17 ± 0.11 
KN-237 
 
701.79 0.89 ± 0.10 0.53 ± 0.00 0.33 ± 0.15 
KN-242 
 





Table AP5: ΔTm values for CDRH at 5 μm, 2 μm, and 1 μm concentration with standard deviations (continued) 
ΔTm values for CDRH 
Code Structure MW 5µm 2 μm 1 μm 
KN-247 
 
715.25 0.68 ± 0.45 0.43 ± 0.26 0.317 ± 0.11 
KN-252 
 
716.80 0.35 ± 0.05 0.18 ± 0.58 0.07 ± 0.13 
KN-257 
 
765.83 0.10 ± 0.43 -0.01 ± 0.66 -0.05 ± 0.36 
KN-267 
 
715.80 0.33 ± 0.11 0.21 ± 0.20 0.11 ± 0.05 
KN-272 
 
661.73 0.11 ± 0.05 0.10 ± 0.00 0.08 ± 0.00 
 
 
